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Abstract 
Streptococcus pneumoniae naturally colonises the human nasopharynx, where it 
normally resides as a commensal. However, any change in the bacterial and host 
condition in the nasopharynx may lead to invasive pneumococcal disease. The 
human nasopharynx is also home to a broad range of other microbiota, which interact 
with S. pneumoniae, consequently impacting on its carriage dynamics. This thesis 
investigated the carriage of S. pneumoniae and other microbiota in the nasopharynx 
of Malawian children and adults, and factors that may impact on this. To characterise 
S. pneumoniae in carriage, a microarray was used, whereas the nasopharyngeal 
microbiota were characterised using 16SrRNA gene sequencing. Results 
demonstrated a broad range of carriage pneumococcal serotypes in Malawian 
children and adults. Carriage of nontypeable serotypes was higher in adults (~20%) 
compared to children (~1%). Based on carriage data only, PCV13 coverage was 60% 
in children and 30% in adults. The low PCV13 coverage demonstrates a high 
prevalence of non-vaccine serotypes in circulation, which may provide the scope for 
serotype replacement post vaccination. For the first time in Malawi, we have 
demonstrated that multiple carriage is not only common but also higher in children 
(40%) than in adults (19%). The study did not find any significant impact on 
serotype specific carriage or the degree of multiple carriage by HIV status. Despite 
the high levels of multiple carriage, there was no evidence of capsule switching in 
our setting. However CPS locus variants of 8 serotypes including the vaccine 
serotype 6B, 19A and 20 were identified. It is not known whether these variants have 
the improved ability to colonise or cause invasive disease, thereby necessitating 
further analysis. Studying other microorganisms in carriage showed that the 
Malawian nasopharyngeal microbiota was dominated by four phyla in both adults 
xi 
 
and children, namely Firmicutes (79%), Proteobacteria (17%), Actinobacteria (3%) 
and Bacteroidetes (1%). The data demonstrated no significant difference in the 
distribution of phyla between adults and children, however there was broader 
microbial diversity amongst HIV negative subjects compared to HIV positive 
subjects. Specifically, HIV infection was associated with a lower prevalence of 
Actinobacteria. Although anti-retroviral therapy (ART) did not impact the 
nasopharyngeal microbiota, our data showed differences in phyla distribution in 
children‟s samples collected from Karonga and Blantyre. Samples from Karonga 
demonstrated a significantly higher carriage of Actinobacteria and Proteobacteria, 
while Firmicutes were predominant in Blantyre. This diversity could possibly be 
attributed to existing differences in age and HIV prevalence between the two sample 
groups. In conclusion, our study has demonstrated a high degree of serotype diversity 
and multiple carriage in the Malawian population, which suggests a greater 
likelihood of serotype replacement post-vaccination. This study therefore, 
recommends further carriage surveillance studies post PCV13 in the Malawian 
population. Such studies should evaluate the impact of PCV13 on carriage in the 
Malawian population, which in turn, will provide an estimate of herd immunity. The 
study has also generated important preliminary findings on dominant phyla in 
carriage, however further studies are recommended to evaluate the impact of other 
microbiota on pneumococcal carriage dynamics.  
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Chapter 1:  Nasopharyngeal carriage of Streptococcus pneumoniae 
 
1.0  Introduction 
The human body is colonised by thousands of species of bacteria and a smaller 
number of viruses, fungi, and protozoa (Schaechter et al., 1998). These microbes are 
termed normal flora because they colonise the human body immediately after birth 
and remain throughout life (Schaechter et al., 1998). Normal flora can colonise many 
sites of the human body including the skin, respiratory tract (nose and oropharynx), 
urinary tract, digestive tract and the genital system (Figure 1.1), while areas such as 
the brain and the circulatory system are normally sterile (Schaechter et al., 1998). 
The nasopharynx is a major ecological reservoir of colonising micro-organisms 
which include potential pathogens such as Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, Staphylococcus aureus and Neisseria meningitidis 
(Pettigrew et al., 2008, Nouwen et al., 2001, Bogaert et al., 2004c, Bogaert et al., 
2005). Colonisation with these pathogens may occur more than once early in life in 
almost all humans (Faden et al., 1997, Faden et al., 1996). In industrialised countries, 
S. pneumoniae, M. catarrhalis and nontypeable H. influenzae can colonise as many 
as 54%, 72% and 33% of children, respectively, by 1 year of age (Faden et al., 
1997). In developing countries such as Malawi and the Gambia, the rates of 
colonisation may be considerably high (Feikin et al., 2003, Kwambana et al., 2011).
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Figure 1.1 Parts of the human body colonised by normal flora 
The figure lists the commonly isolated phyla from these environments (Oliver, 2003, McHardy et al., 2013, Cho and Blaser, 2012, Ahmed et al., 
2007). 
      l i   l fl  
The figure lists the commonly isolated phyla from these environments (Oliver, 2003, McHardy et al., 2013, Cho and Blaser, 2012, Ahmed et al., 
2007). 
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The colonising microbial species may be confined to their original site of attachment, 
where an asymptomatic carrier state is established; however, changes in the host or 
bacterial condition may lead to the spread of these potential pathogens to sterile sites 
such as the bloodstream, where they cause potentially fatal infections such as 
septicaemia (Kyaw et al., 2002, Nouwen et al., 2001). Colonising flora act as 
reservoir and source of bacterial transmission within the community and may 
become pathogens (Tancrede, 1992, Givon-Lavi et al., 2002). S. pneumoniae is an 
example of nasopharyngeal commensal organism, which is known to cause invasive 
pneumococcal disease, and is responsible for over a million deaths worldwide each 
year (Johnson et al., 2010, O'Brien et al., 2009), with the greatest burden experienced 
in sub-Saharan Africa (SSA). Thus realising the importance of carriage in the spread 
of pathogens and the development of disease, it is essential to undertake studies 
aimed at understanding carriage of such pathogens in the nasopharynx, which may 
play a vital role in disease control. 
 
1.1. Streptococcus pneumoniae bacteriology 
Streptococcal species are Gram-positive, non-motile, non-spore forming, catalase-
negative organisms that are naturally found in pairs or chains (Carver et al., 2005). 
Their classification at the genus level is based on a number of factors such as colony 
morphology, haemolysis, biochemical reactions, and serologic specificity. They are 
divided into three groups based on the type of haemolysis on blood agar plates: beta-
hemolytic, gamma-hemolytic or alpha-hemolytic (Facklam, 2002).Beta-hemolytic 
streptococci, which include pyogenes (group A) and agalactiae (group B), undergo 
complete haemolysis of red blood cells resulting in the appearance of a clear zone 
surrounding the colony on blood agar (Facklam, 2002). Gamma-hemolytic 
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streptococci do not undergo any haemolysis and include Enterococcus species such 
as E. faecalis and E. faecium. Alpha haemolytic streptococci are involved in partial 
reduction of haemoglobin (red blood cells) to methemoglobin, shown as a green or 
brown discoloration in the medium surrounding the colony (Facklam, 2002). S. 
pneumoniae and the viridans belong to Alpha-hemolytic streptococci (Kellogg et al., 
2001). The difference between S. pneumoniae and viridans is that the former are 
mostly encapsulated and respond positively to Quellung reaction while all of the 
latter do not have a polysaccharide capsule and they yield a negative result to the 
Quellung test (www.cdc.gov). Another distinguishing feature is that pneumococcal 
strains are bile soluble and sensitive to optochin, while viridans are bile insoluble and 
optochin resistant (Wasilauskas and Hampton, 1984). Pneumococcal cells are 
surrounded by a cell wall, which protects the bacterial cell from bursting by the 
internal pressure, thereby maintaining the structural integrity of the cell (Bui et al., 
2009). The main constituents of pneumococcal cell wall are peptidoglycan and the 
covalently attached wall teichoic acid (WTA) (Vollmer et al., 2008). The 
pneumococcal cell wall is surrounded by a polysaccharide capsule which renders a 
mucoid (smooth) appearance to colonies on agar (Todar, 2010). The polysaccharide 
capsule also defines pneumococcal serotypes based on their reaction to factor typing 
sera. These sera are specific to immunochemical differences that exist between the 
pneumococcal capsular polysaccharides. Based on differences in the immunological 
properties of the polysaccharide capsule, 95 serotypes have been reported (Park et 
al., 2007, Bratcher et al., 2010, Oliver et al., 2013). Serotypes are clustered into 46 
sero-groups based on the heterogeneous structural and chemical composition, and on 
antigenic properties of capsular polysaccharides resulting from biosynthetic locus 
arrangements (Bentley et al., 2006). Pneumococcal strains that lack the 
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polysaccharide capsule have also been identified. These pneumococcal strains have 
usually been described as strains which are optochin sensitive and bile soluble but 
that cannot be typed with either antisera or the multiplex PCR (Shayegani et al., 
1982; Hathaway et al., 2004; Hanage et al., 2006), hence popularly known as 
nontypeable (NT) pneumococcal strains. Analysis with microarray serotyping 
(Chapter 2, section 2.6) revealed that NT strains may have a genotype that matches 
the CPSgene content of known serotypes, resembles remnants of serotypes, contains 
no known CPSgenes or identifies them as non-pneumoniae Streptococcus species 
(Hinds et al, 2009). Recently, whole genome sequencing and analysis of the genes 
between dexB and aliA genes has classified NTs into three groups based on whether 
there is complete deletion of the CPS locus (group NT1), presence of putative novel 
surface protein nspA gene at the CPS locus instead of CPS genes (group NT2) or 
those containing a well-conserved aliB gene cluster (group NT3) (Salter et al., 2012). 
 
1.2. Nasopharyngeal carriage of S. pneumoniae 
By definition, the time when a pneumococcal strain establishes itself within a host is 
known as acquisition, whereas persistent colonisation of the nasopharynx is referred 
to as carriage(Simell et al., 2012a). Nasopharyngeal carriage is a major factor in the 
pathogenesis of pneumococcal disease and is responsible for the spread of the 
pathogen within a given population. It is reported to occur early in life and persists in 
all age groups. Pneumococcal carriage is also reported to be more prevalent in 
children than adults, with colonisation rates increasing from birth to reach a peak 
(>80% in some populations) at the age of 1-2 years, and decreasing with age 
thereafter to less than 10% (Lloyd-Evans et al., 1996, Hussain et al., 2005, Abdullahi 
et al., 2012a, Hill et al., 2006, Regev-Yochay et al., 2010, Abdullahi et al., 2008a). 
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Pneumococcal carriage rates are reported to be higher in the developing regions with 
countries such as Malawi (Feikin et al., 2003), Gambia (Lloyd-Evans et al., 1996, 
Hill et al., 2006) and Nigeria (Adetifa et al., 2012) reporting carriage rates of more 
than 80%in children. In sub-Saharan Africa, the average carriage rate of 63.2% was 
shown in children less than 5 years old, decreasing with age to 28% in those older 
than 15 years (Usuf et al., 2014). In the developed countries, carriage rates are 
relatively lower compared to the developing countries. In Sweden, carriage rates of 
up to 32% were reported in children less than 2 years of age (Aniansson et al., 1992); 
while in the UK a 52% carriage rate was reported in children of the same age range 
(Hussain et al., 2005). 
 
The duration of carriage for the pneumococcus varies and periods of up to 40 weeks 
have been reported (Sleeman et al., 2006, Turner et al., 2012, Gratten et al., 1986). 
The persistence of a serotype in carriage is associated with the biochemistry of a 
polysaccharide capsule, where serotypes with thicker capsules are reported to persist 
for longer durations in carriage compared to serotypes with thinner capsules 
(Hogberg et al., 2007, Weinberger et al., 2009). Such heavily encapsulated serotypes 
have also been shown to exhibit greater ability to escape neutrophil-mediated killing, 
which may prolong their duration in carriage (Weinberger et al., 2009). Other host 
factors such as serotype-specific and CD4+ Th17 cells mediated non-serotype 
specific acquired immune responses have also been reported to play a role in the 
dynamics of pneumococcal carriage in the nasopharynx (Cobey and Lipsitch, 2012, 
Malley et al., 2005). Other reports indicate that less immunogenic serotypes tend to 
be carried for a much longer period of time than the more immunogenic serotypes 
(Rosen et al., 1984, Obaro and Adegbola, 2002). Carriage is also reported to be 
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dependent on seasons with peak rates occurring in the rainy and cold seasons (Gray 
et al., 1980, Abdullahi et al., 2012a). Other risk factors for pneumococcal carriage 
include childcare attendance, number of siblings in the home and health status and 
co-colonisation with other pathogens (Huang et al., 2009, Syrjanen et al., 2001, 
Regev-Yochay et al., 2004a, Bogaert et al., 2001, Abdullahi et al., 2008b).Exposure 
to viral infections in the upper respiratory tract has been reported to be a 
predisposing factor to bacterial colonisation. Viruses are thought to disrupt the 
respiratory mucosal epithelium thereby enhancing bacterial adhesion to respiratory 
epithelial cells (Glennie et al., 2010). In addition, inflammatory response to viral 
infection is thought to up-regulate the expression of molecules utilised by bacteria as 
receptors, eventually promoting adhesion (Jacoby et al., 2007, Peltola and 
McCullers, 2004). A recent study has shown a significant association between viral 
infection and detection of S. pneumoniae in carriage in children (Rodrigues et al., 
2013a). The same study also reported an interesting finding where detection of H. 
influenzae and H. influenzae colonisation density was positively associated with 
rhinitis symptoms in an age independent manner (Rodrigues et al., 2013a). Since 
rhinitis is a viral infection, the finding has led to the hypothesis that H. influenzae 
promotes its own transmission within a given population by inducing or amplifying 
rhinitis in children, which could suggest that carriage may not necessarily be 
asymptomatic (Rodrigues et al., 2013a). 
 
1.2.1. Multiple carriage of S. pneumoniae 
Multiple carriage is the simultaneous carriage of at-least two serotypes in the 
nasopharynx, and is thought to promote horizontal gene transfer (Hiller et al., 2010, 
Thomas and Nielsen, 2005). By promoting horizontal gene transfer, multiple carriage 
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has potentially important clinical implications in a given population as it may 
facilitate the rapid development of antibiotic resistance and vaccine escape through 
capsule switching (Marks et al., 2012, Hiller et al., 2010, Ding et al., 2009, Donkor et 
al., 2011). Capsule switching involves a change of serotype of a single clone by 
alteration or exchange of its CPS locus (Wyres et al., 2013). Multiple carriage also 
impacts the dynamics of pneumococcal carriage through bacterial interference (Shak 
et al., 2012). Multiple serotype carriage (co-colonisation) occurs when more than one 
distinct pneumococcal strains occupy a particular niche at the same time (Brugger et 
al., 2009). 
 
Data on the actual rates of multiple carriage of pneumococcal serotypes in the 
nasopharynx are very limited, however, previous estimates ranged from 1.3 % to 
20% in HIV uninfected adults and children (Gratten et al., 1994, Huebner et al., 
2000a, Hare et al., 2008, Rivera-Olivero et al., 2009, Brugger et al., 2009, Kaltoft et 
al., 2008). With improved serotyping techniques, however, much higher carriage 
rates (48%, n=129) have recently been reported (Turner et al., 2011). Multiple 
carriage in the nasopharygnx could facilitates horizontal gene transfer between 
pneumococcal strains (Marks et al., 2012). By promoting horizontal gene transfer, 
multiple carriage has potentially important clinical implications in a given population 
as it may facilitate the rapid development of antibiotic resistance (Croucher et al., 
2011)and vaccine escape through capsule switching (Brugger et al., 2009). Capsule 
switching involves a change of serotype of a single clone by alteration or exchange 
of its CPS locus (Wyres et al., 2013). 
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Pneumococcal strains are reported to be highly transformable; as such they are 50 
times more likely to undergo horizontal genetic transfer than genetic mutations (Feil 
et al., 2000, Claverys et al., 2009). The occurrence of capsule switch has been 
observed in various settings (Scott et al., 2011, Croucher et al., 2013) including 
Malawi (Everett et al., 2012), and this has implications for the efficacy of capsular 
based polysaccharide vaccines (Brueggemann et al., 2007b). The data on multiple 
serotype carriage prevalence in a given population could provide a basis for 
understanding and even predicting the emergence of new strains under vaccine 
selection pressure (Brugger et al., 2009, Mulholland and Satzke, 2012), especially for 
conditions involving multiple carriage of vaccine and non-vaccine serotypes. 
Multiple carriage data could also be used to explain whether non-vaccine serotypes 
emerging post vaccination are a result of true serotype replacement or unmasking of 
other serotypes (Figure 1.2). Under true serotype replacement, the unvaccinated 
populationmay initially carryboth vaccine and non-vaccine types, while vaccine 
recipients may carry a reduced number of vaccine serotypes and non-vaccine 
serotypes not previously detected. Under unmasking, by contrast, the unvaccinated 
carry non-vaccine serotypes below detectable levels and vaccine serotypes. Post-
vaccination, the low abundant non-vaccine types may become dominant serotypes 
(Figure 1.2) (Lipsitch, 1999). Unmasking is often difficult to detect if only a single 
colony is sampled for serotype analysis (Lipsitch, 1999). 
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Figure 1.2 Serotype replacement model 
A model depicting true serotype replacement (A) and unmasking (B) in carriage 
under vaccine selection pressure. Large circles represent plated samples from 
controls (unvaccinated) and vaccine recipients (vaccinated). The left side shows true 
serotype replacement, while the right side shows unmasking. Serotypes covered by 
vaccine (VT) are shown by open circles, while serotypes not covered by the vaccine 
(NVT) are colour coded black (Lipsitch, 1999). 
 
1.2.2. Detection of multiple carriage 
A major barrier to an accurate estimation of the prevalence of multiple 
pneumococcal carriage is lack of standard methods of detection. Conventionally, 
culture based techniques and serotyping of individual colonies have been employed 
(Kaltoft et al., 2008). Although attempts to increase the sensitivity of culture based 
methods by combining with molecular techniques such as multiplex PCR have been 
made (Rivera-Olivero et al., 2009), this approach still has limited practical 
application for very large numbers of samples (Huebner et al., 2000a) and it is biased 
towards viable and most abundant serotypes, as they are dependent on picking a 
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single colony from an agar plate either for sub-culturing or PCR. Ideally, culture 
independent methods of detecting co-colonisation would give a more accurate 
picture of multiple carriage. A culture independent technique for detection of co-
colonisation based on PCR amplification of a non-coding region adjacent to the 
pneumolysin gene (plyNCR) has been reported (Brugger et al., 2009). The authors 
stated that no amplification was observed when the PCR was conducted on other 
streptococcal and non-streptococcal species, which suggested pneumococcal 
specificity, however the data was not shown. Using restriction fragment length 
polymorphism (RFLP) and terminal RFLP analysis of the plyNCR region, the 
numbers and relative abundance in co-colonising strains were determined (Brugger 
et al., 2009). Although the sensitivity of the technique was slightly higher (50% vs 
40%) than culture based methods, it only works best for samples with at most two 
strains and differences in RFLP detected by one restriction enzyme only (Brugger et 
al., 2009). Thus there is still need for novel methods to fully understand the 
prevalence of multiple carriage in various settings. 
 
1.2.3. Pneumococcal carriage and disease 
The evidence of carriage as a predisposing factor and a first step in pneumococcal 
disease has been demonstrated in animal models, where nasal inoculation with 
pneumococcal strains resulted in development of acute otitis media (AOM) (Peltola 
et al., 2006, van der Ven et al., 1999) and/or invasive disease (Kadioglu et al., 2000, 
Ogunniyi et al., 2007b). In humans, very few studies have been conducted to 
establish this association, with the predominant infection being AOM. Development 
of AOM was associated with serotypes newly acquired (Gray et al., 1980), and not 
necessarily serotypes established in carriage. A recent study demonstrated that 
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human carriage of S. pneumoniae was associated with protection against re-carriage 
and invasive pneumococcal disease. This was attributed to an increase in both 
mucosal and serum IgG levels to pneumococcal proteins and polysaccharide, which 
resulted in an increase in opsonophagocytosis (Ferreira et al., 2013). It has been 
reported that most serotypes cause AOM at a frequency that is proportional to their 
prevalence in carriage (Hanage et al., 2004), suggesting a strong association between 
carriage and the onset of AOM. The most common serotypes causing AOM 
worldwide are 3, 6A, 6B, 9V, 14, 19A, 19F and 23F (Rodgers et al., 2009). The 
association between carriage and invasive disease, however, is complex, i.e., there is 
a discordant relationship in the distribution of serotypes between carriage and 
invasive disease. For example, serotypes 1, 5 and 7F are frequently isolated from 
invasive disease particularly in Africa, Asia and Latin America (Hausdorff et al., 
2000) and often cause disease outbreaks, and yet they are rarely detected in carriage 
(Hanage et al., 2005, Brueggemann et al., 2003, Almeida et al., 2013). The ability to 
cause disease in this case is not determined by the frequency of serotypes in carriage 
but rather by the invasive capacity of a given serotype, which is generally stable 
across the globe (Greenberg et al., 2011). Further evidence for the association 
between acquisition and the onset of disease can be seen in children. It has been 
reported in children, that IPD peaks from 6-11 months, which coincidentally is the 
time when high rates of new pneumococcal acquisitions in carriage are experienced 
(Simell et al., 2012a). Finally, carriage is much higher in children in developing than 
developed regions, with IPD following a similar trend, further highlighting the role 
of pneumococcal serotype acquisition in disease. In adults, the association between 
carriage and invasive disease is not very clear, i.e. there is high IPD incidence at a 
time when the prevalence of pneumococcal carriage is very low, particularly in the 
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elderly (Flasche et al., 2011a, Hussain et al., 2005). Thus the susceptibility of adults 
to IPD may largely be influenced by other medical or social-demographic factors and 
not necessarily carriage prevalence. This suggests that the development of invasive 
pneumococcal disease cannot reliably be predicted by the prevalence of carriage. 
Further information is therefore still required to establish the relationship between 
carriage and disease. The key is with the development of novel serotyping techniques 
such as microarray (Turner et al., 2011), which have the ability to detect multiple 
carriage as well as accounting for less abundant serotypes. 
 
1.3. Infections caused by S. pneumoniae 
The pneumococcus is reported to be the leading cause of bacterial pneumonia, 
meningitis, and sepsis, which contribute substantially to high morbidity and mortality 
worldwide (O'Brien et al., 2009). The highest risk groups for pneumococcal disease 
are children less than 5 years old, the elderly, and persons with chronic underlying 
conditions, such as HIV/AIDS (WHO., 2007). It is estimated that pneumococcal 
infections are responsible for ~1.6 million deaths annually. In children under the age 
of 5 years alone, deaths caused by S. pneumoniae range from ~7000000 to ~1 million 
every year world-wide (2007). The highest pneumococcal mortality rates are 
reported in Africa, with sub-Saharan Africa (SSA) bearing the greatest burden 
(O'Brien et al., 2009) (Figure 1.3).  
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Figure 1.3 Global pneumococcal mortality rate 
Pneumococcal deaths in children aged 1–59 months per 100 000 children younger 
than 5 years (HIV-negative pneumococcal deaths only) (O'Brien et al., 2009). 
 
1.3.1. Global invasive serotype distribution 
The global distribution of serotypes causing invasive disease shows that serotype 14 
is the most commonly isolated serotype in children under the age of 5 years (Johnson 
et al., 2010). The five most common global serotypes accounting for approximately 
60% of all serotypes causing invasive disease in children <5 years are 14, 6B, 1, 19F 
and 23F (Figure 1.4). Serotype 1 was more prevalent among children 2-<5 years of 
age than among the <2 years age group (Johnson et al., 2010, Pearce et al., 2002) 
15 
 
 
 
Figure 1.4 Global distribution of invasive serotypes in children 
The bar graph represents the percentage of each serotype out of the total number of 
isolated strains in children aged less than 5 years (Johnson et al., 2010). The line 
graph represents the cumulative frequency, which shows that serotypes 14 through 
9A account for approximately 95% of all serotypes causing invasive disease in 
children under the age of 5 years globally. 
 
Published data for invasive serotype and serogroup distributions in Europe, USA and 
Asia are similar, although minor differences in the prevalence of other serotypes 
exist. In the Netherlands, the most prevalent serotypes in children are 19F, 6B, 6A, 
9V, and 23F (Bogaert et al., 2001). In the USA and Vietnam, the most commonly 
isolated serotypes were 6B, 14, 19F, 23F (Yeh et al., 2003) and 19, 23, 14, 6, and 18 
(Parry et al., 2000) respectively. There is a lot of overlap between patterns of 
serotype distribution in Africa and other settings (Table 1.1). There has also been no 
major differences in serotype distribution between children with risk factors such as 
day care centre attendance (Bogaert et al., 2001) or upper respiratory tract infections 
and healthy children (Syrjanen et al., 2001, Marchisio et al., 2003), although 
respiratory tract infections are known to impact on carriage (Valles et al., 2006).  
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Table 1.1 Common carriage and invasive serotypes in African children 
 
Reference publication Year Country Age-Group Isolate Serotypes/serogroups 
(Woolfson et al., 1997) 1994 Zambia ≤6 years carried 14*, 19, 23 
(Huebner et al., 2000b) 2000 RSA ≤5 years carried 6B, 19F*, 6A*, 23F, 14, 19A  
(Adegbola et al., 2006) 
(Hill et al., 2008a) 
1996-2003 
2008 
Gambia 
Gambia 
≤6 years 
≤1 year 
invasive 
carried 
1, 5,6A, 14, 19A, 23F 
6B, 19F, 6A, 14, 23F* 
(Joloba et al., 2001) 1995 Uganda ≤3 years carried 19, 6, 23, 9, 14 
(Morais et al., 2007) 
(Valles et al., 2006) 
2003-2006 
2003 
Mozambique 
Mozambique 
≤15 years 
≤5 years 
invasive 
carried 
1, 5, 6A, 6B, 19A, 19F, 14, 23F 
19F, 19A, 23F, 6A, 6B* 
(Huebner et al., 1998) 1998 Botswana ≤5 years carried 14, 19F, 19A, 6A, 6B, 4 
 
*The five most common carriage serotypes in sub-Saharan Africa (Usuf et al., 2014), which also rank among the top seven serotypes causing 
invasive disease in children globally (Johnson et al., 2010).
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1.4. Impact of HIV infection on carriage and invasive disease 
1.4.1. Global estimates of HIV infection 
Globally the total number of people living with HIV is estimated to be 35.3 million, 
with 2.3 million new cases reported in 2012 (Figure 1.5). Sub-Saharan Africa bears 
the greatest burden, with ~70% of the global population of HIV infected people 
living in this region, and reported 1.6 million new HIV infection cases in 2012 
against 2.3 million world-wide (UNAIDS, 2013a, UNAIDS, 2013b). South Africa 
has the largest number (4.3 million) of people living with HIV in the world, while at 
24.8%; Swaziland has the highest rate of HIV prevalence in the world. In Malawi, 
about 1.7 million people live with HIV infection representing 10.6 % of the entire 
Malawian population, which is estimated to be 16 million people. The mortality rate 
due to HIV infection in Malawi is still high although there was a drop from 76, 000 
deaths in 2005 to 43, 000 in 2011. This decrease is attributed to the scale-up of the 
ART program in Malawi (UNAIDS, 2012b). 
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Figure 1.5 HIV prevalence by region  
The region with the highest burden of HIV infection is Sub-Saharan Africa, which 
includes Malawi (UNAIDS, 2012b, UNAIDS, 2013a, UNAIDS, 2013b).  
 
1.4.2. Pneumococcal carriage and disease in the context of HIV infection 
Risk factors for community acquired pneumococcal infections and asymptomatic 
carriage are numerous and diverse. These include extremes of age, low 
socioeconomic status, malnutrition, and conditions which compromise the host 
immune system such as HIV and AIDS (Farr et al., 2000b, Farr et al., 2000a, 
Almirall et al., 2008). HIV infection has emerged as a major global risk factor for 
invasive pneumococcal disease, particularly in adults (Domingo et al., 2009, Gilks et 
al., 1996, Jordano et al., 2004). It has significantly contributed to an increasing 
burden of pneumococcal disease in the developing world, particularly SSA (Zar, 
2004, Nunes et al., 2011a, Gordon et al., 2002). In the USA, persons with HIV 
accounted for 54.2% of patients (n=399) aged between 18 to 64 years who had 
pneumococcal disease (Nuorti et al., 2000). In Kenya, HIV seropositivity conferred a 
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relative risk of 17.8 for pneumococcal infection, among female sex-workers (Gilks et 
al., 1996). In South Africa, similar patterns in children and adults have been 
reported, where HIV infection was a predisposing factor for higher rates of 
pneumococcal disease (Madhi et al., 2007a, Karstaedt et al., 2000, Karstaedt et al., 
2001). It has also been shown that HIV-infected children and adults are susceptible 
to getting infected with pneumococcal strains that are resistant to penicillin treatment 
(Karstaedt et al., 2001, Madhi et al., 2007a), thus frustrating efforts to control 
pneumococcal infections in this group. Similarly, in Malawi, a high HIV prevalence 
has been reported among children and adult patients with invasive pneumococcal 
disease (Gordon et al., 2002, Carrol et al., 2007). 
 
Since pneumococcal carriage precedes disease, several studies have been done to 
determine the impact of HIV infection on carriage. A higher pneumococcal carriage 
rate has been described in a longitudinal cohort study of Zambian mothers, where 
HIV infection increased the risk of colonisation (Gill et al., 2008b). In South Africa, 
HIV infected children had a higher prevalence of colonisation by S. pneumoniae and 
H. influenzae (71.6% and 74.1%, respectively) than did HIV uninfected children 
(50.9 and 52.0% respectively) (Madhi et al., 2007a). Results from a study in USA 
showed that HIV-infected subjects were more likely to be persistent pneumococcal 
carriers and to carry antibiotic resistant strains than were non-HIV infected subjects 
(Rodriguez-Barradas et al., 1997). However, findings from other studies in the USA 
showed that the rate of pneumococcal colonisation in HIV–infected children was 
equal to that of HIV-negative controls (20% vs 19%) (Polack et al., 2000). Similarly, 
in Brazil, there was no significant correlation between carriage in adults and HIV 
status, irrespective of viral load and CD4 lymphocyte count (Nicoletti et al., 2007). 
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The fact that different studies report different findings suggests that the relationship 
between HIV infection and pneumococcal carriage is very complex and therefore 
poorly understood. These discrepancies could be attributed to varying levels to 
which the functionality of the immune system is compromised by HIV infection. 
This was demonstrated in a recent study in Malawian adults where carriage of 
pneumococcal strains was marginally increased in asymptomatic HIV positive 
adults, whereas, a significant increase in carriage rates was observed in symptomatic 
HIV infection (HIV negative-13%, asymptomatic HIV positive-19% and 
symptomatic HIV positive-38%) (Glennie et al., 2012a). Such elevated carriage rates 
in adults were maintained following immune reconstitution by antiretroviral therapy 
(Glennie et al., 2012a). It is clear that the available data on the impact of HIV on 
pneumococcal carriage are inconclusive. These studies, however, did not take into 
account the presence of other microbiota, which are in constant interaction with S. 
pneumoniae and may have an impact on pneumococcal carriage dynamics (Bosch et 
al., 2013). This therefore underscores the need for further investigations.  
 
1.5. Pathogenesis of pneumococcal infections 
The pneumococcus is acquired through contact with infected droplets and its natural 
habitat is the nasopharynx of the human host (Figure 1.6). The pneumococcus can 
cause otitis media, sinusitis, and pneumonia by spreading through the larynx to the 
lower respiratory tract, and then in some cases in blood to cause septicaemia (Shak et 
al., 2012). From blood, the pneumococcus may pass through the blood brain barrier 
to meninges causing meningitis (Obaro and Adegbola, 2002).  
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Figure 1.6 Pathogenic route for pneumococcal infection 
 
The pneumococcus is acquired through contact with infected droplets. Upon 
successful colonisation in the nasopharynx, the pneumococcus can be cleared, spread 
locally to cause mild infections such as sinusitis or otitis media, or it can invade 
lung, brain and blood to cause life-threatening diseases such as pneumonia, 
meningitis and septicaemia respectively (Bogaert et al., 2004a). 
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To cause infection, the pneumococcus is initially dependent on the attachment of 
pneumococcal surface receptors to the host mucosal lining, invasion through 
internalisation of the pneumococcal strains into endothelial cells and evasion of the 
host immune system (Gillespie and Balakrishnan, 2000). This is achieved by 
expressing a wide range of virulence factors (Figure 1.7). The widely studied 
virulence factors include the polysaccharide capsule and both surface proteins and 
secreted proteins (Jedrzejas, 2001, Kadioglu et al., 2008). The pneumococcal 
polysaccharide capsule is the outer-most component of encapsulated pneumococcal 
strains, covalently attached to the cell wall peptidoglycans (Figure 1.7). The capsule 
of serotype 3 however, binds to peptidoglycan through a different mechanism other 
than covalent attachment (Sorensen et al., 1990). Unlike other capsule types, the 
synthesis of serotype 3 capsule does not involve formation of repeat units (Cartee et 
al., 2000) and occurs via a synthase dependent pathway (Cartee et al., 2000). 
Pneumococcal proteins such as surface exposed choline binding proteins, ATP-
binding cassette transporter, metal binding proteins, LPXTG anchored proteins, 
pneumolysin, autolysin, and enolase play various roles in pneumococcal 
pathogenesis as described (Table 1.2), but the function of most pneumococcal 
proteins is still unknown. 
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Figure 1.7 The cell of S. pneumoniae showing virulence factors 
The capsule; the cell wall; choline-binding proteins; pneumococcal surface proteins 
A and C (PspA and PspC); the LPXTG-anchored neuraminidase proteins; 
hyaluronate lyase (Hyl); pneumococcal adhesion and virulence A (PavA); enolase 
(Eno); pneumolysin; autolysin A (LytA); and the metal-binding proteins 
pneumococcal surface antigen A (PsaA), pneumococcal iron acquisition A (PiaA) 
and pneumococcal iron uptake A (PiuA) (Kadioglu et al., 2008). 
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Table 1.2 Pneumococcal virulence factors and function 
Pneumococcal Virulence Factor Main role in colonisation and disease 
 
Polysaccharide capsule (Nelson et 
al., 2007b, Hammerschmidt et al., 
2005) 
Prevents entrapment in the nasal mucus, 
thereby allowing access to epithelial 
surfaces. Also inhibits effective 
opsonophagocytosis. 
Metal-binding proteins  
PsaA (Kadioglu et al., 2008) Component of the ABC transport system, 
which is involved in resistance to oxidative 
stress 
PiaA and PiuA (Kadioglu et al., 
2008) 
Component of the ABC transport system 
acquiring iron for bacterial growth and 
virulence 
Choline-binding proteins  
PspC (Iannelli et al., 2004) Binds to human secretory component on a 
polymeric Ig receptor during the first stage 
of translocation across the epithelium. 
PspA (Rosenow et al., 1997) Prevents binding of C3 onto pneumococcal 
surface. Also binds lactoferrin 
Chop (Weidenmaier and Peschel, 
2008) 
Binds to PAFr on the epithelial surface of 
the human nasopharynx 
LPXTG-anchored proteins  
NanA and NanB (Jedrzejas, 2001) Contributes to adherence, removes sialic 
acids on host glycopeptides and mucin to 
expose binding sites 
Other proteins  
Pneumolysin (Hirst et al., 2004, 
Zhang et al., 2007) 
Cytolytic toxin that also activates 
complement, cytokine and chemokine 
production.  
Enolase (Kadioglu et al., 2008) Binds to fibronectin in host tissues 
PavA (Holmes et al., 2001) Binds to plasminogen within host tissues 
Autolysin (Kadioglu et al., 2008) Digests the cell wall, resulting in the release 
of pneumolysin 
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1.5.1. Pneumococcal adherence to the host mucosal surface 
Respiratory mucus and lysozyme act as the first line of defence against attachment of 
the pneumococcus to host epithelial cells (Coonrod et al., 1991). The pneumococcus 
employs several different mechanisms to overcome mucus entrapment and clearing 
from the mucosal surface. The negative charge present on the pneumococcal 
polysaccharide capsule is thought to repulse the negatively charged sialic acid 
residues of the mucus; subsequently minimizing the chance of entrapment (Nelson et 
al., 2007a). The pneumococcus alters the viscosity of the mucus by de-glycosylating 
mucus glycoconjugates. De-glycosylation of the membrane mucus is facilitated by an 
enzymatic process involving neuraminidase A (NanA), neuraminidase B (NanB), 
beta- galactosidase A (BgaA), and beta-N-acetylglucosaminidase (Vestrheim et al.) 
(King et al., 2006a). The epithelial cilia beating may prevent the pneumococcus from 
binding by clearing it together with the mucus. The pneumococcus utilises 
pneumolysin (Ply), a pore-forming toxin to impair and decrease the beating of the 
ciliated cells on the mucosal epithelium, consequently allowing the pneumococcus to 
effectively bind to epithelial cells (Figure 1.8A) (Feldman et al., 2002, Feldman et 
al., 1990).  
 
Lysozyme is a muramidase enzyme, which targets and cleaves acetylated 
peptidoglycan molecules (Davis et al., 2008). The pneumococcus also has to 
overcome the action of lysozyme released by the host to effectively attach to 
epithelial cells. Peptidoglycan is a polymeric structure of sugars and amino acids 
present in the cell wall of the pneumococcus and several other microorganisms 
(Davis et al., 2008). The pneumococcus expresses two enzymes, peptidoglycan N-
glucosamine-deacetylase A (PdgA) and an O-acetyltransferase (Adr), which 
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deacetylates peptidoglycan molecules on the surface of the pneumococcus, 
conferring resistance to lysozyme destruction on the bacterial cell wall (Figure 1.8B) 
(Davis et al., 2008).  
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Figure 1.8 Pneumococcal attachment to host mucosal epithelium 
(A) Initiation of attachment: breakdown of the mucus lining the epithelium using 
NanA, BgaA, StrH and NanB enzymes.This is complemented by pneumolysin (Ply), 
which interferes with the cell ciliary beating, thereby promoting adherence to 
epithelium. (B) The host releases lysozyme, a proteolytic enzyme that degrades 
peptidoglycans of the pneumococcal cell wall and secretory IgA. The pneumococcus 
employs pdgA and Adr enzymes to inhibit lysozyme, and IgA protease to destroy 
secretory IgA (Mook-Kanamori et al., 2011). 
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1.5.2. The role of host immunity in pneumococcal pathogenesis 
Defence against pathogens in the respiratory tract relies upon the immune 
mechanism located in the airways and alveolar spaces (Asahi et al., 2002, Phalipon 
and Corthesy, 2003), which involves both innate and adaptive immunity (Jambo et 
al., 2010). The innate immune response to colonisation by S. pneumoniae employs 
factors such as C-reactive protein (CRP), an acute-phase protein that is elevated 
during inflammation (Du Clos and Mold, 2004, Gould and Weiser, 2002). CRP 
activates the complement system and also plays an important role in opsonisation 
and inhibition of bacterial attachment to epithelial cells (Gould and Weiser, 2002), 
thereby regulating pneumococcal colonisation to mucosal surfaces. The innate 
immune system also employs an acute inflammatory response by releasing 
neutrophils and macrophages (van Rossum et al., 2005), which aid the adaptive 
immune system to clear colonising bacteria from the mucosal surfaces (Martner et 
al., 2009). The adaptive immune response involves secretion of specific antibodies 
such as IgA and serum IgG, which are mainly produced by B cells (LeBien and 
Tedder, 2008). These antibodies mediate the clearance of pneumococcal strains 
colonising the nasopharynx (Joyce et al., 2009, Sun et al., 2004). A decrease in 
carriage rates from more than 50% in children to less than 10% in adults has been 
shown to correlate with increasing levels of both mucosal and serum antibodies to 
pneumococcal surface polysaccharides (Syrjanen et al., 2001, Zhang et al., 2004, 
Simell et al., 2002). The antibody response to pneumococcal proteins of carried 
strains was investigated in an experimental model of human colonisation in healthy 
adults in the USA (McCool et al., 2002). It was noted that all of the colonised 
subjects mounted a response to pneumococcal surface protein A (PspA) through 
secretion of serum IgG and secretory IgA, whereas subjects not colonised had pre-
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existing antibody to this protein (McCool et al., 2002). A similar study in the UK 
(Wright et al., 2012) showed elevated levels of antigen-specific IgG and IgA in nasal 
washes 6 weeks after pneumococcal carriage challenge compared to baseline. These 
immunoglobulins were targeted towards several proteins on the surface of the 
pneumococcus and not the polysaccharide capsule (Wright et al., 2012). For 
example, the challenge with 23F increased IgG response towards PspA in 
bronchoalveolar lavage (BAL). Thus pneumococcal challenge immunised mucosal 
surfaces through production of anti-protein immunoglobulin (Wright et al., 2012). 
Antibodies are also thought to play an important role in the clearance of colonisation 
because of decreased rates of carriage of vaccine serotypes in vaccinated groups 
(Dagan et al., 2002, Dagan et al., 1997). Findings from other studies, however, seem 
to suggest the hypothesis that natural immunity to colonisation can be acquired 
independently of anti-capsular antibodies (McCool and Weiser, 2004). This 
hypothesis was tested using mutant mice with an impaired response to 
polysaccharide antigens (McCool and Weiser, 2004). It was observed that colonising 
strains were cleared at the same rate as the wild type (parent) strain. It was further 
demonstrated that mice, which lacked mature B cells and failed to produce 
antibodies, were unaffected in the density or duration of colonisation (McCool and 
Weiser, 2004). This clearly suggested that antibodies were not required for clearance 
of pneumococcal colonisation at least in a murine model (McCool and Weiser, 
2004). It has also been shown that immunity to pneumococcal colonisation can be 
induced in the absence of antibody, however, the induced immunity requires the 
presence of CD4 T cells (Malley et al., 2005). The role of CD4 T cells was 
investigated in mice that were T cell-deficient, and those that were congenitally 
deficient or depleted of CD4 T cells at the time of the challenge. It was noted that 
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intranasal immunisation with whole-cell vaccine was completely abolished in these 
mice mutants (Malley et al., 2005). Another related study investigated the CD4 T cell 
proliferative response to pneumococcal virulence proteins in peripheral blood 
mononuclear cells (PBMCs) and adenoidal mononuclear cells (MNCs) taken from 
children (Zhang et al., 2007). It was noted that the proliferation of CD4 T cells after 
stimulation of PBMCs and MNCs with protein antigens was significantly lower in 
children who were culture positive for pneumococcus than in those who were culture 
negative, which suggested the role CD4 T cells play in modulating pneumococcal 
carriage in children (Zhang et al., 2007). An increase in CD4 T cell response has 
been reported to increase with age, which also correlates with a decrease in carriage 
(Cobey and Lipsitch, 2012) and pneumococcal disease, suggesting CD4 T cells play 
a role in controlling pneumococcal carriage and disease (Pido-Lopez et al., 2011, 
Malley et al., 2003). HIV infection is known to decrease the hosts CD4-cell levels 
(Le et al., 2013) and this might have an impact on pneumococcal carriage. Recently, 
an increase in pneumococcal colonisation with decrease in peripheral blood CD4 T-
cell counts and progression of HIV infection in adults (Glennie et al., 2012a) has 
been reported. Further, the HIV and related inflammation are known to impair the 
epithelial barrier function and integrity leading to chronic bacterial colonisation. 
TH17 cells have been shown to mediate acquired immunity to pneumococcal 
colonisation in mice, which would also be expected to occur in humans (Lu et al., 
2008), however, HIV infection impairs adaptive TH17 and memory T- and B-cell 
responses, which may fail to mediate the clearance of mucosal bacteria, or control 
bacterial multiplication following dissemination (Glennie et al., 2010). 
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1.5.3. Evading clearance by the host immune system 
The host immune system employs among others, secretory IgA (sIgA) (Davis et al., 
2008), lactoferrin (Shaper et al., 2004), and complement (Picard et al., 2003, Bogaert 
et al., 2010), to target the pneumococcus at the mucosal site. The sIgA prevents 
pneumococcal binding and promotes bacterial opsonisation, which enables 
phagocytosis by macrophages/monocytes and neutrophils (Finn et al., 2002). 
Naturally, the polysaccharide capsule of the pneumococcus acts as a physical barrier 
to opsonisation by sIgA (Fasching et al., 2007). The pneumococcus also releases 
IgA1 protease, which degrades the host‟s IgA (Weiser et al., 2003). 
 
Lactoferrin on the other hand binds to iron, which is necessary for bacterial 
metabolism (Raphael et al., 1989). This interferes with the viability of the 
pneumococcus in the nasal cavity, consequently preventing colonisation. Free 
lactoferrin (apolactoferrin) has also been reported to have direct bacterial killing 
properties (Shaper et al., 2004, Arnold et al., 1980), thought to occur through 
bacterial cell lysis (Senkovich et al., 2007). The pneumococcus survives the killing 
effect of apolactoferrin by expressing a choline binding pneumococcal surface 
protein A (PspA), which inhibits apolactoferrin by binding to its active site (Shaper 
et al., 2004).  
 
Complement plays an important role in the immune response against S. pneumoniae 
through bacterial opsonisation and phagocytosis (Bogaert et al., 2010, Mortensen and 
Duszkiewicz, 1977). To activate the complement pathway, the innate immune 
defence system utilises C-reactive protein, which binds to phosphorylcholine present 
on the pneumococcal cell surface (Gould and Weiser, 2001, Winkelstein and 
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Tomasz, 1977). To overcome complement dependent killing or clearance from the 
mucosal surfaces, the pneumococcus employs the polysaccharide capsule, which 
prevents complement deposition on pneumococcal cell surface (Hyams et al., 2010). 
Pneumococcal proteins such as pneumolysin (Ply) (Quin et al., 2007), pneumococcal 
surface protein C (PspC) (Dave et al., 2004a), PspA (Quin et al., 2007), and PhpA 
(Zhang et al., 2001) have also been shown to inhibit the deposition of complement on 
pneumococcal surface, consequently preventing complement mediated opsonisation 
and phagocytosis. 
 
1.5.4. Pneumococcal binding to host epithelial cells 
Once the host adherence barrier mechanisms are overcome, the pneumococcus 
makes some structural adjustments in readiness for binding to epithelial cells 
(Cundell et al., 1995b). Notably, the pneumococcal polysaccharide capsule 
undergoes phase variation from opaque (thick capsule) to transparent (thin capsule) 
phase, to expose binding sites on the cell wall surface (Cundell et al., 1995b, Weiser 
et al., 1994). An induction of phase variation is thought to occur during the approach 
of the pneumococcus to the epithelium. The pneumococcus binds to epithelial cell 
glycoconjugates such as N-acetyl-D-galactosamine (GalNac) (Figure 1.9A). The 
binding process is facilitated by the pneumococcal glycosidase Neuraminidase A 
(NanA), which increases the expression of binding sites on GalNac via sialic acid 
cleavage (King et al., 2004, Tong et al., 2001). 
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Figure 1.9 Pneumococcal binding to epithelial cells and internalisation 
 
The pneumococcus initially binds to N-acetyl-D-galactosamine (GalNac) (A) 
followed by attachment to epithelium cell receptors PAFr and PIgR with 
pneumococcal surface proteins ChoP and PspC respectively (B), which facilitates 
internalization by the cell receptors recycling pathway. The pneumococcus also 
crosses the mucosal epithelium into circulation using plasminogen, which degrades 
proteins (adherins) holding cells together. This creates an open gap between the cells 
for migration of the pneumococcus into circulation (C) (Mook-Kanamori et al., 
2011). 
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1.5.5. Pneumococcal translocation through epithelial cells into blood 
Following the attachment of the pneumococcus to epithelial cells by GalNac, 
translocation into circulation is initiated by the binding of the pneumococcus to the 
host platelet activating factor receptor (PAFr) (Cundell et al., 1995a) and polymeric 
immunoglobulin (Jordano et al.) using phosphorylcholine (ChoP) and pneumococcal 
surface protein C (PspC) respectively (Figure 1.9B) (Cundell et al., 1995a, Elm et al., 
2004). The pneumococcus is transported through the mucosal barrier into circulation 
by the recycling pathway of the PAF and pIgR receptors (Figure 1.9B). It has been 
reported that the ChoP-PAFr interaction is common among virulent strains of S. 
pneumoniae (Cundell et al., 1995a). The pneumococcus is also translocated into 
circulation using plasminogen (Pancholi et al., 2003), which is attached to the 
pneumococcal surface by enolase, Gly3Ph and CbpE (Figure 1.9C) (Attali et al., 
2008b). Plasminogen has been reported to degrade protein molecules such as 
adherins, which play an important role in holding epithelial cell junctions together 
(Attali et al., 2008a). Once the junctions are broken, the pneumococcus is allowed 
easy passage across epithelial cells into circulation, consequently causing invasive 
disease. 
 
1.6. Interventions for pneumococcal infections 
1.6.1. Antibiotics 
The most commonly used antibiotics in the fight against pneumococcal infections 
include β-lactam antibiotics such as penicillin and cephalosporins, macrolides, and 
trimethoprim-sulfamethoxazole (TMP-SMX). There is however increasing resistance 
in S. pneumoniae strains to these drugs worldwide (Adegbola et al., 2006, Marton et 
al., 1991, Spika et al., 1991, Karlowsky et al., 2003), including Malawi (Cornick et 
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al., 2011, Cornick et al., 2013, Everett et al., 2011). In general, resistance to 
antibiotics occurs through several biochemical mechanisms: mutations on the target 
protein/gene, drug inactivation through enzymatic activity, transfer of antibiotic 
resistance genes, or prevention of drug access to their targets (Nikaido, 2009). The 
mode of resistance in pneumococcus to β-lactam antibiotics is by alteration in the 
cell wall penicillin binding proteins (PBPs). PBPs play an important catalytic role in 
the synthesis of pneumococcal peptidoglycan. Beta-lactam antibiotics bind PBPs and 
reduce their ability to synthesise peptidoglycan, consequently affecting the integrity 
of the cell wall and viability (Zapun et al., 2008). Thus any alteration in PBPs of a 
given strain results in decreased affinity to β-lactam antibiotics. Point mutations in 
genes encoding PBPs have been implicated in development of pneumococcal 
resistance to β-lactam antibiotics (Reichmann et al., 1996, Hakenbeck et al., 1999, 
Laible et al., 1991). Macrolides function by inhibiting synthesis of bacterial proteins 
through binding to the 23S ribosomal RNA. Pneumococcal strains confer resistance 
to macrolides through modification of the target site mediated by erm genes 
(Edelstein, 2004) or efflux mechanism to remove the antibiotic from the cell by 
employing emf genes (Cochetti et al., 2005). TMP-SMX (co-trimoxazole) inhibits 
dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), which are 
involved in folic acid biosynthetic pathway, by presenting as false substrate 
inhibitors. Resistance to co-trimoxazole is developed when there are mutations 
occurring in genes encoding DHFR (folA) and DHPS (folP) enzymes, such as Ile-
100-Leu mutation, together with a residue 92 substitution of DHFR (Cornick et al., 
2013). Resistance to multiple antibiotics has also been observed. This is thought to 
occur by two possible mechanisms: (i) acquisition of an array of genes within a 
single bacterial cell, each of which confers resistance to a particular drug. Such 
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resistance genes are usually assembled in recombinant plasmids and/or transposons 
(Nikaido, 2009, Ding et al., 2009) and maintained within the bacterial cells within 
the host enabling their efficient transfers within the community; and (ii) increased 
expression of genes that code for multidrug efflux pumps, resulting in a wide range 
of drugs being pumped out of the cells (Nikaido, 2009). 
 
1.6.2. Vaccination 
Development of resistance to antibiotics globally, has adversely limited their usage 
in the control of pneumococcal infections, and this has made the need for vaccine 
usage even greater. The efficacy of pneumococcal vaccines is based on the 
production of opsonising antibodies, and currently, research has focused on the 
development of vaccines which can be effective in children and particular risk 
groups such as immune-compromised patients (Bogaert et al., 2004b).  
 
1.6.2.1. Polysaccharide based vaccines 
The first widely licensed vaccine to prevent pneumococcal infections was a 23-valent 
polysaccharide vaccine (PPV23) (WHO., 2008). PPV23 is composed of pure 
capsular polysaccharides from 23 invasive pneumococcal serotypes (1, 2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). 
These polysaccharides induce the production of anti-capsular immunoglobulin M 
(IgM) via a T-cell independent immunological response (Stein, 1992) (Figure 1.10). 
The response of B-cells is enhanced by the presence of cleavage products of 
complement factor 3 (C3), a ligand for complement receptor 2 (CR2) (Griffioen et 
al., 1991). This is more prominent in adults because young children do not 
effectively express CR2 (Griffioen et al., 1992). This may contribute to the poor 
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immunogenicity of PPV23 in children under 2 years of age (2008). PPV23 is a T-cell 
independent antigen and therefore fails to provide any significant protection against 
mucosal pneumococcal infections or against the spread of pneumococcal strains 
within the community (Eskola and Anttila, 1999). In Uganda, PPV23 was ineffective 
in HIV infected adults (French et al., 2000) and a very low efficacy was observed in 
HIV negative adults (French et al., 1998). In the United States, an alternative 
conjugate vaccine, the seven-valent pneumococcal conjugate vaccine (PCV7) was 
introduced into the routine infant immunisation programme in the United States in 
2000 (Hausdorff et al., 2000). PCV7 has now been subsequently replaced with higher 
valent conjugate vaccines such as PCV10 and PCV13 (Table 1.3), to cover serotypes 
that emerged to cause invasive.  
 
Table 1.3 Pneumococcal vaccine serotypes 
Vaccine Carrier 
Protein 
Serotypes Covered 
7-valent CRM197 4 6B 9V 14 18C 19F 23F       
10-Valent H. 
Influenzae 
proteinD, 
Tetanus 
and 
Diphtheria 
Toxoid 
4 6B 9V 14 18C 19F 23F 1 5 7F    
13-Valent CRM197 4 6B 9V 14 18C 19F 23F 1 5 7F 3 6A 19A 
 
A list of vaccine serotypes included in the 7-, 10- and 13-valent pneumococcal 
conjugate vaccines (adopted from (Isaacman et al., 2010)). 
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The pneumococcal conjugate vaccines are formulated by covalently attaching the 
capsular polysaccharide molecule to a non-toxic immunogenic peptide molecule. The 
polysaccharides in PCV13 for example are covalently bound to a common carrier 
protein, CRM
197
 (a nontoxic mutant diphtheria toxoid) (Esposito et al., 2010). The 
peptide-polysaccharide complex produced is presented in association with MHC II 
molecules to B-cells, thereby mounting a T-cell dependent immune response. The T-
cell mediated immune response has the advantage of producing memory B-cells and 
enhancement of mucosal immune responses through the production of secretory IgA 
and IgG (Lottenbach et al., 1999, Nurkka et al., 2001, Simell et al., 2012b). How 
polysaccharide and conjugate vaccine activate the immune system is summarised in 
the figure below (Figure 1.10) (Ada, 2001).With polysaccharide vaccination, the 
polysaccharide antigen is bound to the surface of a B-cell in lymphoid tissues. The 
immune response to polysaccharide antigens is characterised by the production of 
IgM antibodies (Figure 1.10A), isotype restriction and delayed development 
(Weintraub, 2003). Conjugate vaccines on the other hand can bind in two ways 
(Figure 1.10 B): (i) they bind to dendritic cells by presenting the protein moiety of 
the vaccine to type 2 helper T (Th2) cells; or (ii) they bind to B-cells which express 
surface IgM receptors specific for the carbohydrate component of the 
polysaccharide-protein conjugate vaccine. Once bound, endocytosis and processing 
by the B-cells occurs to produce peptides, which are expressed with class II MHC 
molecules on the surface of B-cells to form the MHC-peptide complex. The MHC-
peptide complex is bound by the activated Th2 cell and triggers the release of 
cytokines such as interleukin (IL)-4, IL-5 and IL-6, which cause the B-cell to 
undergo differentiation and express IgG molecules, which are specific for the 
polysaccharide component of the vaccine. These cells are reported to mature in 
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lymphoid follicles and cells expressing IgG antibodies become plasma cells (Ada, 
2001). 
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Figure 1.10 Antibody response to PPV (A) and PCV antigens (B) 
Covalent coupling of PPV antigen with a protein carrier changes the antigen to T 
cell-dependent (TD). The antigen-presenting cells take up the conjugated PCV 
molecule, internalize it via the membrane immunoglobulin and present the peptides 
of the protein to the T helper cells in association with the major histocompatibility 
complex Class II molecules on their surface. This induces the T helper cells to 
stimulate PS-specific B cells to mature either into antibody-producing plasma cells or 
into memory cells (Ada, 2001). 
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Unlike PPV23, vaccination with conjugate vaccines has been shown to reduce the 
rates of asymptomatic carriage of vaccine serotypes (Pletz et al., 2008), and also 
demonstrated clinical efficacy against IPD caused by vaccine serotypes (VT) in 
infants and young children (Black et al., 2000, Poehling et al., 2006), including 
immuno-compromised HIV-infected adults (French et al., 2010). The USA has seen 
a nearly 100% reduction of invasive disease caused by vaccine serotypes in children 
under the age of 5 years (Pilishvili et al., 2010). Conjugate vaccination has also been 
shown to prevent carriage of serotypes covered by the vaccine (Roca et al., 2011, 
O'Brien et al., 2007), which prevents the spread of such serotypes in a community 
thereby ensuring protection in the unvaccinated groups (herd immunity) (Isaacman et 
al., 2007, Hammitt et al., 2006). The potential limitation facing conjugate vaccines is 
serotype replacement in both disease and carriage (Miller et al., 2011). In the United 
States, a 140% increase in the rate of invasive pneumococcal disease from non-
vaccine serotypes has been reported in children less than 2 years old in the post 
PCV7 era (Singleton et al., 2007). Serotype replacement has also been reported in 
resource poor settings such as Gambia, where carriage of non-vaccine serotypes was 
high (76.9 %) in children who had received three doses of pneumococcal conjugate 
vaccine, compared with 42.5% in controls (Obaro et al., 1996). Similarly, in South 
Africa, in trials of a 9-valent vaccine, there was an increase in carriage of non-
vaccine serotypes from 21 % in controls to 39 % in vaccine recipients (Mbelle et al., 
1999). Conjugate vaccines with wider serotype coverage such as PCV10 and PCV13 
(Dagan, 2009) have taken into account serotypes such as 1, 5, 7F, 3, 6A and 19A 
(Table 1.3), known to cause invasive disease in the post PCV7 era (Isaacman et al., 
2010). In February 2010, the USA added PCV13 to its routine immunization 
program for infants and young children (Li et al., 2009). Worldwide, 96 countries 
40 
 
have incorporated PCVs into routine childhood immunisation programs and 51 
countries in the developing world plan to introduce PCV in the near future (VIMS, 
2013). Through the Global Alliance for Vaccines and Immunisation (GAVI) 
program, the Malawian government introduced PCV13 into the routine infant 
immunisation schedule in November, 2011 (Everett et al., 2012). The estimated 
coverage range of PCV13 in Malawian children was 70-90 % (Everett et al., 2012, 
Cornick et al., 2011). However, it is likely that PCV10 and PCV13 will face similar 
limitations of serotype replacement (Mulholland and Satzke, 2012) associated with 
previous capsular-based vaccines.  
 
1.6.2.2. Protein based vaccines 
To address the shortcomings by polysaccharide based vaccines, pneumococcal 
proteins are currently being explored as targets for development of effective 
pneumococcal vaccines (Ogunniyi et al., 2007a, Darrieux et al., 2013), with several 
protein candidates at various stages of clinical trials (Table 1.4) (Darrieux et al., 
2013). It is thought that vaccines based on invariable and conserved proteins will 
provide cheap, non-serotype dependent protection without compromising efficacy. 
Protein based vaccines are expected to be highly immunogenic because they are T-
cell-dependent antigens, and therefore likely to elicit immunological memory in 
children under the age of 2 years (Ogunniyi et al., 2007a). Previous studies reported 
that monoclonal antibodies against pneumococcal surface protein A (PspA) were 
able to protect mice from invasive pneumococcal disease, even when challenged 
with pneumococcal strains of more than one serotype (McDaniel et al., 1991). 
Although PspA is common to all pneumococcal strains, it is divided into three 
families based on nucleotide and amino acid identity, and each family is further 
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subdivided into different clades. Emerging data seem to suggest that PspA family 
and clade distribution are independent of serotype, age and clinical origin of the 
strains, but are strongly associated with genotype (Rolo et al., 2009). Thus while 
considering proteins as vaccine targets, it is important to pay attention to genetic 
variations that might exist within different pneumococcal proteins. These variations 
may arise from antigen diversity due to gene presence or absence, gene sequence 
variation (e.g. pspA gene) and differential expression. A novel surface protein, 
pneumococcal collagen like protein A (PclA) reported recently (Paterson et al., 2008) 
is a good example of how protein antigen diversity might affect the coverage of 
protein based vaccines. This protein has been shown to contribute to adherence and 
invasion of host cells by S. pneumoniaein vitro, but it demonstrated selective strain 
distribution (Paterson et al., 2008). The pclA gene is not present in all pneumococcal 
strains and this selective distribution was also observed in Malawian strains 
(Croucher et al., unpublished data). It has also been observed that although some 
virulent pneumococcal proteins elicit a significant level of protection in animal 
models, a large number of them remain uncharacterised, and to date, no single 
protein has been able to elicit protection comparable to that achieved by 
pneumococcal conjugate vaccines (Ogunniyi et al., 2007a). Thus exploring the 
possibility of protein antigens in combination with other proteins or with 
polysaccharides may provide more complete and effective coverage than is currently 
the case. A synergistic effect has been observed in animal models using 
combinations of PdB, PspA and PspC even in conditions where individual proteins 
offered little protection (Ogunniyi et al., 2007a).  
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Table 1.4 Pneumococcal protein vaccine targets 
A 
 
Candidate protein 
 
 
Function 
 
Immunological response 
PspA* 
(pneumococcal 
surface protein A) 
Inhibits complement activation (Mukerji et 
al., 2012, Ren et al., 2012) 
Inhibits killing by lactoferrin peptides (Mirza 
et al., 2011, Shaper et al., 2004) 
Induces antibodies that recognise surface of pneumococcal strains and 
promote opsonisation by C3 deposition (Ochs et al., 2008, Ren et al., 2012) 
NanA and NanB 
Neuraminidases  
 
Promotes colonisation (NanA) and survival 
in blood (NanB) (Manco et al., 2006) by 
cleaving terminal sialic acid residues from 
glycoconjugates (King et al., 2006b) 
Antibodies against NanA reduces risk of Otitis media (Long et al., 2004) 
PiuA and PiaA Components of the ABC transport system 
(Kadioglu et al., 2008) required for full 
virulence in animal models of pneumococcal 
infection (Brown et al., 2001a) 
Antibodies raised against these two proteins were protective against 
invasive disease by S. pneumoniae(Brown et al., 2001b) 
 
The proteins are listed in sub-tables A and B. *Proteins that have gone through phase I or II of clinical trials (Darrieux et al., 2013) 
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B 
 
 
Candidate protein 
 
 
Function 
 
Immunological response 
PspC 
Pneumococcal 
surface protein C 
Binds secretory IgA, prevents C3 deposition 
and mediates translocation to sterile sites 
such as blood (Dave et al., 2004b, Dave et 
al., 2004c) 
Antibodies raised against PspC protective against colonisation 
(Balachandran et al., 2002, Hernani Mde et al., 2011). Protection against 
systemic infection inconclusive (Ferreira et al., 2009, Ogunniyi et al., 2001) 
PsaA* 
Pneumococcal 
surface antigen A 
Plays a role in manganese transport 
(Dintilhac et al., 1997) resistance to oxidative 
stress (Tseng et al., 2002)and bacterial 
adhesion (Berry and Paton, 1996, McAllister 
et al., 2004) 
Antibodies raised against PsaA protective against carriage (Pimenta et al., 
2006, Miyaji et al., 2001, Oliveira et al., 2006), with minimal effect against 
systemic disease (Talkington et al., 1996, Gor et al., 2005) 
Ply 
Pneumolysin  
Cholesterol dependent pore forming 
cytolysin (Kadioglu et al., 2008) 
Ply recognition by TLR-4 activates innate immune response to 
pneumococcal infection(Malley et al., 2003) 
PcpA * 
Pneumococcal 
choline-binding 
protein A 
Possible role in bacterial adhesion 
(Seepersaud et al., 2005) and is expressed 
during invasive disease in lungs and blood 
and not nasal mucosa (Glover et al., 2008, 
Johnston et al., 2006) 
Antibodies against PcpA protective against invasive disease (Glover et al., 
2008) and colonisation (Khan and Pichichero, 2012) 
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C 
 
Candidate protein 
 
 
Function 
 
Immunological response 
PhT family 
(PhTA,PhTB, 
PhTC, PhTD*, 
PhTE) 
Inhibit complement deposition on the 
bacterial surface and to bind zinc(Ogunniyi 
et al., 2009, Rioux et al., 2011) 
PhT proteins were shown to confer protection in animal models of nasal 
and lung colonisation, lethal intranasal challenge and sepsis. PhTD was 
shown to be the most protective(Adamou et al., 2001, Godfroid et al., 
2011) 
Whole cell 
pneumococcal 
vaccine (WCV)* 
Shown to induce IL-17 mediated protection 
against intranasal challenge, induces 
antibody formation which is independent of 
CD4+ T cells(Lu et al., 2010) 
Protects against intranasal colonisation by multiple pneumococcal 
serotypes(Malley and Anderson, 2012) 
Ply 
Pneumolysin  
Cholesterol dependent pore forming 
cytolysin(Kadioglu et al., 2008) 
Ply recognition by TLR-4 activates innate immune response to 
pneumococcal infection(Malley et al., 2003) 
PcpA * 
Pneumococcal 
choline-binding 
protein A 
Possible role in bacterial adhesion 
(Seepersaud et al., 2005) and is expressed 
during invasive disease in lungs and blood 
and not nasal mucosa (Glover et al., 2008, 
Johnston et al., 2006) 
Antibodies against PcpA protective against invasive disease (Glover et al., 
2008) and colonisation (Khan and Pichichero, 2012) 
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1.7. Methods for characterising S. pneumoniae in carriage 
1.7.1. Phenotypic methods 
The World Health Organisation established a working group on pneumococcal 
carriage to formulate standard methods for assessing pneumococcal serotypes for 
purposes of PCV vaccine efficacy studies (O'Brien and Nohynek, 2003). The initial 
step in pneumococcal characterisation involves positively identifying the 
pneumococcal strains from carriage based on their sensitivity to Optochin (Bowers 
and Jeffries, 1955) (Figure 1.11). For strains that are optochin resistant, a further bile 
solubility test is conducted (Murray, 1979); where a positive identification is by the 
solubility of the isolate; whereas insolubility or aggregation shows the presence of 
nontypeablepneumococcal strains, acapsular pneumococcal strains or non-
pneumococcal strains. The positively identified pneumococcal strains are then 
further analysed to identify the serotypes present (Satzke et al., 2014).  
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Figure 1.11 Pneumococcal detection method in carriage 
The bold line shows the normal route of characterising optochin sensitive colonies to 
serotype pneumococcal strains. Optochin resistant colonies are characterised by bile 
solubility testing. Bile soluble colonies indicate presence of pneumococcal strains 
and these are further characterised by serotyping (dashed arrow line) (Satzke et al., 
2014). 
 
Quellung reaction. Quellung reaction is the current gold standard for serotyping 
pneumococcal strains as recommended by the WHO pneumococcal carriage working 
group (Satzke et al., 2014). Quellung involves the capsular reaction test 
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(Quellung/Neufed test) with antisera against the 95 known pneumococcal 
polysaccharide capsules (O'Brien and Nohynek, 2003, Satzke et al., 2014). A 
positive result for Quellung reaction involves binding between the capsular 
polysaccharide of pneumococcal strains and the type specific antibody present in the 
typing sera. This binding causes a change in the refractive index of the capsule so 
that it appears swollen, and more visible under a light microscope 
(http://www.cdc.gov). Serotyping by Quellung initially starts with pooled antisera in 
succession until a positive result is seen. To determine sero-group and serotype, 
testing with individual group and serotype-specific antisera included in the pooled 
antisera is subsequently performed. The sensitivity of the Quellung reaction has been 
validated in several laboratories across Europe (Konradsen, 2005). Although 
Quellung serotyping is preferred in laboratories with qualified personnel and enough 
resources, it is still a costly method to perform, is time consuming and requires high 
level of experience to perform satisfactorily (Satzke et al., 2014, Slotved et al., 2004, 
Morais et al., 2007).  
 
Latex agglutination. The WHO pneumococcal carriage-working group has also 
recommended usage of latex agglutination for characterising pneumococcal strains. 
Latex agglutination uses anti-rabbit IgG-coated latex particles sensitized to pooled 
and selected individual serotype-specific antisera (http://www.cdc.gov). Latex 
agglutination is known for its sensitivity and specificity (Satzke et al., 2014). 
Compared with Quellung, the latex agglutination method is less expensive, easier to 
use and does not require a microscope (Gella et al., 1991, Satzke et al., 2014, Slotved 
et al., 2004). The disadvantage of latex agglutination is that it is prone to cross-
reactions, which result in non-specific binding, consequently giving rise to false 
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positive results (Ingram et al., 1979). Latex agglutination methods, including the 
Quellung reaction have been shown to underestimate the prevalence of multiple 
carriage (Turner et al., 2011). In addition, these methods cannot always differentiate 
Streptococcus mitis, Streptococcus oralis, or nontypeable pneumococcal strains from 
typeable pneumococcal strains (Arbique et al., 2004b, McEllistrem, 2009). 
 
1.7.2. Genotypic methods 
Current genotypic methods are based on the knowledge of the pneumococcal 
genome. The sequenced genome of S. pneumoniae consists of a single circular 
chromosome of approximately 2 million base pairs, a G+C content of 40 % and more 
than 2000 open reading frames (ORFs) (Croucher et al., 2009, Tettelin et al., 2001). 
The serotype of a given pneumococcal strain is determined by its polysaccharide 
capsule. The region on S. pneumoniae genome, responsible for the synthesis of 
capsular polysaccharides (CPS locus) has been well characterised. The CPS locus is 
located between dexB and aliA genes (Figure 1.12) and the total size of the 
alternative coding DNA at this locus is approximately 1.8Mbp (Bentley et al., 2006).  
 
 
 
Figure 1.12 A representative CPS locus for serotype 23F 
Capsule biosynthesis genes are shown between dexB and aliA genes (Aanensen et al., 
2007). 
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The capsular polysaccharides (CPSs) are synthesised by two pathways namely: the 
Wzx/Wzy-dependent pathway and the synthase pathway. The CPS genes of 93 
pneumococcal serotypes are synthesised by the Wzx/Wzy pathway, while serotypes 
3 and 37 utilise the synthase pathway, encoded by wchE and tts genes respectively 
(Arrecubieta et al., 1994, Bentley et al., 2006, Llull et al., 1999). The genes encoding 
enzymes for the Wzx/Wzy and synthase pathways are located at the same 
chromosomal location between dexB and aliA genes, except tts gene for serotype 37, 
which is located elsewhere on the pneumococcal chromosome (Llull et al., 1999). 
The CPS biosynthetic genes are known to be orientated in the same direction as the 
dexB and aliA genes (Bentley et al., 2006). The four genes (wzg, wzh, wzd, wze) at 
the 5‟ end of the CPS locus are involved in initiation and modulation, and they are 
conserved with high sequence identity in all strains (Bentley et al., 2006). The fifth 
gene, wchA, encodes the initial glucose phosphate transferase (WchA) in most 
CPSclusters. WchA is responsible for the linkage of glucose phosphate to a 
membrane – associated lipid carrier, initiating the repeat unit biosynthesis (Aanensen 
et al., 2007, Bentley et al., 2006). Among the genes always present downstream are 
the flippase (wzx) and polymerase (wzy) genes, which play a role in transporting the 
repeat unit across the cytoplasmic membrane and linking individual repeat units to 
form lipid-linked CPS (Bentley et al., 2006). Unlike the four genes upstream, there 
are multiple highly divergent or nonhomologous groups of genes such as wzx and 
wzy, which might contribute to the observed variations in the polysaccharide capsule 
structure in various pneumococcal serotypes (Mavroidi et al., 2007). 
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1.7.2.1. PCR based methods 
PCR based methods have widely been used to identify pneumococcal serotypes in 
clinical samples. These methods include Multiplex PCR (Pai et al., 2006, Brito et al., 
2003), Real-time PCR (Pimenta et al., 2013) and single PCR with sequencing (Leung 
et al., 2012). PCR serotyping is dependent on the knowledge of the CPS locus gene 
sequences (Bentley et al., 2006) in order to identify serotypes in a given sample. The 
basis of classification is the presence of genes, which are serogroup/serotype 
specific. The advantage of PCR methods is that they are highly sensitive, easy to use, 
and have the ability to detect non-viable organisms (Satzke et al., 2014). PCR 
techniques are also widely used in resource poor settings (Morais et al., 2007). 
Despite these advantages, PCR methods are not able to discriminate closely related 
serotypes, which are often detected as a group (Morais et al., 2007). In particular, 
there is risk of amplicon contamination for Multiplex PCR (Satzke et al., 2014).  
 
1.7.2.2. Microarray based methods 
Microarrays were developed following the availability of microbial whole genome 
sequences (Doolittle, 2002). Microarrays allow for the simultaneous analysis of 
every gene in the genome, either at the DNA or mRNA level (Ye et al., 2001). 
Microarrays are constructed by depositing probes such as nucleic acids, proteins, 
carbohydrates, and antibodies on a solid surface such as glass. There are two types of 
commonly used DNA microarrays namely: PCR product - based DNA microarray 
and oligonucleotide-based DNA microarrays. PCR product-based microarrays are 
prepared by spotting the PCR amplicons onto a glass microscope slide. Although 
PCR based microarrays offer advantages such as ease of production and relative low 
cost, they are prone to cross-hybridisation between genes that are very similar (Wren 
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et al., 2002), which makes it difficult to detect genetic insertions, inversions, 
duplications or indeed point mutations (Dorrell et al., 2002). Unlike PCR arrays, 
oligonucleotide – based DNA arrays are generated by identifying areas of specificity 
within any gene sequence as targets for hybridisation. Knowledge of the sequence of 
the target DNA is required for synthesising complementary oligonucleotides. The 
advantages of oligonucleotide over PCR based microarrays include a reduction in 
cross-hybridisation and an increase in distinguishing homologous genes (Dorrell et 
al., 2002). To determine the presence of target genes, nucleic acid samples are 
labelled, either chemically or by an enzymatic reaction and then hybridized onto the 
array (Figure 1.13). Unbound and non-specifically bound samples are removed by 
washing using different stringency buffers. The remaining signal resulting from 
specific interactions between probes and target nucleic acids is measured. Only 
probes that hybridize to a labelled complementary target will yield a signal, thereby 
ascertaining the presence of the gene of interest in the sample (Huyghe et al., 2009). 
52 
 
Sample A B 
DNA/RNA 
DNA/RNA transformation 
 and labelling 
Labelled nucleic  
acids mixed 
Hybridisation onto microarray 
 and scanning  
Data analysis 
DNA/RNA 
 
 
Figure 1.13 Microarray workflow 
(http://grf.lshtm.ac.uk/microarrayoverview.htm) 
 
Microarray technology has found wide applications in microbiology such as 
detection of differential gene expression, gene regulation as well as comparative 
genomics (Behr et al., 1999; Richmond et al., 1999; de Saizieu et al., 2000). 
However, the limitation of microarray analyses is that they are restricted to the genes 
present in the reference strain(s) on the microarray, which renders rapid 
identification of acquired DNA in outbreak strains difficult. This thesis describes 
studies using oligonucleotide microarray to characterise serotypes in carriage and 
also estimate the prevalence of multiple carriage in Malawian adults and children. 
Unlike Quellung or latex agglutination, microarray has the enhanced utility to detect 
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not only carriage of multiple strains of S. pneumoniae and their relative abundance 
but also detect the presence of antibiotic resistance genes, novel serotypes and other 
colonising microbial species in the nasopharynx (Newton et al., 2011, Turner et al., 
2011). Microarray also offers the advantage of analysing large number of samples 
within a short period of time and can be optimised to detect non-viable organisms 
(Satzke et al., 2014).  
 
1.7.2.2.1. S. pneumoniae capsular polysaccharide (SP-CPS) microarray 
The SP-CPS microarray is a novel molecular based serotyping technique developed 
by the bacterial microarray group at St George‟s (B G@S) in London. It was 
designed based on the availability of DNA sequences for all the genes responsible 
for the synthesis of the capsular polysaccharide (CPS), which determines serotypes. 
The BμG@S SP-CPSmicroarray (http://www.bugs.sgul.ac.uk) contained several 
thousands of 60mer oligonucleotides probes, with 10 oligonucleotide probes per 
gene (Figure 1.14).  
Oligonucleotide probes 
cps gene (+ve strand) 
cps gene (-ve strand) 
 
Figure 1.14 The CPSgene target regions of the 60-mer oligonucleotides 
There are 10 oligonucleotides per CPS gene and these are spread along the length of 
the target CPS gene on both negative and positive strands and are randomly printed 
on the array. The use of multiple oligonucleotides per CPS gene plays an important 
role in minimising false positives due to cross hybridisation. 
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The long 60mer, in situ synthesised oligonucleotides DNA microarrays are known 
for their high sensitivity. They are also very tolerant of sequence mismatches and are 
thus suitable for the analysis of regions, which are highly polymorphic (Fenart et al., 
2013). These probes detect a number of different entities (Hinds et al., 2009): (a) 
homology group identification (HGID) probes (Chapter 2, section 2.6.4.1) for 
determining serotype by the presence of capsular polysaccharide locus genes, with 
10 oligonucleotide reporters per gene. There are 432 CPS genes known to date, 
however a particular serotype can only contain a subset of these genes (Newton et 
al., 2011); (b) serotype identification (STID) (Chapter 2, section 2.6.4.1) 
oligonucleotides designed to discriminate serotypes with identical HGID; (c) 
pathogen identification (PathID) probes (Chapter 2, section 2.6.4.1) for identifying 
bacterial species other than S. pneumoniae, that are commonly found in 
asymptomatic carriage; (d) antibiotic resistance (AbR) reporters (Chapter 2, section 
2.6.4.1.1) for detecting the presence of antibiotic resistance genetic markers. The 
array used in this study was only designed to detect 10 antibiotic resistance genetic 
markers such as aphA3 (kanamycin resistance) (Werner et al., 2001), 
chloramphenicol acetyltransferase (cat) gene (chloramphenicol resistance), 
erythromycin methylase (ermB/C) genes (erythromycin resistance), macrolide efflux 
(mefA) gene (macrolide resistance) (Arpin et al., 1999, Ardanuy et al., 2005), 
streptothricin acetyltransferase (sat4) gene(streptothricin resistance) (Werner et al., 
2001), and tetK/L/M/O genes as markers for tetracyclines and macrolides resistance 
(Marimon et al., 2006). Apart from detecting serotypes, the BμG@S SP-CPS 
microarray also offers enhanced utility for novel serotype discovery; nontypeable 
(NT) strains investigation, detection of multiple serotype carriage (Chapter 2, section 
2.6.4.3) and performing comparative genomic hybridisation (arrayCGH) using 
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spTIGR4+R6 genome backbone (Hinds et al., 2009). The sensitivity of the 
fluorescent detection enables serotypes in the order of 1% relative abundance to be 
detected in multiple carriage samples. The discovery of novel serotypes is achieved 
by detecting HG profiles that do not match the CPSgene content of any of the 
currently known reference strain serotypes (Hinds et al., 2009). 
 
1.8. The human microbiota 
The pneumococcus colonise the nasopharynx with a wide range of other microbiota, 
and interact constantly (Bosch et al., 2013). Such interactions have potential 
implications for microbial virulence through the exchange of genetic material and the 
aetiology of polymicrobial infections (Rodrigues et al., 2013b, Hiller et al., 2010). 
But the nasopharynx only contains a small part of the entire human microbiota, 
which will be briefly described here. From birth, the human body consists of only 
eukaryotic human cells. However, during the first years of life, the human skin 
surface (Kong et al., 2012), oral cavity (Takeshita et al., 2012), and gut (Yatsunenko 
et al., 2012) are colonised by a wide variety of microbial species such as bacteria, 
archaea, fungi, and viruses. Together, these microbial species constitute what is 
known as the human microbiome or microbiota (Consortium., 2012). The human 
microbiota contains ten times as many cells as the rest of the human body and orders 
of magnitude more genes than the human genome (Consortium., 2012, Qin et al., 
2010, Whitman et al., 1998). The microbial species colonizing the human body are 
normally commensal and play beneficial roles such as food digestion as well as 
maintenance of the human immune system. However, their influence in human 
health and disease is still not fully understood (Huang and Lynch, 2011, Huang et al., 
2011, Kong et al., 2012, Marchesi et al., 2011). Recent studies suggest an association 
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between disease and carriage of certain microbial species. In the USA a shift in the 
composition of rectal mucosal microbiota was associated with HIV infection. In this 
study, genera such as Roseburia, Coprococcus, Ruminococcus, Eubacterium, 
Alistipes and Lachnospira were depleted in HIV-infected subjects, followed by a 
simultaneous and significant enrichment of Fusobacteria, Anaerococcus, 
Peptostreptococcus and Porphyromonas. This change was also accompanied by a 
change in biochemical functions such as amino acid metabolism and vitamin 
biosynthesis, which differed significantly between HIV positive and HIV negative 
controls (McHardy et al., 2013). A shift in nasopharyngeal microbiota during acute 
otitis media characterised by a decrease in commensal bacteria such as 
Staphylococcaceae, Flavobacteriaceae, Carnobacteriaceae and Comamonadaceae, 
has also been reported in children in Switzerland (Hilty et al., 2012). Recently in the 
USA, a study showed a significant shift in the nature of gut microbiome during 
progressive HIV infection (Vujkovic-Cvijin et al., 2013). The authors reported an 
imbalance in the gut microbial community, which was characterised by a low 
representation of beneficial bacteroidia bacteria, and enrichment of proteobacteria in 
HIV-infected subjects. There was also an increase in bacteria responsible for 
catabolizing tryptophan through the kynurenine pathway, which correlated with 
kynurenine levels in HIV-infected subjects (Vujkovic-Cvijin et al., 2013). In Malawi, 
changes in the gut microbiome in children were implicated as a possible causal factor 
in kwashiorkor (Smith et al., 2013). These findings suggest that knowledge of the 
human microbiota and any deviation from the normal microbiota can potentially be 
used as an early detection biomarker for various disease conditions and as a target for 
therapeutic intervention (Morgan and Huttenhower, 2012). 
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1.8.1. Nasopharyngeal microbiota and upper respiratory tract infections 
The bulk of microorganisms in the nasopharynx are commensals while a few may be 
pathogenic because they have been shown to cause disease. Comparing the microbial 
profile between subjects with a particular illness and healthy controls has revealed 
the potential role these pathogens play in disease (Hilty et al., 2012). A study in 
children in the Netherlands showed that the nasopharyngeal microbial profile was 
seasonal and different between samples collected from children in fall/winter and 
spring. It was further reported that Infections caused by these nasopharyngeal 
microbiota occurred primarily in fall and winter, however, it is not clear whether this 
was associated with the corresponding changes in the profile of nasopharyngeal 
microbiota (Bogaert et al., 2011). These studies however, were performed on HIV 
negative subjects. The data on the impact of HIV infection on human microbiome are 
limited particularly those relating to the nasopharynx. As previously described 
(Section 1.8), studies focusing on other parts of the body have shown a difference in 
the microbial communities between HIV positive and HIV negative subjects. It is 
clear from these findings that microbial patterns change during disease conditions, 
however it is not known how the nasopharyngeal microbial communities change 
during HIV infection, highlighting the need for further investigation particularly in 
settings with high HIV disease burden such as Malawi. 
 
1.9. Microbial interaction in the nasopharynx 
1.9.1. Bacterial-bacterial interaction in the nasopharynx 
The interactions among bacterial species occupying the same niche have been well 
documented. These interactions could lead to coexistence (positive association) of 
several species in the same environment or suppression (negative association) of one 
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microbial species by another (Pettigrew et al., 2008), and have a major influence on 
which bacterial species persist in the nasopharynx (Jacoby et al., 2007, Pettigrew et 
al., 2008). To understand the mode of bacterial interactions in the nasopharynx, 
several mechanisms have been proposed. Coexistence for example is thought to 
occur through the release of components such as outer membrane vesicles containing 
proteins that may function to inactivate complement factor C3, thereby enabling 
another species to escape the immune system. M. catarrhalis has been shown to 
protect H. influenzae from complement-mediated killing through the release of 
protective outer membrane vesicles (Tan et al., 2007). Bacteria are also known to 
associate positively by growing and persisting in microbial communities known as 
biofilms, which is a universal attribute of bacteria (Lopez et al., 2010). Biofilms are 
dense aggregates of bacterial cells embedded in a self-produced extracellular matrix 
composed of polysaccharides, DNA and proteins which act as adhesins (Cvitkovitch 
et al., 2003, Lopez et al., 2010). Biofilm formation is important for bacterial survival 
as it enables bacteria to evade the host immune system (Domenech et al., 2013). 
Clinically, biofilm formation has been implicated in various infections such as 
urinary tract infections, chronic otitis media, and chronic tonsillitis (Hatt and Rather, 
2008, Post et al., 2004, Hall-Stoodley et al., 2004) and may confer on the bacteria 
involved the ability to resist antibiotics resulting in infections that may not be easily 
treated (Ito et al., 2009, Mah and O'Toole, 2001). A recent study has also shown that 
biofilm formation plays an important role in genetic recombination by providing an 
enabling environment for species genetic transfer to occur (Marks et al., 2012). 
 
Suppression on the other hand is characterised by the release of substances such as 
hydrogen peroxide (H2O2) by one species that are toxic to competing species. S. 
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pneumoniae is known to produce very high levels of H2O2, which kill S. aureus 
(Regev-Yochay et al., 2006) and H. influenzae (Pericone et al., 2000). S. pneumoniae 
is also reported to express neuraminidase enzyme, which cleaves sialic acids on the 
surface of H. influenzae, limiting its ability to colonise the mucosal surfaces 
(Shakhnovich et al., 2002). Bacterial species such as S. pneumoniae and H. 
influenzae express phosphorylcholine required for bacterial adherence to host 
mucosal surfaces. Pre-exposure to either one of the two species enhances the 
production of antibodies against phosphorylcholine, resulting in the elimination of 
other competing species (Tanaka et al., 2007, Goldenberg et al., 2004). It has also 
been shown in vitro, that phosphorylcholine is required for the survival of S. 
pneumoniae and not H. influenzae. To escape the host immune system, H. influenzae 
may switch off the expression of phosphorylcholine, which gives it a better chance of 
survival than S. pneumoniae (Goldenberg et al., 2004, Weiser et al., 1997). The 
interaction of microbial species with the host‟s immune system also plays a central 
role in the interspecies competition (Lysenko et al., 2005) and must be taken into 
account. For example, an epidemiological study in children found a significant 
negative association between S. pneumoniae and S. aureus among HIV negative 
carriers. This association was not observed in the HIV positives (Madhi et al., 
2007b). 
 
1.9.2. Bacterial and viral interaction in the nasopharynx 
Bacteria are also in constant contact with other microorganisms present in the 
nasopharynx such as viruses. The nature of the interaction between bacteria and 
viruses has been well documented. One example of viral-bacterial interaction 
involves the positive association between influenza virus and S. pneumoniae, where 
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the virus has been shown to promote pneumococcal transmission and disease in 
mouse models (Diavatopoulos et al., 2010, McCullers, 2006). The presence of 
viruses in the nasopharynx is thought to enhance bacterial colonisation and 
subsequent translocation into circulation via several possible mechanisms including: 
(i) disruption of the epithelial barrier (Glennie et al., 2010) (ii) up-regulation of 
adhesion proteins (Ganz, 2003) (iii) production of viral factors such neuraminidases 
which aid in exposing bacterial receptors on mucosal surfaces (McCullers and 
Bartmess, 2003), and (iv) impairment of the host immune system components 
(Kukavica-Ibrulj et al., 2009, McNamee and Harmsen, 2006). Mice infected with 
influenza virus showed increased susceptibility to pneumococcal infection associated 
with impairment of neutrophil function and enhancement of cytokine production 
(McNamee and Harmsen, 2006). A similar study in mice, using human 
metapneumovirus (hMPV) also predisposed virus-infected mice to severe 
pneumococcal infection, which was accompanied by increased levels of 
inflammatory cytokines and chemokines (Kukavica-Ibrulj et al., 2009). Excessive 
production of cytokines can lead to local inflammation and tissue damage, which 
could be a factor for increased susceptibility to secondary bacterial infections. Such 
excessive production of pro-inflammatory cytokines is also experienced during HIV 
infection and is responsible for damaging the mucosal epithelial barrier, leading to 
persistent bacterial colonisation and disease (Glennie et al., 2010). A recent study, in 
humans, highlighted the importance of taking age into account when interpreting the 
interaction between bacteria, and bacteria and viruses in carriage (Rodrigues et al., 
2013a). The study demonstrated a significant age-independent association between 
viral infection in the upper respiratory tract and detection of S. pneumoniae and 
between viral infection and viral load and S. pneumoniae colonisation density. 
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However the study was not able to demonstrate any association in carriage between 
the three bacteria understudy: S. pneumoniae, H. influenzae, and S. aureus 
(Rodrigues et al., 2013a). The summary of microbial species interactions in the 
nasopharynx of a healthy carrier is shown below (Figure 1.15).  
 
S. pneumoniae H. influenzae 
S. aureus M. catarrhalis 
hMPV 
hRV 
RSV 
IV 
PIV 
AdV 
CoV 
 
 
Figure 1.15 Model of bacterial and viral interaction in the nasopharynx 
The proposed model is based on results from carriage experiments conducted on 
mouse models and in-vitro studies. It depicts the cumulative dynamics of bacterial 
and viral interactions during asymptomatic nasopharyngeal carriage as reported in all 
cumulative literature sources. The interactions shown involve four common 
nasopharyngeal bacteria: Streptococcus pneumoniae, Haemophilus influenzae, 
Staphylococcus aureus, Moraxella catarrhalis and seven common respiratory 
viruses: rhinoviruses (hRV), respiratory syncytial virus (RSV), adenoviruses (AdV), 
coronavirus (CoV), influenza viruses (IV), para-influenza viruses (PIV), and human 
metapneumovirus (hMPV). The green lines represent a negative association 
(competition), while black lines represent a positive association (synergism). For 
black dotted lines, evidence of associations is only available from in vitro and/or 
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animal studies. The model shows that viruses and bacteria were engaged in positive 
association only, perhaps the reason for the observed synergism during bacterial and 
viral co-infection. Bacterial-bacterial interactions on the other hand involved both 
positive and negative association (Bosch et al., 2013). 
 
1.10. Impact of vaccination and antimicrobial drugs on microbiota 
Therapeutic and vaccine interventions can alter the microbial interactions in the 
nasopharynx. Several studies have reported competitive associations between S. 
pneumoniae and S. aureus (Xu et al., 2012), raising fears that the introduction of 
PCV7 might increase carriage of S. aureus and disease post-vaccination (Madhi et 
al., 2007b). This has not been the case and on the contrary, PCV7 has been 
associated with an increase in nontypeable H. influenzae in acute otitis media 
aetiology (Dunne et al., 2013), suggesting H. influenzae might become a more 
common cause of AOM in children exposed to pneumococcal conjugate vaccination 
(Xu et al., 2012). In contrast, a 10-year prospective study conducted in children 
predicted that PCV usage could result in less otitis media by H. influenzae given the 
demonstrated association with chronicity arising froma mixture of S. pneumoniae 
and Nontypeable H. influenzae (Dagan et al., 2013). It is evident from the above 
findings that there is a shift in microbial dynamics in carriage under vaccine 
selection pressure, and it is anticipated that PCV13 could result in a similar change in 
carriage dynamics. Currently, data on the total microbial profiles in the nasopharynx 
and how that varies with conditions such as HIV infection are limited, and no such 
data exist for Malawi. 
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1.11. Detection of the human microbiota by 16S rRNA gene analysis 
Conventionally, culture-dependent techniques have for long been employed to 
identify microbial species in different environments. These techniques limited the 
range of organisms to be detected to only those that would actively grow in a 
laboratory culture and made distinguishing the individual components of a 
microbiota challenging. Thus a large proportion of uncultured or low abundance 
microorganisms remained unknown. To overcome this limitation, molecular and 
culture-independent techniques have been employed (Olsen et al., 1986). These 
techniques analyse the DNA/RNA extracted directly from the samples to allow 
investigation of several aspects of microbial communities such as number of 
microbial species present in a given community (taxonomic diversity) as well as 
describing the biological functions which each member of a given community 
performs (functional metagenomics) (Morgan and Huttenhower, 2012). The 
commonly used target for determining microbial diversity is the 16S ribosomal RNA 
(16SrRNA) gene, which is universal in all bacteria (Chakravorty et al., 2007). The 
use of 16S rRNA gene for bacterial classification has found widespread application 
in clinical practice (Clarridge, 2004) as well as scientific investigations (Petti et al., 
2005). The 16S rRNA gene sequence is about 1.5 kbp long and contains both the 
conserved and hypervariable regions (Figure 1.16) (Drancourt et al., 2000).  
 
C1 V1 V2 C2 V3 C3 V4 C4 V5 C5 V6 V7 C6 V8 C7 V9 C8 C9 
1.5 Kbp  
Figure 1.16 Conserved and hypervariable regions of the 16S rRNA gene 
Conserved regions (C1-C9) are shown in grey while variable regions (V1-V9) appear 
in different colours (Petrosino et al., 2009). 
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There are nine hypervariable regions (V1-V9) reported and these show considerable 
sequence diversity among different bacterial species (Chakravorty et al., 2007). The 
diversity of the 16SrRNA sequences forms the basis for differentiation between 
organisms at the genus or indeed species and subspecies level (Drancourt et al., 
2000). Although this diversity is good for identification, there is no single 
hypervariable region that is able to distinguish among all bacteria (Chakravorty et al., 
2007).  
 
1.11.1.   Identification of microbiota by 454 sequencing of 16S rRNA gene 
Sequencing of nucleic acid involves elucidation of the exact order of nucleotides 
present in a given DNA or RNA molecule. Large scale sequencing has traditionally 
been dependent on the automated sanger sequencing method developed by Fred 
Sanger almost 3 decades ago where sequencing was performed using chain 
terminating inhibitors (Sanger et al., 1977). The Sanger sequencing method, regarded 
as the first-generation sequencing, was central to the landmark human genome 
project. However the human genome project was very costly ($3 billion) and took 13 
years to complete in 2003 (Grada and Weinbrecht, 2013). This triggered a shift 
towards sequencing technologies that would provide low cost and accurate genomic 
data within a day (Metzker, 2010). Thus the next generation sequencing (NGS) 
technologies were developed and these offer the advantage of providing a cheaper 
and higher-throughput alternative to sequencing than the traditional Sanger method 
(Metzker, 2010). Several NGS platforms have been developed and these include 
Roche/GS FLX Titanium, Illumina/Solexas GAII, Life Technologies/Ion Torrent 
Personal Genome machine (PGM), Helicose Biosciences and Pacific Biosciences. 
Each of these platforms performs sequencing differently, however, they share some 
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generalized procedures such as template preparation, sequencing and imaging, and 
data analysis (Metzker, 2010). Template preparation involves two different methods: 
clonally amplified templates from single DNA molecules, and single DNA molecule 
templates. Clonally amplified templates are PCR dependent and the reaction may be 
conducted either in a liquid medium (emulsion PCR) (Dressman et al., 2003) or 
solid-phase (Fedurco et al., 2006). Single DNA molecule templates are immobilized 
on the solid support either by the template itself or by the polymerase enzyme, 
however PCR amplification is not required (Metzker, 2010). For the determination of 
microbial species using 16SrRNA genes, 454 pyro-sequencing is commonly used 
(Lee et al., 2013b, Quince et al., 2009). The GS-20 sequencer, with read lengths of 
~100bp, was the first commercially available next generation sequencer released in 
2005 (Margulies et al., 2005). With the current Genome Sequencer FLX system with 
long-read GS FLX titanium chemistry, read lengths of 400-600bp are possible 
(Rothberg and Leamon, 2008). The 454 sequencing is based on sequencing by 
synthesis technology of clonally amplified templates. This technology utilises an 
enzymatic system consisting of DNA polymerase, ATP sulfurylase, and luciferase. 
The incorporation of each nucleotide by DNA polymerase is accompanied by the 
release of inorganic pyrophosphate (PPi). The free PPi acts as a substrate for ATP 
sulfurylase and luciferase enzymes in a coupled reaction, which results in the 
production of light (Nyren, 1987) (Figure 1.17). The amount of light produced is 
proportional to the number of nucleotides incorporated. 
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Figure 1.17 The principle of sequencing-by-synthesis 
The template DNA strand to be sequenced is represented in red, the annealed primer 
is shown in green and the DNA polymerase is shown as the green oval. The 
incorporation of a complementary base (the green “G”) generates inorganic 
pyrophosphate (PPi), which is converted to ATP by the sulfurylase (blue arrow). 
Luciferase (red arrow) uses the ATP to convert luciferin to oxyluciferin, which is 
detected as light (Rothberg and Leamon, 2008). 
 
The 454 sequencing machinery consists of an assembly containing (a) 
deoxynucleotide triphosphates (dNTPs) and (b) a flow cell that includes a fiber-optic 
slide containing wells. The wells are contained on the PicoTiterPlate and are loaded 
with capture beads containing amplified PCR strands plus numerous small beads 
with enzymes. Fitted with a liquid system, the 454 machinery is able to sequentially 
wash the PicoTiterPlate with dNTPs and other necessary reagents. Finally (c), an 
imaging assembly fitted with CCD camera to image the fiber-optic slide, and allows 
the capture of emitted light from the bottom of each individual well, and a computer 
for instrument control operations and visualisation (Figure 1.18) (Rothberg and 
Leamon, 2008). 
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Figure 1.18 The 454 sequencing machine assembly 
The assembly consists of (a) a set of bottles containing the four dNTPs, (b) a flow 
cell that includes a fiber-optic slide containing wells and (c), an imaging assembly 
fitted with CCD camera to image the fiber- optic slide, and a computer for 
instrument control operations and visualisation (Figure 1.18) (Rothberg and Leamon, 
2008, Margulies et al., 2005). 
 
The 454 sequencing occurs in three major steps namely DNA library preparation, 
Emulsion PCR amplification and Sequencing. During library preparation, the 
isolated genomic DNA is fragmented (Figure 1.19A), ligated to adapters, which are 
color coded green and red (Figure 1.19B) and then separated into single strands 
(Figure 1.19C). The adapters are essential for purification, amplification and 
sequencing.  
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Figure 1.19 DNA library preparation 
The fragments containing both A and B (A/B) adapters are selected using avidin-
biotin purification and used in the PCR amplification step (Rothberg and Leamon, 
2008). 
 
The single stranded DNA fragments are bound to their own unique beads and then 
compartmentalized in the droplets of a PCR-reaction-mixture-in-oil emulsion (Figure 
1.20, A and B). PCR amplification occurs within each droplet, resulting in each bead 
carrying multiple copies of a unique DNA template (Figure 1.20 C). Once 
amplification is complete, the oil emulsion is broken and the DNA strands on the 
beads are denatured (Figure 1.20 D). 
 
 
 
Figure 1.20 Emulsion PCR amplification of single stranded DNA 
(Rothberg and Leamon, 2008). 
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Each bead carrying clonally PCR-amplified DNA fragments is deposited into a 
unique well on the fiber-optic-slide together with smaller beads carrying 
immobilized enzymes required for a solid phase pyrophosphate sequencing reaction 
(Figure 1.21) 
 
 
 
Figure 1.21 454 Sequencing of amplified single stranded immobilised DNA 
A single bead containing clonally amplified DNA is deposited per well. On average, 
each well has a diameter of 44um. About 400, 000 reads are obtained in parallel 
(Rothberg and Leamon, 2008). 
 
1.11.2.   Bioinformatic tools for analysing 16S sequences 
Pyrosequencing of PCR amplicons has led to an in-depth understanding of 
environmental microbial diversity (Bates et al., 2011, Lee et al., 2013b) and the 
human microbiome (Bogaert et al., 2011, Consortium., 2012). This is due to high 
read depth where multiples of individual sequence reads are generated 
simultaneously, which provides a tool for estimating the composition and relative 
abundance of microbial operational taxonomic units (OTUs) in a given community. 
However, due to the large number of sequence reads generated and the lack of 
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consensus reference sequences, distinguishing false from true sequence diversity has 
proven difficult. Thus data generated through 16S amplicon pyrosequencing has the 
potential for overestimating species abundances due to artificial sequences arising 
from PCR single base substitutions, PCR chimeras and sequencing errors (Quince et 
al., 2011). Chimeras are hybrid products between multiple parent sequences that are 
generated when incomplete extension occurs during the PCR process and the 
resulting fragment effectively acts as the primer in the next round of PCR (Figure 
1.22) (Quince et al., 2011). 
 
Aborted extension 
Mis-priming 
Extension 
Chimera 
 
 
Figure 1.22 PCR generated chimeric sequences 
Formation of chimeric sequences during PCR amplification of 16S rRNA gene. An 
aborted extension product from an earlier cycle of PCR can function as a primer in a 
subsequent PCR cycle. If this aborted extension product anneals to and primes DNA 
synthesis from an improper template, a chimeric molecule is formed (Haas et al., 
2011). 
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To minimise the impact of sequencing errors on the interpretation of microbial 
diversity, several computational approaches have been developed: (i) removing 
sequence reads with sequencing errors such as ambiguous base calls and mismatches 
to primer sequences (Huse et al., 2010, Quince et al., 2011); (ii) trimming regions of 
the sequence with low quality scores (Chou and Holmes, 2001); (iii) flowgram-based 
clustering, where information obtained by clustering pyrosequencing flowgrams is 
incorporated into the pipeline for removing error reads (Quince et al., 2011, Quince 
et al., 2009, Reeder and Knight, 2010). These approaches however have had very 
limited application because of their requirement for very high computational 
capabilities (Schloss et al., 2011). To minimise the impact of PCR-induced sequence 
artefacts on microbial diversity, several approaches have been developed to identify 
and remove chimeras from the analysis. Three common approaches are known. The 
first approach, ChimeraSlayer (Haas et al., 2011), involves searching the ends of a 
query sequence (30% of the length from each end) against a database of reference 
chimera-free 16S sequence to identify potential parents of a chimera. The second 
approach is Perseus (Quince et al., 2011) which does not use a reference database, 
however it requires a training set of sequences similar to the sequences being 
characterised. Perseus compares query sequences with all pairs of sequences having 
higher abundance is made based on the assumption that a chimera undergoes fewer 
rounds of amplification than its parents. The closest pair is thus selected, and its 
three-way alignment with the query sequence is made. Perseus is performed after 
AmpliconNoise, an algorithm that accounts for sequencing errors and PCR single 
base substitutions. The third approach, Uchime (Edgar et al., 2011) combines 
principles of both ChimeraSlayer and Perseus by either using a database of chimera-
free sequences or detecting chimeras de novo by using sequence abundance data 
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respectively. Recently, an open-source Mothur software, a 16SrRNA data analysis 
tool was developed (Schloss et al., 2009). Mothur is a single software command-line 
computer program that is built upon other pre-existing tools for analysing sequence 
data from microbial communities. Basically, Mothur is used to trim, screen, and 
align sequences; distance matrix-based sequence clustering, assign representative 
sequence reads to operational taxonomic units (OTUs); and to provide an estimation 
of within- ( -diversity) and between- ( -diversity) sample diversity (Schloss et al., 
2009).  
 
1.12. Aims of the study 
1.12.1.  Main objectives 
The primary objective of this study was to investigate nasopharyngeal carriage of 
Streptococcus pneumoniae in Malawian children and adults, prior to the introduction 
of the 13-valent pneumococcal conjugate vaccine (PCV13). S. pneumoniae interacts 
with a wide range of other microorganisms colonising the nasopharynx, which 
impacts on pneumococcal virulence and carriage dynamics. Therefore, this study 
also characterised carriage of nasopharyngeal microbiota in Malawian children and 
adults from matching samples. Recent microarray serotyping and 454 
pyrosequencing technologies were employed to identify S. pneumoniae and other 
microbiota in carriage respectively.  
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1.12.2.  Specific objective 
This study focused on three specific objectives: 
 
1. To characterise the general profile of pneumococcal serotypes in carriage in 
Malawian children and adults. 
 
2. To assess the prevalence of simultaneous carriage of multiple serotypes 
(multiple carriage) in Malawian children and adults. 
 
3. To characterise carriage and composition of nasopharyngeal microbiota in 
Malawian children and adults. 
 
1.13. Significance of the study 
Carriage of S. pneumoniae is considered the first step in the development of invasive 
pneumococcal disease and is also responsible for the spread of the pathogen in a 
given population. Several carriage studies that have been conducted have provided 
information that has helped in formulating disease control strategies. Most 
importantly, carriage studies have been used to estimate the impact of vaccination 
before and after vaccine introduction. Recent reports suggest carriage data can be 
used to (i) aid in licensing and implementation of new vaccines (Goldblatt et al., 
2013) and (ii) accurately estimate post-PCV changes in IPD incidence (Weinberger 
et al., 2013), particularly in settings with poor surveillance system for evaluating 
impact of vaccination. Therefore, the importance of undertaking carriage studies 
cannot be overemphasised. In Malawi, pneumococcal carriage studies are inadequate 
and until now, there has been no report on the prevalence of multiple carriage in this 
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setting. In addition, this is the first time in Malawi that carriage of nasopharyngeal 
microbiota has been characterised. Findings from this study will fill this gap in 
knowledge in the Malawian setting, and provide baseline information that will aid in 
(i) estimating vaccine efficacy and (ii) predicting potential vaccine-induced changes 
in carriage dynamics post-vaccination, which is important in the assessment of the 
effectiveness of clinical interventions for Malawi. 
 
1.14. Structure of the thesis 
Chapter 2 of this thesis outlines methodologies used in this study ranging from 
sample collection through culturing to characterisation of S. pneumoniae by 
microarray and nasopharyngeal microbiome by 454 pyrosequencing. Chapter 3 
outlines the result for the general pneumococcal carriage profile and the prevalence 
of multiple carriage in Malawian children and adults. The dynamics of 
pneumococcal carriage and genetic diversity overtime is presented in Chapter 4. 
Chapter 5 characterises capsular polysaccharide locus variants of S. pneumoniae 
detected in carriage in Malawi and provides preliminary findings on whether the 
variants have an altered ability to colonise and cause death in mouse models. Chapter 
6 describes the nasopharyngeal microbiota in Malawian children and adults. The last 
chapter (Chapter 7) provides a general discussion of the findings from this study, 
outlines major limitations and also provides suggestions for future work to be 
performed in order to address some of the questions arising from this study. 
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Chapter 2: Materials and methods 
 
2.0 Background 
This study was conducted in Malawi (Figure 2.1), a resource poor setting with a high 
burden of HIV infection (Lau and Muula, 2004) and invasive pneumococcal disease 
(IPD) (Gordon et al., 2000). The study was part of an on-going project at the 
Malawi-Liverpool-Wellcome Trust (MLW) Clinical Research Programme 
(http://www.mlw.medcol.mw) in Blantyre, Southern Malawi, investigating the 
pathogenesis, transmission and prevention of bacterial and viral infections in 
Malawi. 
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Figure 2.1 Map of Malawi 
Map of Malawi showing sampling sites in Karonga (KPS) in the Northern region and 
Blantyre (MLW) in the Southern region (http://www.nsomalawi.mw) located 411 
miles apart (http://www.worldcities.us). The red circles on the map identify the 
sampling sites. 
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The MLW offers routine diagnostic testing services to support the Queen Elizabeth 
Central Hospital (QECH) and has an archive of over 5000 pneumococcal strains 
isolated from carriage and invasive pneumococcal disease since 1996. QECH is a 
government funded central hospital with 1250 bed space, provides medical care to a 
population of over 1 million people and has an annual admission rate of 50,000 
people (Everett et al., 2011). The study was also linked to Karonga Prevention Study 
(KPS), a controlled randomised study (CRS) investigating asymptomatic carriage 
and transmission of S. pneumoniae in households in Karonga, Northern Malawi. The 
underlying laboratory work was conducted in four research centers: MLW; the 
Wellcome Trust Sanger Institute (WTSI) (http://www.sanger.ac.uk), Hinxton, 
Cambridgeshire, UK; the Institute of Infection and Global Health (IGH) 
(http://www.liv.ac.uk/infection-and-global-health), University of Liverpool, 
Liverpool, UK and the Bacterial Microarray Group at St Georges Hospital (B G@S) 
(http://www.bugs.sgul.ac.uk), London, United Kingdom (UK) (Figure 2.2). 
78 
 
!
Genome sequencing 
UK, Cambridge, (WTSI) 
Testing pneumococcal 
colonization/invasive potential 
in mouse models 
UK, Liverpool, (IGH) 
Malawi 
Sample collection 
Plate culturing 
DNA extraction 
Quellung serotyping 
Microarray serotyping 
UK, London, (BmG@S) 
 
Figure 2.2 Institutions involved in the study 
 
2.1. Sample selection in children 
Samples from children were conveniently selected from a dataset collected over a 
period of 5 years from 2008. Only samples with a pneumococcal culture positive 
result were picked for this study because the aim was characterise the prevalence of 
multiple carriage among carriers of S. pneumoniae. These samples were accessed 
from the archives in Karonga and Blantyre (Figure 2.3). The Karonga and Blantyre 
sites are 411 miles apart, and this distance provided the opportunity to better 
understand the diversity of pneumococcal carriage in different geographical locations 
within Malawi, although this may be confounded by differences in age as well as 
HIV status. The two variables of key importance in the selection of samples were 
carriage of S. pneumoniae and HIV status of the child. One hundred and sixteen S. 
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pneumoniae culture positive samples were selected (Figure 2.3). Based on resource 
and time constraints, this sample size was adequate for characterising carriage of 
pneumococcal strains and other microbiota in Malawian children. The HIV negative 
children represented 62% (72/116) of the total number of children in the dataset, 
while 38% (44/116) was covered by HIV positive children. More HIV positive 
children were sampled in order to increase the number of pneumococcal carriers to 
address the question of how HIV infection affected carriage. This resulted in a much 
higher HIV prevalence compared to the reported average 10.6% for Malawi 
(UNAIDS, 2012a). Children under the age of five years represented 84% (97/116) of 
the total number of children in the dataset, and 16% (19/116) were 5 years and older. 
Sampling was not based on gender; however the gender distribution was similar with 
males representing 58% (68/116) and females 42% (48/116) of the entire children‟s 
dataset. None of the children had received the 13-valent pneumococcal conjugate 
vaccination now included into Malawi‟s expanded program on immunisation (EPI). 
 
Karonga. Nasopharyngeal swabs were collected from a subset of infants (n=16) 
containing a total of 158 participating infants. Samples were collected at six weeks of 
age and then every four weeks for 12 months. This study analysed samples from any 
four subsequent sampling points, previously shown to be positive for S. pneumoniae 
in each infant. Fourteen infants had their HIV status confirmed while the status of the 
remaining two infants could not be established. For analyses investigating the impact 
of HIV infection, the two samples with unknown HIV status were not included. 
These two samples were only included in the analysis of pneumococcal carriage 
dynamics (Chapter 4), where HIV status was not of key importance. Initial 
processing of samples to identify pneumococcal growth was done in Karonga using 
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conventional techniques of culture on sheep blood agar and gentamicin (SBG) and 
subsequent demonstration of optochin sensitivity amongst alpha haemolytic 
streptococcal species. Following selection of samples, nasopharyngeal swab tips in 
STGG, were then shipped (at -20 C) to Blantyre for further evaluation. Each of the 
infants contributed samples from four consecutive sampling points, confirmed to 
contain S. pneumoniae by Quellung reaction (Section 1.7.1), giving a total of 64 
nasopharyngeal swabs. The longitudinal samples were analysed to provide an insight 
into and to improve understanding of carriage dynamics in children over time 
(Chapter 4).  
 
Blantyre. Samples (n=102) were collected from children reporting to QECH as 
outpatients. These were recruited in two different clinical studies conducted at 
MLW. The first study (H1N1) conducted an in-depth hospital-based on-going 
influenza surveillance study since late 2010, designed to determine the severity and 
hospital case fatality due to seasonal influenza and H1N1 influenza virus. The H1N1 
study recruited both adults and children presenting to the QECH with influenza-like 
illnesses (ILI‟s) and severe acute respiratory infections (SARI‟s). For the purposes of 
this study, only children under the age of 5 years presenting with ILI‟s and not 
SARI‟s were included. SARI‟s were excluded to avoid carriage estimation bias 
because of the known synergism between influenza infection and pneumococcal 
colonisation (Diavatopoulos et al., 2010). All the ILIs sampled were negative for 
influenza. From a total of 154 children with ILI‟s, 49% (76/154) were under the age 
of five years and these were then screened for the presence of S. pneumoniae. A 
positive pneumococcal culture was detected in 72% (55/76) of the total samples 
screened. Two samples did not grow on subsequent culturing and therefore only 53 
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were available for further analysis. A further 49 samples were drawn from a second 
study, which investigated the B Cellular Immunological (BCIM) responses to 
pneumococcal infections by HIV status and usage of antiretroviral therapy (ART). 
BCIM samples comprised of both longitudinal (n=16) and cross-sectional (n=33) 
sets. Longitudinal BCIM samples were collected from asymptomatic HIV positive 
children, at two sampling points: pre-ART and 12 months post-ART. BCIM samples 
provided an opportunity for understanding changes in pneumococcal carriage 
dynamics amongst HIV infected subjects following ART mediated immune 
reconstitution.  
 
Children 
(n=116) 
Karonga 
(n=14) 
Blantyre 
(n=102) 
Longitudinal 
(n=14) 
Cross-sectional 
(n=86) 
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HIV (-) 
(n=13) 
HIV (+) 
(n=1) 
HIV (-) 
(n=59) 
HIV (+) 
(n=27) 
HIV (+) ART (-) 
(n=16) 
HIV (+) ART (+) 
(n=16) 
 
 
Figure 2.3 Sample selection in children 
All samples were collected from children (n=116) using nasopharyngeal swabs. Four 
swabs were taken from each participant in a longitudinal study. The total number of 
nasopharyngeal swabs analysed was 200. 
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2.2. Sample selection in adults 
Adult samples (Figure 2.4) were collected from a larger cross-sectional study in 
Blantyre, investigating the impact of 7-valent pneumococcal conjugate vaccine (PCV 
7) and ART on invasive pneumococcal disease in Malawian adults. Samples were 
collected from adults reporting to QECH as outpatients from 2006 to 2008. All 
samples (n=117) that were culture positive for S. pneumoniae were selected. These 
samples were grouped into HIV negative (n=26) and HIV positive (n=91). The high 
number of HIV positive subjects could possibly highlight the higher rates of 
pneumococcal carriage in HIV positive compared to HIV negative individuals 
(Jordano et al., 2004). 
 
Adults 
(n=117) 
HIV (-) 
(n=26) 
HIV (+) 
(n=91) 
PCV (-) 
(n=16) 
PCV (+) 
(n=4) 
PCV null  
(n=6) 
PCV (-) 
(n=18) 
PCV (+) 
(n=18) 
PCV null 
(n=55) 
 
 
 
Figure 2.4 Sample selection in adults 
All samples were collected from adults (n=117) recruited in a cross-sectional data set 
using nasopharyngeal swabs. The subjects on vaccine were subjected to the 7-valent 
pneumococcal conjugate vaccine (PCV7). Subjects with no available information on 
PCV7 usage were designated PCV null. 
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2.3. Collection of nasopharyngeal samples 
Nasopharyngeal (NP) samples were collected by trained nurses following the WHO 
protocol for the detection of the pneumococcus in carriage (O'Brien and Nohynek, 
2003). Briefly, the subjects‟ head was gently tilted back with the chin kept steady 
(Figure 2.5). A sterile Dacron-tipped nasopharyngeal swab (Medical Wire and 
Equipment, Corsham, United Kingdom) was inserted into the nasopharynx, rotated at 
180 C and then slowly removed after saturating the tip by leaving it in place for 5s. 
Using sterilised scissors, the NP swab tips were aseptically cut off into a labelled 
2.0ml vial containing 1.0ml of skim milk, tryptone, glucose, and glycerine (STGG) 
medium (Gibson and Khoury, 1986), and then stored at -80 C
 
 until required. The 
recovery of pneumococcal strains stored under these conditions is comparable to the 
recovery from direct plating (O'Brien et al., 2001). 
 
!
Nasopharyngeal 
swab 
Head tilted 
 
Figure 2.5 Nasopharyngeal specimen collection 
(http://www.stanfordlab.com)  
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2.4. Culturing of S. pneumoniae 
Nasopharyngeal swabs kept at -80 C and stored in STGG were briefly thawed to ~4 
C and immediately pre-screened for the presence of S. pneumoniae by culturing an 
aliquot (20μl) on SBG. The SBG was prepared following the MLW Standard 
Operating Procedures (Appendix 1(a) and 1(b)). Positive identification of S. 
pneumoniae was by colony morphology and sensitivity to optochin (Oxoid Limited, 
Basingstoke, Hampshire, UK) by disk diffusion (Figure 2.6). Optochin disks are 
made of a water insoluble and sterilized filter paper base (8mm in diameter), 
impregnated with a water-soluble ethylhydrocupreine hydrochloride as an active 
chemical component (Bowers and Jeffries, 1955). Optochin sensitivity differentiates 
S. pneumoniae from other -hemolytic Streptococcus species such as Streptococcus 
viridans, which are optochin-resistant (Bowers and Jeffries, 1955). A confirmatory 
bile (sodium deoxylate) solubility test is often performed to distinguish S. 
pneumoniae from other alpha-hemolytic Streptococcus species that are sensitive to 
optochin (Arbique et al., 2004a). STGG samples containing S. pneumoniae were re-
cultured in a series dilution for subsequent analysis. A series dilution was performed 
to obtain a culture with non-overlapping growth of colonies, to ensure a less 
competitive environment for growth of less abundant serotypes. Briefly, cryotubes 
containing samples in STGG media were vortexed for 10-20 seconds. A series 
dilution (1, 1/10, and 1/100) of STGG suspension was prepared in brain heart 
infusion (BHI) broth (Oxoid, UK). The suspension (50μl) was pipetted onto a 
selective colistin oxolinic acid blood agar (Oxoid, UK) plate and spread evenly. The 
plates were incubated overnight at 37
o
C supplemented with 5% carbon dioxide. An 
enhanced carbon dioxide environment is critical for the isolation of S. pneumoniae, 
because it leads to the production of large mucoid pneumococcal colonies, which can 
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easily be identified (Howden, 1976, Austrian and Collins, 1966). The dilution with 
adequate non-overlapping growth of colonies was taken for further processing. 
 
  B A 
 
 
Figure 2.6 Plate culturing of S. pneumoniae 
S. pneumoniae is cultured on selective gentamicin blood agar or COBA media. An 
inhibition zone of ≥15mm (Gardam and Miller, 1998) around an optochin disk (A) is 
a positive identification of S. pneumoniae, while resistance to optochin, shown by 
lack of an inhibition zone (B) signifies presence of an organism other than S. 
pneumoniae. 
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2.5. DNA extraction 
Culture dependent DNA extraction for microarray serotyping. Sterile phosphate 
buffered saline (PBS) (Sigma-Aldrich, Germany) (1ml) was added to the culture 
plate. Using a spreader, a suspension of all colonies was made by scraping the whole 
plate. The resulting suspension was transferred to a 1.5ml micro-centrifuge tube 
(Eppendorf, Hamburg, Germany) using a 1ml pipette (Starlab, UK). The tubes were 
subjected to centrifugation at 7500rpm for 10minutes to pellet the bacteria. DNA was 
extracted from the bacteria pellet using QIAamp DNA mini kit (Qiagen, Germany) 
based on the manufacturer‟s protocol as follows: the bacterial pellet was re-
suspended in lysozyme 180μl solution (20mg/ml, in buffer containing 20mM Tris-
HCl, pH 8, 2mM EDTA, 1.2% Triton) and incubated for 60minutes at 37 C. EDTA 
(ethylenediamine tetra-acetic acid) is a chelating agent that binds to metallic cofactor 
ions required by DNA degrading enzymes. This inhibits the enzymatic activity of 
these enzymes ensuring high DNA yields. Triton is an anionic detergent that 
denatures cell membrane proteins and disrupts bacterial cells for easy DNA 
extraction. Proteinase K (20μl) and Buffer AL (200μl) were added to the suspension, 
vortexed and then incubated at 56 C for 60minutes. RNase A (100mg/ml, 4μl) was 
added and incubated for 2 minutes at room temperature, followed by a further 
addition of Buffer AL (200μl) and incubation at 70 C for 10 minutes. Proteinase K 
and RNase A are necessary for digesting proteins and RNA, which usually 
contaminate DNA preparations. Absolute ethanol (200μl) was added to the solution 
and mixed by manually turning the micro-centrifuge up and down a few times, to 
ensure adequate precipitation of the DNA. The ethanol solution was added to the 
spin column followed by centrifugation at 8000rpm for 1 minute. The column was 
washed with buffer AW1 (500ul) and centrifuged at 8000rpm for 1 minute followed 
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by a second wash with buffer AW2 (500μl) and centrifuged at 13,000rpm for 
3minutes.The flow through was discarded and the column was placed in a new tube 
after each wash. Residual ethanol was removed by performing a further 
centrifugation at 13,000 rpm for 1 minute. The column was placed in a clean 1.5ml 
tube. Molecular biology grade water (200μl) was added onto the column membrane 
and allowed to stand for 1 minute at room temperature, to ensure the DNA was fully 
solubilised. The DNA was eluted from the column by centrifugation at 13,000 rpm 
for 1 minute. The DNA was quantitated by NanoDrop (ND 1000, Labtech, UK) and 
then stored at 4 C. 
 
Culture dependent DNA extraction for whole genome sequencing. Colonies with 
different morphologies were picked from the plate. Each colony was inoculated into 
brain heart infusion (BHI) broth (9ml) and then incubated overnight at 37 C in 5% 
carbon dioxide. The cells were harvested by centrifugation at 5000g for 5.0 minutes. 
Genomic DNA was extracted using QIAamp DNA mini kit as before. To determine 
the pneumococcal serotypes, the DNA was subjected to PCR amplification using 
CDC multiplex PCR primers (Pai et al., 2006) (Appendix 7 (a)) as follows: 95 C for 
15 mins, followed by 35 cycles of 94 C for 30 secs, 54
 
C for 90 secs, 72
 
C for 60 
secs, followed by 72
 
C for 10 min and then a 4
 
C hold. The PCR amplicons were 
analysed on a Bioanalyser (2100, Agilent Technologies, USA). The PCR step was 
only conducted for pneumococcal serotypes isolated from samples with multiple 
carriage. The DNA for PCR confirmed serotypes were stored at 4 C until further 
analysis by whole genome sequencing. 
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2.6. Molecular serotyping of S. pneumoniae by microarray 
This study used the Streptococcus pneumoniae capsular polysaccharide (SP-CPS) 
microarray assay (Chapter 1, section 1.7.2.2.1), which was developed by the 
bacterial microarray group at St George‟s (B G@S) in London, to detect the 
serotypes in carriage. The BμG@S SP-CPS microarray also offers enhanced utility 
for novel serotype discovery; nontypeable (NT) strains investigation, detection of 
multiple serotype carriage and performing comparative genomic hybridisation 
(arrayCGH) using spTIGR4+ R6 genome backbone (Hinds et al., 2009). The limit of 
detection for the BμG@S SP-CPS microarray is 1% in samples carrying multiple 
serotypes (Hinds et al., 2009). 
 
2.6.1. DNA Labelling 
The Kreatech Universal Linkage System (Kreatech ULS) is a non-enzymatic 
labelling technique consisting of a square planar platinum complex stabilised by a 
chelating diamine, a detectable molecule (marker) such as enzyme or fluorochrome, 
and a leaving group (X) such as chloride or nitrate ion (Figure 2.7A). The leaving 
group is displaced during binding to the N7 position of guanine moieties in nucleic 
acids, to form a co-ordinate bond (Figure 2.7B) (van Gijlswijk et al., 2001, Wiegant 
et al., 1999). 
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Figure 2.7 ULS square planar platinum complex 
The complex is stabilised by a chelating diamine (A) and it binds to the N7 position 
of guanine moieties in nucleic acids, to form a co-ordinate bond (B). (van Gijlswijk 
et al., 2001). 
 
In this study, the purified DNA was heat fragmented by incubating at 95 C in a 
thermocycler (Eppendorf, Germany) for 30 minutes, with a final temperature cycle 
of 4 C for 3 minutes. The DNA was labelled with ULS containing cyanine green 
(ULS-Cy3) and red (ULS-Cy5) fluorescent, maintaining a ratio of 1 l ULS dye per 
1ug DNA in every ULS-Cy3 or ULS-Cy5 labelling. The DNA was incubated at 85 
C for 30 minutes in a thermocycler with a final holding step at 4 C for 3 minutes. 
The labelled DNA was purified using KREApure column to remove non-reacted 
ULS-Cy, which increase background noise if not removed before the hybridisation 
step. 
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2.6.2. Sample preparation, loading and hybridisation 
The purified Cy3/Cy5 labelled DNA (18 l) was mixed with Agilent blocking agent 
(10x, 4.5 l) and Agilent hybridisation buffer (2x, 22.5 l) in a 0.5ml tube. The 
mixture was incubated at 95 C for 5 minutes followed by 37 C for 30 minutes. The 
hybridisation assembly (http://www.agilent.com) was prepared based on 
manufacturers‟ protocol as follows: A clean gasket slide (8x15K) was placed in a 
hybridisation chamber base with the gasket label facing up, and properly aligned 
with the rectangular section of the chamber base. The hybridisation solution (40 l) 
was slowly dispensed onto each of the eight gasket wells in a “drag and dispense” 
manner (Figure 2.8). 
 
Chamber cover 
Bridge 
Thumb screw 
Chamber base 
Gasket 
Sample loading 
 
 
Figure 2.8 Microarray hybridisation assembly 
 
The microarray slide was placed array side down onto the gasket slide, to form an 
array-gasket sandwich. A chamber cover was placed on top of the array slide, and 
gently clamped with the bridge to firmly hold the assembly together. The assembled 
chamber was vertically rotated to assess the mobility of the bubbles. Stationary 
bubbles were moved by gently tapping the assembly on a hard surface. The 
hybridisation chamber (Figure 2.9) was placed in a rotator rack in the hybridisation 
oven (set to 65 C) and rotated overnight at 20rpm.  
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Figure 2.9 Hybridisation chamber 
 
2.6.3. Slide washing and scanning 
The array-gasket sandwich was removed from the hybrid chamber base and quickly 
transferred to a trough containing Oligo aCGH buffer 1 at room temperature. The 
array–gasket sandwich was opened whilst submerged in wash buffer 1.The array 
slide was then transferred to the rack in second trough of wash buffer 1 and stirred 
for 5 minutes. The final wash was performed by transferring the array slide rack to 
trough containing wash buffer 2 at 37 C and stirred for 1 minute. The slide rack was 
gently removed from wash buffer 2 to minimise droplets on the slides. The slide with 
Agilent barcode facing up was placed in a slide holder and then scanned 
immediately. The developed microarray slide was scanned using High-Resolution 
Microarray Scanner (Agilent Technologies, USA). The raw microarray image files 
were automatically read and processed using Agilent‟s feature extraction software 
(version 10.7) (http://www.genomics.agilent.com). 
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2.6.4. Serotype identification 
The output from microarray scanner was analysed by a previously described 
empirical Bayesian model (Newton et al., 2011), which determines serotypes present 
in a given sample by calculating the probabilities of different serotype combinations. 
The relative abundance of each serotype in a sample with multiple serotypes was 
determined using a Bayesian random effects model (Newton et al., 2011) based on 
different fluorescence intensities. The microarray serotype data was analysed using 
Microsoft excel and Stata®11.0 (appendices 2(a) and 2(b)). Following is an 
illustration of the output from microarray, for single and multiple carriage episodes 
involving serotypes 3 and 14. 
 
2.6.4.1. Single carriage identification of the serotype 3 
To establish the pathogen present in a sample, microarray utilises PathID probes. In 
sample 11787, the fluorescence intensity for the pneumococcus was over 10000 
fluorescence units (Figures 2.11) while all the other pathogens were observed at the 
zero-baseline. This suggested that only S. pneumoniae was present in all colonies 
obtained from the culture plate. The pneumococcal serotype in the sample was 
determined using STID probes, which detect the serotype specific genes present at 
the CPS locus. The CPS gene locus products are classified into 249 homology groups 
(HGs) based on amino acid sequence similarity and predicted function (Bentley et 
al., 2006, Aanensen et al., 2007). The CPS locus for wild type pneumococcal 
serotype 3 consists of eight genes and is about 10, 337bp long (Figure 2.10) (Bentley 
et al., 2006). In sample 17787, detection of homology group presence (HGID) 
showed eight HGs (Figure 2.12): 0.01 [wzg], 1.02 [wzh], 2.02 [wzd], 3.02 [wze], 
20.07 [ugd], 196.01 [wchE], 197.01 [galU], and 198.01 [pgm], representing eight 
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CPS genes for serotype 3 (Figure 2.10). The presence of serotype3 in the sample was 
further confirmed by STID analysis. The intensities of all possible serotypes were at 
the zero-baseline, however, the elevated signal intensities for serotype 3 (>30000 
fluorescence units) and nontypeable serotype NT2 (~10000 fluorescence units) were 
observed (Figure 2.13). The presence of NT2 signal intensity could be attributed to 
cross-hybridisation because no additional HGs were detected by HGID to suggest the 
presence of NT2, a further confirmation of single serotype 3 carriage in the sample. 
 
 
 
Figure 2.10 CPS locus genes for wild type pneumococcal serotype 3 
Adapted from (Bentley et al., 2006). The polysaccharide capsule of serotype 3 is 
synthesised via synthase pathway encoded by the wchE gene. 
 
2.6.4.1.1. Identifying antibiotic resistance genes in serotype 3 
Using the microarray AbR probes, the presence of ten common antibiotic resistance 
genes in the pneumococcal genome of was tested. The signal intensity for all these 
genes was at the zero-baseline, which suggested the absence of antibiotic resistance 
genes in serotype 3 (Figure 2.14). 
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Figure 2.11 Purity of pneumococcal species 
The sample (17787) was initially cultured on a pneumococcal selective media, before the DNA was extracted for analysis by microarray. The 
intensities of all other pathogens sit at zero baseline, while the intensity for S. pneumoniae is over 30000, indicating that only S. pneumoniae was 
present in the sample. 
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Figure 2.12 Serotype 3 homology groups 
All the homology groups (horizontal axis) for the CPS genes expected for serotype 3 (sample 17787) were detected as shown (0.01 [wzg], 1.02 
[wzh], 2.02 [wzd], 3.02 [wze], 20.07 [ugd], 196.01 [wchE], 197.01 [galU], and 198.01 [pgm]). The horizontal red line shows the median log 
intensity of the 6824 S. pneumoniae SpTIGR4 and R6 genome probes. 
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Figure 2.13 Detecting serotype 3 presence 
The intensities of all other pathogens sit close to the zero baseline, while the intensity for serotype 3is over 30000, indicating that only serotypes 
3 was present in the sample 17787. 
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Figure 2.14 Detection of antibiotic resistance genes 
The plot shows signal intensities for 10 common pneumococcal antibiotic resistance genes in sample 17787. The intensities for all the antibiotic 
resistance genes were at zero baseline intensity, signifying the absence of such genes from the genome of serotype 3 in sample 17787.Thus this 
sample would be expected to show sensitivity to treatment with the listed antibiotics.
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2.6.4.2. Single carriage identification of serotype 14 
Sample W01654 contained the pneumococcus only and no other pathogen was 
detected (Figure 2.16). The CPS locus for wild-type serotype 14 consists of 14 genes, 
and it is 19918 base pairs long (Figure 2.15). Serotype 14 determination by 
homology group presence showed fourteen HGs (Figure 2.17): 0.01 [wzg], 1.02 
[wzh], 2.02 [wzd], 3.02 [wze], 5.02 [wchA], 7.11 [wzx], 26.01 [wchJ], 27.06 [wchK], 
34.02 [wchN], 76.02 [wchL], 77.02 [wchM], 78.02 [wciY], and 103.02 [wzy], 
consistent with fourteen genes at the CPSlocus for serotype 14. 
 
 
Figure 2.15 CPS locus genes for wild type serotype 14 
Adapted from (Bentley et al., 2006). 
 
Analysis by STID showed elevated signal intensities for serotype 14 (>40000 
fluorescence units), serotype 15B/C (~3000 fluorescence units) and serotype 3 
(20000 fluorescence units) (Figure 2.18). Homology groups for serotypes 3 and 
15B/C were not detected by HGID (Figure 2.17), thus their elevated fluorescence by 
STID could be due to cross-hybridisation. This evidence suggests that sample 
W01654 contained only pneumococcal serotype 14.  
 
2.6.4.2.1. Identifying antibiotic resistance genes in serotype 14 
The signal intensity for tetM antibiotic resistance genes was at 40000 fluorescence 
units. The remaining genes were observed at the zero-baseline suggesting 
insensitivity to tetracycline by this particular serotype 14 (Figure 2.19).
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Figure 2.16 Purity of pneumococcal species 
The sample (W01654) was initially cultured on a pneumococcal selective media, before the DNA was extracted for analysis by microarray. The 
intensities of all other pathogens sit at zero baseline, while the intensity for S. pneumoniae is over 30000, indicating that only S. pneumoniae was 
present in the sample. 
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Figure 2.17 Serotype 14 homology groups 
All the homology groups (horizontal axis) for the CPS genes expected for serotype 14 (sample W01654) were detected as shown. The horizontal 
red line shows the median log intensity of the 6824 S. pneumoniae SpTIGR4 and R6 genome probes. 
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Figure 2.18 Detecting serotype 14 presence 
The intensities of all other pathogens sit close to the zero baseline, while the intensity for serotype 14is over 30000, indicating that only serotypes 
14 was present in the sample (W01654). 
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Figure 2.19 Detecting antibiotic resistance genes 
The plot shows signal intensities for 10 common pneumococcal antibiotic resistance genes in sample W01654. The intensities for 9 out of the 10 
antibiotic resistance genes were at zero baseline intensity, signifying the absence of such genes from the genome of serotype 14 in the sample. 
However, the intensity of tetM gene was very high at >30000 above baseline, signifying the presence of tetracycline resistance gene. Therefore, 
sample W01654 would be expected to show resistance to treatment with tetracycline. 
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2.6.4.3. Identifying multiple carriage involving serotype 3 and serotype 14 
Analysis of pathogens present in sample 18262 by PathID showed elevated 
fluorescence for S. pneumoniae with all other pathogens shown at the zero-baseline 
fluorescence, suggesting only the pneumococcus was present (Figure 2.20). In 
sample 18262, multiple carriage involving serotype 3 and 14 was detected. Analysis 
of homology group presence by HGID, showed a combined total of eighteen HGs 
from serotype 3 and 14 (Figure 2.21). Four overlapping homology groups were 
detected in 0.01, 1.02, 2.02, and 3.02, representing wzg, wzh, wzd and wze genes 
respectively. The signal intensity for serotype 3 HGs was 15000 fluorescence units 
above baseline, which was higher than the 5000 for serotype 14, signifying that 
serotype 3 was the most abundant. Further analysis of serotype presence by STID, 
however, showed elevated signal frequencies for serotypes 3, 14 and nontypeable 
(NT2) (figure 2.22). The observed high frequency for NT2 by STID could be due to 
cross-hybridisation because it was not detected by HGID.  
 
2.6.4.3.1. Identifying antibiotic resistance genes in sample 18262 
 The intensities for 9 out of the 10 antibiotic resistance genes were at baseline 
intensity (Figure 2.23), signifying the absence of such genes from the genomes of co-
colonising serotypes 3 and 14 in sample 18262.However, the intensity of tetM gene 
was very high at >15000 fluorescence units above baseline, signifying the presence 
of tetracycline resistance gene. Based on the signal intensities for serotype 3 
(~15000) and serotype 14 (~5000), the resistance gene could be assigned to serotype 
3.However this requires further analysis by culturing the sample in a tetM selective 
media, where only the serotype carrying a tetM resistance gene would be expected to 
grow. 
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Figure 2.20 Purity of pneumococcal species 
The sample (18262) was initially cultured on a pneumococcal selective media, before the DNA was extracted for analysis by microarray. The 
intensities of all other pathogens sit at zero baseline, while the intensity for S. pneumoniae is over 10000, indicating that only S. pneumoniae was 
present in the sample. 
 
105 
 
 
 
Figure 2.21 Serotype 3 and 14 homology groups 
All the respective homology groups for the CPS genes expected for serotype 3 and14 were detected in sample 18262 as shown. Homology 
groups 0.01, 1.02, 2.02 and 3.02 are common to both serotypes 3 and 14. Homology groups shown in blue and green are unique to serotype 3 and 
14 respectively. This cluster of homology groups confirms co-colonisation of serotype 3 and 14 in sample 18262.The intensity for serotype 3 
HGs is 15000 above baseline, which is higher than the 5000 for serotype 14, signifying that serotype 3 was the most abundant. The horizontal red 
line shows the median log intensity of the 6824 S. pneumoniae SpTIGR4 and R6 genome probes. 
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Figure 2.22 Detection of serotype 3 and serotype 14 presence 
The intensities of all other pathogens sit close to the zero-baseline, while the intensities for serotype 3 and 14 are at least 5000 above the baseline, 
indicating co-colonisation of serotypes 3 and 14 in sample 18262. 
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Figure 2.23 Detecting antibiotic resistance genes 
The plot shows signal intensities for 10 common pneumococcal antibiotic resistance genes in sample 18262.The intensities for 9 out of the 10 
antibiotic resistance genes were at zero baseline intensity, signifying the absence of such genes from the genomes of co-colonising serotypes 3 
and 14 in the sample. However, the intensity of tetM gene was very high at >15000 above baseline, signifying the presence of tetracycline 
resistance gene. Based on the intensity, the resistance gene could be assigned to serotype 3, however this can be confirmed by culturing in the 
sample in a tetM selective media, where only the pneumococcal serotype carrying a tetM resistance gene would be expected to grow.
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2.7. Whole genome sequencing 
Whole genome sequencing was performed on Illumina HiSeq platform (CA, USA). 
Prior to sequencing, the DNA sample was prepared into a sequencing library by 
random fragmentation of DNA sample into pieces each about 200 bases long (Figure 
2.24). Custom made nucleic acid adapters were attached to the blunt ends of the 
sheared DNA fragments, and then flowed through a solid surface containing 
immobilised template nucleic acid fragments that are complementary to the adapters. 
The bound fragments undergo a solid phase bridge PCR amplification to create 
clonal clusters of single stranded DNA molecules, containing identical DNA 
sequences. The amplified fragments are denatured to obtain single stranded DNA 
templates attached to the solid phase. 
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Figure 2.24 Preparation of DNA library for Illumina sequencing 
Randomly fragmented DNA is attached (ligation) to adapters at both ends of the 
fragment. The single stranded fragments are bound to the solid phase and then 
subjected to bridge PCR amplification. After complete amplification, the DNA is 
denatured to obtain single strands prior to sequencing (Mardis, 2008). 
 
The HiSeq illumina platform uses sequencing by synthesis technology, similar to 
Sanger sequencing except for the usage of modified dNTPs. The modified dNTPs 
contain a terminator molecule at 3′ -OH ends to prevent further polymerisation. This 
ensures that only a single nucleotide is added to each growing DNA strand by the 
DNA polymerase enzyme. The sequencing reaction is initiated by adding primers to 
the cluster strand generated by bridge amplification followed by fluorescently 
labelled modified dNTPs and DNA polymerase. The excess nucleotides and DNA 
110 
 
polymerase molecules are washed away; a scan buffer is added to the flow cell to 
capture the image for each lane of the flow cell. Following image capture, the 
fluorescent labels and the 3′-OH blocking groups are removed to prepare the cluster 
strands for another cycle of fluorescent nucleotide incorporation (Mardis, 2008). 
 
2.8. Whole genome assembly 
The sequences were assembled using Velvet, a de novo short sequence read 
assembly using de Bruijn graphs (Zerbino and Birney, 2008) (Figure 2.25). The 
sequence reads for CPS locus variants (Chapter 5) were mapped against respective 
reference sequences (Bentley et al., 2006) using Burrows Wheeler Aligner (Li and 
Durbin, 2009). The SNPS were called using SAMTOOLS, VCFTOOLS and 
BCFTOOLS (Li et al., 2009). The alignment was generated based only on single 
nucleotide polymorphisms (SNPs) from the whole CPSlocus gene sequence. The 
sequence reads for sequential serotypes were mapped against reference genome S. 
pneumoniae ATCC 700669 (Accession number FM211187), and the alignment was 
generated based on whole genome sequence SNPS. The size for most of the contigs 
obtained after assembly ranged from ~20000 to ~60000 base pairs (Appendix 3a), 
while the cumulative length form the largest contig to the smallest contig with at 
least 50% of the total length (N50 contig number) ranged from ~50000 to ~100000 
base pairs (Appendix 3b). 
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Figure 2.25 Assembly of sequence reads using Velvet and VelvetOptimiser 
This is performed in two steps, (1) Velveth converts reads to very short reads (k-
mers) using a hash table, which is a data structure used to implement an associative 
array (key/value pairs), and (2) Velvetg assembles overlapping k-mers into contigs 
via a de Bruijn graph. A de Bruijn graph is described as a compact representation 
based on short reads (Zerbino and Birney, 2008). 
 
2.8.1. Phylogenetic analysis 
By definition, phylogeny refers to the evolutionary history of a group of organisms. 
A phylogenetic tree is often generated to depict an interpretation of phylogeny (Soltis 
and Soltis, 2003). In genetics, evolutionary trees are often estimated from DNA or 
RNA sequences. A determination of the confidence levels for the generated trees is 
by the application of bootstrapping technique. Bootstrapping estimates confidence 
levels of inferred relationships by resampling the original data matrix with 
replacement of the characters, to produce replicate bootstrap data sets. This process 
is repeated many times and phylogenies are reconstructed each time. Once 
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bootstrapping is complete, a consensus tree is constructed from the optimal tree in 
each bootstrap sample. The bootstrap support for any internal branch is the number 
of times it was recovered during the bootstrapping procedure; often referred to as the 
bootstrap value, bootstrap percentage or bootstrap p-value (Efron et al., 1996, Soltis 
and Soltis, 2003). In this study, the phylogeny of sequenced genomes was 
determined using the alignment of SNPs from each genomic sequence with RAxML 
(Stamatakis et al., 2005) by performing 100 bootstraps. The genome of serotype 23F 
S. pneumoniae ATCC 700669 (Accession number FM211187) was used as a 
reference genome for inferring phylogenetic relationships. However, for capsular 
polysaccharide locus variants of serotypes 6B, 19A, and 20, the reference sequences 
of 6B (GenBank® accession no. CR931639), 19A (GenBank® accession no. 
CR931675) and 20 (GenBank® accession no. CR931679) were used respectively. 
The genetic relatedness of these genomes was further established by Artemis, 
ACT
®
(Rutherford et al., 2000, Carver et al., 2005) or Easyfig (Sullivan et al., 2011). 
 
2.8.2. Pneumococcal genotyping by MLST 
Multi-Locus Sequence Typing (http://www.spneumoniae.mlst.net) is a molecular 
typing technique for determining the population structure of bacterial species and 
other related organisms (Maiden et al., 1998). For pneumococcal strains, MLST 
typing is based on characterisation of seven housekeeping genes namely: aroE, gdh, 
gki, recP, spi, xpt and ddl (Enright and Spratt, 1998). In each locus, alleles are 
assigned an arbitrary number based on sequence variations (Maiden et al., 1998). In 
this study, MLST was performed using an in-house script developed by Dr Nicholas 
J. Croucher (get_st.shmlst_genes.embl forward_reads.fastq) at the Wellcome Trust 
Sanger Institute in Cambridge, UK. Briefly, the Illumina short sequencing reads were 
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mapped against the sequences of the seven loci used for sequence typing in order to 
determine the MLST sequences for each of the strains used (Croucher et al., 2011). 
The sequences for each isolate were then analysed using MLST 
(http://www.spneumoniae.mlst.net) in order to determine their allelic profiles and 
corresponding sequence types (STs) (Aanensen and Spratt, 2005). 
 
2.8.3. Genetic recombination 
Genetic recombination involves acquisition of genetic elements from other 
microorganisms through transformation, transduction or conjugative transfer 
(Thomas and Nielsen, 2005). In this study, genetic recombination was assessed in 
Malawian carriage serotypes, using an in-house script for identifying genetic 
recombination events (gubbins.py -a input.aln -p output_prefix -t phylogeny.tre) 
developed by Dr Simon R. Harris at the Wellcome Trust Sanger Institute in 
Cambridge as reported previously (Croucher et al., 2011). Briefly, ancestral 
sequences were reconstructed onto each node of the phylogenetic tree using a 
package of phylogenetic analysis programs called Phylogenetic Analysis using 
Maximum Likelihood (PAML) developed by Ziheng Yang (Yang, 1997). From the 
ancestral sequences, SNPs were reconstructed onto the branches of the phylogeny. 
Recombination events were identified using a sliding window approach along the 
sequences. Genomic regions with high SNP density within the genomes were 
inferred to represent occurrences of the genetic recombination events. This is 
because mutations occur spontaneously in the genomes due to errors in DNA 
replication as such these are uniformly distributed across the whole genome. The 
implication is that sections of the genome with unusually high SNP or polymorphism 
density would indicate nonrandom mutations, and therefore recombination. 
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2.9. The potential of 6B variants to colonise and cause death in mice 
2.9.1. Bacterial strains 
The serotype 6B CPS locus variants used were obtained from the nasopharynx of 
Malawian children. For comparison, previously characterised Malawian invasive 6B 
serotypes (Everett et al., 2012) were included. Pneumococcal strains were routinely 
cultured on blood agar baseplates containing 5% (v/v) horse blood or in brain heart 
infusion (BHI) broth (BHI; Oxoid, Basingstoke, UK) containing 20% (vol/vol) fetal 
bovine serum (FBS; Gibco, Paisley, UK). 
 
2.9.2. Preparation of the challenge dose 
BHI broth (10 ml/tube/strain) was inoculated with four to five colonies taken from a 
fresh culture plate of each respective 6B S. pneumoniae strain and incubated 
overnight at 37 C. Bacteria were harvested by centrifugation (18,000g) and 
resuspended in 1 ml of fresh serum broth (20% FBS in BHI), and the pellet 
suspension was diluted with fresh serum broth to give an optical density at 500 nm of 
0.7. The culture was then incubated at 37 C for a further 4 to 5 hours to reach an 
optical density of 1.6 at 500 nm. Aliquots of this culture were stored at -80 C. 
Viable colony counts of thawed aliquots were performed as described below in 
duplicate on BAB 5% (v/v) horse blood. Right before administration into mice, the 
suspension was thawed slowly at room temperature, and bacteria were harvested by 
centrifugation before re-suspension and dilution at 2.10
7 
CFU/ml in sterile 
phosphate-buffered saline (PBS). 
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2.9.3. Viable cell counting 
Serial dilutions of 20μl samples were performed in sterile 96-well microtiter plates 
(GIBCO, Paisley, UK) containing 180μl/well of sterile PBS per well and serial 
dilutions were made to 10
6
 with each strain. Dried 5% horse blood (v/v) BAB plates 
were marked into six sectors, and three 20μl aliquots of each dilution were plated 
into each sector. Once dry, plates were incubated at 37 C overnight. Colonies were 
counted in sectors containing a measurable number of colonies (between 30 and 
300). 
 
2.9.4. Outbred mouse strain 
MF1 mice (n=10 mice per bacterial isolate) were obtained from Charles River 
Laboratories (Kent, UK). Mice were obtained at 8 weeks old and infected when more 
than 9 weeks old. After arrival, all animals were kept for a minimum of 7 days to 
acclimatise. Following infection, mice were housed in an isolator. 
 
2.9.5. Intranasal challenge of mice and experimental endpoint 
Mice were anaesthetised with a mixture of O2 and isofluorane, and each mouse was 
infected intranasally with 10
6
 CFU S. pneumoniaein a volume of 50μl. The numbers 
of bacteria in the blood were monitored at 6, 12, 24, 48 and 72 hours post-challenge; 
up to 50μl of blood was taken from the tail vein, and viable counts were performed. 
Following infection, mice were closely monitored for the visual development of 
symptoms, as described previously (Morton and Griffiths, 1985). Mice were closely 
monitored for clinical signs of disease and were culled when severely lethargic. The 
time point the animal was scored as severely lethargic was recorded, and the animal 
was then immediately culled by CO2 euthanasia. Data were represented as Kaplan-
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Meier survival curves. Mice were monitored up to 7 days (or 168 hours), at which 
point the experiment was ended. Seven days was the optimised time period to 
monitor the impact of intranasal challenge on mice. Mice that were alive at day 7 
were considered to have survived the pneumococcal challenge. Nasopharynx and 
lungs were removed into 3 and 5 ml of sterile PBS, respectively. Whole blood 
samples were collected by cardiac puncture into sterile heparinized tubes. The tissues 
were then homogenized using an IKA T10 basic Ultra-Turrax® Homogenizer system 
115VAC (IKA, Staufen, Germany). Viable counts in tissue homogenates and in 
blood samples were performed as described above. Monitoring of the challenged 
mice was done in a blinded manner i.e mouse cages were moved around and group 
ID was hidden by the laboratory staff not involved in the experiments during each 
observation. 
 
2.10. Investigating nasopharyngeal microbiota in children and adults 
2.10.1.   The 16S rRNA bacterial classification by 454 pyrosequencing 
The microbial diversity in the nasopahrynx of adults and children was investigated 
using 454 sequencing (Chapter 1, Section 1.11.1) of the PCR amplified V3-V5 
region of the 16S rRNA. The principle of 454 is through sequencing-by-synthesis 
(Rothberg and Leamon, 2008) 
 
2.10.2.   DNA Extraction 
DNA was extracted directly from samples in STGG using a FastDNA spin kit (MP 
Biomedicals, USA) for soil, following the manufacturers‟ protocol. Nasopharyngeal 
swabs in STGG were vortexed briefly. An aliquot of the STGG solution (200 l) was 
transferred into the tube containing a lysing matrix of beads with mixed sizes. 
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Sodium phosphate buffer (978µl) and MT buffer (122µl) were added to the tube and 
sealed securely with parafilm wrap. The MT buffer is composed of molecular grade 
water, Ethylene diamine tetra-acetic acid disodium salt dehydrate, sodium dodecyl 
sulphate, polyvinlypyrolidone and proprietary inorganic salts 
(http://www.mbio.com). Sodium phosphate buffer and MT buffer function to protect 
and solubilize nucleic acids and proteins during cell lysis, and also minimise RNA 
contamination. The mixture was homogenized in Ribolyser cell disrupter (Hybaid) 
for 30 seconds at the speed of 5.5, and then centrifuged at 14, 000g for 5 minutes. 
The supernatant was transferred to a clean 2ml eppendorf tube. The protein 
precipitation solution (PPS) (250µl) was transferred to the eppendorf and mixed 
manually by inverting the tube several times. The mixture was centrifuged as before 
to pellet the precipitate. The supernatant was transferred to a clean 15ml falcon tube. 
The binding silica matrix suspension (1 ml) was added to the supernatant in the 
falcon tube. The samples in the tubes were mixed on the grant-Bio shaker at 
14000rpm for 2 minutes, to allow binding of DNA to the matrix. The tubes were 
placed in a rack for 3-5 minutes to allow the silica matrix to settle. The supernatant 
(500µl) was removed from the top of the tube, without disturbing the settled matrix. 
The remaining sample/matrix mixture was re-suspended by vortexing briefly. The 
suspension (600µl) was transferred into the top of the spin filter tube and centrifuged 
at 14,000g for 1 minute. The silica matrix was held on the column while the filtrate 
(liquid) from the catch tube was removed and discarded. The process was repeated 
until the entire sample in the falcon tube was filtered. The silica matrix on the spin 
filter membrane was washed by carefully re-suspending in SEWS-M (500µl), a wash 
solution composed of water and tris-hydrochloride, and then centrifuged at 14000g 
for 1 minute. The liquid from the catch tube was removed and discarded. A further 
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centrifugation was performed at 14000g for 2 minutes to dry the filter. The filter was 
removed from the catch tube and placed in a clean new tube. The filter was allowed 
to dry by incubation at 30 Con a heating block. The ultra-pure water (DES) (100µl) 
was added to the filter and the silica pellet was carefully re-suspended with a pipette 
tip (being careful to avoid perforating the filter with the pipette tip). The tube was 
then incubated at 55
 
C for 5 minutes to allow efficient dissolution of the matrix 
bound Dante tubes were centrifuged at 14,000g for 1 minute to transfer the eluted 
DNA into the clean tube. For a final wash, the eluted DNA was added into a micron 
30kDa filter containing 400µl of 1x Tris-EDTA (TE) buffer. The solution was 
subjected to centrifugation at 14,000g for 11 minutes, discarding the flow through. 
The micron filter was inverted into a clean 1.5ml tube and centrifuged at 1000 rpm 
for 1 minute to elute the washed DNA (30µl). The DNA was stored at -20 C. 
 
2.10.3. PCR amplification of 16S rRNA 
The V3-V5 region (~450bp) of the16S rRNA genes was PCR amplified from the 
template DNA using universal forward 338F primer and a reverse 926R primer, and 
the Accuprime ™ Taq DNA Polymerase High Fidelity kit (Invitrogen, Germany). 
The reverse primer (Appendix 4) contained an adaptor sequence for 454 sequencing, 
a unique barcode sequence for identification of samples in the mixture, and a 
universal primer sequence for the amplification of the 16S rRNA gene (Figure 2.26) 
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Figure 2.26 Structure of the barcoded reverse 926R primer 
Primers for three different samples (i), (ii), and (iii) are shown. The primer and the 
adaptor sequences are similar for all the samples; however, the barcode is unique to a 
particular sample. The primer is used for 16S rRNA gene amplification 
(Parameswaran et al., 2007). 
 
The binding positions for 338F and 926R primers on the 16S rRNA gene are 338-
355 and 926-907 respectively (Mao et al., 2012). For the amplification of the V3-V5 
16S rRNA region in this study, the forward (338F) and reverse primer (926R) targets 
were at positions 350-400bp (v3f) and 950-900bp (v5r) respectively (Figure 2.27). 
 
also applied and evaluated (Supplementary data). Once
ﬁltered, the reverse Illumina read for each amplicon was
reverse-complementedandmergedwith thecorresponding
forward read, inserting 20 Ns in between. Both forward
and reverse 16S rRNA primers were removed from all
pyrosequencingand Illumina reads. Theprimer sequences
carryper deﬁnitionvery littlephylogenetic information, so
their removal didnot haveanadverseaffect on taxonomic
classiﬁcations. This wasalso supported by testswith and
without primers on the simulated referenceset (data not
shown).
TheNaı¨veBayesianClassiﬁer (RDP-Classiﬁer)wasused
for assigning reads into the new Bergey’s bacterial
taxonomy (29) with abootstrap cut-off of 50%. Trimmed
sequences along with their classiﬁcations were imported
into a MySQL database for efﬁcient storage and advan-
ced querying. To explore an alternative assignment
method, ahierarchical treesummarising read assignments
into theNCBI taxonomy wasconstructed usingMEGAN
(30)onBLASTsearchesagainst apreviouslypublished16S
rRNA—speciﬁc database(31) (with a bit-score threshold
of 86, allowing ten hits per read). Pyrosequencing reads
were aligned using Infernal (32) and associated
covariance models obtained from the Ribosomal
Database Project Group. Phylotype clusters of 97%
similaritywereobtainedbyapplyingthefurthest neighbour
approach using theCompleteLinkageClustering applica-
tionof theRDPpyrosequencingpipeline. Fromthese, rar-
efaction curves, Shannon diversities and Chao1 richness
estimations werecalculated using RDP software. Good’s
coverage was calculated as G= 1 n/N, where n is the
number of singleton phylotypes and N is the total
number of sequencesin thesample.
RESULTS
Insilicopredictionsshowthat classiﬁcation accuraciesare
highly dependent on choiceof region, sequencingtechnol-
ogy and sequencequality
Thecompletesequencesof six tandemvariableregions,
extracted from the 27 013 high-quality full-length
16SrRNA genesreferenceset, wereused to simulate454
Titanium reads, whereas the 150/100/75/50bp of the
ﬂanking ends were used to simulate corresponding
paired-end Illumina reads of varying lengths (Figure 1).
The coverage of both single and paired primers, as
measured by theRDPProbeMatch and matchesagainst
thereferenceset (Table1), weregenerally high except for
theV1/V2, V2/V3and V7/V8regions, in largepart dueto
poor coverage of the single V1-for, V2-for and V8-rev
primers. Many full-length sequences used in the two
reference sets have truncated ends, thereby lacking
complete sequences covering the V1-for and V8-rev
primer regions, which is a likely reason for poor
coveragewith theseprimers.
When ignoring sequencing errors, the 2 150bp
Illumina reads were almost as accurate as the longer
Titanium reads, owing to their concatenated lengths ap-
proaching full Titanium read lengths(Figure3). Not sur-
prisingly, the genus-level accuracies for Illumina reads
dropped as their read lengths decreased. Titanium reads
were, however, still far from full-length 16S rRNA gene
assignment accuracy. Regardless of sequencing technol-
ogy and quality, the V3/V4 and V4/V5 regions were the
most accurate. While in silico—induced errors, as
modelled by error rates provided by the sequencing
vendors (Figure 2), had little effect on the classiﬁcation
accuracies for pyrosequencing reads, they had a signiﬁ-
cantly negative impact for the longer Illumina reads
which had increasingly deteriorating quality after 60bp.
Paradoxically, thelonger Illumina readswereactually less
accuratefor genus-level assignment than theshorter ones,
since error rates increase exponentially with read length.
For example, although theaccuracy for theV4/V5regions
increased with error-freeread lengths, the2 75bp reads
with induced KIT-v4 errors (dashed lines) were slightly
more accurate at genus-level than the corresponding
longer reads. With or without sequencing error,
paired-end 50bp Illumina reads are, however, not worth
pursuing for thesetypesof compositional studies.
SincethisanalysiswasbasedonGIT-related 16SrRNA
genes, we also wanted to investigate whether we would
obtain similar results if this criterion was removed,
i.e. by not restricting referencesequencesto GIT environ-
ments. Consequently, thereferenceset wasincreased to 60
000 high-quality full-length sequences on which we
repeated thesimulations. As displayed in Supplementary
FigureS5, accuracy valuesfor all regionsand read lengths
are lower at all taxonomic levels compared to the GIT-
restricted sequences. Interestingly, the V4/V5 region in
particular showed inferior performanceandwasheremar-
ginally better than theV7/V8region. TheRDP-classiﬁer is
trained on well-characterized 16SrRNA genessequenced
from compositional studies of diverse microbial environ-
ments. As such, GIT-related microbiota are over-
represented relative to non-GIT environments (e.g. 45%
Figure 1. Positions of primer sequences and tandem regions used in this work for 454 titanium and Illumina, mapped along 16S rRNA gene
(co-ordinates based on theEscherichia coli 16SrRNA genesequence). Thearrows ( 100 bases) show approximately Illumina sequence read length.
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Figure 2.27 PCR primer binding positions on 16S rRNA gene 
Adapted from (Claesson et al., 2010). 
 
For each sample, 4-6 PCR reactions were performed. The number of reactions was 
dependent on the yield of the PCR product. The total volume of the reaction mixture 
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per sample was 20μl, mixed as follows: buffer II (2μl), water (15.52μl), forward 
primer, (0.2μl), barcoded reverse primer (0.2μl), Accuprime Taq (0.08μl), template 
DNA (2μl). For the negative control reaction, water or TE buffer instead of DNA 
was used. PCR reactions were performed in a 96-well plate, loading 20μl of the 
reaction mixture in each well. The PCR run conditions were as follows: 94 ºC for 
2mins; (94 ºC for 30secs, 53 ºC for 30secs, 68 ºC for 2mins) x30. The 30 PCR cycle 
number was used to increase the product yield because of the low yield of template 
Dante replicate PCR products for each sample were pooled into a new 1.5ml tube. 
The following was added to precipitate the pooled products: NaCl (1M, 0.3 volumes 
relative to the pooled sample volume) and ice-cold ethanol (100%, 2 volumes 
relative to volume of the new combined (sample + NaCl). The solution was mixed by 
inversion and left overnight at -20 C. This was followed by centrifugation at 4 C at 
16,000rpm for 30mins. The supernatant was gently removed by pipetting and the 
pellet was washed with ice-cold ethanol (70%, 600μl) by centrifugation as before. 
The supernatant was gently removed and the tubes were left to air dry for 30 – 
60mins. The pellet was re-suspended in TE buffer (20μl) and left overnight at 4 C. 
 
2.10.4. Determining the concentration and size of the 16S PCR product 
The concentration of the 16Samplicon was determined using Qubit® 2.0 fluorometer 
(Invitrogen, Life technologies, Austria) following the manufacturers protocol. The 
high sensitivity setting for the qubit was chosen because of the low DNA yield from 
16S PCR amplification. The size of the PCR product (450bp) was confirmed by 
running on a 1% agarose gel (Figure 2.28). A mixture of the pooled 16S PCR 
products from each sample was prepared, by pipetting an appropriate volume to 
contain equal amount of DNA in each sample (equimolar mixture). The total 
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concentration of DNA in the pooled equimolar mixture was ~45ng/ l. The total 
volume of the equimolar mixture was approximately 2.6ml.  
 
Marker 
450bp 
Marker 16S rRNA bands 
 
 
Figure 2.28 Gel image of PCR amplified 16S rRNA 
The 450bp band corresponds to 16S rRNA gene. The samples were run on a 1% 
agarose gel, using ethidium bromide as a fluorescent dye. 
 
2.10.5. Purification of the amplicon mixture 
The equimolar mix was run through a gel clean up with the Wizard SV Gel and PCR 
Clean-Up System (Promega, Madison, USA) following the manufacturers protocol. 
This was necessary to remove unreacted PCR reagents as well as possible primer-
dimers. Primer-dimers are non-specific PCR products resulting from template-
independent primer interactions (Rychlik, 1995). The equimolar mixture was loaded 
onto low melt agarose gel and run with Tris-acetate-EDTA (TAE) buffer in the 
presence of ethidium bromide. The DNA in the gel was visualised and photographed 
using log-wavelength UV lamp. To reduce damage to the DNA, the gel was 
irradiated for not more than 4 seconds. The PCR product was excised using a clean 
scalpel, excluding the primer dimer band (Figure 2.29). The gel slice was transferred 
to the pre-weighed 1.5ml micro-centrifuge tube and the total weight was recorded. 
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The weight of the gel slice was determined as the difference between the total weight 
(gel slice + micro-centrifuge tube) and the weight of the micro-centrifuge tube. The 
membrane binding solution was added to micro-centrifuge tube at a ratio of 10µl of 
solution per 10mg of agarose gel slice. The mixture was incubated at 65
 
C, 
vortexing every few minutes, until the gel slice was completely dissolved. The tube 
was centrifuged briefly to ensure the contents were collected at the bottom of the 
tube. The DNA was recovered from the dissolved gel slice by column centrifugation. 
The dissolved gel mixture was transferred to the SV Minicolumn (Promega, 
Madison, USA) assembly and incubated for one minute at room temperature, 
followed by centrifugation at 16,000xg for a minute. The column was removed from 
the assembly and flow through in the collection tube was discarded. The column was 
placed back on the collection tube. The column was washed by adding 700µl of 
membrane wash solution, and then centrifuged at 16,000xg for one minute. The 
collection tube was emptied as before. The wash step was repeated with 500µl of 
wash solution and centrifuged as before for 5minutes. The collection tube was 
emptied and centrifugation was performed for a further one minute with the column 
lid open to ensure evaporation of any residual ethanol. The SV Minicolumn was 
carefully transferred to a clean 1.5ml micro-centrifuge tube. Nuclease-free water 
(50µl) was applied directly to the center of the column, avoiding touching the 
membrane with the pipette tip. After incubating at room temperature for one minute, 
centrifugation was performed for one minute at 16,000xg.The column was discarded 
and the micro-centrifuge tube containing the eluted DNA was stored at -20
 
C. 
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Figure 2.29 Purification of PCR amplified 16S rRNA 
Purification was performed on a low melt gel (A) using Wizard SV Gel and PCR 
Clean-Up System (Promega, Madison, USA). The 16S rRNA band indicated by the 
arrow in (A) was cut out using a clean scalpel and re-extracted from the gel. The 
purity of the 16S rRNA was confirmed by running on 1% agarose gel (B). 
 
2.10.6. Sequencing of the 16S PCR amplicon 
The 16S PCR amplicons were sequenced using 454 sequencing (Margulies et al., 
2005), on the Genome Sequencer FLX
TM
 System (Roche, Basel, Switzerland). The 
V3-V5 amplicons were sequenced in reverse from the 3
/
 end of the amplicon back to 
the 338f primer, because the barcode was on the reverse 926R primer. The average 
sequence read length obtained was 528 base pairs. 
 
2.10.7. Analysis of 454 16S DNA (16S rRNA) sequences in Mothur 
In this study, quality 16S DNA sequences were obtained using an open-source 
mothur software package (v. 1.30.2) (Schloss et al., 2009). Mothur is a single 
software command-line computer program that is built upon other pre-existing tools 
for analysing sequence data from microbial communities. Basically, mothur can be 
used trim, screen, and align sequences; distance matrix-based sequence clustering, 
assign representative sequence reads to operational taxonomic units (OTUs); and to 
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provide an estimation of within- ( -diversity) and between- ( -diversity) sample 
diversity (Schloss et al., 2009) (Figure 2.31). Each sequence read was identified by 
its barcode followed by the removal of primer sequences. The sequences were 
trimmed using a moving window size of 50 base pairs with the minimum average 
quality score in that window of 35. Therefore trimming was done to the end of the 
last window with an average of over 35. Any sequence containing a homoploymer 
sequence stretch of more than 8 nucleotides and an ambiguous base call “N” was 
removed. Sequence reads shorter than 400 nucleotides were also removed. Since 
sequencing was conducted in reverse, the reverse complement of each sequence was 
obtained. The sequences were then aligned using reference silva alignment template, 
a database of 16S sequences (Quast et al., 2013). The aligned sequences were 
screened to maximise the number of sequences with the longest overlapping span. 
Generation of chimeric sequences is very common during co-amplification of closely 
related sequences such as 16S rRNA genes (Wang and Wang, 1996), and these may 
inflate the number of operational taxonomic units (OTUs). In this study, chimeric 
sequences were identified and removed using perseus, a novel program that removes 
chimeras from raw 454 16S rRNA sequence data, based on sequence abundances 
associated with pyrosequencing data (Quince et al., 2011). The uncorrected pairwise 
distance between aligned DNA sequences was calculated. The aligned DNA 
sequences were then clustered and assigned into OTUs based on a genetic distance 
cut off of 0.03, using the furthest neighbor algorithm as the default option. Thus a 
cluster was defined by sequences that differed by less than 3%. OTUs containing one 
or two reads are usually a result of pyrosequencing errors and these were removed 
from the dataset, together with OTUs detected in the negative controls. Mothur 
detected OTU identities up to the genus level; however an attempt was made to 
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identify specific species in the clustered OTUs, by performing an online BLAST 
search for the candidate sequences. All matching species with ≥98% identity were 
recorded. 
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Figure 2.30 An outline of data analysis in Mothur 
In this study, only alpha diversity was determined because samples were collected 
from the same nasopharyngeal environment (Appendix 5). 
 
2.10.8. Phylogenetic analysis 
The subsampled 16S sequences were aligned in MUSCLE (Edgar, 2004).To 
determine the phylogenetic relationships, a tree of the aligned sequences was 
generated using RAxML (Stamatakis et al., 2005) by performing 100 bootstraps. 
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Chapter 3: Pneumococcal carriage dynamics (cross-sectional) 
 
3.0 Introduction 
Pneumococcal acquisition is thought to play a role in the development of invasive 
pneumococcal disease (Chapter 1, Section 1.2). Therefore by investigating carriage 
we can begin to understand how disease develops and thus develop interventions to 
prevent it. Pneumococcal carriage is also a marker for estimating vaccine coverage 
and efficacy post-vaccination (Goldblatt et al., 2013). Nasopharyngeal carriage of S. 
pneumoniae is common whereas disease is rare (Brueggemann et al., 2003) and 
therefore studying impact of vaccines on carriage in a given population can 
potentially be used as an end point for licensure and implementation of 
pneumococcal vaccines (Goldblatt et al., 2013). The study described in this chapter 
was conducted in Malawi, a resource poor setting with a high burden of HIV 
infection and invasive pneumococcal disease (IPD). Samples were collected from 
Malawian children and adults using nasopharyngeal swabs (Chapter 2, sections 2.0-
2.2). Previous studies in this setting, have described those serotypes associated with 
invasive pneumococcal disease in clinical settings (Cornick et al., 2011, Gordon et 
al., 2002), however very little has been reported with respect to understanding the 
profile of pneumococcal serotypes circulating in carriage across Malawi, with the 
exception of a 1997 study (Feikin et al., 2003). This study reported an 87% 
pneumococcal carriage rate, of which 43% were PCV7 serotypes. However, the 
serotypes were determined using the Quellung reaction, where only a single colony 
was picked from each plate. This resulted in a clear bias towards detection of those 
serotypes in highest abundance and would have missed cases of multiple carriage. 
Although multiple carriage has been reported elsewhere (Turner et al., 2013, Adetifa 
et al., 2012, Brugger et al., 2010), there is only one report on multiple carriage in 
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adults in Malawi (Glennie et al., 2012a) and none on children. In addition Malawi 
does not have adequate information on the profile of carriage pneumococcal 
serotypes circulating within the population. This chapter details the findings on 
serotype distribution and the prevalence of multiple carriage in both Malawian 
children and adults within the context of HIV infection. It is well known that HIV 
infection increases susceptibility to invasive pneumococcal disease through 
immunosuppression and impairment of the mucosal epithelial barrier integrity (Gilks 
et al., 1996, Nazli et al., 2010, Glennie et al., 2012a), however, the impact of HIV 
infection on carriage remains uncertain (Chapter 1, Section 1.4.2).  
 
3.1. Methods 
Serotyping of S. pneumoniae was undertaken by microarray as described in the 
methods section (Chapter 2, Section 2.6), by analysing the DNA extracted from a 
complete plate sweep of all colonies as opposed to a single colony.  
 
3.2. Results 
3.2.1. Pneumococcal carriage in children 
A total of 116 nasopharyngeal swabs from 116 children (Table 3.1) in Blantyre and 
Karonga (Chapter 2, Section 2.1) were used for a first description of multiple 
carriage of pneumococcal serotypes amongst Malawian children. The samples were 
collected prior to the introduction of PCV13 to children in Malawi in 2011, 
providing important background information for estimating the impact of PCV13 
post-vaccination. 
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Table 3.1 Characteristics of children from Karonga and Blantyre 
 
 
 HIV Status Total Median age 
(yrs) (p<0.5) Karonga Blantyre  (Karonga & Blantyre) 
Neg Pos Neg Pos Pos Neg Age IQR 
Male 8 0 38 22 22 46 2.3 1.0 - 4.6 
Female 5 1 21 21 22 26 2.4 1.1 - 5.9 
Median age (yrs) (p<0.001) 
IQR 
4.9 
2.7 - 8.1 
1.4 
0.8 - 3.1 
 
 
This table summarises HIV status by gender and sample origin and also presents 
median age, and interquartile range (IQR). The age range for the whole group is 
0.008-23.3 years. Nasopharyngeal swabs were collected from male (n=68) and 
female (n=48) children, who were either HIV negative (n=72) or HIV positive 
(n=44). 
 
The analysis of pneumococcal carriage in Malawian children by microarray 
identified 176 pneumococcal strains from 116 swabs, clearly demonstrating multiple 
carriage does indeed occur in Malawi. The strains were comprised of 43 distinct 
serotypes and nontypeables (Figure 3.1), and represent a much broader serotype 
distribution than previously reported in Malawi children (Feikin et al., 2003) and 
elsewhere (Adetifa et al., 2012). The serotypes were categorised into those covered 
by the vaccine (VT), not covered by the vaccine (NVT) and NTs. The NVT were 
further sub-categorised as high-invasive potential and low-invasive potential based 
on frequency stratification definitions from previous reports on invasive disease 
(Johnson et al., 2010). These categories were made to provide a simple means of 
distinguishing the 2 populations and highlight the possible NVT that could emerge 
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following the PCV13 impact on the pneumococcal population. All serotypes covered 
by PCV13 were detected and cumulatively, they represented 60% of the overall 
frequency of isolation, taking into account NT strains. The PCV13 coverage was 
estimated to be 61% when NT strains were excluded. This coverage is lower than the 
reported 78.3% PCV13 coverage in under-five children from the same setting 
(Everett et al., 2012) using invasive serotypes, which reflects the broader range of 
serotypes found across carriage. The NVT (39%) and NT serotypes (1%) accounted 
for the remaining proportion of detected serotypes. Serotype 1 was detected only 
three times amongst the children‟s data set, representing a 1.7% (3/176) frequency of 
isolation. In Malawi, serotype 1 is responsible for over 25% of all invasive 
pneumococcal disease cases (Cornick et al., 2011). Furthermore, serotypes 5 and 7F 
were each detected only once representing 0.6% (1/176) of the total carriage 
frequency. In other settings, serotypes 1, 5 and 7F have also been rarely detected in 
carriage although they account for the majority of invasive cases in the world 
(Almeida et al., 2013, Hausdorff et al., 2000). Based on the data from Malawi, the 
most abundant NVT serotype was 15B, followed by 13, 16F, 9L, 10B, 35B, 21, 11D, 
34, 15A, and 35F (Table 3.2). Elsewhere, 9L, 15B, 16F, 21, and 35F were among the 
most frequently isolated NVT serotypes (Abdullahi et al., 2012b, Ercibengoa et al., 
2012, Hill et al., 2008b), which is similar to our findings. 
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Figure 3.1  Serotype specific carriage in children 
Microarray serotyping was used to determine serotypes within each sample (n=116). Results showed 43 serotypes and NTs (Tong et al.). 
Conventionally, NTs are grouped together since there is no specific NT classification at the moment. Cumulatively, all serotypes represented 
99% abundance, while the remaining 1% was covered by NTs. A 60% PCV13 coverage was estimated from the cumulative frequency. 
131 
 
The data presented here demonstrate the breadth of circulating pneumococcal 
serotypes in Malawian children, and presents a higher frequency of serotype isolation 
from the sample population when compared to other settings (Abdullahi et al., 
2012b, Adetifa et al., 2012). These data demonstrate that the proportion and diversity 
of non-vaccine serotypes circulating in Malawian children is high. Post-vaccination, 
these non-vaccine serotypes (Table 3.2) would be the most likely candidates for 
serotype replacement across carriage, and ultimately invasive disease, since non 
vaccine serotypes such as 15B have been reported to cause invasive diseases 
elsewhere (Johnson et al., 2010). 
 
Table 3.2 Carriage of NVT serotypes in children 
Serotype  15B 13 16F 9L 10B 35B 21 11D 34 35A 15A 35F 
Frequency 11 9 7 5 5 4 3 3 3 3 2 2 
 
The frequency represents the number of times each serotype was isolated out of 176. 
 
3.2.2. Pneumococcal carriage by HIV status in children 
Malawi has a high prevalence of HIV infection (UNAIDS, 2012b), and current 
estimates suggest 10.6 % of the population (Chapter 1, Section 1.4.1) is infected. As 
described previously, HIV infection predisposes patients to invasive pneumococcal 
disease (IPD) (Nunes et al., 2011b, Gordon et al., 2002, Carrol et al., 2007). The 
study reported here investigated whether HIV infection had any impact on 
pneumococcal carriage. One hundred and fourteen (114) pneumococcal strains were 
isolated from HIV negative children (n=72) and 62 from HIV positive children 
(n=44) (Figure 3.1). This study was not able to establish any statistically significant 
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difference in the total number of pneumococcal strains isolated by HIV status 
(p<0.6382). At serotype level, 39 distinct serotypes were identified within the HIV 
negative children whereas 22 were identified amongst HIV positive children. 
Twenty-one (21) serotypes were only isolated from HIV negative children and these 
included vaccine types 5, 6A, 7F and 18C. HIV positive children carried 4 non-
vaccine types16A, 18A, 18F and 22F which were not detected in HIV negative 
children, and each of these serotypes was only isolated once from the entire dataset 
(Figure 3.1). These results show that HIV negative children carried a broader range 
of serotypes than HIV positive children, however, this small number of observations 
was considered inadequate to assess the real impact of HIV on serotype distribution. 
Analysis of serotype specific carriage by logistic regression showed that serotype 3 
was more likely to be detected in HIV-positive (6/44) than HIV-negative (1/72) 
subjects (p<0.028; 95% CI 1.3-96.6). However, the isolation of serotype 3 from 1 
HIV negative child only, raises the possibility that this may have occurred by chance, 
which would warrant further investigation.  
 
Next, we investigated whether HIV infection also promoted carriage of vaccine 
serotypes among those infected. Vaccine serotypes are those included in the current 
pneumococcal vaccines; hence the need to particularly focus on their distribution as 
this might have an impact on disease and treatment. HIV infection has been reported 
to play a role in the depletion of CD4 T cells which is essential for clearance of 
pneumococcal strains from the nasopharynx as demonstrated in murine models of 
pneumococcal colonisation (Basset et al., 2007). To achieve this, carriage of three 
serotype categories was investigated: (i) VT, (ii) NVT or (iii) both VT/NVT (Table 
3.3). Each of the three categories took into account both single and multiple carriage 
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events. The percentage of carriers for the VT, NVT and VT/NVT categories was 
36.2% (42/116), 39.7% (46/116) and 24.1% (28/116) respectively. HIV negative 
subjects represented 62.1 % (72/116), and HIV positive subjects 37.9 % (44/116) of 
the total number of samples (Table 3.3). Although the proportion of HIV infected 
children in this study was higher than current HIV prevalence estimates for Malawi 
(Chapter 1, Section 1.4.1), more HIV positive subjects were conveniently sampled to 
increase the numbers for better comparison of findings with HIV negative children. 
Analysis by Pearson‟s chi2(2) t-test showed that HIV infection did not have any 
significant impact on carriage of VT (p<0.1052) and NVT (p<0.8291) alone. 
However, simultaneous carriage of both VT and NVT was slightly significant 
(p<0.0388) with HIV negative children registering higher carriage rates compared to 
HIV positive children. These findings highlight the fact that the relationship between 
carriage and HIV infection is complex and therefore currently not fully understood. 
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Table 3.3 Pneumococcal carriage by HIV status in children 
 
 
 
Carriers of:  
 
Total 
(%) 
 
 
Median age 
(yrs)* 
(IQR) 
 
VT 
(%) 
 
NVT 
(%) 
 
VT/NVT 
(%) 
 
 
HIV 
(-Ve) 
 
22 
(52.4 
 
28 
(60.9) 
 
22 
(78.6) 
 
72 
(62.1) 
 
1.4 
(0.8 – 3.1) 
 
HIV 
(+Ve) 
 
20 
(47.6) 
 
18 
(39.1) 
 
6 
(21.4) 
 
44 
(37.93) 
 
4.9 
(2.7 – 8.2) 
 
Total 
 
42  
(36.2) 
 
46  
(39.7) 
 
28  
(24.1) 
 
116 
 
*p<0.0001 
 
 
This table summarises carriage by HIV status and also presents median age, 
interquartile range (IQR). The age range for the whole group is 0.008-23.3 years 
Carriage by HIV status was investigated using three categories of pneumococcal 
strains: VT only, NVT only or both VT and NVT (valid for multiple serotype carriers 
only). 
 
3.2.3. Pneumococcal carriage by age in children 
Age is an important risk factor for pneumococcal carriage, with carriage decreasing 
with increasing age (Hussain et al., 2005, Adetifa et al., 2012). In this study, we 
investigated if carriage of pneumococcal serotypes decreased with age in Malawian 
children. This would help provide further data to estimate the impact of introducing 
PCV13 to children under the age of two years in the Malawi. Results showed that 
carriage decreased with age (Figure 3.2). Although sample numbers were low for 
older children, the results agreed with literature findings where carriage is reported to 
decrease with age (Hussain et al., 2005). Further analysis was conducted to establish 
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if age differences existed between carriers of VT and NVT types. There was no 
significant difference in ages for carriers of VT (median age 2.0 (0.9-4.4) years)) and 
NVTpneumococcal strains (median age 3.7 (1.1-3.6) years)) (p<0.0956) in our 
context. Vaccinating children aged two years and below in Malawi leaves out a 
larger population of older children who would act as reservoir for the spread of 
vaccine serotypes within the population post-vaccination, which may have a negative 
impact on the benefits of vaccination. However, other studies have reported that 
vaccinating the most affected age group has led to a significant decrease in carriage 
and invasive disease by vaccine serotypes in the unvaccinated population (Hammitt 
et al., 2006, Loughlin et al., 2014, Nzenze et al., 2013). 
 
 
 
Figure 3.2 Carriage of VT and NVT serotypes by age in children 
Forty-two (42) and forty-six (46) children carried the VT and NVT serotypes 
respectively (Table 3.3). Carriage involved either single or as multiple serotypes. 
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3.3. Multiple carriage in children 
As previously described (Chapter 1, Section 1.2.1), multiple carriage is defined as 
the presence of two or more serotypes simultaneously occupying the nasopharynx. 
The availability of multiple carriage data provides important information on 
circulating serotypes in Malawi, which immediately benefit vaccine related 
surveillance studies. In the Malawian children‟s dataset, multiple carriage 
represented 40% (46/116) of all samples analysed, with 27% (31/116) containing two 
serotypes, 11% (13/116) containing three and 2% (2/116) containing four capsular 
types (Figure 3.3A). Multiple carriage rates are therefore very high compared to 17.3 
% reported previously in Portugal among unvaccinated children (Valente et al., 
2012), where serotyping was also performed using microarray. The association 
between serotypes in multiple carriage events was investigated across sub-groups 
involving two (Figure 3.3B), three (Figure 3.3C) and four serotypes (Figure 3.3D). 
Results from this initial analysis showed that carriage occurred randomly (Appendix 
6), such that the association among serotypes in multiple carriage could not be 
established, however this would require further investigations to be conclusive. 
Using relative abundance estimates from the array data, we determined the most 
abundant serotypes in multiple carriage involving vaccine and non-vaccine 
serotypes, as these would most likely be detected by conventional serotyping 
techniques such as Quellung and latex agglutination. Results showed that VT and 
NVT serotypes were most abundant in 46.4% (13/28) and 53.6% (15/28) of multiple 
carriage events respectively. Thus using conventional methods, VTs would be 
undetected in 53.6% of these samples, thereby underestimating vaccine coverage. 
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Figure 3.3 Multiple carriage in children 
Carriage of multiple pneumococcal serotypes in both HIV positive and HIV negative 
children is shown in (A). Multiple carriage was found in 40% of samples tested, with 
co-colonising samples expressing two (27%) three (11%) or four (2%) capsular 
types. Figures B, C, and D show the specific serotype distribution in samples with 
two, three and four co-colonising serotypes respectively. 
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3.3.1. Multiple carriage by gender and age in children 
In this study, the gender distribution was slightly skewed toward males (n=68) than 
females (n=48) (Table 3.1). Gender has previously been shown to have an impact on 
carriage of S. pneumoniae (Coles et al., 2001, Simell et al., 2008, Mackenzie et al., 
2010). In this study, we investigated if gender had an impact on multiple carriage 
(Figure 3.4). Multiple carriage was higher in females 45.8% (22/48) than males 
35.2% (24/68), however this did not reach statistical significance (p<0.25) (Figure 
3.4). The mean number of serotypes carried by males and females was 1.5 0.09 and 
1.6  0.11 respectively (p=0.24), which further showed the lack of association 
between gender and multiple carriage in Malawian children.  
 
!
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Four STs 
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Two STs 
(n=15), 31% 
Three STs 
(n=7), 15% 
A B 
 
Figure 3.4 Multiple carriage by gender in children 
Male and female children are represented by chart A and B respectively.  
 
The relationship between age and carriage of S. pneumoniae is well documented 
(Hussain et al., 2005), however, it is not clear if age has a similar impact in the 
context of multiple carriage in children. In this study, the association between age 
and multiple carriage was investigated by comparing the age differences amongst 
single and multiple serotype carriers (Figure 3.5). The median age for single carriers 
(n=70) or multiple carriers (n=46) of pneumococcal serotypes was 2.6 (1.1-5.0) years 
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and 1.96 (1.1-3.9) years respectively (p<0.28). These results could not establish any 
association between age and carriage of multiple serotypes in Malawian children, 
although the inadequate number of samples analysed could confound this 
observation. However, in contrast, this thesis has shown that multiple carriage is 
higher in Malawian children (Chapter 3, section 3.3) compared to adults (Chapter 3, 
section 3.5), which highlights the fact that multiple carriage decreased with age.  
 
 
 
Figure 3.5 Multiple serotype carriage by age in children 
 
3.3.2. Multiple carriage by HIV status and CD4 count in children 
HIV infection impairs the function and integrity of the mucosal membrane (Nazli et 
al., 2010), including the nasopharynx, which compromises the ability of the 
membrane to clear colonising microorganisms (Glennie et al., 2010). We 
hypothesised that HIV infection would predispose those affected to higher 
prevalence of multiple carriage. To test this hypothesis, the prevalence of multiple 
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carriage between HIV negative and HIV positive subjects was compared (Figure 
3.6).  
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Figure 3.6 Multiple carriage by HIV status in children 
Multiple carriage was 43% in HIV negative (A, n=72) and 34% in HIV positive 
children (B, n=44) 
 
The majority of children in both the HIV negative (n=72) and HIV positive (n=44) 
groups carried one serotype followed by two, three and four serotypes. There was no 
difference in the mean number of serotypes carried by HIV negative (1.6) and HIV 
positive (1.5) children (p<0.1659). As shown in Figure 3.6, multiple carriage was 
higher in HIV negative (43%, 31/72) than HIV positive subjects (34%, 15/44), 
however the difference was not statistically significant (p<0.34), which would 
suggest that HIV infection did not have an impact on multiple carriage. Although a 
similar finding has also been reported in adults from the same setting (Glennie et al., 
2012a), there was significant age difference (p<0.0001) in years between HIV 
positive children (4.9 years (2.7 – 8.2)) and HIV negative children (1.4 years (0.8 – 
3.1)) which may have affected the outcome.  
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HIV infection lowers the peripheral blood CD4 T cell counts of the infected 
individuals which is associated with an increase in the incidence of bacterial 
pneumonia (Hirschtick et al., 1995) and pneumococcal colonisation (Glennie et al., 
2012a). In this study, we investigated whether lowering CD4 count and HIV 
progression increased the prevalence of multiple carriage in infected children. Data 
on CD4 cell percentage was only reported for 79.5% (35/44) of the HIV positive 
children‟s data set. In young children, CD4 cell percentage rather than count is 
widely used to determine immune status, disease progression and when to start 
treatment (Moore et al., 2006, Gebo et al., 2004, Hulgan et al., 2007). In this subset, 
there were more carriers of single serotypes (n=28) than multiple serotypes (n=20) 
(Figure 3.7). The frequency of single serotype carriers was shown to decrease with 
increase in CD4 percentage; however this could be attributed to a decrease in the 
number of children with high CD4 % values. Unlike single carriage, there was no 
change observed in the prevalence of multiple carriage with CD4 percentage in the 
children understudy (Figure 3.7). This finding corresponds to a recent report in 
Malawian adults, where multiple carriage rates remained unchanged regardless of 
CD4 count value (Glennie et al., 2012a). 
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Figure 3.7 Multiple serotype carriage by CD4 percentage 
CD4 cell percent values were reported for a subset (n=48) of the children‟s‟ data set.  
 
3.3.3. Pneumococcal carriage by ART in HIV infected children 
The impact of antiretroviral therapy on pneumococcal carriage dynamics in HIV 
positive subjects was investigated. The hypothesis was that following the possible 
occurrence of ART mediated immune reconstitution; the pneumococcal-specific T-
cell proliferation should regulate pneumococcal carriage and colonisation by 
multiple serotypes. Longitudinal samples were collected from a subset of children 
(n=16) in Blantyre, pre- and 12 months post-ART. Results (Figure 3.8) showed that 
17 pneumococcal serotypes were detected pre-ART, which was less than the 21 
serotypes detected post-ART, however this difference was not statistically significant 
(p<0.3368). A significant overlap in the profile of serotypes detected pre- and post-
ART was also observed. Using Pearson‟s chi2(2) t-test, we observed no difference in 
the distribution of VT or NVT in carriage between samples analysed pre- and post-
ART (p<0.298). These findings were not able to establish the real impact of ART on 
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pneumococcal carriage dynamics within 12 months of use. It is likely that ART did 
not achieve immune reconstitution in this short period of time, which could 
contribute to the observed lack of impact on pneumococcal carriage. This however, 
requires further investigation because poor restoration of pneumococcal specific T-
cell proliferative response and elevated levels of pneumococcal carriage following 
ART have been reported elsewhere (Cassol et al., 2013, Glennie et al., 2012a). 
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Figure 3.8 Pneumococcal carriage by ART usage in children 
 
The  children’s  longitudinal  samples  (n=16)  were  collected  Pre- and Post-ART. An 
investigation into the impact of anti-retroviral therapy on multiple carriage showed 
that multiple carriage was significantly higher (p<0.0325) in samples collected 12 
months Post-ART 62.5% (10/16) than those collected Pre-ART 25% (4/16) (Figure 
3.9). Although the results show that high levels of colonisation with multiple 
serotypes were sustained following ART regimen, the sample numbers were small to 
be conclusive. Hence, the need for further studies to establish if indeed HIV infected 
children on ART are more likely to be carriers of multiple serotypes, which would 
make them a reservoir for person-to-person spread of S. pneumoniae.  
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Figure 3.8 Pneumococcal carriage by ART usage in children 
 
e c il re ‟s l it i al sa les ( 16) ere collected Pre- and Post-ART. An 
investigation into the i pact of anti-retroviral therapy on multiple carriage showed 
that ultiple carriage as significantly higher (p<0.0325) in samples collected 12 
months Post-ART 62.5  (10/16) than those collected Pre-ART 25% (4/16) (Figure 
3.9). Although the results show that high levels of colonisation with multiple 
serotypes were sustained following ART regimen, the sample numbers were small to 
be conclusive. Hence, the need for further studies to establish if indeed HIV infected 
children on ART are more likely to be carriers of multiple serotypes, which would 
make them a reservoir for person-to-person spread of S. pneumoniae.  
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Figure 3.9 Multiple carriage by ART usage in children 
Multiple carriage was 25% in samples collected pre- (A) and 62% post-ART (B) 
from children‟s longitudinal data set. 
 
3.4 Pneumococcal carriage in adults 
The adult‟s pneumococcal carriage data presented in this section was derived from 
nasopharyngeal swabs taken from a cross-sectional dataset (n=117) comprising of 
HIV negative (n=26) and HIV positive (n=91) adults. All the subjects presented here 
formed part of a slightly larger dataset (n=136) in a study reported previously 
(Glennie et al., 2012a). From 117 swabs, 144 pneumococcal strains were detected. 
Within the 144 strains, 40 distinct serotypes and NTs (Figure 3.10) were detected. 
Only 12 of the 13 PCV13 serotypes were identified in adults, with serotype 9V 
undetected. Failure to detect carriage of serotype 9V in adults may be due to chance, 
although serotype 9V alongside 6B, 14, 19F and 23F are recognised as paediatric 
serotypes (Feikin et al., 2005). Cumulatively, PCV13 serotypes represented 30% of 
the overall frequency of isolation taking into account NTs. Excluding NTs, PCV 
coverage was estimated to 38.5%, which is less than 62% reported elsewhere 
(Adetifa et al., 2012). This would suggest higher diversity of circulating 
pneumococcal serotypes in Malawian adults, however, a less sensitive latex 
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agglutination method and not microarray was used for serotyping in the Nigerian 
study, which could contribute to the observed differences. The remaining 
pneumococcal strains in adults (70%) comprised non-vaccine (NVT) serotypes 
(50%) and NTs (20%). NVT serotypes, defined as either having a high invasive 
potential or low invasive potential (Section 3.2.1), represented 30% and 20% of the 
total isolation frequency of pneumococcal serotypes respectively (Figure 3.10). 
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Figure 3.10 Serotype specific carriage of S. pneumoniae in adults 
The samples (n=117) were sub-divided into HIV negative (HIV-) and HIV positive (HIV+). Serotypes present in each sample were characterised 
by microarray. Results showed 40 distinct serotypes (82%) and NTs (18%) representing a total frequency of isolation of 144.  
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Considering PCV13 serotypes alone, the most abundant serotypes ranked in order of 
decreasing population frequency of isolation were: 3, 19F, 14, 6A, 23F, 6B, 19A, 4, 
18C, 1, 5 and 7F.Serotype 1, 5 and 7F were detected once in single serotype adult 
carriers in the entire data set, each representing 0.7% (1/144) of the total frequency 
of serotype isolation. As previously described, both serotypes 1 and 5 are the most 
common causes of invasive disease in Malawi (Everett et al., 2012, Cornick et al., 
2011) and elsewhere (Esteva et al., 2011), however they are rarely detected in 
carriage (Almeida et al., 2013). The NVT serotypes present in adults and their 
frequency of isolation are shown in the figure below (Figure 3.11). Serotypes 16F, 
10B, 11D, 13, 17F and 21 were the most commonly isolated NVTs in adults 
representing a total frequency of isolation of 28. 
 
 
 
Figure 3.11 Carriage of nonvaccine serotypes in adults 
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3.4.1 Pneumococcal carriage by HIV status in adults 
By HIV status, the adult‟s dataset was grouped into HIV negative (n=26) and HIV 
positive (n=91) individuals (Chapter 2, Section 2.2). The distribution of 
pneumococcal serotypes in the two cohorts was investigated to establish if HIV 
infection had any impact on the observed diversity of pneumococcal carriage. Thirty-
two (32) pneumococcal strains were isolated from HIV negative adults (n=26) and 
112 from HIV positive adults (n=91) (Figure 3.10). There was no statistical 
difference in serotype distribution by HIV infection (p<1.0), however, because of the 
limited sample size, this may not be conclusive. Seventeen (17) distinct serotypes 
were identified within the HIV negative individuals whereas 40 were identified 
amongst HIV positive individuals. Within those 40 serotypes, all the serotypes 
detected in the HIV negative cohort were also present which demonstrated an 
overlap across carriage by HIV status. The results for serotype distribution after sub-
categorising HIV positive individuals by CD4 count are presented in Figure 3.12.Of 
the 91 HIV positive individuals, the CD4 count data was available for 79 subjects. 
Samples were stratified into two groups: CD4 250 (n=44) and CD4>250 (n=35). 
Within this subset 40 pneumococcal serotypes were identified and 19 of those 
serotypes were common to both cohorts. Those with CD4 250, had 13 serotypes 
(10B, 18A, 5, 7C, 7F, 12F, 13, 18F, 20, 22F, 31, 37, 46) which were only isolated 
from this cohort, whereas 8 serotypes (21, 9L, 1, 4, 6B, 18C, 33A, 45) were 
identified only in those with CD4>250. The large proportion (47.5% (19/40)) of 
serotypes common to both cohorts suggested no difference existed in the distribution 
of serotypes. This was further supported by calculating the mean number of 
serotypes carried per individual, with those having CD4 250 registering 1.25 (1.07-
1.42), similar to those with CD4>250 who registered 1.13 (1.03-1.23).  
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Figure 3.12 Pneumococcal carriage by CD4 count in adults 
Two groups of samples from HIV positive adults were compared based on whether their CD4 count was less than or equal to 250 (CD4 250) or 
greater than 250 (CD4>250). Overall, 40 pneumococcal serotypes (76%) and NTs (24%) were identified. 
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3.4.2 Pneumococcal carriage by ART in HIV infected adults 
In this study, a broader range of pneumococcal serotypes was observed in those 
individuals with low CD4 counts. Previous findings have shown an increase in 
colonisation rates following a drop in CD4 count (Rodriguez-Barradas et al., 1997). 
We investigated whether ART usage had any impact on pneumococcal carriage in 
adults (Figure 3.13). The dataset comprised 19 adults on ART (ART+) and 35 ART 
naïve adults. The dataset yielded 72 pneumococcal strains with 28 distinct serotypes 
(67%) and NTs (33%), by microarray. From the ART negative cohort, 46 
pneumococcal strains were detected, which comprised 24 distinct serotypes and NTs; 
while the ART positive group yielded 26 pneumococcal strains, comprising 13 
distinct serotypes and NTs. Further analysis showed that 15 serotypes (14, 10B, 23A, 
4, 6B, 7C, 12F, 15B, 17F, 18A, 18C, 20, 22F, 37, 38) were only detected in adults 
not exposed to ART, while 4 serotypes (5, 6A, 33A, 45) were only isolated from 
adults on ART. The data in our study showed that subjects who were ART naïve 
carried a broader range of pneumococcal serotypes than the ART+ group, however 
the difference was not statistically significant (p<0.2541). Similarly, there was no 
difference in the mean number of serotypes carried between subjects who were ART 
naïve (1.31, 1.13-1.50) and those exposed to ART (1.37, 1.08-1.66). Given the 
limitation with sample numbers, these findings reported here would warrant further 
investigation to establish the actual impact of ART on carriage.
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Figure 3.13 Pneumococcal carriage by ART in HIV infected adults 
Two groups were compared based on whether they were on anti-retroviral therapy (ART+) or not. A total of 72 pneumococcal strains were 
isolated, with 28 distinct serotypes (67%) and NTs (33%) detected.
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3.5 Multiple carriage in Malawian adults 
Pneumococcal carriage in children is higher than in adults (Hussain et al., 2005, 
Adetifa et al., 2012). In this study, we investigated whether this was true with respect 
to multiple carriage. Results showed that 19% (22/117) of the adult population 
(Figure 3.14A) carried at least two serotypes in their nasopharynx. The maximum 
number of serotypes carried at any one time was 3 and this was observed in 4% 
(5/117) of the adult population. The majority of multiple carriage in adults involved 
2 serotypes (15% (17/116)). Compared with children (Section 3.3), the results 
showed that multiple carriage was lower in adults by 21%. By HIV status, multiple 
carriage rates were similar in HIV negative (16%, 4/26) (Figure 3.14B) and HIV 
positive (20%, 18/91) (Figure 3.14C) adults, which supports previous observations 
where multiple carriage was not affected by HIV status (Glennie et al., 2012a). The 
same study reported an increase in colonisation rate with a decrease in CD4 count in 
adults (Glennie et al., 2012a). In this study, we investigated if CD4 count had any 
impact on multiple carriage in adults. To achieve this, the two sub-groups with 
CD4 250 (n=44) and CD4>250 (n=35) were compared. Multiple carriage was 
detected in 18.2% (8/44) of the samples from the CD4 250 group and 17.1% (6/35) 
in samples from individuals with CD4>250, demonstrating no difference in carriage 
of multiple serotypes. Similarly, multiple carriage was also unaffected by ART 
usage, with those exposed to ART having a 31.5% (6/19) while 28.6% (10/35) was 
observed in individuals who were ART naïve. This is in agreement with previous 
findings where elevated levels of pneumococcal colonisation were maintained in 
adults established on ART (Glennie et al., 2012a). 
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Figure 3.14 Multiple carriage in adults 
The prevalence of multiple carriage in Malawian adults (A) was ~19 % (22/117). By 
HIV status, multiple carriage was 16% (4/26) in HIV negative subjects (B) and 20% 
(18/91) in HIV positive subjects (C). 
 
Further assessment of serotype associations in multiple carriage (Figure 3.15) 
showed 4 serotypes (10B, 31, 29, and 23A) that were only isolated from multiple 
carriage events involving three serotypes, while 18 serotypes (3, 33A, 23F, 13, 21, 
9L, 38, 6B, 28F, 4, 35A, 45, 22F, 7B, 37, 19A, 14, 19F) were only isolated from 
multiple carriage events involving two serotypes. This was done to characterise 
possible associations among serotypes in multiple carriage, but due to a small 
number of samples carrying multiple serotypes, we were not able to make such 
deductions, hence the need for further investigations. However, nontypeable 
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serotypes (Chapter 1, section 1.1) were isolated from both events of multiple 
carriage. Cumulatively NTs were present in 43.8% of all multiple carriage events 
(Figure 3.15). NTs have been widely isolated in other carriage studies (Marsh et al., 
2010, Scott et al., 2012), and in this study, we found that NTs appear in multiple 
carriage events more than any other serotype (p<0.0058) in Malawian adults. By 
carrying high proportion of NTs, Malawian adults may contribute to the development 
of antibiotic resistance in Malawi because the presence of NTs in multiple carriage 
with encapsulated serotypes would promote the dissemination of antibiotic resistance 
genes (Marsh et al., 2010, Hauser et al., 2004, Chewapreecha et al., 2014).
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Figure 3.15 Serotypes isolated from multiple carriage in adults  
Nontypeable serotypes (NT) were most likely to be detected in multiple carriage with encapsulated S. pneumoniae and cumulatively, NTs 
represented 45% of the total frequency of isolation.
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Figure 3.15 Serotypes isolated from multiple carriage in adults 
Nontypeable serotypes (NT) were most likely to be detected in multiple carriage with encapsulated S. pneumoniae and cumulatively, NTs 
represented 45% of the total frequency of isolation.
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3.6 Discussion 
Historically, there has been a reliance on serological techniques such as the Quellung 
reaction and latex agglutination for pneumococcal serotyping (O'Brien and Nohynek, 
2003). The limitation of using serological techniques in serotyping is that they are 
expensive, labour intensive, and are biased towards detecting the most abundant 
serotype in subjects carrying multiple serotypes. In this study, the diversity of 
pneumococcal carriage in Malawian children and adults was determined by 
microarray (Chapter 2, section 2.6), which does not only detect serotypes, but also 
carriage of multiple serotypes and their relative abundance (Turner et al., 2011).  
 
A broad range of carriage pneumococcal serotypes in Malawian children and 
adults. Serotype distribution across children (Section 3.2.1) and adults (Section 3.4) 
was equally broad with a total of 43 and 40 distinct serotypes and NTs detected 
respectively. This diversity was higher than any previously reported study in Malawi 
(Feikin et al., 2003) or elsewhere in Africa (Adetifa et al., 2012). Based on carriage 
data, PCV13 serotypes coverage was estimated at 31% in adults, which was lower 
than the 60% in children, suggesting that the vaccine would likely be more effective 
in children compared to adults. Based on invasive disease surveillance data, PCV13 
coverage in Malawi was reported to be 88% (Cornick et al., 2011). The difference in 
PCV13 coverage estimates between carriage and invasive strains is to be expected as 
there is a more diverse range of serotypes in carriage compared to those commonly 
associated with invasive disease. Failure to adequately account for serotype 1 in 
carriage could also contribute to the apparent low coverage of PCV13. Therefore 
coverage estimates based on carriage data should be interpreted in this context when 
considering using them as supplementary or alternative endpoint for licensure of 
157 
 
vaccine in a given population (Goldblatt et al., 2013). 
 
The low PCV13 coverage estimates based on carriage also suggest that a large 
proportion of NVT serotypes would remain in circulation post-vaccination. For a 
resource poor setting such as Malawi, this is of concern because an increase in 
carriage of NVT post PCV introduction (Obaro et al., 1996), may be followed by an 
increase in NVT IPD (Vestrheim et al., 2010). Although our data suggest a high 
likelihood of serotype replacement occurring in Malawi post vaccination (Link-
Gelles et al., 2013), it is not possible to predict which serotypes those might be, 
because the reasons a particular NVT serotype increases after vaccine introduction 
remain unclear (Link-Gelles et al., 2013). Previously, it has been reported that a non-
vaccine serotype 22F (with low carriage prevalence) was associated with 
replacement disease post PCV7 (Flasche et al., 2011b). In our dataset, serotype 22F 
was isolated in carriage from both children and adults, making it one of the most 
likely serotypes to cause replacement disease post PCV13 in Malawi. The predicted 
post vaccination effect however can only be verified by conducting post vaccination 
surveillance of pneumococcal serotypes in carriage and/or disease. 
 
Nontypeable serotypes represented <2% and 18% of all serotypes detected in 
Malawian children and adults respectively. In other settings, NT carriage rates of up 
to 18% (n=97) (Mackenzie et al., 2009, Marsh et al., 2007) and 6% (n=218) 
(Ercibengoa et al., 2012) have been reported in children, which were higher than 
Malawian children for similar sample sizes. In Thailand (n=234, mother infant pairs), 
carriage of NTs in children and adults (mothers) was 10.5% and 29.6% respectively 
(Turner et al., 2012), which was higher than Malawi, although in both settings, NT 
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carriage rates were higher in adults than children. The reasons for higher carriage of 
NTs in adults than children remain unknown. Further observation showed that NTs 
were frequently isolated from multiple carriage with encapsulated pneumococcal 
strains in our setting (Section 3.5), which may increase the chance of genetic 
exchange with encapsulated pneumococcal strains (Chewapreecha et al., 2014).  
 
Multiple carriage is higher in Malawian children than adults. The prevalence of 
multiple carriage in Malawian children (Section 3.3) was 40% (46/116), higher than 
that observed elsewhere (Valente et al., 2012). The prevalence of multiple carriage in 
Malawian adults (Section 3.5) was 19% (22/117), which was lower than the 
prevalence in children. The maximum number of serotypes isolated from multiple 
carriage in children was 4, isolated from 1.7% (2/116) of the children‟s population. 
In adults, the maximum number of serotypes carried at any one time was 3 and this 
was observed in 4% (5/117) of the entire adult population, whereas in children 
multiple carriage involving 3 serotypes was detected in 11 % (13/116) of the 
children‟s population. The majority of multiple carriage events across children and 
adults involved 2 serotypes, which was also higher in children (27% (31/116)) than 
adults (15% (17/117)). The observed difference in multiple carriage between 
children and adults could be attributed to the developing immune system in children, 
which might not be able to regulate pneumococcal carriage as well as the developed 
immunity in adults (Granat et al., 2009, Glennie et al., 2012b). Other factors such as 
having young siblings in the home and breast-feeding, which impact on carriage in 
children (Regev-Yochay et al., 2004b, Reisman et al., 2013), may also play a role in 
the observed higher multiple carriage rates in children. 
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In addition to promoting horizontal gene transfer (Donkor et al., 2011), multiple 
carriage has also been associated with an increase in the density of pneumococcal 
carriage in the nasopharynx (Brugger et al., 2010). Recently, studies have shown a 
correlation between an increase in the density of S. pneumoniae in carriage and 
pneumonia in adults (Albrich et al., 2012, Vu et al., 2011), suggesting density could 
be used as a diagnostic marker. However, in a setting with high rates of multiple 
carriage, the diagnosis of pneumoniae based on bacterial density needs to be 
interpreted with caution (Shak et al., 2012). A recent study has shown a decrease in 
multiple carriage following vaccination (Valente et al., 2012). It remains to be see 
whether multiple carriage would decrease post-vaccination in Malawi. A decrease in 
multiple carriage would consequently decrease the available pool of genes required 
for genetic recombination (Chapter 5, Section 5.2.1). However, recombination rates 
are still likely to accelerate among vaccine serotypes under vaccine selection 
pressure (Brueggemann et al., 2007a, Croucher et al., 2013) as a survival mechanism. 
The consequence of which is to give rise to new strains that may not be responsive to 
vaccination. Malawi introduced routine pneumococcal vaccination with PCV13 as 
part of the infant expanded programme on immunisation in November 2011 (Everett 
et al., 2012), targeting children aged 2 years and below. The PCV13 schedule is 
recommended for children aged between 2-71 months (Table 3.4) and adults aged 50 
years and above (http://www.cdc.gov). In Malawi, the Ministry of Health 
recommends administration of a 3-dose PCV13 schedule to children at 6, 10 and 14 
weeks old. We have shown in our study, that carriage of PCV13 serotypes is similar 
in Malawian children across the age range of 0-12 years. However, vaccinating 
children under the age of 5 years has been reported to be effective at reducing 
transmission to older children and adults (Section 3.2.3), thereby ensuring herd 
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immunity. PCV13 is expected to reduce carriage and invasive disease by VT 
serotypes in the vaccinated population in Malawi, however, elimination of VT 
serotypes is followed by carriage of less abundant non-vaccine serotypes, which has 
led to NVT invasive disease in other settings (Singleton et al., 2007, Flasche et al., 
2011b, Weinberger et al., 2011). Further carriage studies post-vaccination would be 
recommended to assess the impact of vaccine introduction.  
 
Table 3.4 PCV13 routine vaccination schedule 
 
Age at first dose 
(months) 
Primary PCV13 series PCV13 booster dose 
 
2-6 
 
3 doses 
 
1 dose at age 12-15 
months 
 
7-11 
 
2 doses 
 
1 dose at age 12-15 
months 
 
12-23 
 
2 doses 
 
- 
 
24-59 (healthy) 
 
1 dose 
 
- 
 
24-71 (children with 
immunocompromising 
conditions) 
 
2 doses 
 
- 
 
A recommendation by the advisory committee on immunization practices (ACIP), 
United States, 2010 (http://www.cdc.gov). 
 
Impact of HIV infection on pneumococcal carriage and multiple carriage in 
Malawian children and adults. We showed that HIV negative children (Section 
3.2.2) carried a broader range of serotypes compared to HIV positive children. Of all 
the serotypes detected in children‟s data set, only serotype 3 was more likely to be 
carried in HIV infected than un-infected individuals. Although serotype 3 was 
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isolated in adults, its association with HIV infection was not observed (Section 
3.4.1). Such a finding therefore requires further investigations; since there is a 
possibility it may have occurred by chance. HIV infection did not have a significant 
impact on the prevalence of multiple carriage (p<0.34) although it was higher in HIV 
negative (43%, 31/72) than HIV positive children (34%, 15/44). There was also no 
significant difference (p<0.5447) in the prevalence of multiple carriage between HIV 
negative (15%, 4/26) (Figure 3.14B) and HIV positive (20%, 18/91) (Figure 3.14C) 
adults, which suggested the lack of association between HIV infection and multiple 
carriage in Malawian children and adults, as previously reported in Malawian adults 
(Glennie et al., 2012a).  
 
Pneumococcal carriage diversity in adults was higher in the HIV positive compared 
to HIV negative adults (Section 3.4.1). However, there was no significant difference 
in the diversity of serotypes in carriage by HIV status (p<0.7090) because of a huge 
overlap in serotypes detected in the two groups. This finding is consistent with a 
previous carriage study in the USA (Rodriguez-Barradas et al., 1997), where no 
significant difference was observed in the carriage prevalence of any serotype 
between HIV-infected and –uninfected adults. Among the HIV positive adults, 
carriers with low CD4 count (CD4 250) had a wider range of serotypes than those 
with high CD4 counts (CD4>250). It is known that CD4 counts are lower in HIV 
positive patients and previous work in Malawi has shown colonisation rates increase 
with decreasing CD4 counts (Glennie et al., 2012a). HIV infection has been reported 
to impair the innate and adaptive immune system and also compromises the integrity 
and function of the epithelial barrier (Glennie et al., 2010). This renders the host 
mucosal barrier ineffective at regulating carriage and could explain why there is 
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broad range of pneumococcal serotypes carried in HIV positive subjects, particularly 
those with low CD4 counts.  
 
Impact of ART on carriage and multiple carriage in HIV infected children and 
adults. HIV infected subjects have a depleted number of peripheral blood CD4 T 
cells which (Cassol et al., 2013) is associated with prolonged colonisation of mucosal 
pathogens such as S. pneumoniae (Glennie et al., 2010). Anti-retroviral therapy 
(ART) reconstitutes the immune system by increasing CD4 T cell levels (Le et al., 
2013), which is expected to enable the host immune system mount a better response 
against pneumococcal carriage. The usage of ART in children (Section 3.3.3) did not 
result in any significant difference (p<0.3368) in the distribution of pneumococcal 
serotypes in samples collected pre- and post-ART. Similarly, ART did not have any 
impact on serotype distribution in adults (p<0.9435) although subjects who were 
ART naïve carried a broader range (25, n=35) of pneumococcal serotypes than the 
group on ART (14, n=19). Having shown that ART did not have an impact on 
serotype distribution in both children and adults in our context, we investigated 
whether this also applied to carriage of multiple serotypes. Whilst ART showed no 
effect on multiple carriage in the adult population (Section 3.4.2), there was a 
significant increase of multiple carriage in HIV positive children (p<0.038), 
following ART introduction (Section 3.3.2). Recently, it has been reported that 
although there is an increase in CD4 cells following ART usage, there is a 
persistence of defects in pneumococcal specific T cell proliferation (Glennie et al., 
2012a) which results only in partial reconstitution of the immune system (Cassol et 
al., 2013). This could contribute to the lack of change in multiple carriage 
prevalence; following ART usage in Malawian adults and children, however there is 
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need to establish if immune reconstitution was achieved in this context before such 
conclusions can be made. In addition, further analysis on a larger dataset and also 
after prolonged usage of ART would be recommended, given a study in Brazil 
reported lower risk of colonisation by S. pneumoniae following prolonged ART 
usage (Nicoletti et al., 2007). 
 
3.7 Conclusion 
This chapter has demonstrated the carriage of a broad range of serotypes amongst 
children and adults in Malawi. These serotypes included those covered by the current 
conjugate vaccine (PCV13), with an estimated 60% and 30% coverage in children 
and adults respectively; and a wide variety of non-vaccine serotypes. The coverage is 
lower than 88.8% estimate based on invasive disease in Malawian children ranging 
from 2 months to 16 years old (Cornick et al., 2011). This difference could be 
attributed to prevalence of serotype 1 which was present at very low abundance in 
carriage in our dataset yet it is the most commonly isolated serotype from invasive 
disease in Malawi. This suggests that estimating coverage based on carriage data 
only can be misleading. Our dataset had a large proportion of non-vaccine serotypes 
detected in both children and adults and potentially, these non-vaccine serotypes will 
be freely transmitted within the population. This may create a perfect environment 
for serotype replacement post vaccination, which may affect the benefits of PCV13 
introduced in Malawi in 2011, if it translates to disease by non-vaccine serotypes 
(Weinberger et al., 2011). The data has also demonstrated for the first time in 
Malawi, a high prevalence of multiple carriage in Malawian children (40%) and a 
relatively lower prevalence in adults (19%). It is therefore recommended that 
nationwide post-vaccination pneumococcal carriage and disease surveillance be 
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established to monitor the impact of vaccination. By HIV status, HIV negative 
children carried a broader range of serotypes than HIV positive children, whereas a 
significant overlap in carriage serotypes was observed in adults by HIV infection. 
HIV infection did not show an impact on the prevalence of multiple carriage in 
Malawian children and adults. There was also no impact of ART usage on multiple 
carriage in adults, however, multiple carriage was significantly higher in samples 
collected from children post-ART than pre-ART. The data on carriage by HIV status 
in our setting requires further investigation because to date the relationship between 
carriage and HIV infection is still not fully understood. A summary comparing the 
findings in adults and children is presented in table 3.5. 
 
165 
 
Table 3.5 Summary of carriage findings in children and adults 
 
Variable 
 
General 
Children (n=116) Adults (n=117) 
1 Total isolation freq.  176 144 
2 Serotypes 43 (99%; cum. percent) 40 (82%; cum. percent) 
3 Nontypeables 1% (cum. percent) 18% (cum. percent) 
4 PCV coverage 60% 31% 
5 Multiple carriage 40% 19% 
 
HIV status HIV (Costa et 
al.) 
(n=72) 
HIV (+ve) 
(n=44) 
HIV (Costa et 
al.) 
(n=26) 
HIV (+ve) 
(n=91) 
 
1 Total isolation freq. 114 62 32  112 
2 Serotypes 39 22 17 40 
3 Nontypeables 0.8% 0.2% 5% 13% 
5 Multiple carriage 43% 34% 16% 20% 
    
ART Usage 
 
 ART (-) 
(n=16) 
ART (+ve) 
(n=16) 
 
 ART (-) 
(n=19) 
ART (+ve) 
(n=35) 
5 Multiple carriage  25% 62%  31.5% 28.6% 
 
166 
 
Chapter 4:  Pneumococcal carriage dynamics (longitudinal) by 
microarray and Quellung serotyping 
 
4.0. Introduction 
Children are colonised by a number of different strains of S. pneumoniae from birth 
(Hussain et al., 2005, Lloyd-Evans et al., 1996). The duration of nasopharyngeal 
carriage can vary with each serotype. Generally in children, a single serotype can be 
carried for up to three months (Hill et al., 2008b, Turner et al., 2012). Factors that 
affect the duration of serotype carriage include the host immunity (Goldblatt et al., 
2005). The duration of carriage for all serotypes has been shown to decrease with age 
(Cobey and Lipsitch, 2012) due to the acquisition of nonspecific immunity to 
pneumococcus (Cobey and Lipsitch, 2012, Hogberg et al., 2007). This immunity is 
thought to be largely dependent on CD4+ T helper -17 cells (Malley et al., 2005, Lu 
et al., 2008). Other factors such as competitive interaction with other colonising 
bacteria in the nasopharynx (Bosch et al., 2013), viral co-infections (Diavatopoulos 
et al., 2010), as well as thickness of the capsule (Hogberg et al., 2007) have all been 
shown to impact on carriage duration. It has also been reported that the duration of 
carriage is inversely proportional to the invasive capacity of a given serotype 
(Sleeman et al., 2006). Having analysed the cross-sectional carriage of S. 
pneumoniae in both adults and children (Chapter 3), we then investigated how 
carriage of S. pneumoniae varied with time in an individual. The aim was to 
understand levels of pneumococcal transmission and describe pneumococcal genetic 
diversity over-time given their relevance to disease control. This chapter therefore 
discusses carriage of S. pneumoniae over time in infants less than 12 months old, 
from a rural population in Karonga, taking advantage of a larger study of 
167 
 
pneumococcal carriage undertaken at the Karonga Prevention Study (Chapter 1, 
section 1.0). 
 
4.0.1 Methods 
The detailed methods for this section are outlined in chapter 2. Briefly, the profile of 
carriage pneumococcal serotypes was defined using a subset of longitudinal samples 
(n=16) randomly selected from a larger dataset of 158 participating infants in 
Karonga (Chapter 2, Section 2.1). This sample size was adequate for understanding 
how carriage varied in a given child over the chosen period of time; however, to 
understand carriage dynamics of the entire population, analysing a larger dataset 
would be recommended. The overall aim of this study was to understand the 
transmission of pneumococcal strains in carriage. Although sampling was conducted 
every four weeks from birth up to one year (Chapter 2, Section 2.1), this study only 
analysed samples from four subsequent sampling points, previously shown to be 
positive for S. pneumoniae in each subject. The DNA was isolated (Chapter 2, 
Section 2.5) and used to identify pneumococcal serotype(s) at each sampling point 
by microarray (Chapter 2, section 2.6). Whole genome sequencing (Chapter 2, 
section 2.7) was performed on each serotype to determine the genetic diversity. Prior 
to microarray serotyping, pneumococcal serotypes at each sampling point were 
initially identified using Quellung, which was employed as a routine serotyping 
technique commonly used in a clinical laboratory set up. This provided an 
opportunity to define and compare the serotypes identified at each sampling point by 
the two serotyping methods. 
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4.1. Results 
4.1.1. Serotype concordance between microarray and Quellung reaction 
Sixty-three (63) pneumococcal strains were detected; however only 52 were 
successfully serotyped using Quellung to yield 24 distinct serotypes (Figure 4.1). 
The serotypes of the remaining 11 strains could not be characterised, and were thus 
designated as unidentified (UD). While nontypeable serotypes could not be identified 
by Quellung reaction, it must be pointed out that the full panel of antisera for 
Quellung reaction was not available. This may have contributed to „UD‟ serotypes, 
and not necessarily failure by Quellung to identify serotypes. The microarray 
detected 102 pneumococcal strains, which was 62% higher detection rate compared 
to Quellung. The microarray provided a serotype on all the pneumococcal strains, 
yielding 26 distinct serotypes and nontypeables (Figure 4.1). These findings suggest 
that the microarray was able to detect more pneumococcal strains and was able to 
ascribe a serotype to each strain detected. The inflated number of serotypes was 
attributed to the detection of multiple carriage by the microarray. Conventional 
serotyping by the Quellung reaction was employed as a routine serotyping technique 
commonly used in a clinical laboratory set up and there was no attempt to determine 
multiple carriage by this technique at the time of initial sampling. The requirements 
to (i) undertake multiple Quellung reactions to determine serotype and (ii) have a full 
set of antisera to complete this process make it a hugely unfeasible process 
particularly for large scale carriage studies.  
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Figure 4.1  Serotypes detected by microarray and Quellung reaction 
For this cross-sectional data analysis, only samples from the first sampling point were used. The data showed a wider range of serotypes detected 
using microarray serotyping compared to the Quellung reaction.
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To determine the concordance between the two serotyping methods, only samples for 
which a serogroup/serotype was assigned by both methods were compared. A 
common serogroup type was identified in 91% (48/52) of all pneumococcal strains, 
which is in agreement with previous findings (Turner et al., 2011). The agreement by 
serotype was 70% (37/52), which was lower than serogroup concordance suggesting 
the difficulty by the two methods to resolve pneumococcal serotypes particularly 
within a given serogroup because they are closely related. To determine the accuracy 
of detection by Quellung only the most abundant serotype in multiple carriage events 
were considered. Results showed that Quellung reaction detected the most abundant 
serotype in 67% (22/33) of multiple carriage events, demonstrating that Quellung 
serotyping was likely to detect the most abundant serotypes in multiple carriage as 
opposed to the least abundant ones (Table 4.1). This is attributed to the fact that in a 
routine clinical laboratory set-up, only a single colony is picked for serotyping by the 
Quellung, thus the most abundant serotype has a higher probability of being sampled 
for analysis. With such a bias, Quellung reaction most underestimate the number and 
serotype profiles in circulation, which may have negative implications for assessing 
the impact of vaccination as well as understanding transmission of pneumococcal 
strains within the community. 
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Table 4.1 Serotyping by microarray and Quellung reaction 
 
Sample 
 
Sampling 
point 
Microarray (Relative abundance) Quellung 
A 1 *19F (95%) + NT4a (5%) 19F 
 2 *19F (99%) + 9V (1%) 19F 
 3 *9V (65%) + 19F (35%) 9A 
 4 *9V (94%) + 19F (3%) + 37 (3%) 9V 
B 1 *16F (99%) + NT4a (1%) 16F 
 2 *9V (95%) +NT4b (3%) + 37 (2%) 9V 
 3 NT4b (55%) + 37 (45%) 18B 
C 1 *14 (54%) + 23B (46%) 14 
 2 *23B (94%) + 14 (6%) 23B 
D 1 NT3b (41%) + 35B (37%) + NT2 (22%) 35 
 2 *19F (99%) + NT4a (1%) 19F 
E 1 *19F (93%) + 35F (7%) 19F 
 2 35F (58%) + 19F (42%) UD 
 3 35F (95%) + 19F (5%) 15A 
F 1 *15B (98%) + 16F (2%) 15B 
 2 *15C (87%) + 3 (13%) 15B 
 3 6B (76%) + 16F (24%) UD 
 4 *6B (82%) + NT3b (18%) 6B 
G 1 *11D (85%) + NT4a (15%) 11 
 2 *19A (89%) + 11D (11%) 19A 
H 1 *16F (60%) + NT3b (20%) + NT2 (20%) 16F 
 2 *9V (59%) +16F (41%) 9V 
I 1 *10B (51%) + NT4b (44%) + 34 (5%) 10B 
J 1 9L (91%) + 23B (9%) 23B 
 2 *23B (95%) + 10A (5%) 23F 
 3 *9L (85%) + 23B (5%) 9N 
K 1 16F (51%) + 14 (49%) 17F 
 2 NT3b (67%) + NT3a (33%) UD 
 3 NT3B (89%) + 14 (11%) UD 
L 1 21 (68%) + 6B (33%) 6B 
 2 *4 (80%) + 21 (20%) 4 
 3 *23F (99%) + 4 (1%) 23B 
 4 *23F (74%) + NT3b (26%) 23F 
 
Strains detected by Quellung reaction were present as the most abundant (*) in 
multiple carriage events by microarray. (UD) denotes unidentified serotypes. 
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4.1.2. Pneumococcal carriage dynamics over time by microarray 
The carriage dynamics of specific pneumococcal serotypes over time was 
investigated using longitudinal samples from a subset of children (n=16) in Karonga. 
The aim was to establish whether the ability by microarray to detect low abundance 
pneumococcal strains would extend the measured carriage duration of pneumococcal 
strains and whether there was any difference by serotype. A total of 63/64 (one 
sample did not grow on subsequent culturing) samples collected at four sequential 
time points from each of the 16 children were analysed. Serotyping by microarray 
yielded 26 distinct serotypes, including nontypeablestrains and at each sampling 
point, at least one strain was detected. Quellung reaction only identified one serotype 
at each sampling point and this was largely the most abundant serotype in multiple 
carriage events.  
 
Carriage dynamics of single serotypes over time. Microarray results showed that 
25% (4/16) of the children carried a single serotype at each sampling point (Table 
4.2 A). These children were C3, C9, C12, and C13.Three of the 4 children (C3, C9, 
C13) carried the same serotype at three subsequent sampling points (Table 4.2 A and 
B) and a different serotype was detected at each sampling point for the remaining 
child (C12) (Table 4.2 C). These data indicate that over time, carriage of a particular 
serotype persisted in a given individual, while in other cases; different serotypes 
were carried at each sampling point highlighting the complexity of carriage. 
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Table 4.2 Serotype specific carriage dynamics overtime by microarray 
A 
  
Decreasing frequency of isolation 
 
C W NT 6B 19F 14 16F 9V 23B 10A 21 4 9L 11D 35F 37 18C 19A 23F 3 5 6A 10B 15B 15C 19B 34 35B 45 
1 0                            
4                            
8                            
12                            
  
2 0                            
4                            
8                            
12                            
  
3 0                            
4                            
8                            
12                            
  
4 0                            
4                            
8                            
12                            
  
5 0                            
4                            
8                            
12                            
 
The samples were collected from 16 children (C) every four weeks (W). The shaded regions denote carriage of a given pneumococcal serotype at 
each sampling point. The data is divided into three tables: A, B, and C 
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B 
  
Decreasing frequency of isolation 
 
C W NT 6B 19F 14 16F 9V 23B 10A 21 4 9L 11D 35F 37 18C 19A 23F 3 5 6A 10B 15B 15C 19B 34 35B 45 
6 0                            
4                            
8                            
12                            
  
7 0                            
4                            
8                            
12                            
  
8 0                            
4                            
8                            
12                            
  
9 0                            
4                            
8                            
12                            
  
10 0                            
4                            
8                            
12                            
  
11 0                            
4                            
8                            
12                            
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C 
 
  
Decreasing frequency of isolation 
 
C W NT 6B 19F 14 16F 9V 23B 10A 21 4 9L 11D 35F 37 18C 19A 23F 3 5 6A 10B 15B 15C 19B 34 35B 45 
12 0                            
4                            
8                            
12                            
  
13 0                            
4                            
8                            
12                            
  
14 0                            
4                            
8                            
12                            
  
15 0                            
4                            
8                            
12                            
  
16 0                            
4                            
8                            
12                            
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Carriage dynamics of multiple serotypes over time. Out of the 16 children, 12 
were shown to carry multiple serotypes at one sampling point (n=1), two sampling 
points (n=4), three sampling points (n=4) and all the four sampling points (n=3) 
(Table 4.2). This represented 75% (12/16) multiple carriage, however based on the 
total number of samples (n=63) from each sampling point, multiple carriage was 
detected in 33 samples which represented 52 % (33/63) multiple carriage rate 
(Section 4.1.4). The relative abundance (%) of each of the serotypes in multiple 
carriage was measured based on fluorescence intensity on microarray. This allowed 
the progression of serotypes in carriage over time to be tracked. For example, 
serotypes 19F and 35F (Figure 4.2) were detected at the first three sampling points 
(wk0 wk4, and wk8).  
 
 
Figure 4.2 Dynamics of multiple serotype carriage over time 
Showing carriage of two serotypes at each sampling point with changing relative 
abundance (%) over time (weeks). In brackets are serotypes detected by Quellung 
method. Pneumococcal strains that could not be serotyped by Quellung were 
designated UD (undetermined). 
177 
 
The relative abundance for serotype 19F decreased from 93% to 5%, while 35F 
increased from 7% to 95% within the same time period. None of the two serotypes 
(19F and 35F) were detected at the fourth sampling point except for a nontypeable 
serotype (NT). Figure 4.3 demonstrates carriage of serotype 19F across all four 
sampling points, with decreasing relative abundance over time. 
 
 
 
Figure 4.3 Dynamics of multiple serotype carriage over time 
Showing carriage of two or three serotypes at each sampling point with changing 
relative abundance (%) over time (weeks). In brackets are serotypes detected by 
Quellung method. 
 
At the first sampling point (wk0), serotype 19F existed as the most abundant 
serotype (95%) in multiple carriage with nontypeable serotype (NT) representing the 
remaining 5%. Across the three further sampling points, 19F remained but with a 
concurrently increasing relative abundance of serotype 9V. The relative abundance 
of serotype 19F decreased from 99% to 3%, while serotype 9V went from a low 1% 
178 
 
relative abundance to become the most abundant serotype at 94%. An additional 
serotype, serotype 37, at 3% relative abundance was detected at the last sampling 
point. The results above show a time dependent variation in relative abundance, 
which could be attributed to competition among colonising bacteria or evolving host 
immune response. Using the microarray, the acquisition of new serotypes was well 
demonstrated, for example, serotypes NT and 37 (Figures 4.2 and 4.3) were only 
present at the last sampling point although they were not observed at the previous 
three sampling points.  
 
4.1.3. Genetic diversity of pneumococcal serotypes over time 
4.1.3.1. Whole genome sequencing 
Analysis by whole genome sequencing was performed only on pneumococcal 
isolates detected at more than one sampling point. The aim was to determine whether 
or not, there were any genetic similarities between isolates from subsequent sampling 
points, given the high rates of genetic transformation that the pneumococcus 
undergoes, which sometimes occurs within a very short period of time (Calix et al., 
2012a), genetic analysis would determine if this had occurred. The pneumococcal 
serotypes were isolated from a re-culture of the original sample. Single colonies were 
picked and inoculated into BHI broth. The bacteria were harvested and DNA 
extracted as indicated previously (Chapter 2, section 2.5). To confirm the serotype at 
each sampling point, the DNA from each sample was subjected to PCR analysis by 
amplifying serotype specific genes within the capsular polysaccharide locus (Pai et 
al., 2006) (Appendix 7a). The PCR amplicons were analysed on a Bioanalyser 
(Chapter 2, section 2.5), which generated fluorescence units (FU) vs base pair (bp) 
length graphs (Electropherograms) of the respective amplified genes for each 
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serotype (Figures 4.4) (Appendix 7b). Serotypes were positively identified by the 
presence of a band with the expected size on a gel. For example, the identity of 
serotype 9L was established through the amplification of the wzx gene with an 
expected size of 516 base pairs. Serotypes 11D and 19F were both identified by 
amplifying wzy genes but with expected sizes of 304 and 463 base pairs respectively 
(Figure 4.4). 
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Figure 4.4 Bioanalyser electropherograms 
This confirmed the presence of 9L (512bp, wzx), 11D (466bp, wzy) and 19F (311bp, 
wzy), as previously determined by microarray. Similar electropherograms (Appendix 
4b) were generated for 6B (250bp, wciP), 9V (816bp, wzy), 16F (716bp, wzy), 23B 
(199bp, wzx), 23F (384bp, wzy), and 35F (517bp, wzy) (Pai et al., 2006, da Gloria 
Carvalho et al., 2010, Dias et al., 2007). 
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4.1.3.2. Multi-locus sequence typing 
MLST was performed on whole genome sequences using an in-house script 
developed at the Sanger Institute in Cambridge (UK). The aim was to establish 
whether subsequent serotypes belonged to the same or different genotypes, which in-
turn would inform the dynamics of carriage in the children over time. The genotype 
of each serotype was defined based on the MLST allelic profile obtained from the 
MLST database (http://www.spneumoniae.mlst.net) (Table 4.3). Thirty-seven 
pneumococcal strains were analysed: 6B (x5), 9L (x3), 9V (x2), 10A (x3), 11D (x3), 
14 (x2), 16F (x3), 19F (x8), 23B (x3), 23F (x2), and 35F (x3). The MLST allelic 
profiles for 90% (28/37) of the pneumococcal strains analysed were successfully 
obtained. Of these, 50% (14/28) allelic profiles not reported in the database, and their 
sequence types were thus designated as „novel‟. The sequence types for the 
remaining 14 samples were retrieved from the database: 10A (x3) (ST 5483), 14 (x2) 
(ST 63), 19F (ST 6095 (x5) and ST 347 (x2) and 23F (x2) (ST 802). In 9 
pneumococcal samples, the sequence types were unknown because the allele number 
for at-least one locus could not be established; hence they were reported as „nd‟ (not 
determined) (Table 4.3). The allelic profile for 6B serotypes isolated from two 
different children matched at only one (xpt) of the seven loci, while in serotype 19F, 
2 of the three children carried sequence type 6095 at all sampling points with the 
remaining child carrying sequence type 347. This suggested that more than one 
genotype of 6B and 19F were in circulation. The data showed that a particular 
individual carried the same pneumococcal genotype over the entire sampling period, 
however genotype variations were observed among different carriers of the same 
serotype. There is a possibility the genotype could change if carriage persisted for a 
much longer period of time, however this would require further investigation. 
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Table 4.3 Multilocus sequence typing 
 
A 
Sample 
Accession # 
Sero-
type 
Sequence-type  
 
 
Cluster 
MLST allelic profile 
AroE gdh gki recP spi xpt ddl Closest ST matchNotes 
ERS67710 6B    1 43 29 1 77 1 14  Double locus variant at gdh and spi alleles, 
ERS67708 6B  Novel-1  C3 1 43 29 1 77 1 14 8783 isolated from carriage NT in china 
ERS67709 6B    1 43 29 1 77 1 14   
ERS67687 6B  Novel-3  C8 2 8 1 10 17 1 19 2863; 4441;  Double locus variant (gki/ddl) alleles (2863)  
ERS67688 6B    2 8 1 10 17 1 19 5266 and gdh/gki (4441/5266) alleles 
ERS67700 9L    2 12 8 8 27 28 5 4914 Double locus variant at gdh/spi alleles (4914, 9L) 
ERS67701 9L  Novel-5  C10 2 12 8 8 27 28 5 8833 Andgdh/xpt alleles (8833, 9L) 
ERS67702 9L    2 12 8 8 27 28 5   
ERS67681 9V  nd  C14 nd 5 36 3 6 1 6   
ERS67680 9V    nd 5 36 3 6 1 6   
ERS67677 10A    8 11 255 47 6 346 9  Four different strains isolated from blood in Mozambique 
ERS67679 10A  5483  C1 8 11 255 47 6 346 9   
ERS67678 10A    8 11 255 47 6 346 9   
ERS67699 11D    2 18 6 10 17 20 19 5266 Single locus variant at xpt allele (22A), isolated from  
ERS67698 11D  Novel-2  C7 2 18 6 10 17 20 19  bacteremia in Kenya 
ERS67697 11D    2 18 6 10 17 20 19   
ERS67703 14 63  C6 2 5 36 12 17 21 14  Similar ST present in serotypes: 15A, 23F, 
ERS67704 14   2 5 36 12 17 21 14  19A, 19F and 23A from Europe and USA 
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B 
Sample 
Accession # 
Sero-
type 
Sequence-type  
 
 
Cluster 
MLST allelic profile 
AroE gdh gki recP spi xpt ddl Closest ST matchNotes 
ERS67705 16F    50 5 1 nd 6 88 14   
ERS67706 16F  nd  C4 50 5 1 nd 6 88 14   
ERS67707 16F    nd   nd  nd  nd  nd  nd nd   
ERS67675 19F    12 8 9 104 3 20 417  Isolated from bacteraemia in Kenya 
ERS67674 19F  6095  C11 12 8 9 104 3 20 417   
ERS67676 19F    12 8 9 104 3 20 417   
ERS67689 19F  6095  12 8 9 104 3 20 417  Isolated from bacteraemia in Kenya 
ERS67692 19F  nd C12 nd  nd nd nd nd   nd  nd   
ERS67694 19F  6095  12 8 9 104 3 20 417   
ERS67682 19F  347 C13 12 8 9 3 3 20 57  Isolated from blood in South Africa and carriage in Norway 
ERS67683 19F    12 8 9 3 3 20 57   
ERS67686 23B    2 43 54 5 7 20 6 5419 Double locus variant (gdh/recP, 6B) from blood in Mozambique 
ERS67684 23B  Novel-4 C9 2 43 54 5 7 20 6 6078 Triple locus variant (gdh/spi/xpt, 6A) from bacteraemia in Kenya 
ERS67685 23B    2 43 54 5 7 20 6 7530 Triple locus variant (gdh/recP/spi, 34) from carriage in Nepal 
ERS67712 23F  802 C5 10 13 53 1 72 38 31  Similar ST present in serotypes: 19F (China), 5 and 19A (Gambia) 
ERS67711 23F    10 13 53 1 72 38 31   
ERS67690 35F   8 11 255 47 13 346 nd   
ERS67691 35F  nd C2 nd  nd nd nd  nd  nd  nd    
ERS67693 35F    8 11 255 47 13 346 nd   
 
Sub-tables A and B show genotyping by MLST.
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4.1.3.3. Phylogenetic analysis 
A phylogeny is used to describe the evolutionary relationship among various 
biological species based on their physical or genetic properties. In this study, a 
phylogenetic analysis was performed on all subsequent serotypes to establish 
whether serotypes isolated from different sampling points were genetically related. 
This would consequently provide information on whether carriage at each sampling 
point over time involved the same strain or a different strain. The tree was generated 
based only on SNPs of whole genomes (Chapter 2, Section 2.9.1), using the genome 
of serotype 23F (FM211187) as standard reference (Figure 4.5). The sample 
accession numbers were used to identify respective serotypes at each sampling point. 
The serotypes appear in brackets immediately after the accession numbers. The tree 
generated 14 clusters (C1 to C14) (Figure 4.5). Each cluster was linked to the 
serotype and the child providing the samples. Serotypes contained in clusters C2 
(35F) and C12 (19F) were isolated from a single child. Serotype 6B showed two 
clusters, each containing two (C8) and three (C3) samples respectively. It was 
determined that clustering in 6B serotypes was linked to two different children 
providing the samples. Similarly, 19F serotypes belonged to three different clusters 
corresponding to three different children who provided the samples. This showed 
that similar serotypes isolated from different subjects were not phylogenetically 
related, and this was prominent in serotype 6B. However, similar serotypes, isolated 
from the same child, were phylogenetically related and belonged to the same cluster. 
Further, each cluster was shown to contain serotypes, which belonged to the same 
genotype (Table 4.2). These findings suggest two things: (i) there is high genetic 
diversity of carriage serotypes in Malawian children and (ii) the same serotypes 
isolated from subsequent sampling points in a given child over time belonged to the 
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same phylogenetic cluster suggesting they were genetically similar; a finding 
supported by MLST genotyping (Table 4.2). 
!
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Figure 4.5 Maximum likelihood phylogenetic tree 
The tree was generated using the SNPs of the whole genome of S. pneumoniae. The 
green arrows on the right indicate strains belonging to the same sequence type (in 
brackets), which were either known, novel, or not determined as defined before 
(Section 4.6.2). 
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4.1.3.4. Genetic distance between subsequent serotypes 
Genetic distance is a measure genetic difference between closely related species 
(Nei, 1972). To determine genetic distance, pairwise genetic distance (d) between 
strains was calculated as a Hamming distance. Hamming distance compares each 
nucleotide base in aligned genomic sequences of two sequences selected from the 
generated multiple sequence alignment. For example, the genetic distance between 
ACGTTACGA and ATGCTATGA is 3. In the present study, the genetic distance 
was determined (Figure 4.6), to establish whether subsequent serotypes at each 
sampling point belonged to the same or different strains.  
 
For clusters containing two serotypes (Figure 4.5), the comparison yielded a single 
value for SNPs differences as there could only be one comparison made: C4_16F (5 
SNPs); C5_23F (5 SNPs); C6_14 (3 SNPs); C8_6B (12 SNPs); C13_19F (16 SNPs) 
and C14_9V (11 SNPs). In brackets are values for the SNPs differences between 
serotypes at two subsequent sampling points. However, for all the clusters containing 
three serotypes (C1, C2, C3, C7, C9, C10, C11, C12), three possible SNPs 
comparisons were made, yielding a maximum number of three SNPs values. The 
results (Figure 4.6) showed SNPs differences existed between subsequent serotypes; 
however these differences were not statistically significant, suggesting that at each 
subsequent sampling point, each child carried the same genotype from the same 
strain. 
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Figure 4.6 Genetic distance based on SNPs  
Genetic distance was derived for serotypes from subsequent sampling points. Each 
graph represents a particular serotype from a given phylogenetic cluster (Figure 4.5): 
C1, C2, C3, C7, C9, C10, C11, C12. 
 
A comparison of SNPs in serotypes with the same genotype but isolated from 
different carriers, showed a much higher difference in genetic distances compared to 
those from the same carrier regardless of similarities in genotype (Table 4.5). This 
would suggest carriage of different strains in each infant belonging to the same 
geographical area. 
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Table 4.3 Genetic distance based on whole genome SNPs 
 
 
 
Genetic distance was generated for similar serotypes from different carriers. Each 
cluster shown was from a different infant carrier. *Belonged to the same genotype. 
  Genetic distance 
Serotype Cluster Sampling point 1 Sampling point 2 
 
19F 
C11/C13 5395 5386 
C11*/C12* 1631 1616 
C12/C13 6346 6408 
6B C3/C8 18912 18277 
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4.2. Discussion 
This chapter has investigated the sensitivities of using microarray serotyping and the 
conventional Quellung reaction at detecting pneumococcal serotypes in carriage, 
using longitudinal samples from children. The data generated relate to the diversity 
and dynamics of pneumococcal carriage in Malawian children. 
 
Sensitivity of molecular serotyping by microarray compared with Quellung 
reaction. Pneumococcal serotype distribution was analysed in a longitudinal 
children‟s dataset (n=16), using Quellung and microarray serotyping. The microarray 
identified 62% more serotypes than the Quellung reaction because of multiple 
carriage detection although the number of distinct serotypes detected was not 
significantly different (Figure 4.1). Nontypeable serotypes were only detected by 
microarray, whereas the Quellung reaction reported several unidentified serotypes. 
Serogroup concordance between the Quellung reaction and microarray platforms, 
across each sampling point was 91%, a high level of agreement, similar to a previous 
report on concordance between latex agglutination and microarray serotyping, where 
a 95.2% concordance by serogroup was reported (Turner et al., 2011). However the 
endpoint in most carriage studies is to estimate vaccine coverage, at the level of 
serotype. An investigation into serotype concordance showed a 70% (37/52) 
agreement between the two methods with microarray detecting several additional 
serotypes not identified by Quellung reaction. In addition, Quellung reaction was 
biased towards detecting the most abundant serotype in samples containing multiple 
serotypes, leaving the less abundant serotypes unreported. These data suggest 
Quellung reaction underestimates the profile of serotypes in circulation and 
inadequate for providing a good estimate of vaccine coverage in a given population. 
190 
 
Although Quellung reaction has a number of limitations, as previously discussed, it 
is still regarded as the gold standard (O'Brien and Nohynek, 2003) and has provided 
good data on serotypes prevalent in invasive disease in various settings (Johnson et 
al., 2010) including Malawi (Cornick et al., 2011). However, it still lacks the 
required sensitivity to detect serotypes present in low abundance in carriage, which is 
key to understanding the differences in serotype distribution in carriage and disease 
and to effectively monitor the impact of vaccine implementation.  
 
Dynamics of pneumococcal carriage over-time. This study has shown that carriage 
of pneumococcal serotypes is very diverse in the Malawian setting with a high 
prevalence of multiple carriage (Chapter 3, Section 3.3 and 3.5). Overall results 
suggested no change in serotype distribution over the entire sampling period. 
However, the frequency with which pneumococcal strains belonging to different 
serotypes were isolated from subsequent sampling points was high for carriers of 
both single and/or multiple serotypes; suggesting high level of pneumococcal 
transmission. The complexity of carriage dynamics was further demonstrated in a 
large number of multiple serotype carriers, where the abundance of one serotype was 
seen to increase with a simultaneous decrease in the abundance of other co-
colonising serotypes (Figures 4.2 and 4.3). This could be attributed to competition 
among co-colonising serotypes, which shows an important role multiple carriage 
plays in regulating the distribution of pneumococcal serotypes in carriage. The 
maturation of the host immunity overtime is also another factor that regulates 
carriage dynamics (Bogaert et al., 2009, Cobey and Lipsitch, 2012). 
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Genetic diversity of pneumococcal serotypes carried over-time. The genetic 
diversity over time was investigated by analysing whole genome sequences of all 
serotypes that were isolated from sequential sampling points. Altogether sequences 
for 37 pneumococcal strains (11 distinct serotypes) from 13 children were analysed. 
MLST analysis showed that pneumococcal strains belonging to different serotypes 
had different genotypes, and there was no evidence of capsule switch observed. 
Capsule switch is reported to have occurred in a particular setting if two different 
serotypes express the same genotype. However the genotype of pneumococcal 
strains belonging to the same serotype but isolated from different children was 
inconclusive (Table 4.2). For example serotype 19F was isolated from three different 
children, two children carried ST6095 while the remaining child carried ST347. The 
only two 6B serotypes sequenced in this section showed they belonged to two 
different genotypes, highlighting the previously reported genetic diversity in 
serogroup 6 (Elberse et al., 2011). Two different genotypes were also detected in 6B 
serotypes obtained from two different infants. These data demonstrate the high 
diversity of pneumococcal genotypes circulating in Malawi. The sequence type of 
pneumococcal strains belonging to the same serotype and isolated from the same 
infant at sequential sampling points remained unchanged. To confirm whether the 
infants carried the same strain at each sampling point, the genetic distance based on 
SNPs differences was compared (Section 4.1.3.4). The analysis showed no major 
differences in the genetic distance for each serotype at each sampling point 
suggesting that over-time; the child carried the same strain (Figure 4.6). However, 
the difference in the genetic distance between similar serotypes (including those with 
same genotype) from different carriers was high (Table 4.5), which suggested 
carriage of different strains.  
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4.3. Conclusion 
We have demonstrated that the serogroup concordance between microarray and was 
high (93%) than their agreement on serotype level (70%). We have also 
demonstrated, by microarray, that pneumococcal carriage is as diverse as it is 
dynamic in Malawian children. Thus depending on the objectives of a particular 
study, microarray though relatively costly, would provide more accurate information 
on carriage dynamics, consequently benefiting the assessment of vaccine impact. We 
have also shown that serotypes in circulation are genetically diverse; however 
despite high levels of multiple carriage, there was no evidence of capsule switch in 
this cohort. 
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Chapter 5: Characterisation of capsular polysaccharide locus 
variants 
 
5.0. Introduction 
The capsular polysaccharide biosynthetic genes are located within the CPS locus, 
flanked bydexB and aliA genes. The polysaccharide capsule defines serotype, and 
based on the pattern of reactivity with the factor typing sera, 95 individual serotypes 
are currently recognised (Park et al., 2007, Bratcher et al., 2010, Oliver et al., 2013). 
The capsule is a target for the host antibodies and has been shown to maintain the 
survival of the pneumococcus in the host by acting as a barrier to the host killing by 
phagocytosis. The capsule is central to the design of pneumococcal conjugate 
vaccines. Under vaccine selection pressure, or indeed naturally, the pneumococcus 
may undergo genetic changes within the CPS locus to maintain its survival within 
the host. Thus genetic changes within the CPS locus may alter the capsular 
polysaccharide biochemical structure, which could lead to capsule change or switch 
consequently impact on pneumococcal virulence and response to treatment 
strategies. In this study, molecular serotyping was performed by microarray which 
has the enhanced ability to detect novel serotypes (Newton et al., 2011). Microarray 
detected sequence divergence and absent or highly divergent genes within the CPS 
locus of some serotypes. These were designated CPS locus variants. Whole genome 
sequencing was performed on such serotypes to identify the genetic changes that 
might have occurred at the CPS locus. This chapter presents a genomic analysis of 
the subset of serotype variants detected by microarray in the entire data set. 
Specifically, the analysis focused on genetic variations at the CPS locus of whole 
genomes of types 6B and 19A, which are covered by the current conjugate vaccine 
194 
 
(PCV13) and have been isolated from invasive disease in Malawi (Cornick et al., 
2011) and non-vaccine types 9l, 15B, 20, 23B and 29. 
 
5.0.1 Methods 
The detailed methods for this section are outlined in Chapter 2, sections 2.7 to 2.9.5 
 
5.0.2 Results 
5.1. Analysis of the CPS locus variants by phylogeny and MLST 
The phylogenetic relatedness of the CPS locus variants, together with previously 
characterised Malawian invasive serotypes was determined. The comparison was 
based on SNPS across the whole genome, mapping the sequences to the reference 
serotype 23F strain ATCC700669 (FM211187). The tree was generated using 
RAxML (Stamatakis et al., 2005) by performing 100 bootstraps. Results showed that 
phylogenetic clustering was not dependent on sero-group (Figure 5.1) alone, 
however, all serotypes belonging to a particular sero-group and sharing MLST alleles 
at six or seven loci formed a single cluster, which resulted in 6 main clusters (cluster 
A-F). Therefore clustering was associated with similarities across both sero-group 
and genotype. The CPS locus variants of serotype 6B and 19A were phylogenetically 
very diverse as they were interspersed throughout the tree (Figure 5.1).  
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Figure 5.1 Phylogenetic analysis CPSlocus variants 
Serotypes are shown by their respective sample accession number and the variants 
are colour coded red. Malawian wild type invasive serotypes (colour coded black) 
were also included in the tree for comparison. The tree was generated by whole 
genome alignment of SNPs from each genomic sequence with RAxML, by 
performing 100 bootstraps. The bootstrap values for each branch are indicated. The 
black arrows show clusters (A-E) for respective serotypes. The SNPs were identified 
using reference Streptococcus pneumoniae strain ATCC700669 (FM211187). 
 
The two serotype 6B variants (ERS096166 and ERS096165) and a previously 
characterised invasive 6B (ERS006775) serotype belonged to cluster E. MLST 
analysis showed that ERS006775 and ERS096166 belonged to the same sequence 
type while ERS096165 was only a single locus variant of the two serotypes, with a 
variation at allele number 6 (xpt gene) (Table 5.1). A search on MLST database 
(MLST[database]) revealed that the closest sequence type match for ERS096166 and 
ERS096165 were ST 6382 and ST 7744 isolated from South Africa, respectively, 
where alleles at six of the seven loci were shared. Each of the remaining three 6B 
variants (ERS096173, ERS096172 and ERS096169) exhibited very unique allelic 
profiles with ERS096173 and ERS096172 matching at only a single xpt gene, while 
ERS096169 did not have any matching allele (Table 5.1). As expected, these three 
variants were located on different branches of the tree (Figure 5.1). It was further 
observed that the 6B (ERS096169) variant and wildtype 15B (ERS006735) were 
phylogenetically related, as they were located on same branch (cluster A). However, 
MLST analysis showed a single locus variation (gdh) between the two serotypes, 
which could suggest that capsule switch did not occur.  
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Table 5.1 MLST analysis of CPS locus variants 
Strain ID Serotype ST aroE gdh gki recP spi xpt ddl 
 
ERS006770 6A 2790 8 9 4 13 15 20 5 
ERS006739 6A 2285 7 9 4 13 15 20 28 
ERS006760 6A 2987 7 13 4 16 6 1 6 
ERS006747 6A Novel 12 5 4 5 6 19 6 
ERS006775 6B Novel 10 9 4 5 15 20 28 
ERS006757 6B Novel 97 9 4 13 15 20 14 
ERS096173 6B Novel 2 8 1 10 17 1 19 
ERS096172 6B Novel 1 43 29 1 77 1 14 
ERS096166 6B Novel 10 9 4 5 15 20 28 
ERS096165 6B Novel 10 9 4 5 15 4 28 
ERS096169 6B Novel 54 5 4 5 36 142 269 
ERS003578 6C 2902 2 10 4 18 6 112 14 
ERS006733 6C 2902 2 10 4 18 6 112 14 
ERS067700 9L Novel 2 12 8 8 27 28 5 
ERS067702 9L Novel 2 12 8 8 27 28 5 
ERS096174 9L Novel 2 12 8 8 27 28 5 
ERS067701 9L Novel 2 12 8 8 27 28 5 
ERS006735 15B Novel 54 9 4 5 36 142 269 
ERS096155 15B 7522 1 32 97 5 6 88 17 
ERS024514 19A Novel 12 19 2 17 15 22 14 
ERS024528 19A Novel 7 13 53 6 6 6 8 
ERS003570 19A 2062 1 5 53 32 14 20 199 
ERS096157 19A 2062 1 5 53 32 14 20 199 
ERS096158 20 5435 2 5 36 12 6 20 269 
ERS096159 20 Novel 13 5 4 5 6 28 168 
ERS096162 23B Novel 33 5 54 63 17 20 168 
ERS067685 23B Novel 2 43 54 5 7 20 6 
ERS067684 23B Novel 2 43 54 5 7 20 6 
ERS067686 23B Novel 2 43 54 5 7 20 6 
ERS096176 29 5483 8 11 255 47 6 346 9 
 
The genotype of the carriage variants is compared to wild type invasive serotypes. 
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The 19A variant (ERS096157) was located on cluster F, together with a well-
characterised Malawian 19A invasive serotype (ERS003570), both belonging to 
sequence type 2062. ST 2062 has previously been isolated from invasive disease in 
South Africa. The remaining two 19A serotypes existed in different branches on the 
tree and showed genotypes, which either had no matching alleles with other 19A 
serotypes (ERS024514) or had only one allele shared with genotype ST 2062 
(ERS024528). These results suggest that vaccine serotypes 6B and 19A are 
genetically very diverse. Pneumococcal vaccination may exert selective pressure on 
vaccine serotypes such as 6B and 19A, leading to the emergence of novel and non-
vaccine serotype, which may compromise the response of these serotypes towards 
vaccination. The variants of serotype 9L (ERS096174) formed cluster E with the 
three previously identified 9L Malawian invasive strains. All the 9L were 
phylogenetically similar and shared the same MLST allelic profile (Table 5.1) with 
novel sequence type. A query on MLST database (http://www.spneumoniae.mlst.net) 
generated ST 4914 (9L) and ST 8833 (9L), as the closest match to Malawian 9L. 
These were isolated in South Africa from blood and cerebrospinal fluid (CSF) of 
patients diagnosed with bacteraemia and meningitis respectively, and only shared 
alleles at five of the seven loci with the Malawian 9L serotypes. The 15B variant 
(ERS096155) did not cluster with any of the invasive serotypes from Malawi, 
however its sequence type (ST 7522) had one exact match to the carriage 15B/C 
isolate on MLST database reported in Kathmandu, Nepal.  
 
The two-serotype 20 variants (ERS096159 and ERS096158) appeared on different 
branches of the tree and had very different allelic profiles. The sequence type for 
ERS096159 was unknown, however it was closely related to ST 7651 (serotype 20), 
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a carriage isolate detected in Nepal, and shared alleles at six loci. The variant shared 
alleles at five loci with ST 5392 (serotype 20) isolated from carriage in Kenya and 
invasive disease in India. The sequence type for the second serotype 20 variant (ST 
5435, ERS096158) has been isolated from invasive disease in South Africa. The 23B 
variant (ERS096162) was located elsewhere on the tree and not together with 23B 
invasive serotypes in cluster C, and shared only two of the seven alleles. A search in 
the MLST database showed close similarity between the Malawian 23B variant 
(ERS096162) and ST7687 isolated from carriage in Nepal and shared alleles at five 
loci. The sequence type ST 5483 for the serotype 29 variant (ERS096176) has been 
isolated from invasive disease in Mozambique. These results show that there is high 
genotype diversity among serotype variants in carriage and invasive wildtype 
serotypes in Malawi and that most of the genotypes were novel. A search on the 
MLST database showed close similarity with Strains from South Africa, 
Mozambique and Kenya. There is a lot of migration of people amongst these 
countries, either as migrant workers or traders, which could facilitate the spreading 
of such strains across these nations.  
 
5.2. Characterising the CPSlocus for serotype 6B variant 
Serotype 6B is one of the serotypes covered by the current 13-valent pneumococcal 
conjugate vaccine, and is the second most common cause of invasive disease 
globally, after serotype 14 (Johnson et al., 2010). In Malawi, it is second to serotype 
1 as the most commonly isolated serotype from sterile sites such as blood and CSF 
(Cornick et al., 2011). Any changes occurring at the CPS locus of serotype 6B may 
lead to changes in the structure of the polysaccharide capsule and may render the 
variant unresponsive to the vaccine-induced immunity (Temime et al., 2008, 
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Brueggemann et al., 2007a). In this study, carriage 6B variants represented 34% 
(16/37) of all variant serotypes detected. The 6B variants had previously been 
isolated from invasive disease in the Netherlands (Elberse et al., 2011), and based on 
nucleotide differences in genes at the CPS loci, three subtypes of 6B serotypes were 
defined: 6B-I, 6B-II, and 6B-III (Elberse et al., 2011). To determine whether 
Malawian 6B variants belonged to any of the above sub-groups, a phylogenetic 
comparison based only on SNPs within the CPS locus was conducted. The 
comparison was also extended to previously characterised Malawian invasive 6B 
strains (Figure 5.2). The phylogeny was divided into three distinct clusters: Cluster 1, 
Cluster 2, and Cluster 3. The clustering clearly showed that Malawian 6B carriage 
variants were distinct from the invasive strains. All Malawian invasive 6B strains 
belonged to cluster 1, while cluster 2 contained invasive 6B variants from the 
Netherlands. All the strains in cluster 2 were shown to either belong to serotype 6B 
subtype 1 (6B-I) and/or 6B subtype 2 (6B-II) only (Elberse et al., 2011). The 
Malawian carriage 6B variants belonged to cluster 3 together with two variants 
(JF911507.1 and JF911504.1) from the Netherlands, members of 6B subtype 3 (6B-
III) (Elberse et al., 2011). This suggested that the Malawian 6B variants belonged to 
subtype 6B-III. Although all the Malawian 6B variants belonged to 6B-III, they 
exhibited very distinct genotypes, with virtually no concordance across any of the 
seven alleles for 6B-III (Table 5.2). These data show that the Malawian 6B variants 
are phylogenetically distinct from the Malawian wildtype invasive 6B serotypes; 
however we have shown that the Malawian 6B variants in carriage belong to the 
serotype 6B subtype III (6B-III) by forming a single cluster with 6B-III from the 
Netherlands. 
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Figure 5.2 Phylogenetic analysis of serotype 6B variants 
The tree includes wild type invasive 6B serotypes and carriage 6B variants from Malawi, and invasive 6B variants from the Netherlands. All 
carriage strains are shown in blue while invasive strains are color-coded red. The origin of the samples is colored red (Malawi) and green 
(Netherlands). The tree was generated using the alignment of SNPs from the CPSlocus genomic sequence for each serotype with RAxML, by 
performing 100 bootstraps. The SNPs were identified using reference 6B-III Streptococcus pneumoniae strain JF911507 (Elberse et al., 2011). 
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Table 5.2 MLST profile of the CPS locus variants 
 
The analysis includes two 6B-III subtype references from the Netherlands. Parameters marked (*) show the closest matching ST from the MLST 
database (http://www.spneumoniae.mlst.net), which include sample source (blood, carriage or csf) as well as country of origin (region).
 
Strain ID 
 
Serotype 
 
Country of 
 origin 
 
ST 
 
aroE 
 
gdh 
 
gki 
 
recP 
 
spi 
 
xpt 
 
ddl 
 
Closest 
matching ST* 
 
Source* 
 
Region* 
 
JF911504.1 
 
6B-III 
 
Netherlands 
 
Novel 
 
7 
 
6 
 
1 
 
8 
 
6 
 
1 
 
14 
  Netherlands 
 
JF911507.1 
 
6B-III 
 
Netherlands 
 
90 
 
5 
 
6 
 
1 
 
2 
 
6 
 
3 
 
4 
  Netherlands 
 
ERS096173 
 
 
6B 
 
Malawi 
 
Novel 
 
2 
 
8 
 
1 
 
10 
 
17 
 
1 
 
19 
2863 (33D) (DLV) 
4441 (6C)(DLV) 
5266 (22A) (DLV) 
Unknown 
Blood 
Blood 
Denmark 
Israel 
Kenya 
 
ERS096172 
 
6B 
 
Malawi 
 
Novel 
  
1 
 
43 
 
29 
 
1 
 
77 
 
1 
 
14 
 
8783 (NT)(DLV) 
 
Carriage 
 
China 
 
ERS096166 
 
6B 
 
Malawi 
 
Novel 
 
10 
 
9 
 
4 
 
5 
 
15 
 
20 
 
28 
6382 (6A)(SLV) 
7744 (6A)(SLV) 
CSF 
Unknown 
South Africa 
 
ERS096165 
 
6B 
 
Malawi 
 
Novel 
 
10 
 
9 
 
4 
 
5 
 
15 
 
4 
 
2 
6382 (6A)(DLV) 
7744 (6A)(DLV) 
CSF 
Unknown 
South Africa 
 
 
ERS09616 
 
6B 
 
Malawi 
 
Novel 
 
54 
 
5 
 
4 
 
5 
 
36 
 
142 
 
269 
 
8050 (6A)(SLV) 
 
Carriage 
 
The Gambia 
 
ERS096157 
 
19A 
 
Malawi 
 
2062 
 
1 
 
5 
 
53 
 
32 
 
14 
 
20 
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Blood/CSF 
 
South Africa 
 
ERS096159 
 
20 
 
Malawi 
 
Novel 
 
13 
 
5 
 
4 
 
5 
 
6 
 
28 
 
168 
 
5392 (20)(DLV) 
7651 (20)(DLV) 
Carriage/CSF 
Carriage 
Kenya/India 
Nepal 
 
ERS096158 
 
20 
 
Malawi 
 
5435 
 
2 
 
5 
 
36 
 
12 
 
6 
 
20 
 
269 
 
 
 
Blood 
 
South Africa 
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5.2.1. Genetic recombination within the CPS locus of 6B variants 
With reference to the published 6B strain CR931639, all the 6B strains from carriage 
and invasive disease in Malawi harboured SNPS within their CPS loci; however, the 
average SNPs density for variants in carriage (50.7 snps/kb/strain) was higher than 
invasive 6B strains (9.0 snps/kb/strain). Further analysis was conducted to determine 
if such SNPs translated to genetic recombination and whether differences existed 
between the variants and invasive 6B strains. Results showed four regions of 
recombination in all the 6B variants. These occurred in wzg, wciO, rmlA and rmlC 
genes (Figure 5.3), which respectively, encode for an integral membrane regulatory 
protein, putative ribitol transferase, glucose-1-phosphate thymidylyltransferase, and 
dTDP-4-keto-6-deoxy-D-glucose 3,5-epimerase. All the invasive 6B serotypes 
showed recombination in rmlA gene. Two strains (ERS050261 and ERS003549) 
showed recombination in aliB, tnp and wzg genes, while one isolate (ERS012090) 
showed recombination in rmlD gene in addition to the rmlA gene. The aliB gene is a 
pseudogene for oligopeptide binding protein. The tnp is a transposon, which is a 
mobile genetic element implicated in horizontal gene transfer, while rmlD gene 
encodes for dTDP-4-keto-L-rhamnose reductase, which is essential for the synthesis 
of rhamnose sugar, a component of the polysaccharide capsule. All the 
recombination events in the 6B variants were ancestral, suggesting they have been 
maintained throughout the subsequent generations. This would suggest they might 
offer a selective advantage to the variant, thereby enabling it survive its environment 
and replicate successfully, or they could be neutral with no selective pressure to 
remove them. 
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Figure 5.3 Genetic recombination within the CPSlocus of serotype 6B variants 
The blocks in red and blue colour indicate regions of recombination within the CPS locus for each isolate. The blue colour block indicates that 
recombination in that particular region(s) was only detected in one isolate, and therefore a recent event. The red colour blocks shows 
recombination occurred in more than one strain and therefore an ancestral event. There were more events of recombination observed in carriage 
CPS locus variants of serotype 6B than invasive strains. 
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5.2.2. A deletion within HG263 gene of serotype 6B 
The HG263 gene is a member of the homology group 263 and encodes a putative 
LicD-family phosphotransferase protein (Bentley et al., 2006). This protein is 
involved in the transfer of a glycosyl group from activated donor molecule to 
specific acceptor molecule (http://www.uniprot.org), synonymous with 
polysaccharide capsule biosynthesis transferase required for repeat unit construction. 
In this study, the CPS locus gene sequences for the reference and variant 6Bs were 
compared. The sequence identity ranged from 90 to 100% with the lowest sequence 
identity observed in the first six genes, which includes four initiation genes (wzg, 
wzh, wzd, wze) and two-type specific genes (wchA and wciN) (Figure 5.4).  
 
 
 
Figure 5.4 The CPS locus genes of serotype 6B variant 
A 300 base pair deletion within the HG263 gene was observed in the wild type 6B 
(R) (CR931639) and not in the 6B variant (V, ERS096173). The figure was 
generated by EasyFig® (Sullivan et al., 2011). 
 
R_6B 
V 
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A genetic variation was detected in the HG263 gene between 6B variants and the 
reference wild type 6B serotype. The carriage 6B variants contained an intact allele 
of the HG263 gene, which was about 579 base pairs in length. The reference and all 
invasive 6B serotypes harboured a HG263 gene with a 300 base pair deletion 
resulting in a frame shift mutation (Figure 5.4). This gene was annotated as a 
pseudogene and therefore non-functional (Bentley et al., 2006). Mutants of LicD-
family phosphotransferase gene have been reported with a reduced ability to take up 
choline; decreased ability to adhere to host cells and to be less virulent (Zhang et al., 
1999). Thus by harbouring an intact allele of the LicD gene, it is not clear whether 
the variants will have an enhanced ability to colonise the nasopharynx or cause 
invasive disease. To test the validity of this observation, human mouse model 
experiments were conducted using the wild type 6B strain BHN418 (ST138) as 
control. 
 
5.3. Testing the invasive ability of Malawian serotype 6B variants 
The ability of pneumococcal 6B variants to cause invasive disease was tested in 
mouse models (Chapter 2, section 2.9), using the carriage 6B (BH418) strain as 
reference. For comparison, previously characterised invasive 6B serotypes from 
Malawi were also tested. Results showed that the 2 invasive 6B serotypes 
(ERS012143/ERS050336) were the most able to cause lethal systemic disease after 
intranasal challenge and caused death of all mice after 50 hours (Figure 5.5). 
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Figure 5.5 Invasive ability of serotype 6B variants 
The Kaplan-Meier plot showing the invasive ability of serotype 6B variants. Mice 
(n=10 per bacterial isolate) were infected intranasally with 10
6
 CFU S. pneumoniae 
per mouse in a volume of 50 l. The graphs in green represent mice challenged with 
three different carriage 6B variants strains, whilst graphs in blue represent mice 
inoculated with three different 6B invasive strains. The graph color-coded red 
represents the reference carriage 6B sample. Mice survival was monitored up to 168 
hours, at which point the experiment was ended. 
 
This was followed by control 6B serotype (BH418, ST138), which caused death of 
90% of mice after 150 hours. The invasive strain ERS096173 caused death to 60% of 
the mice challenged and was the least able to cause invasive disease among the three 
invasive strains tested. All the mice challenged with the carriage 6B variant strain 
ERS096166 survived throughout the entire assay period, suggesting inability by this 
strain to cause disease. The remaining 2 carriage strains: ERS096165 and 
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ERS096173 were able to cause systemic disease after intranasal challenge; however 
the latter was most lethal as it caused death to 60% while the former only managed to 
kill 30% of the mice understudy. The mortality rate by the carriage 6B strain 
ERS096173 was similar to that for invasive 6B strain ERS003549 after 150 hours, 
however death for mice challenged with the invasive strain occurred much earlier. 
Analysis by log-rank (Mantel-Cox) test showed that survival curves were 
significantly different (p<0.0001). Further, a comparison of the Kaplan-Meier curves 
showed a significant trend in survival scores across the carriage 6B variants and wild 
type invasive 6B strains (p<0.0001). Thus overall, the survival rate of mice 
challenged with the 6B variants was higher than the rate for the invasive 6B strains, 
suggesting the variants were less invasive and less able to cause disease compared to 
invasive 6B types.  
 
5.4. An inversion of rmlD gene in serotype 19A variant 
Serotype 19A is also one of the PCV-13 serotypes and globally it is ranked number 8 
as the most invasive disease causing serotype (Johnson et al., 2010). Serotype 19A 
was a major cause of serotype replacement disease in various settings post PCV-7 
introduction (Cohen et al., 2011, Brueggemann et al., 2007a). Microarray serotyping 
detected serotype 19 as a CPS locus variant with missing rmlD gene. The rmlD gene 
together with three other similar genes (rmlA, rmlB, rmlC) encodes for proteins 
involved in the synthesis of rhamnose sugar, a component of the pneumococcal 
capsule (Graninger et al., 1999). The molecular structure of wild type serotype 19A 
polysaccharide capsule is composed of rhamnose, N-acetylmannosamine, and 
glucose, as a repeat unit (Bentley et al., 2006). The pattern of SNPs within the 19A 
CPS locus variant and rmlD gene inversion was identical to serotype 19A-I subtype 
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(Elberse et al., 2011), however the sequence types were different. To investigate 
genetic changes within the 19A CPS locus, whole genome sequences were obtained 
and the CPSgenes were annotated in artemis (Rutherford et al., 2000). The genetic 
comparison diagrams were then generated using EasyFig (Sullivan et al., 2011). 
Results showed ~100 % sequence similarities in the CPS genes for the 19A variant 
and 19A reference, except for rmlD gene which showed only 77% sequence 
similarity (Figure 5.6). The lower sequence similarity signifies mismatches in the 
sequences possibly due to SNPs within the gene or it could be attributed to the fact 
that the rmlD gene in the variant was oriented in the opposite direction compared to 
other rml genes and the rest of the CPS locus genes. 
 
 
Figure 5.6 The CPS locus genes of serotype 19A variant 
The CPS locus genes of the 19A variant (V, ERS096157) compared with a reference 
serotype 19A (R) CR931675). An inversion in rmlD gene (red colour) was observed 
in the variant. The figure was generated using EasyFig® (Sullivan et al., 2011). 
 
 
 
V 
R 
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5.5. A deletion within the whaF gene in serotype 20 variant 
In this study, two serotypes belonging to sero-group 20 were detected as CPS locus 
variants by microarray serotyping. The CPS gene sequence of the two variants of 
serotype 20 showed a 716 base pair deletion within the whaF gene, and their 
sequences identity with the reference ranged from 76 to 100% (Figure 5.7). The 
whaF gene is located between the wciD and wzx genes within the CPS locus and is 
963 base pairs in length. It encodes for putative glycosyl transferase (GT) protein 
(Bentley et al., 2006), which mediates the transfer of glycosyl ( Glc) residue in the 
capsular polysaccharide repeat unit. The serotype 20A subtype contains a mutation in 
the whaF gene which leads to loss in gene function (Calix et al., 2012b).  Through a 
deletion of the whaF gene, the variant in our dataset would be expected to have a 
capsular polysaccharide structure similar to 20A subtype. However, further analysis 
would be required to elucidate the actual capsular polysaccharide structure, as well 
as their ability to colonise or cause invasive diseases. 
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Figure 5.7 The CPS locus genes of serotype 20 variant  
The CPS locus genes of serotype 20 variants from a child (V_1, ERS096159) and adult (V_2, ERS096158) was compared to reference serotype 
20 (R) (CR931679). A 716 base pair deletion of the whaF gene (color-coded red) was observed in the variants. The figure was generated using 
EasyFig® (Sullivan et al., 2011).
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5.6. Novel serotype containing genes from serotype 29 and 35B 
The pneumococcus is a highly transformable organism that readily undergoes genetic 
recombination through horizontal gene transfer. Multiple carriage is thought to be a 
pre-requisite for horizontal gene transfer. Evidence of genetic recombination in the 
pneumococcus has been widely reported (Croucher et al., 2013, Everett et al., 2012, 
Hanage et al., 2009, Marks et al., 2012). Recombination involving antibiotic 
resistance and CPS locus genes has a bearing on treatment strategies. Novel 
serotypes containing a mosaic cluster of CPS genes from different serotypes have 
been reported (Salter et al., 2012). In this study, a novel variant serotype containing 
all the 12 CPS genes from serotype 29 and a wciG gene from 35B was obtained 
(Figure 5.8, V). The novel serotype showed a higher sequence similarity to serotype 
29 than 35B and it is likely that the wciG gene occurred as an insertion into the CPS 
locus of serotype 29. The wciG gene encode for O-acetyltransferase enzyme, which 
is responsible for O-acetate substitution on the galactofuranose (Galf) residues in the 
repeat unit of the polysaccharide capsule (Calix et al., 2012b). The repeat unit of the 
capsular polysaccharide for the wild type serotype 29 consists of three molecules of 
Galf and one molecule of N-acetylgalactosamine pyranose (GalpNAc) without 
acetylation (Bentley et al., 2006). Therefore in our setting, there is a possibility that 
the incorporation of wciG gene into the CPS locus of serotype 29 would introduce O-
acetylation at the Galf moiety of the capsular polysaccharide. Consequently, this may 
enhance the ability of the 29 variant to successfully colonise the nasopharynx, as it 
will be expected to evade the host lysozyme activity. 
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Figure 5.8 The CPS locus genes of serotype 29 variant 
The CPS locus genes of serotype 29 variant (V, ERS096176) were compared with reference types 29 (R_29) (CR931694) and 35B (R_35B) 
(CR931705). The variant from an HIV positive adult single carrier, showed a possible serotype 29 and 35B hybrid by harbouring both wcjH 
(blue), unique to serotype 29 and wciG (red), unique to serotype 35B. The figure was generated using EasyFig® (Sullivan et al., 2011).
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5.7. Characterisation of CPS locus variants of serotypes 9L, 15B and 23B 
Serotypes 9L, 15B and 23B are not included in the current vaccine; however, they 
have been reported to cause invasive disease elsewhere (Rodgers et al., 2009). The 
microarray serotyping reported divergence in wcjE, wzy, and wcjB genes in 9L 
variant. However, analysis of whole genomes of serotype 9L only showed a 
mismatch in wzy gene, and the sequence similarity ranged from 83-100% for the 
entire CPS locus (Figure 5.9). The wzy gene encode for polymerase enzyme, which is 
responsible for linking individual repeat units to form lipid-linked polysaccharide 
capsule (Bentley et al., 2006). Any variation in this important gene is likely to 
compromise the synthesis of the polysaccharide capsule, which could render the 
variant un-encapsulated. Serotype 15B was determined by microarray to be divergent 
in wchA and wchK genes. Unexpectedly, analysis of CPS locus sequences showed 
high sequence similarity (80-100%) between the 15B variant and the reference 
(Figure 5.10). The anomaly detected by microarray could be attributed to cross-
hybridisation, which is a common occurrence in assays involving microarray. The 
variant of serotypes 23B were suspected to have genetic variations in gene wchX, 
rmlA and rmlC gene. Sequence comparison showed a mismatch in wchW gene only, 
with percentage sequence identity ranging from 84% to 100% (Figure 5.11). The 
wchW gene encodes for a putative glycosyltranferase protein, which also belongs to 
type-specific genes. Changes in this gene may impair capsule synthesis or lead to the 
synthesis of a novel capsule, consequently affecting the pneumococcal phenotype.  
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Figure 5.9 The CPSlocus genes of serotype 9l variant 
The CPS locus genes of serotype 9l variant (V, ERS096174) compared with a reference serotype 9l (R_9l) CR931646). The figure was generated 
using EasyFig® (Sullivan et al., 2011). 
R_9l 
V 
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Figure 5.10 The CPS locus genes of serotype 15B variant 
The CPS locus genes of serotype 15B variant (V, ERS096155) compared with a reference serotype 15B (R_15B) CR931664). The figure was 
generated using EasyFig® (Sullivan et al., 2011). 
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Figure 5.11 The CPS locus of serotype 23B variant 
The CPS locus genes of serotype 23B variant (V, ERS096162) compared with a reference serotype 23B (R_23B) CR931684). The figure was 
generated using EasyFig® (Sullivan et al., 2011). 
V 
R_23B 
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5.8. Discussion 
The pneumococcal polysaccharide capsule defines the serotype (Bentley et al., 2006) 
and is essential for the successful colonisation and transmission of S. pneumoniae by 
acting as a barrier to phagocytic killing by the host immune system (Weinberger et 
al., 2009). The capsule is also a target for current conjugate vaccine formulations. To 
survive under such conditions, the pneumococcus can alter its CPS locus, through 
genetic recombination, which could ultimately lead to vaccine escape through 
serotype switching. In Malawi, unrelated serotypes with the same sequence type 
have been isolated from invasive disease in Malawi, suggesting occurrence of 
possible recombination within the CPS locus pre-vaccination (Everett et al., 2012). 
In the present study, the CPS locus variants of vaccine-associated serotypes 6B, 19A 
and 20, and non-vaccine serotypes 29, 9l, 15B and 23B were detected. Serotype 6B 
is among the top five serotypes in circulation together with serotypes 1, 5, 6A and 
14, cumulatively responsible for over 50% of all invasive disease in Africa, Asia and 
Europe (Johnson et al., 2010). In Malawi, serotype 6B is the second most isolated 
strain from invasive disease in children after serotype 1 (Cornick et al., 2011). In our 
data set, serotype 6B variants were genetically distinct from invasive 6B serotypes 
and had a significantly high SNPs density within the CPS locus. There were also 
more recombination events occurring in carriage 6B variants than the wild-type 
invasive strains. Genetic recombination involves the integration of foreign DNA in 
the chromosome of a recipient cell, mediated by bacteriophages (transduction) 
(Canchaya et al., 2003), direct cell-to-cell contact (conjugation) (Chen et al., 2005), 
or uptake of exogenous DNA from the environment (transformation) (Claverys et al., 
2009), and it is reported to occur primarily in carriage. Such levels of recombination 
in 6B could be driven by the high multiple carriage rates observed in the Malawian 
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setting (Donkor et al., 2011). Of particular concern is that such recombination is 
occurring in the absence of vaccine selection pressure, and may naturally lead to the 
generation of vaccine escape strains, thereby negatively affecting the efficacy of the 
vaccine. In mouse models, the 6B variants are showing clear indications of being less 
invasive. In addition, each of the 6B variants exhibited the sequence types not 
reported elsewhere, which makes their invasive potential unknown. One key 
difference in genes within the CPS locus was the presence of an intact allele of the 
HG263 gene in all the 6B variants, while the wild type invasive 6B strains and the 
reference contained a base pair deletion (~300bp) within the HG263 gene resulting in 
a frame shift mutation (Figure 5.4). HG263 gene is a member of the LicD transferase 
family of proteins involved in lipopolysaccharide biosynthesis (Lysenko et al., 
2000). LicD mutants have a reduced ability to take up choline; decreased adherence 
to host cells and are less virulent (Zhang et al., 1999). Thus by harboring an intact 
LicD gene, our 6B variants may have a colonisation advantage over the wild type, 
which may facilitate increased invasive potential and/or allow for vaccine escape. 
However, in the absence of other factors such as vaccination, antibiotic use and HIV 
infection, the trends in colonisation and invasive potential may decrease due to the 
acquisition of nonspecific immunity to the pneumococcus by the host (Cobey and 
Lipsitch, 2012). The potential of the 6B variants to cause invasive disease was 
investigated in mice, through intranasal challenge (Figure 5.5). Whereas most mice 
infected with invasive 6B serotypes died, the survival rate among mice challenged 
with 6B variants was very high suggesting that the variants were less invasive when 
compared to either the wild type invasive strains or the reference carriage BHN418 
6B strain. Having established that the variants were poor at causing invasive disease, 
further work is required to investigate the ability of the variants to colonise the 
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nasopharynx through monostrain carriage experiments. In addition, further 
investigations using mouse models are still required to establish how the variants will 
respond towards vaccination, through intranasal challenge of unvaccinated mice and 
those vaccinated with PCV13. 
 
The CPS locus variant of serotype 19A was shown to have an inversion in the rmlD 
gene (Figure 5.6). The rmlD gene is part of a four CPS gene cluster including rmlA, 
rmlB and rmlC, which encode four enzymes required in the synthesis of dTDP-L-
rhamnose from D-glucose 1-phosphate (Li et al., 2003). Although inversions are 
known to maintain the overall amount of the genetic material (Griffiths et al., 2000), 
recent findings suggest gene inversions may lower the expression level of the 
affected gene, resulting in abnormalities at phenotypic level (Naseeb and Delneri, 
2012). An inversion in rmlD gene for serotype 19A has been reported previously 
(Elberse et al., 2011, Morona et al., 1999), with the promoter sequence located 
upstream of the rmlD gene (Morona et al., 1999). Other streptococcal species such as 
mitis and oralis have also been shown to contain an rmlD gene, which is oriented in 
the opposite direction (Yoshida et al., 2005). In our setting, the rmlD gene inversion 
in the 19A variant may impair the function of the whole rml gene cluster, necessary 
for rhamnose biosynthesis. Failure to synthesise rhamnose may render the 19A 
variant non-capsulate, since rhamnose forms part of the repeat unit structure for the 
polysaccharide capsule (Bentley et al., 2006). This could compromise the response of 
the 19A variant towards vaccine-induced immunity.  
 
Recently, a capsular polysaccharide structural difference has been reported within 
serogroup 20, due to truncation and loss of function of the whaF gene (Calix et al., 
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2012b). The whaF gene is located between the wciD and wzx genes (Figure 5.7), and 
encodes for putative glycosyl transferase (GT) protein (Bentley et al., 2006). The 
truncation in the whaF gene correlated with the loss of an Glc residue in the 
capsular polysaccharide repeat unit of serotype 20A (Calix et al., 2012b). In contrast, 
the Malawian serotype 20 variants had a 716bp deletion within the whaF gene. This 
deletion would render the whaF gene non-functional, leading to a loss of an aGlc 
residue in the capsular polysaccharide repeat unit of the variant. This suggests the 
serotype 20 variants circulating in Malawi belong to subtype 20A. It is unclear how 
this deletion will impact on the invasiveness of this serotype 20 variant, although 
studies have shown that invasive strains of serotype 20B harbour an intact allele of 
the whaF gene (Calix et al., 2012b). 
 
The presence of a novel serotype in our dataset, which contained CPSgenes from 
serotype 29 and a single wciG gene from serotype 35B (Figure 5.8) provided 
evidence of interspecies horizontal gene transfer occurring naturally in Malawi. The 
wciG gene is responsible for the acetylation of the galactofuranose (Galf) residues in 
the repeat unit of the pneumococcal polysaccharide capsule. Acetylation describes a 
reaction that introduces an acetyl functional group into a chemical compound and has 
been reported to occur in 90% and 80% of bacteria and human proteins respectively. 
Acetylation can be used to modulate gene functionality, and also occurs as a co-
translational and post-translational modification of proteins. The cell of several 
bacterial species including S. pneumoniae is surrounded by a peptidoglycan 
exoskeleton, which consists of a polymer of the dissacharide N-acetylmuramic acid 
(MurNAc)
2
-( -1,4)- N-acetylglucosamine (GlcNAc) and associated stem peptides 
(Laaberki et al., 2011). This polymer is responsible for maintaining the shape of the 
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bacteria and its resistance to cytoplasmic turgor pressure. Peptidoglycan has been a 
target of many antimicrobial compounds including lysozyme, which is present in 
mucosal secretions and acts as the major effector of innate immunity. To inhibit the 
hydrolytic activity of lysozyme, bacteria use several mechanisms including O-
acetylation of the MurNac moiety of peptidoglycan (Laaberki et al., 2011). A direct 
correlation between the levels of O-acetylation and resistance to lysozyme activity 
has been reported in several bacterial species such as Staphylococcus aureus (Bera et 
al., 2006) and Neisseria gonorrhoea (Rosenthal et al., 1983). By acquiring a wciG 
gene, the polysaccharide capsule of serotype 29 variant would be acetylated at the 
Galf moiety. This may consequently enhance the ability of the 29 variant to 
successfully colonise the nasopharynx, as it will be expected to evade the lysozyme 
activity by the host. Whether the additional gene will alter the invasiveness of 
serotype 29 variant is subject to further investigation. 
 
5.9. Conclusion 
This chapter has highlighted the existence of high levels of genetic diversity in 
strains belonging to the same serotype in Malawi, as indicated by their phylogenetic 
clustering as well as multi-locus sequence typing. Also highlighted is the occurrence 
of genetic recombination within the CPS locus, which could have arisen through 
horizontal gene transfer due to high levels of multiple carriage in Malawi. Most 
importantly, such genetic variations occurred in the absence of vaccine selection 
pressure. For a resource poor setting such as Malawi, genetic changes at the CPS 
locus can be disastrous as they have the potential to generate strains that may be 
unresponsive to vaccine treatment strategies. Recently, Malawi enrolled PCV13 to 
under-five children and naturally, the pneumococcal strains would be expected to 
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alter their genetic make-up as a survival mechanism, and it would be important to see 
how the CPS loci of vaccine serotypes change once the vaccine takes full effect. 
Although this study has revealed the occurrence of genetic variations within the 
CPSloci of various serotypes in the absence of vaccine selection pressure, it has not 
been able to establish the full extent of the prevalence of the variants due to limited 
sample size. In-addition, this study lacked sequenced wild type serotypes isolated 
from carriage in Malawi, which would be an ideal reference for comparing variations 
at the CPS locus and other characteristics. To address the listed limitations, work is 
currently underway to characterise serotype variants on a larger scale and also 
determine their ability to colonise and cause invasive diseases using mouse models.  
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Chapter 6:  Nasopharyngeal microbiota in Malawian children and 
adults 
 
6.0 Introduction 
The human body is colonised by a vast array of microorganisms, which are largely 
commensal. As discussed in the introduction (chapter 1, Section 1.8), these play 
important roles in the development of the host immune system and aid metabolism 
(Morgan and Huttenhower, 2012). The role of microbiota in human health and 
disease is currently not well documented, however, studies have shown a shift in the 
composition of the gut microbiome under disease conditions such as Kwashiorkor 
(Smith et al., 2013) and inflammatory bowel disease (Walker et al., 2011). A similar 
shift has also been reported in the nasopharyngeal microbiota during acute otitis 
media (Hilty et al., 2012). Seasonality has also been implicated in driving changes in 
microbial composition (Bogaert et al., 2011). The nasopharynx is also colonised by a 
wide range of microorganisms (Kwambana et al., 2011, Pettigrew et al., 2008). 
However, previous studies in both adults and children from different settings have 
consistently reported carriage in the upper respiratory tract of at least one of the 
following five phyla: Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria and 
Fusobacteria (Bogaert et al., 2011, Lemon et al., 2010, Frank et al., 2010, Gong et 
al., 2013). The major differences in various settings existed in the relative 
proportions of each phyla which could be attributed to a number of different factors 
that include environmental conditions such as seasonality (Bogaert et al., 2011, 
Harrison et al., 1999), methodological factors that range from sampling to analysis 
(Rapola et al., 1997) as well as upper respiratory tract infections (Syrjanen et al., 
2001). The basic characteristics of each of the aforementioned phyla are outlined 
225 
 
below based on information from NCBI (http://www.ncbi.nlm.nih.gov): Firmicutes 
are Gram-positive bacteria consisting of three major classes: Bacilli, Clostridia and 
Erysopelotrichi. Proteobacteria are considered a major group of bacteria and they 
are all Gram-negative. The six major classes that constitute Proteobacteria are 
Alphaproteobacteria, Betaproteobacteria, Acidithiobacillia Gammaproteobacteria, 
Deltaproteobacteria, and Epsilonproteobacteria. Bacteroidetes are Gram-negative 
bacteria and they consist of three large groups: Bacteroidetes, Flavobacteria and 
Sphingobacteria. Actinobacteria are Gram-positive organisms, which are grouped 
into one major class Actinobacteria; while Fusobacteria are Gram-negative bacilli 
also grouped into one class Fusobacteria. In the study presented in this thesis, we 
investigated for the first time the profiles of the nasopharyngeal microbiota in 
Malawian children and adults, in a setting with high prevalence of HIV infection and 
invasive pneumococcal disease. The results showed that four phyla Firmicutes, 
Proteobacteria, Bacteroidetes and Actinobacteria dominated nasopharyngeal 
microbiota in Malawi.  
 
6.1. Methods 
The detailed methods and baseline characteristics of the subjects recruited (Table 
6.1) are as previously outlined (Chapter 2, Sections 2.1 and 2.2). Briefly, samples 
from Karonga were collected from infants in their communities, while samples in 
Blantyre were collected from children and adults reporting to the Queen Elizabeth 
Central Hospital as outpatients. Only carriers of S. pneumoniae were included in the 
analysis, which may have a fundamental impact on carriage dynamics of other 
microbiota in the nasopharynx. 
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Table 6.1 Baseline characteristics of children and adults sampled 
   
  
Location 
HIV Status  
Total (n)  HIV- HIV+ 
Children Karonga 16  16 
Blantyre 10 25 35 
Adults Blantyre 19 36 55 
 Total (n) 45 61 115 
 
 
The subjects included HIV positive adults and children who were also on 
cotrimoxazole prophylaxis. The use of cotrimoxazole prophylaxis could potentially 
alter the profile of microbiota in carriage (Varon et al., 2000). The DNA was 
extracted directly from the nasopharyngeal swabs taken from both adults and 
children (Chapter 2, section 2.3); followed by a PCR amplification of the V3-V5 
variable region of the 16S rRNA gene using barcoded reverse primers (Appendix 4). 
The 454 sequencing platform was employed to sequence the 16S rRNA PCR 
amplicons. The sequences generated were analysed using Mothur (Schloss et al., 
2009) (Appendix 5) to remove the sequencing artefacts, align and cluster the 
sequences into operational taxonomic units, and describe the alpha diversity of the 
nasopharyngeal samples. 
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6.2. Results 
6.2.1. Sampling depth 
To establish if sampling was adequate (sampling depth) to account for all the 
phylotypes present in the nasopharynx of adults and children, rarefaction curves were 
generated (Gotelli and Colwell, 2001). Rarefaction curves are mainly used to 
compare the number of species between distinct groups of samples with varying 
number of samples (Lee et al., 2007). These are constructed by plotting the number 
of species in each group of samples obtained by randomly subsampling the reads 
from each group at different levels or frequencies (Gotelli and Colwell, 2001). 
Initially, all the curves increase rapidly with an increase in the sample size and 
gradually begin to plateau as more and more samples are added. The initial increase 
is attributed to identification of dominant species; while only rare and very few 
species are identified with an increase in sampling depth, resulting in graphs 
reaching a plateau (Colwell et al., 2012). In the present study, rarefaction curves 
were used to assess the optimum number of sequence reads to account for all 
operational taxonomic units (OTUs) (Section 6.1.2) in a given sample. Results 
showed that further increase in the number of sequence reads beyond the 1000 value 
did not have a significant impact on the number of OTUs obtained (Figure 6.2). The 
assumption was therefore made that subsampling 1000 16S rRNA sequence reads 
per sample would account for most OTUs present in both adults and children‟s 
samples. 
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Figure 6.1 Rarefaction curves 
Rarefaction curves comparing the number of reads with the number of OTUs 
(phylotypes) found in the DNA isolated from the nasopharynx of Malawian children 
(A and B) and adults (C). Each line graph corresponds to an individual sample. 
Overall, graphs formed a plateau beyond 1000 reads. 
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6.2.2. Operational taxonomic units 
The nasopharyngeal microbiota was characterised by sequencing of the PCR 
amplified 16S rRNA gene (Chapter 2, section 2.10.6). The 454 sequencing generates 
sequence tags that are divergent or nearly identical. All the nearly identical 
sequences, which are thought to represent a taxonomic clade, are placed in one 
cluster and are collectively known as the Operational Taxonomic Unit (Morgan and 
Huttenhower, 2012). In this study, the Mothur software package (Schloss et al., 
2009) was employed to assign 16S rRNA sequences to OTUs, using the default 
furthest neighbour approach at a distance of 3%. The total number of 454 sequence 
reads was 214 754.Of the sample set, 61 were below the ideal read count ( 1000 
reads) while 81 were acceptable as their count was above the threshold value of 1000 
reads (Figure 6.2). 
 
 
Figure 6.2 Sample frequency versus 454 sequence reads. 
Samples with >1000 reads (81 sequences in total) were considered to have an 
adequate sampling depth for further analysis. 
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The sequence reads were subsampled to 1000 reads per sample which based on the 
rarefaction curves generated (Figure 6.1), were thought to account for most of the 
OTUs in the dataset. Sub-sampling resulted in the removal of all samples with 
sequence reads below 1000. The sub-sampled sequence reads were analysed in 
Mothur (Chapter 2, section 2.10.7) to improve their quality by removing PCR 
generated chimeric sequences and other sequencing errors, further decreasing the 
number of samples and OTUs present. Originally, the total number of OTUs 
identified was 173 OTUs contained in116 individuals. The combined process of sub-
sampling and sequence cleaning resulted in the reduction of OTUs to 46 (73% 
reduction in number of OTUs), contained in 58 (43% reduction in sample size) 
subjects. Analysis of the 46 OTUs identified showed that 9 OTUs are associated with 
microorganisms frequently isolated from plant, soil or aquatic environments. A study 
in the Netherlands reported representatives of Cyanobacteria, which were thought to 
reflect plant chloroplasts obtained through inhalation, as well as environmental 
contaminants such as Deinococcus-Thermus, Nitrosopira, Planctomycetes and 
Chloroflexi (Bogaert et al., 2011). Other environmental contaminants have also 
frequently been detected as common reagent contaminants (Salter et al., 2014) which 
impact sequence-based microbiome analysis and were thus excluded from the 
original data: Acidobacteria (Ward et al., 2009); Novosphingobium (Sohn et al., 
2004); Caulobacter (Hu et al., 2005); Mesorhizobium (Kaneko et al., 2000); 
Rhodospirillales; Bacillus licheniformis (De Clerck and De Vos, 2004); Bacillus 
niacini (Nagel and Andreesen, 1991); Acidovorax (Shrestha et al., 2013, Schaad et 
al., 2008) ; Dyella (Weon et al., 2009); Chitinophagacea; Sediminibacterium (Kim et 
al., 2013); and most Alphaproteobacteria (Williams et al., 2007); Xanthomonads 
(Jones et al., 2000) and Sphingobacteria. Further analysis was performed on the 
231 
 
remaining 37 OTUs, which represented 21% (37/173) of all the OTUs detected. The 
total number of sequence reads per sample for the 37 OTUs was 1267, with OTU173 
(70% (892/1267)) as the most dominant (Figure 6.3). As previously described, 
OTU173 was dominant and was detected in each sample in the entire dataset. The 
remaining 36 OTUs showed a very low representation at 30 % (375/1267) of the 
total number of reads for the 37 OTUs (Figure 6.3).  
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Figure 6.3 Sequence reads per sample in each OTU  
The graph was generated using data from both adults and children. The graph represents 37 OTUs with an average of 1267.53 sequence reads per 
sample. The number of sequence reads per sample showed the abundance of each OTU in the dataset. The primary axis represents OTU173, 
which was the most abundant (70.4%; 892.36/1267.53). The remaining 36 OTUs are plotted using the secondary y-axis for clarity because of 
their low sequence reads per sample.  
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Figure 6.3 Sequence reads per sample in each OTU 
The graph was generated using data from both adults and children. The graph represents 37 OTUs with an average of 1267.53 sequence reads per 
sample. The number of sequence reads per sample showed the abundance of each OTU in the dataset. The primary axis represents OTU173, 
which was the most abundant (70.4%; 892.36/1267.53). The remaining 36 OTUs are plotted using the secondary y-axis for clarity because of 
their low sequence reads per sample.  
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6.2.3. Classification of OTUs into taxonomic phyla 
In this study, all the OTUs identified were classified into 4 taxonomic phyla namely: 
Firmicutes (79%), Proteobacteria (17%), Actinobacteria (3%), and Bacteroidetes 
(1%) (Figure 6.4). In brackets is the relative abundance of each phylum expressed as 
a percentage. These phyla have been reported in other settings (Bogaert et al., 2011, 
Lemon et al., 2010, Frank et al., 2010), however there is variation within the 
dominant phyla. For example, in the USA, the nasopharyngeal microbiota among 
healthy adults was dominated by Actinobacteria (68%), Firmicutes (27%), 
Proteobacteria (4%), Bacteroidetes (1.4%), and Fusobacteria (0.21%), however this 
shifted in hospitalised patients in the same setting with Firmicutes (71%) being the 
most abundant phyla followed by Actinobacteria (27%) (Frank et al., 2010). The 
increase in the abundance of Firmicutes in hospitalised patients was attributed to an 
increase in carriage of S. aureus and S. epidermis acquired from the hospital 
environment (Frank et al., 2010). This could also help explain the disproportionately 
high prevalence of Firmicutes in the Malawian setting because 86% (100/116) of all 
Malawian samples were collected from subjects who reported to Queen Elizabeth 
Central Hospital in Blantyre as outpatients. The remaining samples originated from 
infants in households in Karonga (Chapter 2, Section 2.1). 
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Figure 6.4 Taxonomic phyla and their relative abundance 
The figure shows four phyla detected in the nasopharynx of Malawian children and 
adults. The most predominant phylum was Firmicutes followed by Proteobacteria, 
Actinobacteria and Bacteroidetes. 
 
At the genus level (Table 6.2), the Firmicutes mainly consisted of the streptococcal 
species (73%), with Staphylococcus, Bacillus, Gemella, Helcococus, Weissella and 
Lactobacillus comprising a very small fraction (6%) of the total microbiota. 
Proteobacteria, which were the second most isolated phyla (17%) were dominated 
by Acinetobacter (4.45%) followed by Moraxella (3.18%), Pseudomonas (1.99%) 
Klebsiella (1.22%) and Haemophilus (0.89%). The remaining 5.27% comprised 
Neisseria, Pantoea, Massilia, Curvibacter and Burkholderia. Three genera were 
detected from the Actinobacteria phylum, the most predominant being 
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Corynebacterium (2.71%), followed by Arthrobacter (0.16%) and 
Propionibacterium (0.06%). Bacteroidetes were the least abundant phyla in the 
nasopharynx and these comprised two genera: Porphyromonas (1.18%) and 
unclassified Flavobacteriacea (0.04%). Compared to studies investigating 
nasopharyngeal microbiota in other settings (Bogaert et al., 2011, Chaban et al., 
2013), there were similarities in the identities of the phyla and genera detected, 
however variations existed in the relative proportions of each phyla and dominant 
groups within each phyla. 
 
236 
 
Table 6.2 Profile of nasopharyngeal genera 
A 
Phyla Class* Order* Family* Genus OTU Reads/sample 
Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus OTU_173 70,40% 
Bacilli Bacillales Bacillaceae Bacillus OTU_169 3,49% 
Bacilli Bacillales Staphylococcaceae Staphylococcus OTU_160 1,31% 
Bacilli Lactobacillales Streptococcaceae Streptococcus OTU_132 1,25% 
Bacilli Lactobacillales Streptococcaceae Streptococcus OTU_171 1,17% 
Bacilli Lactobacillales Camobacteriaceae Dolosigranulum OTU_137 0,71% 
Bacilli Lactobacillales Leuconostocaceae Weissella OTU_076 0,71% 
Bacilli Bacillales Staphylococcaceae Gemella OTU_090 0,10% 
Bacilli Lactobacillales Lactobacillaceae Lactobacillus OTU_059 0,04% 
Clostridia Clostridiales Peptostreptococcaceae Helcococcus OTU_164 0,03% 
Actinobacteria 
 
Actinobacteria Actinomycetales Corynebacteriaceae Corynebacterium OTU_165 2,13% 
Actinobacteria Actinomycetales Corynebacteriaceae Corynebacterium OTU_103 0,30% 
Actinobacteria Actinomycetales Corynebacteriaceae Corynebacterium OTU_159 0,26% 
Actinobacteria Actinomycetales Micrococcaceae Arthrobacter OTU_115 0,16% 
Actinobacteria Actinomycetales Propionibacterineae Propionibacterium OTU_107 0,06% 
Actinobacteria Actinomycetales Corynebacteriaceae Corynebacterium OTU_117 0,02% 
Bacteroidetes 
 
Bacteroidia Bacteroidales Porphyromonadaceae Porphyromonas OTU_006 0,63% 
Bacteroidia Bacteroidales Porphyromonadaceae Porphyromonas OTU_109 0,55% 
Flavobacteria Flavobacteriales Flavobacteriaceae Unclassified OTU_085 0,04% 
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B 
Phyla Class* Order* Family* Genus OTU Reads/sample 
Proteobacteria 
 
Gammaproteobacteria Pseudomonadales Moraxellaceae Acinetobacter OTU_155 4,46% 
Gammaproteobacteria Pseudomonadales Moraxellaceae Moraxella OTU_167 2,75% 
Gammaproteobacteria Pseudomonadales Pseudomonadaceae Pseudomonas OTU_106 1,99% 
Gammaproteobacteria Pseudomonadales Moraxellaceae Acinetobacter OTU_163 1,52% 
Gammaproteobacteria Enterobacteriales Enterobacteriaceae Klebsiella OTU_172 1,22% 
Gammaproteobacteria Pseudomonadales Pseudomonadaceae Pseudomonas OTU_158 0,96% 
Gammaproteobacteria Pasteurellales Pasteurellaceae Actinobacillus OTU_029 0,79% 
Gammaproteobacteria Enterobacteriales Enterobacteriaceae Pantoea OTU_154 0,65% 
Betaproteobacteria Neisseriales Neisseriaceae Neisseria OTU_080 0,49% 
Gammaproteobacteria Pseudomonadales Moraxellaceae Moraxella OTU_161 0,43% 
Gammaproteobacteria Pasteurellales Pasteurellaceae Haemophilus OTU_149 0,41% 
Betaproteobacteria Burkholderiales Oxalobacteraceae Massilia OTU_153 0,36% 
Gammaproteobacteria Pasteurellales Pasteurellaceae Haemophilus OTU_142 0,23% 
Gammaproteobacteria Pasteurellales Pasteurellaceae Haemophilus OTU_170 0,14% 
Gammaproteobacteria Pasteurellales Pasteurellaceae Haemophilus OTU166 0,11% 
Betaproteobacteria Burkholderiales Commonadaceae Curvibacter OTU_138 0,05% 
Betaproteobacteria Neisseriales Neisseriaceae Neisseria OTU_021 0,04% 
Betaproteobacteria Burkholderiales Burkholderiaceae Burkholderia OTU_002 0,02% 
 
The genera belonged to four different phyla: Firmicutes, Proteobacteria, Actinobacteria, and Bacteroidetes, presented in tables A and B. *The 
class, order and family for each genus were obtained from the NCBI taxonomy browser (http://www.nlm.nih.gov).  
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6.3. Distribution of OTUs in children and adults 
As previously described (Section 6.2.2), the general microbial diversity was analysed 
using samples that were subsampled to 1000 reads and with no duplicates for proper 
comparison of the whole dataset. This reduced the total number of samples from 116 
to 58 samples. The 58 samples were from 58 subjects comprising children (n=40) 
and adults (n=18). The children were subdivided into HIV negative (n=21) and HIV 
positive (n=19). Adults were grouped into HIV negative (n=4) and HIV positive 
(n=14). From these samples, the total OTU richness was described by generating 
Venn diagrams in Mothur (Appendix 7). OTU richness defines the total number of 
OTUs present, while evenness measures the homogeneity of abundances in a given 
sample or environment (Bock et al., 2007, Thompson and Eithers, 2003). Results 
showed a total number (richness) of 38 OTUs in both adults and children (Figure 
6.5). The total number of OTUs in children (n=40) was 28, which was less than the 
34 OTUs detected in adults (n=18). The two cohorts however, had 23 OTUs in 
common (Figure 6.5). These findings suggest that age had an impact on the number 
of colonising microorganisms, with adults having more OTUs present than children. 
The diversity of OTUs in adults and children was further analysed using the inverse 
Simpson diversity index (Zhou et al., 2002). The diversity index measures microbial 
diversity by considering both richness (total number present) and evenness (level of 
diversity) and an increase in the inverse Simpsons diversity index corresponds to an 
increase in diversity (Zhou et al., 2002). Results showed no significant difference in 
the microbial diversity between children and adults (P<0.4058) (Figure 6.6), 
although this may not be definitive because of a limited sample size. 
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Figure 6.5 OTU richness in children and adults 
The diagram was generated in Mothur to show the richness of microorganisms 
colonising adults (n=18) and children (n=40). In the figure, children are represented 
as „kids‟. 
 
 
240 
 
 
 
Figure 6.6 Inverse Simpson diversity index in children and adults 
There was no significant difference in microbial diversity between children and 
adults (P<0.4058). 
 
The microbial diversity in children and adults was further assessed using principal 
component analysis (PCA) (Figure 6.7). This was achieved using Bray-Curtis 
similarity cluster analysis or index of dissimilarity (Bray and Curtis, 1957) which 
describes the relative proportion of OTUs as well as their presence or absence in 
different communities. If two environments have the same microbial species 
composition; the Bray-Curtis index is assigned a value „0‟ and „1‟ when the 
microbial composition is completely different. 
 
241 
 
0.0 -0.2 -0.4 -0.6 -0.8 
0.6 
0.4 
0.2 
0.0 
-0.2 
adult 
child(B) 
child(K) 
child(P) 
HIV- 
HIV+ 
Category 
Status 
Axis 1 
A
x
is
 2
 
 
Figure 6.7 Bray-Curtis microbial diversity (PCA plots) 
Principal component analysis plots presenting a two dimensional microbial diversity 
in adults and children by HIV status. The symbols correspond to individual subjects, 
clustered based on OTU diversity. This diversity is represented in a graph generated 
in mothur (Appendix 7) by statistically correlating every OTU with each axis (Axis 1 
and Axis 2) on the PCA matrix. Children‟s samples were collected from Blantyre 
(Child (B) and Child (P)) and Karonga (Child (K)) while all adult samples were from 
Blantyre. 
 
The results showed that the microbial composition in adults was very similar to each 
other (Figure 6.7) because the median values for the diversity score in both axes 1 
and 2 were similar and close to the zero co-ordinates (Table 6.3). Children displayed 
a greater diversity in microbial composition amongst themselves, with samples 
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observed to scatter in the axis1 direction (Figure 6.7). This was also evident in the 
difference in the median diversity score for axis1: 0.25 (CI: -0.18-0.31) and axis2: -
0.077 (CI: -0.19-0.08) (Table 6.3). 
 
Table 6.3 Median diversity score in children and adults 
 
 Median diversity (Interquartile range) 
 
Axis Children Adults 
 
1 0.25 (-0.18-0.31) -0.058 (-0.36-0.24) 
 
2 -0.077 (-0.19-0.08) 0.087 (-0.14-0.26) 
 
 
The table describes the median diversity score for children’s and adults samples in both 
axes 1 and 2. 
 
The scatter of the samples in the axis1 direction was caused by children‟s samples 
from Karonga, whilst samples from children in Blantyre belonged to the same cluster 
with adult samples. Using Spearman‟s rank correlation test in Mothur, the correlation 
coefficient for each OTU to the axes in the principal component analysis file was 
determined. Results showed that three OTUs: OTU173 (Streptococcus), OTU167 
(Moraxella), and OTU165 (Corynebacterium) were largely responsible for the 
scatter in Axis1 direction; while OTU167 (Moraxella) and OTU160 
(Staphylococcus) influenced the scatter in Axis2 in the PCA analysis. These findings 
suggest that there is high variation in microbial composition among children in 
Karonga, whereas microbial composition was less diverse and similar in children and 
adults from Blantyre.  
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6.4. Distribution of phyla in children and adults 
Previously (Chapter 3, sections 3.2.1 and 3.4), a high diversity of pneumococcal 
serotype carriage was shown in Malawian adults and children, with no marked 
differences in the diversity between the two groups. In this chapter, we investigated 
whether the distribution of the four phyla detected was also similar in Malawian 
children and adults. The data was analysed in Mothur using Metastats (Appendix 
8(a)), which is a statistical method designed to detect differentially abundant features 
between microbial communities i.e. features that are enriched or depleted in two 
different populations or environments (White et al., 2009).  
 
A comparison of phyla diversity between children and adults. In our study, the 
four phyla: Actinobacteria, Firmicutes, Proteobacteria and Bacteroidetes were 
detected in both adults and children (Figure 6.8). Results showed no significant 
difference in the distribution of Actinobacteria, Firmicutes and Proteobacteria 
between children and adults (Table 6.4). 
 
Table 6.4 Distribution of phyla in children and adults 
 
 
Phyla 
 
Child (mean) 
 
Adult (mean) 
 
  
p-value 
 
Actinobacteria 
 
0.022850 
 
0.045389 
 
0.790210 
 
Bacteroidetes 
 
0.000555 
 
0.000834 
 
0.028391 
 
Firmicutes 
 
0.899107 
 
0.875984 
 
0.732268 
 
Proteobacteria 
 
0.077488 
 
0.077792 
 
0.994006 
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However, Bacteroidetes were shown to be significantly higher in adults than children 
(P<0.028) (Table 6.4). Bacteroidetes comprised three OTUs (Table 6.2): OTU006 
(Porphyromonas), OTU109 (Porphyromonas) and OTU085 (Ornithobacterium). 
There was no significant difference in the distribution of OTU006 (P<0.76) and 
OTU109 (P<0.48) between children and adults (Appendix 8 (a)) suggesting equal 
prevalence. However, OTU085 was significantly higher in adults than children 
(p<0.001), but further analysis showed that OTU085 was only isolated from a single 
adult sample (Figure 6.9), meaning the observed difference in the distribution of 
Bacteroidetes may not be a true reflection of differences at the population level. The 
impact of a single carrier observed in this analysis highlights the need for conducting 
such studies on a large dataset. Our findings however, are in agreement with a recent 
study, which demonstrated a shift in the microbiota of the human skin and nares with 
age (Oh et al., 2012), where a higher prevalence of Firmicutes, Bacteroidetes, and 
Proteobacteria was reported in the nares of children than adults. 
 
A comparison of phyla diversity in children from Blantyre and Karonga. There 
was no significant difference in the distribution of Bacteroidetes in the two regions 
(p<0.52) (Table 6.5); however, the proportions of Actinobacteria, Firmicutes and 
Proteobacteria were significantly different (Table 6.5). The phyla Actinobacteria 
were significantly higher in children from Karonga than Blantyre (P<0.023) (Table 
6.5). Actinobacteria comprised three genera: Corynebacterium (OTU165, OTU103, 
OTU159 and OTU117). The data demonstrated that there was a significantly high 
carriage prevalence of OTU 165 (p<0.0099) in children from Karonga, which may 
have contributed to the significantly higher carriage of Actinobacteria (P<0.023) in 
Karonga compared to Blantyre. All samples from Karonga were collected from HIV 
245 
 
negative children, and high carriage of Corynebacterium in Karonga is consistent 
with high carriage of Corynebacterium among HIV negative subjects. 
 
Table 6.5 Distribution of phyla in children 
 
 
Phyla 
 
Karonga (mean) 
 
Blantyre (mean) 
  
p-value 
 
Actinobateria 
 
0.049751 
 
0.004917 
 
0.022977 
 
Bacteroidetes 
 
0.001137 
 
0.000167 
 
0.523477 
 
Firmicutes 
 
0.795831 
 
0.967957 
 
0.007992 
 
Proteobacteria 
 
0.153281 
 
0.026959 
 
0.015984 
 
A comparison between children from Karonga and Blantyre. 
 
In contrast, Firmicutes were significantly higher in children from Blantyre than those 
from Karonga (P<0.0079). By composition Firmicutes contained 10 OTUs (Table 
6.2) but only three OTUs (OTU137, OTU160 and OTU173) showed a significant 
difference in the distribution between children in the two regions (Appendix 8(b)). 
OTU160 (Staphylococcus aureus) was significantly higher in children from Blantyre 
than Karonga (P<0.0099). Apart from differences in age and HIV status in the two 
groups, children‟s samples in Blantyre were collected from a hospital setting 
(Chapter 2, section 2.1) which might have increased their risk of exposure to carriage 
of S. aureus (Shibabaw et al., 2013), a commensal microorganism whose main 
ecological niche is the human nasopharynx (Kluytmans et al., 1997). Carriage of 
OTU173 (Streptococcus) was significantly higher in children from Blantyre than 
Karonga (P<0.024), suggesting high exposure to this genus in hospital among 
children in Blantyre. Thus, the high prevalence of Firmicutes in Blantyre is 
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influenced by the combined prevalence of S. aureus and Streptococcus. OTU137 
(Dolosigranulum pigrum) was significantly higher in children from Karonga 
(P<0.00899) than Blantyre. D.pigrum was isolated from 6 out of 16 children in 
Karonga and none from Blantyre (Figure 6.9), suggesting localised distribution of 
this genus. D. pigrum is a Gram-positive catalase-negative coccus and a commensal 
inhabitant of the upper respiratory tract. It is reported to be a rare opportunistic 
pathogen causing non or ventilator associated pneumonia and septicaemia 
(Hoedemaekers et al., 2006, Lecuyer et al., 2007) and more recently corneal 
infection (Sampo et al., 2013). 
 
The distribution of Proteobacteria was significantly higher in children from Karonga 
than Blantyre (P<0.015984). Proteobacteria was comprised of 18 OTUs; however 
only 3 OTUs namely OTU163 (Acinetobacter), OTU167 (Moraxella), and OTU172 
(Klebsiella) showed a significant difference in their distribution between the two 
regions. OTU172 was only isolated from one child in Blantyre (Figure 6.14) so the 
observed significant difference is not be representative of the prevalence at the 
population level. OTU163 was isolated from 3 children in Blantyre and none in 
Karonga (Figure 6.14). Acinetobacter is common in hospital settings (Fournier and 
Richet, 2006, Munoz-Price and Weinstein, 2008) and this may explain why it was 
exclusively isolated form children in Blantyre whose samples were obtained during 
their visit to the hospital. Acinetobacter is a Gram-negative bacterium that is 
associated with contaminating environmental microorganisms (Tanner et al., 1998), 
however certain species are commensal of the human skin (Chu et al., 1999) and the 
nasopharynx (Anstey et al., 2002, Wolf et al., 2001). OTU167 represented 
Moraxella, which was isolated from children in both regions; however, it was highly 
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predominant and was detected in virtually all the children in Karonga (P<0.002). The 
children in Karonga were infants, much younger than the older children in Blantyre 
( 2years). The age difference could play a role in the observed carriage prevalence 
of Moraxella, which has been reported to be higher in children (75%) than adults (1-
3%) (Verduin et al., 2002). The genus Moraxella belongs to Moraxellaceae family 
comprising Gram-negative, oxidase and catalase positive coccobacilli; and 
commensally reside in the upper respiratory tract (Laukeland et al., 2002). These 
findings give an indication that there is a difference in the distribution of 
nasopharyngeal microbiota in children from the two regions, however, further 
analysis of samples of similar age and HIV status from the two regions would be 
recommended to establish whether indeed the observed differences could be 
attributed to differences in geographical location.  
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Figure 6.8 Distribution of Phyla in children and adults 
Figure (A) shows the distribution of Proteobacteria, Firmicutes, Bacteroidetes and Actinobacteria in Malawian children and adults. Figure (B) 
shows distribution of Bacteroidetes and Actinobacteria for clarity because their relative abundance was very low.
A 
B 
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Figure 6.9 Distribution of microbial genera in children and adults 
Sections „A‟ and „B‟ represent children from Blantyre and Karonga respectively, „C‟ represents adults. The red squares signify carriage 
(presence) while the blue squares signify non-carriage (absence). 
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6.5. Distribution of OTUs and Phyla by HIV status 
A high proportion of samples in this dataset were collected from HIV positive (n=35) 
compared to HIV negative (n=23) subjects. We investigated whether HIV infection 
had any impact on the distribution of OTUs and Phyla in carriage.  
 
OTU distribution. The analysis identified 24 OTUs in HIV positive children 
(n=19), which was higher than 12 OTUs identified in HIV negative children (n=21) 
with 8 OTUs in common. However, the difference in OTU distribution was not 
statistically significant (P<0.0923). Again this may not be definitive because of the 
limited sample size. The total number of OTUs in HIV negative (n=4) and HIV 
positive (n=14) adults was 14 and 28 respectively, while 9 OTUs were shared 
(Figure 6.4). The difference in OTU distribution in adults was not statistically 
significant (P<0.3894). These results suggest that although OTU richness was higher 
in HIV infected adults and children, the differences observed were not statistically 
significant. Further analysis by the inverse Simpson diversity index however, showed 
that the microbial population was more diverse in HIV negative than HIV positive 
children and adults (P<0.0409) (Figure 6.10). This suggests that although HIV 
infected subjects had large number of OTU, they were mainly comprised of related 
species, leading to a decrease in microbial diversity following HIV infection. This is 
also supported by a previous study where a depletion of some commensal 
microorganisms in rectal mucosa among the HIV infected and replacement with a 
few opportunistic pathogens was observed (McHardy et al., 2013). It is not clear why 
HIV infected subjects had less microbial diversity compared to HIV negative 
individuals. The question is whether the compromised immune function in HIV 
positive individuals allows colonisation and spread of a particular group of microbial 
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species, which prevents others from attaching to the mucosal surface. Addressing 
this question would require further investigation.  
 
 
 
Figure 6.10 The inverse Simpson diversity index 
There was higher microbial diversity in HIV negative than HIV positive adults and 
children (P<0.0409). 
 
Phyla distribution. A shift from the normal profile of microbiota in various disease 
conditions has been documented (Costa et al., 2012, Cho and Blaser, 2012). HIV 
infection has been shown to be associated with changes in the microbial profiles 
amongst infected individuals (Saxena et al., 2012). In this study, the distribution of 
microbial species at the phylum and genus levels between HIV positive and HIV 
negative subjects was investigated. The aim was to establish if there would be a shift 
in nasopharyngeal carriage of different microbial species following HIV infection in 
Malawian children and adults. Results showed that all the four phyla (Bacteroidetes, 
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Firmicutes, Proteobacteria and Actinobacteria) were detected in both HIV positive 
and HIV negative subjects (Figure 6.8). There was no significant difference in 
carriage of Bacteroidetes (P<0.061), Firmicutes (P<0.088) and Proteobacteria 
(P<0.419) between the two cohorts, but the distribution of Actinobacteria was 
significantly higher in HIV negative than HIV positive subjects (P<0.007) (Table 
6.6). 
 
Table 6.6 Distribution of phyla by HIV status 
  
Phyla 
 
HIV +Ve (mean) 
 
HIV -Ve (mean) 
  
P-Value 
 
Actinobacteria 
 
0.003667 
 
0.064400 
 
0.006993 
 
Bacteroidetes 
 
0.000576 
 
0.000728 
 
0.061136 
 
Firmicutes 
 
0.935869 
 
0.833932 
 
0.088911 
 
Proteobacteria 
 
0.059887 
 
0.100940 
 
0.418581 
 
At the genus level, Actinobacteria comprised Corynebacterium (OTU165, OTU103, 
OTU159 and OTU117); Arthrobacater (OTU115) and Propionibacterium (OTU107) 
(Table 6.2). There was no significant difference in the prevalence of Arthrobacter 
(P<0.621), Propionibacterium (P<0.424) and Corynebacterium (OTU159 (P<0.107), 
OTU117 (P<0.138)) between HIV positive and HIV negative subjects. However, 
OTU103 (Corynebacterium accolens) and OTU165 (Corynebacterium 
pseudodiptheriticum) were significantly reduced in HIV positive than HIV negative 
subjects, with p-values of 0.02 and 0.007 respectively (Appendix 8(c)). Thus 
OTU103 (Corynebacterium accolens) and OTU165 (Corynebacterium 
pseudodipthericum) were responsible for the significant shift in the prevalence of 
Actinobacterium by HIV status. The reason why the prevalence of C. 
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pseudodipthericum and C. accolens are reduced in HIV positive subjects is not clear, 
although competition with other co-colonising bacteria may influence diversity 
because S. aureus has been reported to associate negatively with C. 
pseudodipthericum and positively with C. accolens(Uehara et al., 2000). Our data 
however showed no significant difference in carriage of S. aureus (OTU 160) 
(Appendix 8 (c)) suggesting involvement of other host or environmental factors 
(Glennie et al., 2010). 
 
6.6. Discussion 
This study investigated the composition of nasopharyngeal microbiota of children 
(n=40) and adults (n=18) in the context of high prevalence of HIV infection and 
invasive pneumococcal disease. The aim was to determine if the distribution of the 
microbiota in the nasopharynx varied between adults and children and whether HIV 
infection resulted in a shift from the baseline microbiota in healthy individuals. The 
individuals were grouped based on their respective HIV serostatus; HIV negative 
(n=23) and HIV positive (n=35). The results showed 4 taxonomic phyla 
(Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria) and 37 species level 
phyla type (OTUs) were predominant in the Malawian samples. Firmicutes (79%) 
were the most abundant phyla, followed by Proteobacteria (17%), Actinobacteria 
(3%) and Bacteroidetes (1%). The types of phyla detected in Malawian adults and 
children are consistent with the findings in healthy children from the Netherlands 
(Proteobacteria (64%), Firmicutes (21%), Bacteroidetes (11%), Actinobacteria 
(3%), Fusobacteria (1.4%)) (Bogaert et al., 2011) and healthy adults from China 
(Actinobacteria (38.1%), Firmicutes (31.7%), Proteobacteria (5.4%), Bacteroidetes 
(1.4%)) (Ling et al., 2013). Other settings also reported similar composition: Egypt 
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in healthy adults (Actinobacteria, Firmicutes and proteobacteria) (Frank et al., 
2010), Canada in pandemic H1N1 children and adults patients (Actinobacteria, 
Firmicutes, Proteobacteria) (Chaban et al., 2013) and USA in healthy adults 
(Firmicutes, Actinobacteria) (Lemon et al., 2010). It can be deduced from the above 
studies that Proteobacteria, Firmicutes, Bacteroidetes and Fusobacteria are the 
commonly isolated taxa from the nasopharynx of both children and adults across the 
world. These findings suggest that the human upper respiratory tract fundamentally 
shares a similar collection of commensal bacterial families across all age ranges. 
There are however variations in the dominant phyla or species based on the subjects 
state of health, age and geographical location (Garcia-Rodriguez and Fresnadillo 
Martinez, 2002). In Malawi, for example there was a disproportionately high 
representation of Firmicutes across all age ranges, compared to other settings. The 
reasons why Malawians had such a high abundance of Firmicutes are not clear. 
However, this could be influenced by a bias in the sampling of the Malawian dataset 
where only carriers of S. pneumoniae were analysed, as indicated previously 
(Chapter 2, Sections 2.1 and 2.2).  
 
Diversity of nasopharyngeal microbiota by age. To investigate if age had an 
impact on nasopharyngeal microbiota, the profile of microbial species identified in 
children and adults was compared. Results showed that both children and adults 
carried the same profile of microbial species: Firmicutes, Proteobacteria, 
Actinobacteria, and Bacteroidetes which is consistent with other reports (Bogaert et 
al., 2011, Hilty et al., 2012). The profile of phyla between children and adults in 
Malawi was similar, however Bacteroidetes were significantly higher in adults than 
children (P<0.028). Elsewhere, prevalence of Bacteroidetes in the intestines has also 
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been reported to be significantly higher in adults than children (P<0.02) (Ringel-
Kulka et al., 2013). This suggests an age dependent variation in the distribution of 
Bacteroidetes. The total richness was also found to be higher in adults than children 
(P<0.0085) although there was no difference in species diversity (P<0.4058), 
suggesting equal distribution of phyla in adults and children. This finding is similar 
to that of pneumococcal carriage, where no significant difference in diversity was 
observed between children and adults (Chapter 3). On the contrary a previous study 
in Canada, also conducted on a limited sample size (n=65) showed a trend towards 
increasing species diversity with age (Chaban et al., 2013). Their study was 
conducted on patients with the pandemic H1N1 influenza (Chaban et al., 2013), 
while our dataset had a high representation of samples from HIV infected subjects. 
The difference in phyla proportions between this and our study could also be 
attributed to the use of cpn60 (Chaban et al., 2013) and 16S rRNA genes as 
respective markers for bacterial identification. For studies using 16S rRNA, the 
choice of the variable region for comparing findings in different settings is important 
because no single variable region is adequate to identify microbial diversity in 
different environments (Chakravorty et al., 2007). The identities of nasopharyngeal 
phyla in studies using different 16S rRNA variable regions are similar however 
marked differences occur in their proportions (Chaban et al., 2013, Bogaert et al., 
2011). Unlike the study in Canada, the estimation of diversity index in our dataset 
was difficult because it was largely influenced by carriage of one dominant OTU173 
(streptococcal species) in both adults and children. This suggested that any 
differences in less abundant OTUs would not have a major impact on the overall 
population diversity. 
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The impact of HIV infection on the profile of nasopharyngeal microbiota. HIV 
infection has been reported to predispose patients to increased carriage and 
susceptibility to disease by mucosal bacteria (Pan et al., 2005). The increased 
carriage is attributed to the impairment of membrane integrity and function because 
of an influx of pro-inflammatory cytokines in the presence of the virus (Glennie et 
al., 2010). HIV infection and several other infections have widely been reported to 
cause a shift in the diversity of microbiota (McHardy et al., 2013, Costa et al., 2012, 
Clemente et al., 2012). In this study, we investigated whether HIV infection did 
indeed have an impact on the diversity of nasopharyngeal flora in Malawian children 
and adults. Results showed no significant difference in the total number of species 
carried by both HIV positive and HIV negative children and adults combined, 
however the species diversity was higher in HIV negative compared to HIV positive 
subjects (P<0.0409). Furthermore, the species C. accolens and C. 
pseudodiptheriticum from the phyla Actinobacteria were significantly reduced in 
HIV positive children and adults, with p-values of <0.02 and <0.007 respectively, 
consistent with previous findings on the impact of HIV infection on nasopharyngeal 
microbiota (McHardy et al., 2013). It is not quite clear why there is a reduction of 
these specific species in HIV infected subjects, however, the compromised immune 
function in the HIV infected individuals has been reported to alter carriage dynamics 
at the mucosal site (Glennie et al., 2010), which may increase the competition for 
colonisation. Antibiotic use has been reported to alter the profile of normal flora in 
carriage (Varon et al., 2000). Usage of co-trimoxazole prophylaxis in the HIV 
infected is recommended as it has been shown to reduce mortality (Nunn et al., 
2008). Co-trimoxazole has also been reported to alter microbial carriage dynamics in 
the nasopharynx (Gill et al., 2008a, Arason et al., 1996). Therefore the use of co-
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trimoxazole in Malawian HIV infected adults and children who were exclusively 
from Blantyre, may have contributed to the observed differences in microbial 
carriage dynamics in the two regions.  
 
Microbial diversity in children. Environmental factors have been shown to play an 
important role in the diversity of the human microbiota (Levy and Borenstein, 2013). 
In this study, children‟s samples were collected from Blantyre and Karonga, over 
400 miles apart (Chapter 2, section 2.0). Using a collectors curve, the species 
richness was found to be higher in children from Karonga than Blantyre (Figure 6.1). 
Analysis of species diversity by principal component analysis (Bray-curtis 
Dissimilarity Index) showed higher diversity in children from Karonga than 
Blantyre, suggesting a shift in the profile of nasopharyngeal microbiota in children 
from the two regions. The phyla detected in the two regions were the same and these 
included: Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria. Carriage of 
Actinobacteria was significantly higher in children from Karonga than Blantyre 
(P<0.023) and this was mainly due to the dominating Corynebacterium species 
(P<0.0099). Similarly, the carriage of Proteobacteria was significantly higher in 
children from Karonga than Blantyre (P<0.015), mainly due to Moraxella species 
(P<0.002). These results show Corynebacterium and Moraxella species were 
enriched in children from Karonga and were thus responsible for the increased 
prevalence of Actinobacteria and Proteobacteria in Karonga respectively. The 
distribution of Dolosigranulum pigrum was significantly higher in Karonga than 
Blantyre (P<0.009). It was further shown that D. pigrum was only localised to 
children in Karonga and none from Blantyre. Firmicutes were significantly higher in 
children from Blantyre than Karonga (P<0.0079), and this was mainly due to the 
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significantly high carriage of Staphylococcus aureus (P<0.0099) and Streptococcus 
(P<0.024). Overall Staphylococcus aureus and Streptococcus influenced the 
observed higher prevalence of Firmicutes in Blantyre than Karonga. These data show 
the shift in nasopharyngeal microbiota distribution between Karonga and Blantyre. 
All children in Karonga were infants (less than 12 months old) and exclusively HIV 
negative while the Blantyre samples were drawn from children under the age of five 
years and adults (including HIV positive individuals). However, a comparison in 
phyla distribution by HIV status in children was not made because of the 
dramatically reduced sample numbers after subsampling. The observed difference in 
microbial distribution in children could therefore arise from age differences in the 
two groups. Karonga samples were obtained from a rural setting whereas Blantyre 
samples were from the urban children reporting to hospital as outpatients. The 
difference in sampling source may also contribute to the diversity of microbial 
distribution in carriage.  
 
6.7. Conclusion 
In conclusion, findings from this study show that four phyla (Firmicutes, 
Bacteroidetes, Actinobacteria and Bacteroidetes) dominate nasopharyngeal 
microbiota in Malawian children and adults. No difference was observed in the 
distribution of these microorganisms in children and adults, suggesting no overall 
impact by age differences. However, there was a difference in microbial distribution 
between children from Karonga and Blantyre, which could possibly be attributed to 
HIV status because all samples from Karonga were HIV negative. Actinobacteria 
and Proteobacteria were dominant in Karonga whilst Firmicutes were dominant in 
Blantyre. Analysis of the impact of HIV infection on microbial distribution for the 
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whole dataset, showed a significant decrease in carriage of Actinobacteria (P<0.007). 
While the present study has characterised for the first time the nasopharyngeal 
microbiota in the Malawian population; and has also shown that HIV infection 
potentially influence carriage dynamics of the nasopharyngeal microbiota, there were 
limitations which made data interpretation difficult. The obvious limitation was a 
dramatic decrease in sample size following clean up and subsampling of the 454 
sequences. The data also had a disproportionately high carriage of Firmicutes, which 
overshadowed the remaining three phyla making analysis of diversity scores 
difficult. Because of the important role microbiota plays in health and disease, 
further studies are recommended (Chapter 7, section 7.8) to address the current 
limitations.  
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Chapter 7: General discussion and conclusions 
 
7.1 Introduction 
This thesis has characterised nasopharyngeal carriage of S. pneumoniae and other 
microbiota in Malawian children and adults. Specifically, pneumococcal carriage and 
the prevalence of multiple pneumococcal serotype carriage were addressed (Chapter 
1, Section 1.12). Carriage data is important in any setting for estimating impact of 
vaccination before and after it has been introduced (Goldblatt et al., 2013) and can be 
modelled to reflect changes occurring in invasive disease post vaccination 
(Weinberger et al., 2013). Carriage data have previously been generated for Malawi 
(Feikin et al., 2003) using Quellung and latex agglutination methods, however this 
was inadequate. The present study used microarray, which has the enhanced ability 
to determine carriage of multiple serotypes and detection of novel serotypes. By 
microarray, less abundant serotypes (usually missed by conventional Quellung and 
latex agglutination methods) were identified and this provided a good estimate of 
serotype diversity in Malawi. In addition, this data will form a good basis for 
estimating the impact of PCV13 introduction in Malawi. The last question addressed 
carriage of other nasopharyngeal microbiota in Malawian children and adults. These 
microbiota are involved in different modes of interaction which may impact on 
pneumococcal dynamics as well as virulence. The current study was not designed to 
characterise such interaction but identify for the first time to profile of 
nasopharyngeal microbiota in the Malawian setting. 
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7.2 Pneumococcal carriage in children and adults 
Broad serotype diversity in Malawi children and adults. The study has 
demonstrated a broad range of pneumococcal serotypes and traces of nontypeable 
pneumococcal strains carried in Malawian children (Chapter 3, Section 3.2.1). 
Although pneumococcal carriage is generally higher in children than adults (Regev-
Yochay et al., 2004b, Hussain et al., 2005, Mackenzie et al., 2010, Adetifa et al., 
2012), our study showed that among carriers, pneumococcal serotype distribution 
was as equally diverse in adults (Chapter 3, Section 3.4) as it was in children. The 
high carriage diversity in adults could be attributed to the high representation of 
samples from HIV positive adults who were shown to carry a broader range of 
serotypes than HIV negative adults (Chapter 3, Section 3.4.1). HIV infection has 
been shown to significantly increase the risk of pneumococcal colonisation in adults 
(Gill et al., 2008b), which is thought to be associated with a defective pneumococcal 
specific Th1 response (Glennie et al., 2012a) and impairment of mucosal membrane 
barrier integrity (Glennie et al., 2010). PCV13 coverage of vaccine serotypes in 
Malawian children was estimated at 60% while in adults it was 30%, which is low 
compared to the 88% estimate in children and 50 % in adults based on strains from 
invasive disease in the same setting (Cornick et al., 2011, Everett et al., 2012). Such 
low estimate of PCV13 coverage highlights the higher diversity of serotypes in 
carriage, and suggests that carriage data may underestimates PCV13 coverage in a 
given population. Although carriage estimates for vaccine coverage were low, the 
fact that carriage is more common than disease (Brueggemann et al., 2003) it 
provides a good alternative for estimating vaccine efficacy. It is thought that the 
impact of any vaccine on carriage can be used as a guide for licensing and 
implementing new vaccines (Goldblatt et al., 2013), and recently it has also been 
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shown that modelling of carriage data can be used to estimate post-PCV changes in 
incidences of invasive pneumococcal disease in settings with no population-based 
surveillance systems for monitoring IPD incidences such as Malawi (Weinberger et 
al., 2013). This was achieved by estimating the change in carriage prevalence for 
each serotype in each study, followed by the calculation of the average change 
among vaccine and nonvaccine serotypes (Weinberger et al., 2013). These values 
were then multiplied by the proportion of IPD caused by each serotype during the 
pre-PCV period to obtain an estimate of post-PCV disease incidence (Weinberger et 
al., 2013). There were also a high proportion of non-vaccine serotypes (NVTs) 
circulating in children (40%) and adults (70%). It is well described (Weinberger et 
al., 2011, Mulholland and Satzke, 2012, Flasche et al., 2011b) that NVTs are 
responsible for serotype replacement post-vaccination and the eventual emergence of 
replacement disease. Serotype replacement in carriage has also been demonstrated in 
populations using PCV13 in the USA (Lee et al., 2013a) and Canada (Ricketson et 
al., 2014).  Failure by PCV13 to reduce carriage of vaccine serotypes has also been 
demonstrated in children over two years of age (Lee et al., 2013a), and this can have 
a negative impact on herd immunity. The real impact of vaccination in a given 
population can only be assessed through a post-vaccination carriage and IPD 
surveillance, necessitating the need for maintaining on-going surveillance and the 
initiation of broader carriage studies post PCV13 introduction across Malawi. 
 
High carriage of nontypeable serotypes in adults compared to children. Carriage 
of nontypeable S. pneumoniae accounted for 20% of all serotypes detected in adults 
and for 1.8% in children demonstrating a higher carriage of NT in adults than 
children. Higher carriage of NTs in adults is consistent with a study in Israel, 
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conducted on a much larger dataset, where NT represented 23.7% of all strains in 
adults and 5.2% in children (Regev-Yochay et al., 2004b). And a study from 
Thailand-Myanmar border area also showed a higher proportion of adults (mothers) 
carrying NT pneumococcal strains (29.6%) than infants (10.5%) using latex 
agglutination and Quellung reaction (Turner et al., 2012). These studies consistently 
show higher carriage of NT in adults compared to children. However, the reasons for 
this observation remain unclear. Reporting of NTs is often difficult because of their 
atypical colony morphology, which may misidentify NTs as non-pneumococcal 
streptococci (Turner et al., 2012). Therefore in reports using different serotyping 
methods, it is difficult to compare the findings and draw meaningful conclusions. In 
our study, it is extremely unlikely that NTs were misidentified, because the presence 
of pneumococcal strains was confirmed by microarray using PathID (Chapter 2, 
section 1.19). Our results therefore suggest that carriage of NTs in Malawi is more 
common among adults than children. A recent study has demonstrated high rates of 
genetic recombination occurring in nontypeable strains, and has also shown the 
occurrence of capsule switch event between encapsulated and nontypeable strains 
(Chewapreecha et al., 2014). Given the high rates of antibiotic resistance among NTs 
(Porat et al., 2006), the adult population will act as a source of genetic material that 
may provide a means to confer virulence and antibiotic resistance genes back to 
encapsulated pneumococcal strains.  
 
High prevalence of multiple carriage in Malawian children compared to adults. 
This thesis has reported, for the first time, the prevalence of pneumococcal multiple 
pneumococcal serotypes carriage in Malawian children (Chapter 3, section 3.3) and 
adults (Chapter 3, section 3.5). Multiple carriage was detected on 40% (46/116) 
264 
 
across all the children‟s samples analysed and 19% (22/117) in adults (Chapter 3, 
section 3.5). This study was not able to establish the association between particular 
serotypes in multiple carriage because co-carriage of serotypes occurred at random. 
In adults, however, nontypeable serotypes were frequently isolated from multiple 
carriage with encapsulated pneumococcal strains more than any other serotype 
(P<0.0058) (Chapter 3, section 3.5). To the knowledge of the author, this is the first 
time the association between NTs and encapsulated pneumococcal strains has been 
identified in multiple carriage events. The association between NTs and encapsulated 
pneumococcal strains could not be established in children, possibly because of the 
extremely low prevalence of NTs in this cohort (1.8%). Multiple carriage has been 
reported in other settings, which allowed comparisons to be made with findings 
reported here. In The Gambia, multiple carriage was 19% (n=69) in children under 
the age of 2 years (Donkor et al., 2011), using microarray serotyping, which is low 
compared to Malawi despite using the identical molecular method. This difference 
can be attributed to differences in sampling. While the Gambian study estimated 
multiple carriage from analysing multiple colonies form the culture plate, The 
Malawian study used a plate sweep of all colonies (Chapter 2, section 2.5), which 
increased the chance of getting multiple serotypes. Similar to Malawian children, a 
study in Spain detected multiple carriage in 39% (41/105) of healthy children under 
the age of five years, by analysing a plate sweep of all colonies using multiplex PCR 
(Ercibengoa et al., 2012). In Thailand, a carriage study in children less than 2 years 
old (n=955) reported a low 12.9% prevalence of multiple carriage (Turner et al., 
2013), by latex sweep serotyping, although this detected three times higher rates of 
multiple carriage compared to the standard WHO method (O'Brien and Nohynek, 
2003) in the same study, suggesting that analysing all colonies from a plate culture 
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enhances multiple carriage detection. These studies reinforce the importance of 
methodology for accurate determination of carriage and multiple carriage in a given 
setting (Rapola et al., 1997). Other factors that have an impact on multiple carriage 
estimates include vaccination, which has been shown to lower multiple carriage in 
the vaccinated groups (Valente et al., 2012). This is unlikely in our dataset because 
the samples were collected prior to vaccine introduction in Malawi. However it 
would be interesting to monitor whether PCV13 would also reduce multiple carriage 
in a Malawian setting. 
 
7.3 Impact of HIV infection on pneumococcal carriage 
This thesis has shown that HIV negative children carry a broader range of serotypes 
compared to HIV positive children (Chapter 3, section 3.2.2). This suggests that HIV 
infection may result in a decrease in carriage serotype diversity in Malawian 
children. A recent study showed that serotype diversity in carriage was sensitive to 
the form of acquisition on nonspecific immunity and the strength of anti-capsular 
immunity. Since HIV infection compromises the hosts‟ immune system and function, 
it may explain why serotype diversity was higher in HIV negative than HIV positive 
children. In contrast, HIV positive adults carried a wider range of serotypes than HIV 
negative adults (Chapter 3, section 3.4.1) (Glennie et al., 2012a), however this was 
not statistically significant, suggesting the impact of HIV infection on carriage could 
not be demonstrated in adults. These results support recent findings in South Africa 
where carriage prevalence of pneumococcal serotypes was not different between 
HIV positive and HIV negative mothers (Nunes et al., 2013). Similarly another study 
also found no significant difference in the prevalence of pneumococcal serotypes 
between HIV positive and HIV negative adults (Rodriguez-Barradas et al., 1997). 
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The impact of HIV infection on carriage however is not fully understood because 
different studies have reported different findings, which highlights the need for 
further studies. In Kenya for example, there was no difference in the distribution of 
serotypes between the HIV-infected and population-based samples (Abdullahi et al., 
2012a) in children under 2 years of age. In Zambia, HIV infection was reported as a 
risk factor for pneumococcal colonisation in mothers (Gill et al., 2008b). The impact 
of HIV infection on multiple carriage could not be demonstrated in both children and 
adults, which supports previous findings in Malawian adults (Glennie et al., 2012a). 
Different findings from different settings above, highlight the complexity of carriage 
in the context of HIV infection, as previously stated, and underscores the need for 
continued studies to fully understand how HIV infection influences carriage. 
 
7.4 Carriage of capsular polysaccharide variants in Malawi 
We have shown that genetic variations exist within the CPS loci of carried 
pneumococcal strains in both Malawian adults and children (Chapter 4). The 
predominant CPS variants belonged to serotype 6B, although variants of serotypes 
19A, 20, and 29 were also detected. These variations occurred naturally i.e. without 
any vaccine selection pressure since samples were collected prior to the introduction 
of PCV13. Natural transformation of pneumococcal strains leading to capsule 
switching has previously been reported in Malawi (Everett et al., 2012). Variants of 
serotype 6B have previously been reported in the Netherlands (Elberse et al., 2011) 
and our variants were phylogenetically similar to 6B subtype III, although they 
exhibited different genotypes (Chapter 5, section 5.2). Such changes occurring 
within the CPS locus have the potential for compromising vaccine efficacy; as such 
it is not clear how the CPS locus variants observed in Malawi will respond towards 
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the vaccine. Further testing in mouse models to establish the ability of the variants to 
colonise, cause invasive disease or indeed escape the vaccine is currently underway. 
Preliminary findings suggest that the 6B variants colonise better than the wild type 
and are less invasive (unpublished), which is not surprising considering they were 
carriage serotypes. However, there are reports suggesting that these 6B variants 
could belong to the newly discovered serotype 6E (Ko et al., 2013). Further analysis 
of whole genomes and CPS gene variations is therefore required, to determine 
whether indeed the Malawian 6B variants belong to the recently discovered serotype 
6E. 
 
7.5 Nasopharyngeal microbiota in Malawian children and adults 
Characterisation of the nasopharyngeal microbiota in Malawian adults and children 
showed four taxonomic phyla: Firmicutes (79%); Proteobacteria (17%); 
Actinobacteria (3%) and Bacteroidetes (1%) (Chapter6). Malawian adults and 
children demonstrated a disproportionately higher prevalence of Firmicutes, 
particularly streptococcal species in carriage than reported in other settings (Bogaert 
et al., 2011, Frank et al., 2010, Ling et al., 2013). Although the reasons for these 
observations are not clear, Malawian samples only included carriers of S. 
pneumoniae, which may have contributed to the disproportionately high prevalence 
of Firmicutes. However, to confirm whether indeed Firmicutes are the most 
predominant phyla in Malawi, further microbiome studies in both carriers and non-
carriers of S. pneumoniae are recommended. A comparison of microbial diversity 
showed no variability in the distribution of phyla between adults and children in 
Malawi. Elsewhere, in Canada, a trend towards higher nasopharyngeal microbial 
diversity with age has been reported (Chaban et al., 2013). Unlike Malawi, where 
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16S rRNA was used as a target in a cohort with high HIV positive sample 
representation, the Canadian study (Chaban et al., 2013) used cpn60 gene, as a 
universal target for microbial identification among the cohort diagnosed with H1N1 
influenzae, which may contribute to the observed differences in microbial diversity. 
Other factors that have been reported to influence the apparent microbial diversity in 
different settings include contaminating DNA present in DNA extraction kits. Such 
contaminants are thought to critically impact the results, particularly those obtained 
from samples containing a low microbial biomass (Salter et al., 2014). Knowledge of 
common kit contaminants can enable comparisons of microbial diversity in settings 
using different reagents to be made. In this thesis, DNA contamination from kits was 
minimised by performing a blank DNA extraction containing all the reagents except 
the sample for each analysis. The impact of HIV infection on microbial diversity in 
Malawi was also investigated. Previous studies have shown that HIV infection 
causes a shift from the normal microbiota in humans (Saxena et al., 2012, McHardy 
et al., 2013). Our findings showed a significant decrease in carriage of 
Actinobacteria following HIV infection (P=0.007), although carriage of 
Bacteroidetes (P=0.061), Firmicutes (p=0.088) and Proteobacteria (p=0.419) 
remained unchanged. This suggests HIV infection does impact microbial carriage 
dynamics in the nasopharynx, however the ART mediated immune reconstitution did 
not have any impact on the richness and diversity of the nasopharyngeal microbiota 
in this dataset. 
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7.6 Study limitations 
7.6.1 Sampling 
Sample handling. The samples used for this study were retrieved from the MLW 
freezer archive, which is maintained at-80
 
C in STGG (Chapter 2, section 2.4). To 
determine the microorganism present, the samples were thawed to 4
 
C and then 
cultured on media. Culturing from frozen samples has been associated with loss in 
viability of certain pneumococcal serotypes, which for culture dependent methods, 
may affect the spectrum of serotypes obtained (Abdullahi et al., 2007) as well as 
underestimate the prevalence of multiple carriage. Analysing samples in the shortest 
possible time after collection to minimise the effect of freezing would be optimal. 
Employing culture independent molecular methods, which will improve detection of 
non-viable microorganisms, is also recommended.  
 
Sample selection 
1. Our study only analysed samples from nasopharyngeal swabs that were 
confirmed to contain pneumococcal strains. This likely introduced a bias in sample 
selection, which may have an impact on the reported distribution of pneumococcal 
strains, and microbiota in the nasopharynx. The bias can be minimised by including 
samples that are culture negative for S. pneumoniaein the analysis. 
 
2. In order to understand the carriage dynamics in households overtime, a subset 
of samples was collected from infants at longitudinally. Samples from parents and 
older siblings were not available at the time of the study, which consequently made it 
difficult to fully understand the actual pneumococcal transmission dynamics in this 
setting. We suggest inclusion of other household members in future carriage 
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surveillance studies. 
 
3. The longitudinal samples were only collected from four sampling points at 
four weeks interval, which is not an adequate for understand carriage dynamics in 
relation to duration of carriage and relationships among serotypes present in multiple 
carriage. We recommend sampling over a longer period of time.  
 
7.6.2 Microarray serotyping 
This thesis utilised microarray to characterise serotypes in carriage (Chapter 2, 
section 2.6). Unlike the Quellung reaction or latex agglutination, microarray has the 
enhanced utility to detect not only multiple carriage of S. pneumoniae and their 
relative abundance but it can also detect the presence of antibiotic resistance genes, 
novel serotypes and other colonising microbial species in the nasopharynx (Newton 
et al., 2011). Microarray also offers the advantage of analysing large number of 
samples within a short period of time and can be optimised to detect non-viable 
organisms (Satzke et al., 2014). The disadvantage of using microarray is that the 
reagents and equipment required are very costly, and demands a high level of 
technical expertise for array data analysis (Satzke et al., 2014). But most importantly, 
the array is not able to distinguish closely related serotypes because of identical 
sequences at the CPS locus. This limitation can be overcome by including more 
stringent targets for identification of each serotype (Satzke et al., 2014). Despite 
these limitations, microarray is still more sensitive than conventional methods and 
has wider applications (Turner et al., 2011). 
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7.6.3 Detection of nasopharyngeal microbiota 
Limitations with 16S rRNA. The 16S rRNA gene (1550bp long) is universal in all 
bacteria, and has been widely used to estimate phylogenetic relationships among 
bacterial species (Clarridge, 2004). In clinical settings, the 16S rRNA gene has been 
used to accurately identify organism misidentified by conventional phenotypic 
methods (Petti et al., 2005). Despite the increasing use in clinical and other settings, 
the16S rRNA approach has some limitations:  
 
1. The 16S rRNA gene sequencing can only classify bacteria up to genus level 
and there is currently no universal definition for the identification of species through 
16S rRNA gene sequencing (Janda and Abbott, 2007).  
 
2. Failure to distinguish closely related species for example, the 16S rRNA 
genes for species such as Bacillus globisporus and Bacillus psychropilus share over 
99.5% sequence similarity, however the whole genome DNA homology is less than 
50% (Fox et al., 1992). This suggests that the sequence similarity by 16S rRNA does 
not necessarily imply accurate identification.  
 
3. The accurate identification of bacteria by 16S rRNA sequences is as good as 
the quality and completeness of the nucleotide sequences deposited into the public 
database, however the database has been reported to be incomplete and has 
sequencing errors (Boivin-Jahns et al., 1995, Ashelford et al., 2005).  
 
Limitations with 454 sequencing: To characterise nasopharyngeal microbiota in 
our cohort, our study employed the 454 pyrosequencing (Chapter 2, section 2.11.6) 
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by sequencing the PCR amplified 16S rRNA gene. Although 454 sequencing has 
longer read length than the others and operates as a high-throughput sequencing tool 
(Rothberg and Leamon, 2008), it is more expensive per base and requires a 
substantial amount of starting material compared to other platforms such Illumina, 
Genome Analyser and Applied Biosystems (Roh et al., 2010). The major limitation 
facing 454 pyrosequencing and other NGS platforms is the production of sequences 
that are artefacts of PCR (Qiu et al., 2001) and sequencing (Quince et al., 2011, 
Schloss et al., 2011). These inflate the number of operational taxonomic units in a 
given sample, giving rise to erroneous results. The other problem is failure to 
accurately call long homopolymer bases, and the accuracy of base calling has been 
shown to decrease with increase in the length of the homopolymer, which are 
wrongly reported as insertions or deletions (Quinlan et al., 2008). For accurate 
determination of microbial species, it is necessary to improve the quality of the 
sequences generated by identifying and removing the sequence artefacts. To resolve 
these problems, bioinformatics tools are employed (Quince et al., 2011, Schloss et 
al., 2011). This study employed Mothur, a single piece of software, built on several 
pre-existing software for describing and comparing microbial communities (Schloss 
et al., 2009), in Malawian adults and children. 
 
7.7 Conclusions 
The study, on which this thesis is based, characterised the nasopharyngeal carriage of 
S. pneumoniae and other microbiota in Malawian children and adults. The results 
demonstrated that Malawian children and adults possess a diverse distribution of 
pneumococcal serotypes in carriage. The PCV13 coverage estimates was higher in 
children (60%) than adults (30%), suggesting higher carriage of vaccine serotypes in 
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children and supports the rationale behind the introduction of introducing PCV13 to 
children in Malawi. In addition, the data have also shown that carriage of non-
vaccine serotypes (NVTs) was also very high in Malawian children and adults, 
suggesting the NVTs may act as reservoir for serotype replacement post-vaccination. 
Serotype replacement becomes a major clinical issue if it leads to NVT disease, 
which may override the benefits of vaccine introduction. For the first time in 
Malawi, the data have shown that multiple carriage is not only common but is more 
prevalent in children (40%) than adults (19%). Multiple carriage provides an ideal 
environment for horizontal gene transfer that drives pneumococcal evolution events 
such as acquisition of virulence and antibiotic resistance genes as well as capsule 
switch. There is evidence of genetic changes within the CPS loci of both vaccine and 
non-vaccine serotypes occurring naturally in the Malawian population, possibly due 
to high multiple carriage prevalence. However, this may accelerate under vaccine 
selection pressure and may have a negative impact on treatment. Malawi is a setting 
with high prevalence of HIV infection and invasive disease. While the prevalence of 
pneumococcal carriage is also high, the impact of HIV on carriage has never been 
investigated in Malawi. Generally, the data presented in this thesis has demonstrated 
no significant impact by HIV infection on the distribution of single or multiple 
pneumococcal serotypes carriage in both children and adults. Finally, the study 
investigated carriage of other microbiota colonising the nasopharynx because their 
presence could heavily impact on pneumococcal carriage dynamics as well as its 
virulence. The data have shown that Firmicutes, Proteobacteria, Actinobacteria and 
Bacteroidetes dominate carriage in the nasopharynx of Malawian adults and 
children, and there was no significant difference in the distribution of these phyla by 
age. However, carriage of Actinobacteria was significantly reduced in the HIV 
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infected. Although new data is presented here, providing new insights and scope for 
the future work, carriage still remains a complex web of interactions between host 
and the commensal microbial population. It requires further investigation to untangle 
its dynamics and build on the data generated in this thesis. 
 
7.8 Future work 
The carriage data presented in this thesis has provided valuable information on 
pneumococcal serotype distribution, and also provided preliminary data on the 
prevalent microbiota in carriage in Malawian children and adults. However the 
findings from this study do not only highlight the need to address many questions 
raised with a larger and better-matched sample sets, but also provide the basis for 
estimating much more accurately the size of the samples needed.  
 
Surveillance of pneumococcal serotypes in carriage. In this study, sampling for 
determining carriage of pneumococcal serotypes in both adults and children was 
conducted before the introduction of pneumococcal conjugate vaccination in Malawi. 
Therefore the data presented in this study provides good pre-vaccine background 
information for estimating vaccine coverage and also act as a basis for determining 
how serotype profile changes in carriage post-vaccination. In Malawi, PCV13 was 
only introduced to children below the age of 2 years. To monitor the direct impact of 
vaccination in this group, further surveillance of pneumococcal strains in carriage 
amongst the vaccinated children would be recommended. Since PCV has also been 
shown to reduce carriage of vaccine serotypes among the unvaccinated persons 
through herd immunity, there should be expanded surveillance of pneumococcal 
carriage in the unvaccinated children and adults, to monitor this impact.  
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Dynamics of pneumococcal carriage over-time. To fully understand the dynamics 
of pneumococcal carriage in Malawian children overtime, further work is 
recommended. In particular, there would be need to sample mother/infant pairs over 
a longer period of time. This will provide the information on carriage dynamics as 
well as an estimate of carriage duration.  
 
Investigating the ability of CPS locus variants to colonise and cause disease. The 
work presented in this thesis has shown that carriage serotypes in Malawi are 
genetically diverse. In particular, there is natural occurrence of genetic variation 
within the CPS loci of both vaccine and non-vaccine carriage serotypes. Such 
variations may generate serotypes, which are resistant to vaccination, and also 
modulate the virulence of other serotypes, which rarely cause invasive disease. To 
establish the real impact of such genetic changes on the phenotype of pneumococcal 
strains, further work is planned as follows: 
 
1. Characterise whole genomes of CPS locus variants and comparing them to 
wild type serotypes in order to reveal differences other than those detected at the 
CPS locus; in particular focusing on genes that encode for virulent pneumococcal 
surface proteins. 
 
2. Investigate the ability of the variants to colonise and cause invasive disease 
using mouse models. This work is currently in progress in our research group 
beginning with serotype 6B as a vaccine serotype as one of the most commonly 
isolated serotype from carriage and invasive disease in Malawi. 
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3. Investigating the response of the variants towards vaccination with conjugate 
vaccines. This will initially be achieved using mouse models as above, and secondly, 
through a post-PCV surveillance carriage study to determine any changes in the 
prevalence of the variants, since conjugate vaccination has been reported to decrease 
the carriage of vaccine serotypes.  
 
Nasopharyngeal microbiome. To clearly characterise microbial diversity in 
carriage in Malawi, further analysis of nasopharyngeal microbiota is recommended. 
The samples used to characterise the nasopharyngeal microbiota were preselected 
based on carriage of S. pneumoniae. The results reported in this study showed 
extremely high carriage of streptococcal species belonging to Firmicutes, which 
made the estimate of diversity scores difficult. Further work on nasopharyngeal 
microbiota in this setting should include samples from both carriers and non-carriers 
of S. pneumoniae, to avoid over representation by one species. 
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Appendices 
 
Appendix 1 (a) Sheep bleeding SOP 
 
MLW.SOP.L.MICRO.035 version 2 
 
Background: Whole blood is used in some microbiological media cultures. This 
blood is usually obtained from either sheep or horses. Sheep or horse blood is free 
from antibiotics, which may affect the media performance. Sheep are easily kept and 
they can be bled as required. Sheep do not cause problems when bleeding unlike 
other animals. 
 
Purpose: The purpose of this SOP is to describe the procedure to be followed to 
bleed the sheep at MLW safely to obtain sterile good quality blood. 
Responsibilities: Media Technician/Lab Technical Staff 
 
Procedure 
 
Materials A good bleeding bench; Tray; Pair of scissors; Clean scalpel blade; Spirit 
or 70% alcohol; Blood bag (450ml with sodium citrate anticoagulant); Pair of 
forceps; Nitrile gloves; Cotton wool 
 
Storage conditions It is advised that sheep blood should be stored in the fridge at the 
temperature range of between 2-8
0
C. All flammable liquids should be stored in a 
flammables cabin. 
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Test procedure 
 Carefully lay the sheep on its left side. 
 Using a pair of scissors and scalpel blade, shave the right side of the sheep‟s
 neck where the jugular vein is near the shoulder. 
 Locate the vein. 
 Decontaminate the site using cotton wool and spirit or a 70% alcohol swab.
 Allow the site to dry. 
 Clip the blood bag tubing near the needle using a pair of forceps. 
 Carefully press the vein to the side of the shoulder and insert the needle into
 the vein. 
 Unclip a pair of forceps and hold the needle carefully, check for the flow of
 blood into the bag. 
 As the blood flows steadily into the bag, regularly mix the blood with 
 anticoagulant. 
 Hold until the bag is filled and once again clip the tubing. 
 Carefully remove the needle while holding dry cotton wool near the insertion
 and press gently on the insertion site with the cotton wool after removal of 
 the needle until blood stops flowing. 
 Tie a knot in the blood bag tubing. 
 Cut off the needle of the blood bag and dispose of it in a sharps bin. 
 Sheep should be only be bled once every three months. Each sheep has a tag
 number on its ear, and the number of the sheep that has been bled is recorded
 in a logbook, together with the date. The logbook is kept in the Media room
 at MLW. 
 As soon as bleeding is completed, a gardener should be asked to provide 
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 water and sheep feed to the bled sheep to drink and eat respectively. 
 A sick sheep is not supposed to be bled until it fully recovers. 
 
Quality control. It is the responsibility of the sheep bleeder to make sure that blood 
is not contaminated during and after the bleeding process. 
 
Health and safety 
 Follow health and safety guidelines as laid down in the MLW Laboratory 
 Health and Safety Manual 
 Ensure all sharps are handled with care, and disposed of according to the 
 waste disposal section of the MLW Health and Safety Manuals. 
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Appendix 1 (b) Sheep Blood Agar (layered) + Gentamicin (SBG) 
 
MLW.SOP.L.MEDIA.009 version1 
 
Materials. Sheep Blood Agar Base (Oxoid – CM0854); Nutrient Agar Base (Oxoid 
– CM0003); Sheep Blood (see MLW.SOP.L.MICRO.035for sheep bleeding 
procedure); Codomycin (Gentamicin) 80µg/2ml vial; Distilled Water; Sterile 25ml 
Pipettes; Disposable plastic 90mm Petri dishes. 
 
Procedure Nutrient Agar (bottom) layer. Dissolve 28g of Nutrient Agar base 
powder in 1L of distilled water; Autoclave at 121
o
C for 15 minutes; Cool to 50
o
C in 
the water bath; Aseptically dispense 10ml into sterile Petri dishes and allow to set 
whilst on a flat, level surface. 
 
Procedure Sheep Blood (top) layer 
 Dissolve 40g of Sheep Blood Agar base powder in 1L of distilled water 
 Autoclave at 121oC for 15 minutes  
 Cool to 50oC in the water bath 
 Aseptically add 70ml of Sheep Blood and mix. 
 Aseptically add 32µl of Codomycin (from 80µg/2ml vial) giving a final 
 concentration of 2.56µg/L 
 Aseptically dispense 10ml into a Petri dish already containing a set 10ml 
 layer of nutrient agar and allow to set whilst on a flat, level surface. 
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Storage Conditions. Dry all plates in the 37
o
C aerobic incubator overnight before 
storing them at 2-8
o
C until required. 
 
Quality control organisms.  
Escherichia coli 10418 
Staphylococcus aureus NCTC 6571 
Streptococcus pneumoniae NCTC 12977
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Appendix 2 (a)  Stata®11.0:Microarray serotyping in children 
 
cd "/Users/arox/Desktop/Naor_Arox_Data_Analysis/Arox_Clement_20121217" 
log using Arox_Naor_Children_VT_NVT.smcl, replace 
use "Arox_Naor_Children_VT_NVT.dta"  
* Checking for missing data and categorical variables distribution 
Foreach x in vars hiv_status age gender bacterialload cd4p malaria { 
tab `x' m  
} 
bysort hiv_status: sum age, det 
di as red "calculates the median age of HIV negative and HIV positive subjects" 
ranksum age, by(hiv_status) 
di as red "calculates the p-value of the median age of HIV negative and HIV positive 
subjects"  
logistic vt hiv_status 
graph box age,by(vt, title(Age by carriage of 13VT)note /* 
*/("Two-sample Wilcoxon rank-sum (Mann-Whitney) test p=0.08""median age 
difference 1.6 years")) 
graph save Children_box_age_vt.gph, replace 
kdensity age if vt==1, addplot (kdensity age if vt==0) title(Age by carriage of/* 
*/13VT)note("Two-sample Wilcoxon rank-sum (Mann-Whitney) test 
p=0.08""median age difference 1.6 years") 
graph save Children_kdensity_age_vt.gph, replace 
egen agecat=cut(age),at(0(1)15) label 
tab agecat vt 
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kdensity agecat if vt==1, addplot (kdensity agecat if vt==0) title(Age by carriage of 
13VT)legend(lab(1 13VT carrier) lab(2 non-13VT carrier)) note("Two-sample 
Wilcoxon rank-sum (Mann-Whitney) test p=0.08""median age difference 1.6 years") 
graph save Children_kdensity_agecat_vt.gph, replace 
twoway ///  
 (histogram agecat if vt==1, freq disc fc(navy) ylab(,angle(horizontal))) ///  
 (histogram agecat if vt==0, freq disc fc(cranberry) ylab(,angle(horizontal))) 
/// 
 , /// 
 legend(lab(1 13VT carrier)lab(2 non-13VT carrier)) /// 
 title(Age by carriage of 13VT) /// 
note("Two-sample Wilcoxon rank-sum (Mann-Whitney) test p=0.08""median age 
difference 1.6 years") 
 graph save Children_Hist_agecat_vt_1.gph, replace 
for each var of varlist a19f - nt1{ 
 quietly count if missing(`var') 
 di as red r(N) as yellow " records missing data in " as green "`var'" 
} 
* Carriage rate of at least 1 serotype: 
gen nocarriage=(a19f==0 & a14==0 & a23f==0 & a6b==0 & a6a==0 & a3==0 & 
a19a==0 & /// 
   a4==0 & a18c==0 & a9v==0 & a1==0 & a5==0 & a7f==0 & 
a15b==0 &/// 
   a13==0 & a16f==0 & a35b==0 & a21==0 & a10a==0 & 
a20==0 & a45==0 &/// 
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   a22f==0 & a15c==0 & a10b==0 & a11d==0 & a9l==0 & 
a15a==0 & a35a==0 & /// 
   a35f==0 & a37==0 & a34==0 & a18a==0 & a16a==0 & 
a18f==0 &/// 
   a33a==0 & a7c==0 & a7b==0 & a22a==0 & a33d==0 & 
a38==0 & a11a==0 &/// 
   a24b==0 & a2==0 & nt2==0 & nt3b==0 & nt4a==0 & 
nt4b==0 & nt1==0) 
tab nocarriage 
di as red "Dataset includes only carriers" 
* Carriage of 13vPCV Vaccine Types:    
gen VT13=(a19f==1| a14==1| a23f==1| a6a==1| a6b==1| a3==1| a19a==1| a4==1| 
a18c==1| a9v==1| a1==1| a5==1| a7f==1) 
gen numstgt1=(inrange(numst,2,.)) 
tab numst numstgt1  
lab def multi 0 "single ST" 1 "multiple ST" 
lab val numstgt1 multi 
ttest age, by(numstgt1) 
bysort numstgt1: sum age, det 
di as red "calculates the median age of single vs multiple serotype carriers" 
ranksum age,by(numstgt1) 
di as red "calculates the p-value of the median age of 13VT carriers and non-carriers"  
graph box age,by(numstgt1, title(Age by single or multiple carriage)note(t-test/* 
*/p=0.33)) 
di as red "Although mean age for those with multiple carriage is younger by /* 
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*/0.86 years (10.3 months),"_newline"the differnce is not statistically significant." 
graph save Children_age_numstgt1_box.gph, replace 
tabstat cd4p, s(mean) by(numst) 
ttest cd4p, by(numstgt1) 
graph box cd4p,by(numstgt1, title(CD4 percent by single or multiple carriage)note(t-
test p=0.47)) 
graph save Children_cd4p_numstgt1_box.gph, replace 
tab numstgt1 gender, col chi 
graph pie, over(numstgt1) by(gender, note({&chi}{superscript:2}--test p=0.253) 
legend(off) /* 
*/title(Single or multiple carriage)subtitle(by gender)) plabel(_all name, 
color(white)size(medlarge)) 
graph save Children_numstgt1_gender_pie.gph, replace 
tab numst gender, col chi 
graph pie, over(numst) by(gender, note({&chi}{superscript:2}--test p=0.34) 
legend(off)title(Number of serotypes carried)subtitle(by gender)) plabel(_all name, 
color(white)size(medlarge)) 
graph save Children_numst_gender_pie.gph, replace 
di as red "There is no association between CD4 percent and multiple carriage" 
* Bacterial load by risk factor 
tab bacterialload hiv_status, col 
tab bacterialload gender, col 
tab bacterialload malaria, col 
tabstat age,s(mean) by(bacterialload) 
tabstat cd4p,s(mean) by(bacterialload) 
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nptrend cd4p, by(bacterialload) 
logistic hiv_status bacterialload 
capture logistic age bacterialload 
logistic gender bacterialload 
di as red "No association between risk factors and bacterial load" 
foreach var of varlist a19f - a16a a33a - nt1{ 
 tab `var' gender, col chi exact 
 logistic `var' gender 
} 
* Serotype specific carriage by HIV status 
foreach var of varlist a19f - a16a a33a - nt1{ 
 tab `var' hiv_status, col chi exact 
 logistic `var' hiv_status 
} 
di as red "ST3 is 11.2 (95%CI 1.3 to 96.6) times more likely in HIV infected, 
p=0.03"_newline "Interpret with caution, would probably fail after Bonferroni 
correction" _newline"No other ST carriage associated with HIV" 
* Distribution graph 
preserve 
keep sample a19f- nt1 
collapse (sum) a19f- nt1 
outsheet using st_distribution.csv, c replace 
restore 
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* Cumulative distribution graph 
keep sample a19f- nt1 
foreach var of varlist a19f - nt1{ 
 gen `var'dummy=`var' 
} 
*13VT 
bysort sample: replace a7fdummy=0if 
a19fdummy==1|a14dummy==1|a23fdummy==1|a6bdummy==1|a6adummy==1 /* 
*/|a3dummy==1|a19adummy==1|a4dummy==1|a18cdummy==1|a9vdummy==1|a1d
ummy==1|a5dummy==1 
*invasive potential ST 
bysort sample: replace a2dummy=0if 
a19fdummy==1|a14dummy==1|a23fdummy==1|a6bdummy==1|a6adummy==1|a3du
mmy==1 /* 
*/|a19adummy==1|a4dummy==1|a18cdummy==1|a9vdummy==1|a1dummy==1|a5d
ummy==1|a7fdummy==1|a15bdummy==1|a13dummy==1 
* no invasive potential ST 
bysort sample: replace 
a38dummy=0ifa19fdummy==1|a14dummy==1|a23fdummy==1|a6bdummy==1|a6ad
ummy==1|a3dummy==1|a19adummy==1|a4dummy==1|a18cdummy==1|a9vdummy
==1|a1dummy==1|a5dummy==1|a7fdummy==1|a15bdummy==1|a13dummy==1 
* nontypeables 
bysort sample: replace nt1dummy=0if 
a19fdummy==1|a14dummy==1|a23fdummy==1|a6bdummy==1|a6adummy==1|a3du
mmy==1|a19adummy==1|a4dummy==1|a18cdummy==1|a9vdummy==1|a1dummy=
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=1|a5dummy==1|a7fdummy==1|a15bdummy==1|a13dummy==1 
foreach var of varlist a19fdummy-a15bdummy{ 
 egen `var'_sum=sum(`var') 
 gen `var'_prop=`var'_sum/_N 
} 
collapse a19fdummy_sum-a15bdummy_prop 
foreach var of varlist *_sum { //check here is _sum should be _prop 
 gen `var'_cum=`var' 
} 
log close 
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Appendix 2 (b) Stata®11.0:  Microarray serotyping in adults 
 
cd "/Users/arox/Desktop/Naor_Arox_Data_Analysis" 
log using Arox_Adults_20130416.smcl, replace 
use "Arox_Adults_20130416.dta"  
* Data edit 
drop a9v 
replace a28f=0 if missing(a28f) 
drop in 118 
* Checking for missing data and categorical variables distribution 
Foreach x in vars cd4 hiv_status art_usage multi_carriage pcv7_usage { 
tab `x', m 
* Carriage rate of at least 1 serotype 
gen nocarriage=(a3==0 & a19f==0 & a14==0 & a6a==0 & a23f==0 & a6b==0 & 
a19a==0 & /// 
   a4==0 & a18c==0 & a1==0 & a1==0 & a5==0 & a7f==0 & /// 
   a16f==0 & a13==0 & a10b==0 & a21==0 & a35b==0 & 
a20==0 & a15b==0 & /// 
   a22f==0 & a45==0 & a7b==0 & a11d==0 & a9l==0 & 
a35a==0 & a23a==0 & /// 
   a28f==0 & a34==0 & a18a==0 & a33a==0 & a38==0 & 
a29==0 & a18f==0 &/// 
   a37==0 & a7c==0 & a46==0 & a31==0 & a12f==0 & a48==0 
& nt4a==0 & /// 
   nt2==0 & nt4b==0 & nt3b==0) 
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tab nocarriage 
ttest hiv_status,by(VT7) 
* Mean number of serotypes carried 
egen numst=rowtotal(a3 - nt3b) 
tab numst 
sum numst 
ci numst 
foreach var of varlist hiv_status pcv7_usage art_usage cd4_count{ 
 di as yellow "T-test of mean number of serotypes carried by `var':" 
 ttest numst,by(`var') 
 di ""_newline"" 
} 
tab hiv_status pcv7_usage 
tab hiv_status numst, col chi 
graph bar numst, over(hiv_status) title(Mean number of serotypes carried) /* 
*/subtitle(by HIV status) ytitle(mean number of serotypes carried)note(t-test p=0.36) 
graph save Adults_hivstat_bar_serotypes.gph, replace 
* Serotype specific carriage by HIV status 
foreach var of varlist a3-nt3b{ 
 tab `var' hiv_status, col chi exact 
 logistic `var' hiv_status  
} 
di as red "serotype 13 was frequently isolated from HIV negative than HIV positive 
subjects p=0.01" 
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* Serotype specific carriage by ART usage 
foreach var of varlist a3-nt3b{ 
 tab `var' art_usage, col chi exact 
 logistic `var' art_usage  
} 
* Serotype specific carriage by PCV7 usage 
foreach var of varlist a3-nt3b{ 
 tab `var' pcv7_usage, col chi exact 
 logistic `var' pcv7_usage  
} 
* Serotype specific carriage by CD4 count 
foreach var of varlist a3-nt3b{ 
 tab `var' cd4_count, col chi exact, if hiv_status==1 
 logistic `var' cd4_count   
} 
* Cumulative distribution graph 
keep sample a3- nt3b 
foreach var of varlist a3 - nt3b{ 
 gen `var'dummy=`var' 
} 
*13VT 
bysort sample: replace a20dummy=0if 
a23fdummy==1|a6adummy==1|a19fdummy==1|a14dummy==1|a3dummy==1 /* 
*/|a7fdummy==1|a1dummy==1|a6bdummy==1|a4dummy==1|a18cdummy==1|a19a
dummy==1|a5dummy==1 
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*High invasive potential ST 
bysort sample: replace a7bdummy=0if 
a23fdummy==1|a6adummy==1|a19fdummy==1|a14dummy==1|a3dummy==1 
|a7fdummy==1|a1dummy==1|a6bdummy==1|a4dummy==1|a18cdummy==1|a19adu
mmy==1|a5dummy==1|a20dummy==1|a16fdummy==1|a15bdummy==1|a13dummy
==1|a22fdummy==1|a10bdummy==1|a35bdummy==1|a21dummy==1|a45dummy==
1 
* Low invasive potential ST 
bysort sample: replace nt2dummy=0if 
a23fdummy==1|a6adummy==1|a19fdummy==1|a14dummy==1|a3dummy==1|a7fdu
mmy==1|a1dummy==1|a6bdummy==1|a4dummy==1|a18cdummy==1|a19adummy=
=1|a5dummy==1|a20dummy==1|a16fdummy==1|a15bdummy==1|a13dummy==1|a2
2fdummy==1|a10bdummy==1|a35bdummy==1|a21dummy==1|a45dummy==1 
* nontypeables 
bysort sample: replace nt4bdummy=0if 
a23fdummy==1|a6adummy==1|a19fdummy==1|a14dummy==1|a3dummy==1|a7fdu
mmy==1|a1dummy==1|a6bdummy==1|a4dummy==1|a18cdummy==1|a19adummy=
=1|a5dummy==1|a20dummy==1|a16fdummy==1|a15bdummy==1|a13dummy==1|a2
2fdummy==1|a10bdummy==1|a35bdummy==1|a21dummy==1|a45dummy==1 
di _N 
collapse (sum) *dummy 
clear 
log close 
viewArox_Adults_20130416.smcl 
exit 
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Appendix 3 (a)  Whole genome data: Contig size 
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A plot showing the size of contig sequences obtained versus frequency. The size for 
most of the contigs obtained after assembly ranged from ~20000 to ~60000 base 
pairs.  
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Appendix 3 (b)  Whole genome data: Number of N50 contigs 
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A plot showing the number of N50 contig sequences obtained versus frequency. The 
cumulative length form the largest contig to the smallest contig with atleast 50% of 
the total length (N50 contig number) ranged from ~50000 to ~100000 base pairs. 
 
 
 
 
386 
 
Appendix 4 Barcoded reverse primers 
 
(sub-tables A-E) 
 
A 
Barcode  Sample  Reverse Primer_926R (primer_barcode_adaptor) 
GB1 BC1 CCATCTCATCCCTGCGTGTCTCCGACTCAGAACGCACGCTAGCCGTCAATTCMTTTRAGT 
GB2 BC2 CCATCTCATCCCTGCGTGTCTCCGACTCAGAACTCGTCGATGCCGTCAATTCMTTTRAGT 
GB3 BC3 CCATCTCATCCCTGCGTGTCTCCGACTCAGAACTGTGCGTACCCGTCAATTCMTTTRAGT 
GB4 BC4 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGAGATGTCGACCGTCAATTCMTTTRAGT 
GB5 BC5 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGCTGCAGTCGCCGTCAATTCMTTTRAGT 
GB6 BC9 CCATCTCATCCCTGCGTGTCTCCGACTCAGAATCAGTCTCGTCCGTCAATTCMTTTRAGT 
GB7 BC10 CCATCTCATCCCTGCGTGTCTCCGACTCAGAATCGTGACTCGCCGTCAATTCMTTTRAGT 
GB8 BC11 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACACTATGGCCCGTCAATTCMTTTRAGT 
GB9 BC12 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACATGTCTACCCGTCAATTCMTTTRAGT 
GB10 BC18 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACGAGCCACACCGTCAATTCMTTTRAGT 
GB11 BC19 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACGGTGTCTACCGTCAATTCMTTTRAGT 
GB12 BC20 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACTAGATCCGCCGTCAATTCMTTTRAGT 
GB13 BC21 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACTGTTCATGCCGTCAATTCMTTTRAGT 
GB14 BC22 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAGACCACTCACCGTCAATTCMTTTRAGT 
GB15 BC23 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAGAGTCGGCTCCGTCAATTCMTTTRAGT 
GB16 BC27 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAGCAGTGGTCCCGTCAATTCMTTTRAGT 
GB17 BC29 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAGCTAGCTTGCCGTCAATTCMTTTRAGT 
GB18 BC30 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAGTGCTTCATCCGTCAATTCMTTTRAGT 
GB19 BC34 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAGTTGCGCGACCGTCAATTCMTTTRAGT 
GB20 BC35 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATCACTTAGCCCGTCAATTCMTTTRAGT 
GB21 P1 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATGATCGTTCCCGTCAATTCMTTTRAGT 
GB22 P4 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATGTCACGTGCCGTCAATTCMTTTRAGT 
GB23 P5 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATTCAGCGCACCGTCAATTCMTTTRAGT 
GB24 P8 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCACATACATCCCGTCAATTCMTTTRAGT 
GB25 P9 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCAGACGATGCCCGTCAATTCMTTTRAGT 
GB26 P12 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCAGCGACTAGCCGTCAATTCMTTTRAGT 
GB27 P13 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCGCAGAGTCACCGTCAATTCMTTTRAGT 
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B 
Barcode  Sample  Reverse Primer_926R (primer_barcode_adaptor) 
GB28 P16 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCTCGATCAGACCGTCAATTCMTTTRAGT 
GB29 P17 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCTGTCTCTCTCCGTCAATTCMTTTRAGT 
GB30 P20 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGACGTCTTAGCCGTCAATTCMTTTRAGT 
GB31 P21 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGAGTGCTATCCCGTCAATTCMTTTRAGT 
GB32 P24 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGATGCGACCACCGTCAATTCMTTTRAGT 
GB33 P25 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGCAACTGCTACCGTCAATTCMTTTRAGT 
GB34 P28 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGCGATACTGGCCGTCAATTCMTTTRAGT 
GB35 P29 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGCGCAGATACCCGTCAATTCMTTTRAGT 
GB36 P32 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGCTATCTGGACCGTCAATTCMTTTRAGT 
GB37 P33 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGCTCATGGATCCGTCAATTCMTTTRAGT 
GB38 P36 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGGATCGTCAGCCGTCAATTCMTTTRAGT 
GB39 P37 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGGTGAGTGTCCCGTCAATTCMTTTRAGT 
GB40 P40 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGTACTCAGTGCCGTCAATTCMTTTRAGT 
GB41 P41 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGTCTGTAGCACCGTCAATTCMTTTRAGT 
GB42 P44 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGTGAGAGAATCCGTCAATTCMTTTRAGT 
GB43 P45 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGTGCCGTAGACCGTCAATTCMTTTRAGT 
GB44 P48 CCATCTCATCCCTGCGTGTCTCCGACTCAGACGTTAGCACACCCGTCAATTCMTTTRAGT 
GB45 P49 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTACAGCCTATCCGTCAATTCMTTTRAGT 
GB46 P52 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTACGTGTGGTCCGTCAATTCMTTTRAGT 
GB47 P53 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTAGCTCCATACCGTCAATTCMTTTRAGT 
GB48 P56 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTATTGTCACGCCGTCAATTCMTTTRAGT 
GB49 P57 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCACGGTATGCCGTCAATTCMTTTRAGT 
GB50 P60 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCAGATACTCCCGTCAATTCMTTTRAGT 
GB51 M1 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCGATTCGATCCGTCAATTCMTTTRAGT 
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C 
Barcode  Sample  Reverse Primer_926R (primer_barcode_adaptor) 
GB52 M2 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCGCACAGGACCGTCAATTCMTTTRAGT 
GB53 M3 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCTTCTAGAGCCGTCAATTCMTTTRAGT 
GB54 M4 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTGACAGCCATCCGTCAATTCMTTTRAGT 
GB55 M5 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTGATCCTAGTCCGTCAATTCMTTTRAGT 
GB56 M6 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTGTACGCGTACCGTCAATTCMTTTRAGT 
GB57 M7 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTGTCGAAGCTCCGTCAATTCMTTTRAGT 
GB58 M10 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTGTGACTTCACCGTCAATTCMTTTRAGT 
GB59 M11 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTTGTAGCAGCCCGTCAATTCMTTTRAGT 
GB60 M12 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAACACGTCTCCCGTCAATTCMTTTRAGT 
GB61 M13 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGACCGTCAGACCCGTCAATTCMTTTRAGT 
GB62 M14 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGACGTGCACTGCCGTCAATTCMTTTRAGT 
GB63 M16 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGACTGCGTACTCCGTCAATTCMTTTRAGT 
GB64 M17 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAGAGCAAGTGCCGTCAATTCMTTTRAGT 
GB65 M19 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAGCAAGAGCACCGTCAATTCMTTTRAGT 
GB66 M20 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAGTAGCTAAGCCGTCAATTCMTTTRAGT 
GB67 M21 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAGTCCTGAGCCCGTCAATTCMTTTRAGT 
GB68 M22 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGATACACGCGCCCGTCAATTCMTTTRAGT 
GB69 M23 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGATCGGCTCGACCGTCAATTCMTTTRAGT 
GB70 M24 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGATCTCTGCATCCGTCAATTCMTTTRAGT 
GB71 M25 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGATGTTCTGCTCCGTCAATTCMTTTRAGT 
GB72 M27 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCACACCTACACCGTCAATTCMTTTRAGT 
GB73 M29 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCACGAGCCTACCGTCAATTCMTTTRAGT 
GB74 M30 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCAGCACTTGTCCGTCAATTCMTTTRAGT 
GB75 M31 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCAGTCGCGATCCGTCAATTCMTTTRAGT 
GB76 M32 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCATATGAGAGCCGTCAATTCMTTTRAGT 
GB77 M33 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCCATACTGACCCGTCAATTCMTTTRAGT 
GB78 M34 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCGACTGTGCACCGTCAATTCMTTTRAGT 
GB79 M36 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCGAGCTATCTCCGTCAATTCMTTTRAGT 
GB80 M37 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCGCTGATGTGCCGTCAATTCMTTTRAGT 
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D 
Barcode  Sample  Reverse Primer_926R (primer_barcode_adaptor) 
GB81 M38 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCGTAGGTCGTCCGTCAATTCMTTTRAGT 
GB82 M41 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCTATCCACGACCGTCAATTCMTTTRAGT 
GB83 M42 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCTCCATACAGCCGTCAATTCMTTTRAGT 
GB84 M43 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCTCTCAGAGGCCGTCAATTCMTTTRAGT 
GB85 M44 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCTGACTAGTCCCGTCAATTCMTTTRAGT 
GB86 M48 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCTTGACAGCTCCGTCAATTCMTTTRAGT 
GB87 M49 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGGACGCACTGTCCGTCAATTCMTTTRAGT 
GB88 M50 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGGCTACACGACCCGTCAATTCMTTTRAGT 
GB89 M52 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGGTGTGATCGCCCGTCAATTCMTTTRAGT 
GB90 M54 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTACGCTCGAGCCGTCAATTCMTTTRAGT 
GB91 M55 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTACTGCAGGCCCGTCAATTCMTTTRAGT 
GB92 M57 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTAGTATCCTCCCGTCAATTCMTTTRAGT 
GB93 M58 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTCACATCACTCCGTCAATTCMTTTRAGT 
GB94 M59 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTCCATAGCTGCCGTCAATTCMTTTRAGT 
GB95 M60 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTCTACTCTGACCGTCAATTCMTTTRAGT 
GB96 M61 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTCTCGCATATCCGTCAATTCMTTTRAGT 
GB97 M62 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTGAGAGAAGCCCGTCAATTCMTTTRAGT 
GB98 M64 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTGCGATGCGTCCGTCAATTCMTTTRAGT 
GB99 M65 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTGGATGCTCTCCGTCAATTCMTTTRAGT 
GB100 M66 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTGTCACGGTGCCGTCAATTCMTTTRAGT 
GB101 M67 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTGTTCGATCGCCGTCAATTCMTTTRAGT 
GB102 M68 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTTAGTGCGTCCCGTCAATTCMTTTRAGT 
GB103 M69 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTTCAGACGCTCCGTCAATTCMTTTRAGT 
GB104 M70 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTTCTACGTCACCGTCAATTCMTTTRAGT 
GB105 M71 CCATCTCATCCCTGCGTGTCTCCGACTCAGATAATCTCGTCGCCGTCAATTCMTTTRAGT 
GB106 K1 CCATCTCATCCCTGCGTGTCTCCGACTCAGATACACGTGGCGCCGTCAATTCMTTTRAGT 
GB107 K3 CCATCTCATCCCTGCGTGTCTCCGACTCAGATACAGAGCTCCCCGTCAATTCMTTTRAGT 
GB108 K4 CCATCTCATCCCTGCGTGTCTCCGACTCAGATACGTCTTCGACCGTCAATTCMTTTRAGT 
GB109 K5 CCATCTCATCCCTGCGTGTCTCCGACTCAGATACTATTGCGCCCGTCAATTCMTTTRAGT 
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E 
Barcode  Sample  Reverse Primer_926R (primer_barcode_adaptor) 
GB110 K6 CCATCTCATCCCTGCGTGTCTCCGACTCAGATACTCACTCAGCCGTCAATTCMTTTRAGT 
GB111 K7 CCATCTCATCCCTGCGTGTCTCCGACTCAGATAGCTCCATACCCGTCAATTCMTTTRAGT 
GB112 K8 CCATCTCATCCCTGCGTGTCTCCGACTCAGATAGGCGATCTCCCGTCAATTCMTTTRAGT 
GB113 K9 CCATCTCATCCCTGCGTGTCTCCGACTCAGATATCGCTACTGCCGTCAATTCMTTTRAGT 
GB114 K12 CCATCTCATCCCTGCGTGTCTCCGACTCAGATATGCCAGTGCCCGTCAATTCMTTTRAGT 
GB115 K16 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCACGTAGCGGCCGTCAATTCMTTTRAGT 
GB116 K19 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCACTAGTCACCCGTCAATTCMTTTRAGT 
GB117 K20 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCAGGCGTGTGCCGTCAATTCMTTTRAGT 
GB118 K21 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCCGATCACAGCCGTCAATTCMTTTRAGT 
GB119 K24 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCCTCAGTAGTCCGTCAATTCMTTTRAGT 
GB120 K29 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCGATCTGTGGCCGTCAATTCMTTTRAGT 
GB121 K35 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCGCGGACGATCCGTCAATTCMTTTRAGT 
GB122 K36 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCGCTCGAGGACCGTCAATTCMTTTRAGT 
GB123 K37 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCGTACAACTCCCGTCAATTCMTTTRAGT 
GB124 K38 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCTACTACACGCCGTCAATTCMTTTRAGT 
GB125 K40 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCTCTGGCATACCGTCAATTCMTTTRAGT 
GB126 K43 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCTGAGCTGGTCCGTCAATTCMTTTRAGT 
GB127 K49 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCTGGTGCTATCCGTCAATTCMTTTRAGT 
GB128 K54 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCTTAGACTGCCCGTCAATTCMTTTRAGT 
GB129 K56 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGACCATCGTGCCGTCAATTCMTTTRAGT 
GB130 K57 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGACTCATTCGCCGTCAATTCMTTTRAGT 
GB131 K58 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGAGACTCCACCCGTCAATTCMTTTRAGT 
GB132 K59 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGATCGAGAGACCGTCAATTCMTTTRAGT 
GB133 K60 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGCACTGGCGACCGTCAATTCMTTTRAGT 
GB134 K61 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGCAGCTCAGTCCGTCAATTCMTTTRAGT 
GB135 K62 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGCCTGAGCAGCCGTCAATTCMTTTRAGT 
GB136 K63 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGCGTAGTGCGCCGTCAATTCMTTTRAGT 
GB137 K64 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGGATACGCTCCCGTCAATTCMTTTRAGT 
The V3-V5 region of the 16S rRNA was amplified. The Universal forward primer was 
338F:CCTATCCCCTGTGTGCCTTGGCAGTCTCAGACTCCTACGGGAGGCAG
CAG 
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Appendix 5 Mothur analysis 
 
(v. 1.30.2) 
 
A.  Sequence cleanup/clustering 
/software/pathogen/external/apps/usr/bin/mothur 
mothur > summary.seqs(fasta=Arox_repeat.fasta) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 1 44 44  0  2  1 
2.5%-tile: 1 131 131  0  4  14087 
25%-tile: 1 549 549  0  4  140866 
Median:  1 552 552  0  4  281732 
75%-tile: 1 554 554  0  4  422598 
97.5%-tile: 1 567 567  1  5  549377 
Maximum: 1 1195 1195  25  31  563463 
Mean: 1 538.513 538.513 0.0581014 4.11425 
# of Seqs: 563463 
 
mothur>trim.seqs(fasta=Arox_repeat.fasta,oligos=Arox_repeat.oligos,qfile=Arox_r
epeat.qual,maxambig=0,maxhomop=8, flip=T, bdiffs=0, pdiffs=0, 
qwindowaverage=35, qwindowsize=50, minlength=400) 
 
mothur > summary.seqs(fasta=Arox_repeat.trim.fasta) 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 1 400 400  0  4  1 
2.5%-tile: 1 401 401  0  4  5369 
25%-tile: 1 409 409  0  4  53689 
Median:  1 415 415  0  4  107378 
75%-tile: 1 425 425  0  4  161066 
97.5%-tile: 1 483 483  0  5  209386 
Maximum: 1 531 531  0  7  214754 
Mean: 1 420.08 420.08 0 4.03635 
# of Seqs: 214754 
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mothur > unique.seqs(fasta=Arox_repeat.trim.fasta) 
mothur>summary.seqs(fasta=Arox_repeat.trim.unique.fasta,name=Arox_repeat.tri
m.names) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 1 400 400  0  4  1 
2.5%-tile: 1 401 401  0  4  5369 
25%-tile: 1 409 409  0  4  53689 
Median:  1 415 415  0  4  107378 
75%-tile: 1 425 425  0  4  161066 
97.5%-tile: 1 483 483  0  5  209386 
Maximum: 1 531 531  0  7  214754 
Mean: 1 420.08 420.08 0 4.03635 
 
mothur>align.seqs(fasta=Arox_repeat.trim.unique.fasta,reference=silva.bacteria.fas
ta) 
mothur > summary.seqs(fasta=Arox_repeat.trim.unique.align) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 7705 27656 400   0  4 1 
2.5%-tile: 8507 27659 401   0  4 672 
25%-tile: 10239 27659 409   0  4 6714 
Median:  10275 27659 417   0  4 13427 
75%-tile: 10351 27659 429   0  4 20140 
97.5%-tile: 10369 27659 490   0  6 26182 
Maximum: 11890 28426 531   0  7 26853 
Mean: 10190.6 27658.7 422.86 0 4.11958 
# of Seqs: 26853 
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mothur>screen.seqs(fasta=Arox_repeat.trim.unique.align,start=10370,end=27656,
maxhomop=6,name=Arox_repeat.trim.names,group=Arox_repeat.groups,qfile=Arox
_repeat.qual, alignreport=Arox_repeat.trim.unique.align.report) 
mothur>summary.seqs(fasta=Arox_repeat.trim.unique.good.align,name=Arox_rep
eat.trim.good.names) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 7705 27656 400   0  4 1 
2.5%-tile: 9804 27659 401   0  4 5366 
25%-tile: 10247 27659 409   0  4 53654 
Median:  10279 27659 415   0  4 107308 
75%-tile: 10351 27659 425   0  4 160962 
97.5%-tile: 10368 27659 483   0  5 209250 
Maximum: 10370 28426 531   0  6 214615 
Mean: 10229.7 27649.7 420.092 0 4.03632 
# of unique seqs: 26815; total # of seqs: 214615 
 
mothur>unique.seqs(fasta=Arox_repeat.trim.unique.good.filter.fasta,name=Arox_r
epeat.trim.good.names) 
mothur>summary.seqs(fasta=Arox_repeat.trim.unique.good.filter.unique.fasta,nam
e=Arox_repeat.trim.unique.good.filter.names) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 1 772 392   0  4 1 
2.5%-tile: 1 772 398   0  4 5366 
25%-tile: 1 772 398   0  4 53654 
Median:  1 772 398   0  4 107308 
75%-tile: 1 772 398   0  4 160962 
97.5%-tile: 1 772 399   0  5 209250 
Maximum: 1 772 404   0  6 214615 
Mean: 1 769.62 399.189 0 4.03629 
# of unique seqs: 8135 
total # of seqs: 214615 
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mothur>pre.cluster(fasta=Arox_repeat.trim.unique.good.filter.unique.fasta,name=
Arox_repeat.trim.unique.good.filter.names, diffs=1) 
Mothur>summary.seqs(fasta=Arox_repeat.trim.unique.good.filter.unique.precluste
r.fasta, name=Arox_repeat.trim.unique.good.filter.unique.precluster.names) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 1 772 392   0  4 1 
2.5%-tile: 1 772 398   0  4 5366 
25%-tile: 1 772 398   0  4 53654 
Median:  1 772 398   0  4 107308 
75%-tile: 1 772 398   0  4 160962 
97.5%-tile: 1 772 399   0  5 209250 
Maximum: 1 772 404   0  6 214615 
Mean: 1 769.62 399.192 0 4.03337 
# of unique seqs: 3918 
total # of seqs: 214615 
 
mothur>chimera.perseus(fasta=Arox_repeat.trim.unique.good.filter.unique.preclus
ter.fasta, name=Arox_repeat.trim.unique.good.filter.unique.precluster.names) 
mothur>remove.seqs(accnos=Arox_repeat.trim.unique.good.filter.unique.precluster
.perseus.accnos,fasta=Arox_repeat.trim.unique.good.filter.unique.precluster.fasta,na
me=Arox_repeat.trim.unique.good.filter.unique.precluster.names,group=Arox_repeat
.good.groups) 
mothur>summary.seqs(fasta=Arox_repeat.trim.unique.good.filter.unique.precluster
.pick.fasta, name=Arox_repeat.trim.unique.good.filter.unique.precluster.pick.names) 
 
  Start End NBases Ambigs Polymer NumSeqs 
Minimum: 1 772 392   0  4 1 
2.5%-tile: 1 772 398   0  4 5357 
25%-tile: 1 772 398   0  4 53565 
Median:  1 772 398   0  4 107130 
75%-tile: 1 772 398   0  4 160694 
97.5%-tile: 1 772 399   0  5 208902 
Maximum: 1 772 404   0  6 214258 
Mean: 1 769.623 399.191 0 4.03307 
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# of unique seqs: 3747 
total # of seqs: 214258 
 
mothur>dist.seqs(fasta=Arox_repeat.trim.unique.good.filter.unique.precluster.pick.f
asta) 
mothur>cluster(column=Arox_repeat.trim.unique.good.filter.unique.precluster.pick
.dist, name=Arox_repeat.trim.unique.good.filter.unique.precluster.pick.names) 
mothur>make.shared(list=Arox_repeat.trim.unique.good.filter.unique.precluster.pi
ck.an.list, group=Arox_repeat.good.pick.groups, label=0.03) 
 
 
B.  Alpha Diversity (Output files plotted in Excel/Stata v.11) 
 
Using file name: Arox_repeat_clean.shared 
mothur > sub.sample(shared=Arox_repeat_clean.shared, size=1000) 
Output File Names: Arox_repeat_clean.0.03.subsample.shared 
mothur>collect.single(shared=Arox_repeat_clean.shared,calc=chao-invsimpson, 
freq=5) 
mothur>collect.single(shared=Arox_repeat_clean.0.03.subsample.shared, 
calc=chao-invsimpson, freq=5) 
mothur>rarefaction.single(shared=Arox_repeat_clean.shared, calc=sobs, freq=100) 
mothur>summary.single(shared=Arox_repeat_clean.0.03.subsample.shared,calc=n
seqs-coverage-sobs-invsimpson) 
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C.  Determining species diversity by Age, HIV status, PCV and ART Usage 
using Venn command in mothur 
 
Generating Venn diagrams in mothur to compare species distribution.For example, 
determining species diversity between HIV positive and HIV negative children.Data 
processing was as follows: 
1. Making a copy of the „subsampled.shared‟ file. 
2. Removing all adults‟ samples. 
3. Removing all the duplicated samples from longitudinal data set, so that there is 
only one sample per child.  
4. All HIV positive and negative columns were added together and called „HIVpos‟ 
and „HIVneg‟ respectively. 
5. This generated a shared file (Kids_HIV.shared) with only two samples in it. A 
tab-delimited format of the shared file was used to generate Venn diagrams in 
mothur. 
6. Using mothur to generate Venn diagram 
 
mothur > venn(shared=Kids_HIV.shared)  
 
The scaleable vector graphic (svg) file produced can be viewed in Firefox, Safari or 
any other browser. The above procedure was repeated to determine species diversity 
for other parameters such as Age, PCV and ART usage. 
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D.  Principal component analysis using Bray Curtis and Jaccard 
 
Bray Curtis is employed to determine the type of species present in a given sample 
and their proportions, while Jaccard determines only the species present (Porat et 
al.). 
 
mothur>dist.shared(shared=Arox_repeat_clean.0.03.subsample.shared,calc=braycu
rtis-jclass) 
mothur > pcoa(phylip=Arox_repeat_clean.0.03.subsample.braycurtis.0.03.lt.dist) 
mothur > pcoa(phylip=Arox_repeat_clean.0.03.subsample.jclass.0.03.lt.dist) 
mothur >metastats(shared=Adults_children.shared, design=Adults_children.design)  
mothur > metastats(shared=Child_BT_KA.shared, design=Child_BT_KA.design) 
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Appendix 6 Multiple carriage in children 
 
Sample Microarray Serotypes (Relative abundance) Number of 
serotypes Sero1 (%) Sero2 (%) Sero3 (%) Sero4 (%) 
A-718* 19F (95) NT4a (5)     2 
B-439 16F (99) NT4a (1)     2 
C-710 NT3b (41) 35B (37) NT2 (22)   3 
D-927* 19F (93) 35F (7)     2 
E-117 15B (98) 16F (2)     2 
F-607 10B (51) NT4b (44) 34 (5)   3 
G-940* 21 (68) 6B (32)     2 
H-539* 23F (54) 15B (33) 14 (12) NT3b (1) 4 
I-067 15B (96) 11D (4)     2 
J-808* 23F (54) 18A (39) 6B (7)   3 
K-086* 3 (57) 34 (29) NT4a (14)   3 
L-556* 15B (72) 6A (28)     2 
M-651* 3 (99) 35A (1)     2 
N-516* 10B (89) 19A (6) 45 (5)   3 
O-535* 13 (89) 3 (11)     2 
P-590 NT3b (86) 10B (14)     2 
Q-650* 23F (98) 19F (2)     2 
R-636* NT3b (73) 4 (17) 35B (11)   3 
S-698 2 (55) NT4b (45)     2 
T-697 10B (87) NT3b (13)     2 
U-656 35B (83) 13 (17)     2 
V-587* 19F (99) 16A (1)     2 
X-1Y7* 1 (42) 14 (37) 3 (21)   3 
Y-2D4 15B (99) 18F (1)     2 
Z-2IH* 1 (95) NT2 (5)     2 
AA-064 15B (99) 9L (1)     2 
AB-1YA* 15C (48) 14 (46) 38 (6)   3 
AC-2C2* NT3b (66) 1 (19) NT2 (16)   3 
AD-2DR* NT3b (53) 18C (47)     2 
AE-22U* 6B (63) NT2 (37)     2 
AF-238* 13 (44) NT2 (36) 14 (20)   3 
AG-728* 3 (57) 15B (43)     2 
AH-1VK* 15B (50) 5 (44) 6B (6)   3 
AI-1YH* 23F (87) 20 (13)     2 
AJ-1YZ* 13 (77) 6B (23)     2 
AK-22W* 7C (89) NT4a (5) 37 (5) 14 (1) 4 
AL-122* 9L (70) 19F (27) 14 (3)   3 
AM-2M2* 23F (51) 9V (26) 11A (23)   3 
AN-2M9* 14 (96) 7F (4)     2 
AO-811* 19F (71) 23F (29)     2 
AP-693* 6A (92) 9V (8)     2 
AQ-2M3* 6A (91) NT2 (9)     2 
AR-1XY* 15A (65) 6A (35)     2 
AS-1VS* 19A (59) 4 (41)     2 
AT-235* 19F (67) 33D (18)     2 
AU-568* 19F (67) 6B (33)     2 
 
Samples involving a vaccine type in multiple carriage are marked with a (*).
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Appendix 7 (a) Multiplex PCR serotyping primers 
 
 
Serotype 
 
Primers 
 
Nucleotide Position 
 
Product size (bp) 
 
Gene target 
 
Accesion no. 
 
Reference 
6B  AAT TTG TAT TTT ATT CAT GCC TAT ATC TGG -f 8656 250 wciP CR931639 (Pai et al., 2006) 
6B  TTA GCG GAG ATA ATT TAA AAT GAT GAC TA -r 8877    (Pai et al., 2006) 
9L  GAA CTG AAT AAG TCA GAT TTA ATC AGC -f 11948 516 wzx CR931647 (Dias et al., 2007) 
9L  ACC AAG ATC TGA CGG GCT AAT CAA T -r 12439    (Dias et al., 2007) 
9V  GGG TTC AAA G TC AGA CAG TG A ATC TTA A -f 9966 816 wzy CR931648 (da Gloria Carvalho et al., 2010) 
9V  CCA TGA ATG A AA TCA ACA TT G TCA GTA GC -r 10753    (da Gloria Carvalho et al., 2010) 
10A  GGT GTA GAT TTA CCA TTA GTG TCG GCA GAC -f 12423 628 wcrG CR931649 (Pai et al., 2006) 
10A  GAA TTT CTT CTT TAA GAT TCG GAT ATT TCT C -r 13021    (Pai et al., 2006) 
11D  GGA CAT GTT CAG GTG ATT TCC CAA TAT AGT G -f 11640 463 wzy CR931653 (Pai et al., 2006) 
11D GAT TAT GAG TGT AAT TTA TTC CAA CTT CTC CC -r 12071    (Pai et al., 2006) 
14  GAA ATG TTA CTT GGC GCA GGT GTC AGA ATT -f 7959 189 wzy CR931662 (Dias et al., 2007) 
14  GCC AAT ACT TCT TAG TCT CTC AGA TGA AT -r 8119    (Dias et al., 2007) 
16F  GAA TTT TTC AGG CGT GGG TGT TAA AAG -f 11679 716 wzy CR931668 (da Gloria Carvalho et al., 2010) 
16F  CAG CAT ATA GCA CCG CTA AGC AAA TA -r 12371    (da Gloria Carvalho et al., 2010) 
19F  GTT AAG ATT GCT GAT CGA TTA ATT GAT ATC C -f 11135 304 wzy CR931678 (Pai et al., 2006) 
19F  GTA ATA TGT CTT TAG GGC GTT TAT GGC GAT AG -r 11407    (Pai et al., 2006) 
23B  CCA CAA TTA G CG CTA TAT TCA TTC AAT CG -f 13227 199 wzx CR931684 (da Gloria Carvalho et al., 2010) 
23B  GTC CAC GCT GAA TAA AAT GAA GCT CCG -r 13399    (da Gloria Carvalho et al., 2010) 
23F  GTA ACA GTT GCT GTA GAG GGA ATT GGC TTT TC -f 8768 384 wzy CR931685 (Pai et al., 2006) 
23F  CAC AAC ACC TAA CAC TCG ATG GCT ATA TGA TTC -f 9119    (Pai et al., 2006) 
35F  GAA CAT AGT CGC TAT TGT ATT TTA TTT AAA GCA A -f 7374 517 wzy CR931707 (Pai et al., 2006) 
35F  GAC TAG GAG CAT TAT TCC TAG AGC GAG TAA ACC -r 7858    (Pai et al., 2006) 
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Appendix 7 (b) Bioanalyser electropherograms 
 
Confirmed the presence 6B (250bp, wciP), 9V (816bp, wzy), 16F (716bp, wzy), 23B 
(199bp, wzx) and 23F (384bp, wzy). This confirmed the presence of 23B (199bp, wzx) 
and 35F (517bp, wzy). 
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Appendix 8 (a) OTU distribution in children and adults 
 
OTU mean(children) mean(adults) p-value 
Otu085 0.000000 0.000056 0.000999 
Otu107 0.000000 0.000444 0.000999 
Otu002 0.000000 0.000111 0.000999 
Otu029 0.000000 0.000222 0.000999 
Otu144 0.000000 0.000056 0.000999 
Otu126 0.000000 0.000056 0.000999 
Otu167 0.062950 0.010111 0.027972 
Otu137 0.002600 0.000056 0.152847 
Otu117 0.000000 0.000111 0.187812 
Otu076 0.000400 0.000000 0.209790 
Otu149 0.001950 0.005444 0.212787 
Otu154 0.000050 0.000944 0.264735 
Otu160 0.010750 0.003222 0.283716 
Otu161 0.000950 0.000222 0.287712 
Otu170 0.000350 0.001389 0.391608 
Otu142 0.000125 0.001944 0.396603 
Otu005 0.000075 0.000000 0.412587 
Otu159 0.000625 0.003556 0.446553 
Otu080 0.000600 0.000056 0.462537 
Otu109 0.000500 0.000056 0.483516 
Otu061 0.000050 0.000000 0.498501 
Otu014 0.000050 0.000000 0.500500 
Otu011 0.000100 0.000000 0.502498 
Otu164 0.000050 0.000056 0.628372 
Otu155 0.003850 0.032389 0.640360 
Otu103 0.000825 0.003111 0.685315 
Otu133 0.000025 0.000056 0.713287 
Otu006 0.000050 0.000722 0.760240 
Otu163 0.000075 0.018222 0.778222 
Otu021 0.000025 0.000000 0.782218 
Otu106 0.002850 0.001000 0.786214 
Otu132 0.001350 0.000167 0.790210 
Otu172 0.003525 0.005111 0.791209 
Otu165 0.021400 0.038167 0.797203 
Otu166 0.000175 0.000222 0.858142 
Otu017 0.000050 0.000000 0.881119 
Otu115 0.000100 0.000000 0.901099 
Otu173 0.881200 0.871833 0.904096 
Otu090 0.000075 0.000000 0.912088 
Otu171 0.002250 0.000389 0.984016 
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Appendix 8 (b) OTU distribution in children 
 
Otu Karonga (mean) Blantyre (mean)  p-value 
Otu172 0.000000 0.005875 0.000999 
Otu115 0.000000 0.000167 0.000999 
Otu006 0.000000 0.000083 0.000999 
Otu017 0.000000 0.000083 0.000999 
Otu167 0.148688 0.005792 0.001998 
Otu137 0.006500 0.000000 0.008991 
Otu160 0.000188 0.017792 0.009990 
Otu173 0.788375 0.943083 0.023976 
Otu165 0.047125 0.004250 0.029970 
Otu163 0.000000 0.000125 0.048951 
Otu106 0.000000 0.004750 0.052947 
Otu142 0.000000 0.000208 0.097902 
Otu103 0.001500 0.000375 0.148851 
Otu154 0.000000 0.000083 0.207792 
Otu159 0.001125 0.000292 0.226773 
Otu021 0.000000 0.000042 0.305694 
Otu061 0.000125 0.000000 0.312687 
Otu011 0.000250 0.000000 0.314685 
Otu014 0.000125 0.000000 0.331668 
Otu005 0.000188 0.000000 0.342657 
Otu161 0.001625 0.000500 0.368631 
Otu132 0.000000 0.002250 0.413586 
Otu109 0.001125 0.000083 0.496503 
Otu164 0.000063 0.000042 0.507493 
Otu149 0.001250 0.002417 0.509491 
Otu170 0.000250 0.000417 0.548452 
Otu133 0.000000 0.000042 0.691309 
Otu166 0.000063 0.000250 0.698302 
Otu080 0.001313 0.000125 0.720280 
Otu155 0.000063 0.006375 0.763237 
Otu076 0.000063 0.000625 0.820180 
Otu090 0.000000 0.000125 0.823177 
Otu171 0.000000 0.003750 0.926074 
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Appendix 8 (b) OTU distribution in children 
 
Otu Karonga (mean) Blantyre (mean)  p-value 
Otu172 0.000000 0.005875 0.000999 
Otu115 0.000000 0.000167 0.000999 
Otu006 0.000000 0.000083 0.000999 
Otu017 0.000000 0.000083 0.000999 
Otu167 0.148688 0.005792 0.001998 
Otu137 0.006500 0.000000 0.008991 
Otu160 0.000188 0.017792 0.009990 
Otu173 0.788375 0.943083 0.023976 
Otu165 0.047125 0.004250 0.029970 
Otu163 0.000000 0.000125 0.048951 
Otu106 0.000000 0.004750 0.052947 
Otu142 0.000000 0.000208 0.097902 
Otu103 0.001500 0.000375 0.148851 
Otu154 0.000000 0.000083 0.207792 
Otu159 0.001125 0.000292 0.226773 
Otu021 0.000000 0.000042 0.305694 
Otu061 0.000125 0.000000 0.312687 
Otu011 0.000250 0.000000 0.314685 
Otu014 0.000125 0.000000 0.331668 
Otu005 0.000188 0.000000 0.342657 
Otu161 0.001625 0.000500 0.368631 
Otu132 0.000000 0.002250 0.413586 
Otu109 0.001125 0.000083 0.496503 
Otu164 0.000063 0.000042 0.507493 
Otu149 0.001250 0.002417 0.509491 
Otu170 0.000250 0.000417 0.548452 
Otu133 0.000000 0.000042 0.691309 
Otu166 0.000063 0.000250 0.698302 
Otu080 0.001313 0.000125 0.720280 
Otu155 0.000063 0.006375 0.763237 
Otu076 0.000063 0.000625 0.820180 
Otu090 0.000000 0.000125 0.823177 
Otu171 0.000000 0.003750 0.926074 
 
